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ABSTRACT 
 
The prevalence of obesity and overweight has dramatically increased throughout the world 
and becomes a major health concern. In obesity, adipose tissue expansion is associated with 
increased macrophage infiltration and marked change in cytokine/chemokine production. 
Macrophage-derived factors significantly alter adipose cells function, inducing inflammatory 
responses, reducing insulin sensitivity and impairing differentiation capability which may 
contribute to obesity-related metabolic disorder such as insulin resistance and type 2 diabetes. 
Human adipose cells (preadipocytes and adipocytes) play an important role in adipose tissue 
remodelling but their role in the development of insulin resistance and type 2 diabetes 
remains to be established. Identification of the major factors that mediate the detrimental 
effects of macrophages on adipose cells may offer potential therapeutic targets. IL-1β, a pro-
inflammatory cytokine, is suggested to be involved in the development of insulin resistance. 
In this thesis, different models of cells in adipose tissue were used to establish the effect of 
the crosstalk between them on the function of adipose cells, including human primary 
preadipocytes, adipocytes, THP-1 macrophages (cell line) and peripheral blood-derived 
macrophages. More specifically, this work investigated the role of IL-1β in macrophage-
adipose cells cross-talk which affects the insulin signalling pathway, inflammatory response 
and adipocyte development in adipose tissue.  
The results presented in this thesis reveal that basal expression of insulin signalling proteins 
(IR, IRS-1 and PI3K-p85α) was present and detectable in both human adipose cells. IL-1β 
modulated the expression of insulin signalling proteins including IR (Y1185), IRS-1(Ser612) 
and Akt (Ser473) in human preadipocytes upon insulin stimulation. Furthermore, IL-1β 
mediated macrophage-induced modulation of the insulin signalling molecules in human 
preadipocytes. In mature adipocytes, IL-1β significantly modulated protein abundance of 
insulin signalling molecules, including IRS-1, PI3K-p85α and Glut4 and phosphorylation of 
IR and Akt.  
In addition, IL-1β mediated macrophage-induced expression and release of the pro-
inflammatory cytokine/chemokines (IL-6, IL-8, MCP-1 and RANTES) in both human 
adipose cells. Blocking IL-1β activity, its receptor binding and production can partially or 
totally restore the expression of insulin signalling proteins and insulin responsiveness in both 
adipose cells. IL-1β antagonism also protected against macrophage-stimulated release of the 
pro-inflammatory cytokines/chemokines and macrophage-inhibited release of adiponectin. 
Additionally, both IL-1β and MC medium reduced lipid accumulation by reducing expression 
of the adipogenic factors including C/EBPα, PPARγ and aP2 and stimulating lipolysis in 
human adipocytes.  
In conclusion, the results of this thesis suggest that IL-1β mediates, at least in part, the effect 
of macrophages on insulin signalling and pro-inflammatory response in human adipose cells. 
Therefore, blocking IL-1β may serve as a beneficial target for reducing obesity-associated 
inflammation and insulin resistance in human adipose tissue. 
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1 Introduction 
 
1.1 Obesity 
1.1.1 Prevalence of obesity   
According to an expert technical consultation, which was organized in the mid  
1990’s, the first ever World Health Organization (WHO) report was published about 
considering  obesity with high importance and awareness. The prevalence of obesity 
and overweight has dramatically increased throughout the world and become a major 
health concern (WHO, 2000). Interestingly, obesity has significantly increased in 
developing economic countries, such as China, India, Brazil and South Africa, 
particularly in metropolitan areas where people are more exposed to high caloric 
foods with low physical activity (Lobstein, 2011).  
 
Information from epidemiological studies from 199 countries using systemic analysis 
showed that approximately 1 billion adults were estimated to be overweight in the 
world in 2008, and half billion were obese (Finucane et al., 2011). In fact, obesity has 
also been found to affect both genders and all age groups, even the children  (Kimm 
and Obarzanek, 2002), making it one of the most common chronic disorders in 
childhood, adolescent and adulthood. In England, for example, The National Child 
Measurement Programme (NCMP) provides the latest figures on children obesity, 
and this report showed that in 2013/14 more than a fifth of 4-5 year olds and third of 
10-11 year olds were either overweight or obese (NCMP, 2015). Interestingly, it was 
estimated that the positive energy balance (over nutrition) increases mortality among 
people who suffered from obesity related complications more than people who will 
die due to food deficiency (malnutrition) (Mukhopadhyay et al., 2005). 
 
Lean et al. stated that the prevalence of obesity has increased 20% in adult European 
citizen, 40-70% in the Gulf States and Polynesian islands, and the prevalence of 
obesity now exceeds 15% in most European countries (Lean et al., 2006). According 
to some national surveys such as a report revealed by the National Audit Office 
(NAO) in England ~ over half of women and two thirds of men were either 
overweight or obese (NAO, 2001). In the USA, more than 60% of people aged 20 
and older (approximately 170 million) are overweight, 27% of adult American (about 
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70 million) are obese putting them at health risk (Hedley et al., 2004). Therefore, in 
the USA, the number of obesity-attributable deaths reached approximately 325,000 
deaths each year, and cost the country annually billions of dollars to cover direct and 
indirect medical expense such as disability and lost productivity annually (Allison et 
al., 1999, Katzmarzyk and Janssen, 2004).    
  
The prevalence of obesity varies between different countries, populations and further 
variations are found with age and gender. Moreover, a cluster of etiological factors 
involved in obesity development include both genetic and environmental factors that 
it is classified as a “multifactorial disorder”. Environmental factors require genetic 
tendency to induce the development of obesity. Alterations in endocrine functions, 
even though rare, are also an important cause of obesity. However, significant 
changes in economic, social, cultural, and environmental factors play key roles in the 
onset of obesity (Al-Malki et al., 2003). 
 
1.1.2 Definition of obesity  
The fundamental definition for both obesity and overweight is an abnormal or 
excessive fat (adipose tissue) accumulation that affects health (Marinou et al., 2010). 
Based on a simple calculation in which weight in kilograms divided by height square 
in meters (kg/m²) reflects the body mass index (BMI) for human body weight. BMI 
is considered as a potential indicator of obesity in humans by providing a comparable 
analysis of prevalence rates worldwide (James et al., 2001, Seidell and Flegal, 1997). 
According to BMI values human obesity status can be classified into several 
categories as in Table 1.1, where individuals with BMI ≥ 25 kg/m² and >30 are 
defined as overweight and obese, respectively. There are other methods such as waist 
hip ratio and imaging techniques which can be utilized to diagnose obesity by 
measuring body weight and fat distribution.  
 
1.1.3 Assessment of obesity  
Worldwide increase of obesity has resulted in the need to understand body fat 
distribution and its health consequences. Therefore, quantifying body composition in 
humans, particularly adipose tissue is essential to define how an excess of fat is being 
related to health risks (Davies and Cole, 1995). There are several techniques for 
diagnosis of obesity by measuring excess amount of accumulated adipose tissue and 
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identifying its location in whole and regional human body. These techniques include 
anthropometric and imaging techniques (Scafoglieri et al., 2014).  Anthropometric 
techniques, such as BMI, skinfold thickness, waist circumference (WC) and waist 
hip ratio (WHP), have the advantages of being cheap, quick and easy. For this reason 
they are used in most clinical and epidemiological researches that studied obesity and 
its consequence. However, measures such as BMI also have limitations. BMI only 
measures total body weight without providing any data about the actual amount of 
body fat and where it is stored. Other anthropometric techniques (skinfold thickness, 
WC and WHP) are better to measure central obesity (visceral fat) than BMI (WHO, 
2011, Scafoglieri et al., 2014, Chan et al., 2003). Imaging techniques including, but 
not limited, Computerized Tomography (CT) and Magnetic Resonance Imaging 
(MRI) are more accurate than anthropometric measures, providing separate 
measurements for specific fat depots (subcutaneous and visceral fat). However, these 
techniques are expensive and more likely complicated that need skilled and trained 
individuals to work on them. The use of imaging techniques substantially increases 
our understanding of the complex links between the body composition and various 
metabolic disorders and diseases (Lustgarten and Fielding, 2011, Ross, 2003, Smith 
et al., 2001). 
 
Table 1-1: World Health Organization (WHO) classification of 
obesity  
 
 
 
 
 
 
 
 
 
 
Table shows BMI values that classify human body weight and obesity status into 
several categories, adapted from WHO (2000).  
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1.2 Obesity associated metabolic disorders 
1.2.1 Obesity and type 2 diabetes 
Obesity is associated with a wide range of metabolic disorders, including 
hypertension, hyperlipidemia, atherosclerosis and type 2 diabetes (Kahn and Flier, 
2000). The global prevalence of type 2 diabetes has increased during the last decades 
and has been confirmed by the World Health Organization as one of the major 
worldwide health problems (Tack et al., 2012). Type 2 diabetes is also known as 
non-insulin dependent diabetes mellitus (NIDDM) (WHO, 1999). Type 2 diabetes is 
estimated to increase from 171 million cases in 2000 to 377 million in 2030, and the 
highest proportion of type 2 increase will be seen in developing countries (Wild et 
al., 2004). The main reasons for this is due to increased incidence of obesity and a 
sedentary lifestyle with physical inactivity (Barnes, 2012). There are multiple factors 
contributing to the possibility of developing type 2 diabetes, such as having a family 
history of type 2 diabetes (Morris et al., 1989), glucose intolerance (Edelstein et al., 
1997), insulin resistance, previous incidence of gestational diabetes mellitus (Kim et 
al., 2002), obesity ( more specifically in visceral depots) (Wang et al., 2005b), 
physical inactivity (Kriska et al., 2003) and poor diet (particularly high fat diet) 
(Marshall and Bessesen, 2002).  
 
The increase in the worldwide prevalence and severity of obesity is considered to be 
strongly responsible for the pandemic emergence of type 2 diabetes (Yaturu, 2011). 
It has become clear that lifestyle change, in most developed countries, towards 
physical inactivity and nutritional oversupply underlies the emergence of type 2 
diabetes as a health problem in parallel with obesity (Diamond, 2003). Type 2 
diabetes is strongly associated to obesity, particularly abdominal obesity (Wang et 
al., 2005b). Meta-analysis studies demonstrated that the association between these 
two conditions was observed in both genders those have higher BMI and waist 
circumference (Guh et al., 2009). Interestingly, not all obese people have type 2 
diabetes. However, most patients with type 2 diabetes are found to be overweight or 
obese (Daousi et al., 2006). People can tackle and prevent overweight, obesity and 
type 2 diabetes by making change in their sedentary life style habits for example, 
increasing physical activity and reducing over consumption of high energy foods 
(Yaturu, 2011). The major origin for the association between these two health 
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problems is that obesity has the ability to induce inflammation (Lumeng and Saltiel, 
2011a, Hotamisligil, 2006). Indeed, inflammation is considered as a crucial element 
of the aetiology of obesity-related insulin resistance and the development of type 2 
diabetes (Xu et al., 2003, Cancello and Clement, 2006). Moreover, studies in obese 
mice and humans suggest that increased macrophage accumulation in adipose tissue 
during obesity might provide a causative link between inflammation and metabolic 
disorders such as insulin resistance and type 2 diabetes (Cancello and Clement, 2006, 
Weisberg et al., 2003, Xu et al., 2003). 
 
1.2.2 Insulin resistance and type 2 diabetes  
Insulin resistance manifests as an alteration in peripheral insulin target organs from 
insulin sensitive organs to insulin resistant organs (Vollenweider, 2003). Insulin 
resistance is a characteristic feature in type 2 diabetes and obesity plays an important 
pathophysiological role in both health conditions (Vollenweider, 2003). Insulin 
resistance is defined as a disorder in which a normal or elevated level of insulin 
provides insufficient biological responses (Cefalu, 2001), classically this definition 
usually refers to impaired sensitivity to insulin stimulated tissue glucose uptake 
(Reaven, 2004). Insulin resistance is characterized by decreased glucose uptake into 
peripheral tissue (skeletal muscle, adipose tissue and liver) leading to  
hyperinsulinemia, increased  hepatic glucose production, and reduced insulin action 
to inhibit lipolysis in adipose tissue (Schenk et al., 2008). The combination between 
insulin resistance in peripheral tissues and low insulin secretion due to dysfunction in 
β cells in pancreas leads to development type 2 diabetes (Kasuga, 2006). 
 
Insulin is the most efficient hormone that potently stimulates lipogenesis via 
increased glucose uptake in adipocytes by translocation of glucose transporter-4 
(GLUT-4) from the intracellular compartment to the plasma membrane 
(Zimmermann et al., 2009). These effects occur after insulin binds to its receptor at 
the fat cell surface, consequently activating its tyrosine kinase activity (Saltiel and 
Kahn, 2001). Moreover, insulin also influences the expression of lipogenic enzymes 
including pyruvate dehydrogenase, fatty acid synthase and acetyl-CoA carboxylase 
(Assimacopoulos-Jeannet et al., 1995). This may be mediated by the transcription 
factor sterol regulatory element binding protein-1 (SREBP-1) which in turn mediates 
the effects of glucose on lipogenic gene expression (Kersten, 2001). In human 
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adipose tissue, increased expression of lipogenic enzymes are associated with 
improved insulin sensitivity (Roberts et al., 2009). 
 
1.3 Adipose tissue organ 
In 1551, the Swiss naturalist Conrad Gessner became the first person that identified 
adipose tissue in animals (Cannon and Nedergaard, 2008). Adipose tissues can be 
recognized as a significantly specialised loose connective tissue that contains energy 
in the form of fat, particularly triglycerides (TGs). Structurally, adipose tissue is 
classified into two forms: white adipose tissue (WAT) and brown adipose tissue 
(BAT), but each one has specific functions in the human body (Symonds, 2012, 
Cinti, 2001). WAT consists of two main depots, which are subcutaneous and visceral 
depots. The subcutaneous depot is composed from anterior and posterior which 
collectively forming 60-70% of adipose organ while remaining mass of adipose 
organ is visceral depot (Cinti, 2006). Visceral depots are rich with blood supply and 
are more innervated than subcutaneous depots (Wajchenberg, 2000). There are many 
other smaller fat depots in human body including epicardial and intermuscular which 
may provide particular functions related to their neighbouring tissues (Sacks and 
Fain, 2007, Cinti, 2001). On a cellular level, adipocytes are considered as the main 
cellular component, and they are larger than other cells in adipose tissue due to 
stored lipid droplets (Eto et al., 2009). In addition, there are a number of other 
cellular components located in adipose tissue, mainly in stromal-vascular fraction 
(SVF), including endothelial cells, smooth muscle cells, fibroblasts, blood cells, 
preadipocytes and immune cells (Collins et al., 2005).  
 
1.3.1 Forms of Adipose Tissues: 
1.3.1.1 Brown adipose tissues (BAT) 
BAT is prominently different from WAT in several aspects such as anatomical 
distribution, histological appearance and physiological functions (Figure1.1) 
(Trayhurn, 1993, Cinti, 2001). However, both BAT and WAT are able to store 
energy as TGs in droplets through a process termed lipogenesis, and both also release 
stored energy as free fatty acids and glycerol by a process called lipolysis (Lowell 
and Flier, 1997). These metabolic functions are mediated by large number of genes, 
which are highly expressed in both depots of adipose tissues (Himms-Hagen J., 1989, 
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Lowell and Flier, 1997). BAT appears in the human body, particularly in the first 
decade of life. With ageing, BAT gradually disappears and is replaced with WAT 
(Heaton, 1972). BAT which is located in peripheral area such as the interior 
abdominal wall and inter scapular area, are the first to disappear (Heaton, 1972). On 
the other hand, BAT found in deep areas of the body such as areas around the 
kidneys and aorta and in the neck and mediastinum, appears to be more preserved for 
longer time, roughly for eight decades later (Klingenspor and Fromme, 2012). With 
regard to BAT cellular components, brown adipocytes are smaller in size compared 
with white adipocytes, and it has a round nucleus located in the centre of each cell 
(Lowell and Flier, 1997). The triglycerides of the BAT are deposited in multiple lipid 
droplets which are referred to as 'multilocular' (Klingenspor and Fromme, 2012). In 
addition, there are large numbers of mitochondria in the cytoplasm of adipocytes, 
which are distinguished by existence of overcrowded cristae (Lowell and Flier, 
1997). However, the most unique feature of brown adipocytes is their expression of 
uncoupling protein-1 (UCP1-) (Nicholls and Locke, 1984). 
 
Regarding its role, BAT has a thermoregulatory role and is considered as the main 
player for heat production (non-shivering thermogenesis) (Trayhurn, 1993, 
Klingenspor and Fromme, 2012, Smith and Roberts, 1964). Thermogenesis is mainly 
regulated by two effects. Firstly, the release of noradrenalin from the sympathetic 
nerve system (sympathetic activity) that leads to an increase in both BAT hyperplasia 
and biogenesis of mitochondria (Trayhurn P., 1986). The second effect comes from 
UCP-1 which is located in the inner mitochondria membrane, which serves to 
uncouple mitochondrial respiration, by allowing proton translocation mechanism to 
take place in the mitochondria of BAT (Nicholls and Locke, 1984). The expression 
of UCP-1 is in response to either thermogenic stimulus, such as exposure to cold or 
thermogenic inhibitor, such as exposure to warm or hot weather (Himms-Hagen J., 
1989). The importance of BAT in maintaining the energy homeostasis and in the 
modulation of body fat mass has been shown by a number of studies (Trayhurn, 
1993, Cypess and Kahn, 2010). For example, transgenic mice (with reduced BAT) 
exhibited highly developed obesity with glucose intolerance and reduced insulin 
sensitivity (Hamann et al., 1995). Early study has shown that developing obesity in 
rodent models was partly due to impaired thermogenesis in BAT (Himms-Hagen, 
1979).  
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1.3.1.2 White adipose tissues (WAT) 
WAT is a major adipose depot in mammals. WAT consists of mostly mature 
adipocytes which make ~50% of the total cellular component of the tissue (Hausman 
et al., 2001) and constitutes approximately 90% of the tissue volume (Lee et al., 
2012). The another fraction in WAT is stromal vascular fractions (SVF) which 
contains preadipocytes and other cell types such as macrophages, endothelial cells, 
smooth muscle cells, fibroblasts and immune cells (Figure 1.2) (Ouchi et al., 2011, 
Collins et al., 2005).  In human, WAT is distributed in two main depots, the 
subcutaneous (under skin) and intra-abdominal (visceral) adipose tissues 
(Wajchenberg, 2000). White adipocytes are spherical with diameters varying 
between 20-200 µm (Lee et al., 2012). A single large lipid droplet fills most of the 
adipocyte’s intercellular space, thus the cytoplasm and nucleus are compressed in a 
thin area. Moreover, white adipocytes have a small numbers of mitochondria in 
comparison with brown adipocytes (Symonds, 2012). In addition, WAT is not highly 
innervated and vascularized as obvious appeared in BAT counterpart. Each white 
adipocyte can be connected to at least one capillary. The capillary acts as a main 
supplier to a vascular network of WAT (Symonds, 2012, Collins et al., 2005). 
 
Based on an anatomical study, the WAT appearance starts approximately at 14 
weeks of gestation (Kahn, 2012 ). Following this, the first WAT pads appear in the 
head and neck continued by abdominal pads; lastly WAT pad appear in the lower 
limbs (Kahn, 2012 ). Areas of WAT with abundant vascular supply appear to 
develop earlier than those with a low vascular supply (Langin et al., 2009). 
Classically, it is thought that the main function of WAT is to store a large amount of 
fat as energy in the form of TGs, which is important for the regulation of energy 
homeostasis (Korner et al., 2009, Symonds, 2012, Langin et al., 2009). However, 
WAT has recently been recognized to have an endocrine function since WAT 
secretes a variety of proteins, collectively named adipokines, which contribute to the 
regulation of energy homeostasis and insulin sensitivity (Kwon and Pessin, 2013).  
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1.3.2 Other cellular components of Adipose tissue: 
1.3.2.1 Stromal vascular fraction (SVF) 
The subcutaneous fat depot is an abundant source of SVF (Gimble et al., 2011). SVF 
is the second major cellular component in the adipose tissue. SVF contains a large 
pool of preadipocytes that was discovered by Poznanski et al. in 1971 following the 
enzymatic digestion of adipose tissue (Ng et al., 1971). These cells generally appear 
in a fibroblast-like morphology; thus they are indistinguishable from factual 
fibroblasts once they are grown in cell culture (Bourgeois et al., 1983). In addition, 
SVF contains fibroblasts, endothelial cells, vascular cells and  immune cells 
including macrophages, dendritic cells, and T lymphocytes, all involved in a 
complex cross-talk with  cells of adipocyte linage (preadipocytes and adipocytes) 
(Patrick Jr, 2000, Ouchi et al., 2011). Interestingly, SVF also contains unidentified 
stem cells which are differentiated into a range of cell types including adipocytes, 
myocytes, chondrocytes and osteoblasts under optimized cell culture conditions 
(Bunnell et al., 2008, Zuk et al., 2002). The results of in vitro culture encouraged 
researchers to use SVF as source to isolate cells (Koh et al., 2011). 
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Figure 1-1: Histological and cellular appearance of white adipose 
tissue (WAT) and brown adipose tissue (BAT) 
 
 
         
 
 
 
 
 
 
 
 
 
 
The multilocular brown adipocyte is characterized by numerous mitochondria as 
shown in the left half of the figure, while the unilocular white adipocyte has a small 
number of mitochondria as shown in the right half of the figure. 
 
1.3.2.2 Brite cells (beige cells) 
Brite cells are the novel brown adipocytes that appear among WAT, and are often 
called “brite or beige” cells (Giralt and Villarroya, 2013). These cells are closer to 
the cell lineage of white adipocytes, and are derived from precursor cells different 
from those in classical BAT (Petrovic et al., 2010).  Brite cells are the result of a 
process called browning of WAT in which adipocytes are recruited at locations of 
WAT due to a thermogenic stimulus, such as prolonged cold exposure (Giralt and 
Villarroya, 2013). Brite cells can be distinguished from white adipocytes by the 
presence of structural gene markers for classic brown adipocyte including 
Peroxisome proliferator-activated receptor-γ (PPARγ), Peroxisome proliferator-
activated receptor gamma coactivator 1-α (PGC-1α), Cidea and  Elovl3 but lacking 
in both  developmental genes and the myogenic signature that define classical brown 
adipocytes (Petrovic et al., 2009). Similar to white adipocytes, brite cells have an 
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extremely low basal expression of UCP-1; however, they can express high levels of 
UCP-1 as brown adipocyte upon stimulation by cold or pathways that elevate 
intracellular cyclic AMP (cAMP) (Wu et al., 2012).  
 
1.3.3 Development of adipocytes 
In WAT, adipocytes play a central role to regulate energy homeostasis in the whole 
body by storing food energy (Korner et al., 2009, Symonds, 2012, Langin et al., 
2009). When energy intake is higher than energy expenditure, an increase in WAT 
growth occurs, which involves both an increase in the volume of existing adipocytes 
(hypertrophy) and an increase in the number of new adipocytes from precursor 
adipocytes (hyperplasia) (Gregoire et al., 1998). Adipocytes are genetically 
determined to not exceed a certain maximal size; thus adipose tissue has another 
alternative mechanism to regenerate adipocytes by de novo adipogenesis from 
adipocyte precursor cells, which is called hyperplasia (Spalding et al., 2008).  Sine 
Green and his colleagues established the first adipose cell culture system (3T3-L1 
derived from murine), there are large number of studies using adipocyte precursors 
as a model for the study of cell differentiation (Green and Kehinde, 1975). 
Differentiation, also known as adipogenesis, is the transition process from 
undifferentiated cell state (fibroblast-like preadipocytes) into mature adipocytes 
(round lipid-filled fat cells) (Butterwith, 1994). 
 
There are many cellular events that occur in the differentiation process such as 
growth arrest, clonal expansion, early differentiation, and terminal differentiation 
(Hausman et al., 2001). The main two phases of differentiation in the intermediates 
between multipotent mesenchymal precursors and mature adipocytes, include 
determination and terminal differentiation (Rosen and MacDougald, 2006a). In 
determination phase pluripotent stromal precursors commit themselves to adipocyte 
lineages which become preadipocytes but they lose their potential to convert to other 
cell types (Hansen et al., 1999). In terminal differentiation, the preadipocytes 
differentiate into mature adipocytes, accompanied by a change in morphology from 
fibroblast-like structures to the unilocular appearance of the mature fat cell. Terminal 
differentiation offers preadipocytes with mechanisms related to lipid transport and 
synthesis, insulin sensitivity, and the secretion of adipocyte-specific proteins (Hansen 
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et al., 1999). These changes are coupled with alterations in the surrounding the ECM 
and cytoskeleton (Hansen et al., 1999).   
 
 
Figure 1-2: Structure and composition of white adipose tissue 
(WAT) 
 
 
        
 
 
 
Edited_version 
 
 
 
 
 
 
 
 
      
This figure shows the cellular heterogeneity of WAT (mature adipocytes, 
preadipocytes, fibroblasts, blood vessel components and immune cells), adapted 
from Ouchi, Parker et al. (2011). 
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Differentiation has been found to be regulated by a number of environmental, 
genetic, hormonal, and pharmacological factors as well as positive energy balance 
(Sethi and Vidal-Puig, 2007). The above factors act modulates specific receptors to 
transduce external growth and differentiation signals through a cascade of 
intracellular events (Gregoire et al., 1998). These regulators have previously been 
demonstrated to affect differentiation in in vitro culture experiments using several 
cell models, such as preadipocyte cell lines derived from murine (3T3- L1 and 3T3-
F442A), human primary preadipocytes, primary stromal-vascular fraction, 
embryonic fibroblasts and bone marrow stromal cells, all of which can be 
differentiated into adipocytes under optimised cell culture conditions (Butterwith, 
1994, Gregoire et al., 1998).  
 
Genetic transcription factors, including members of the PPAR families and the 
CCAAT/enhancer-binding protein (C/EBP), play a key role in adipogenesis and 
maintenance of adipocyte phenotypes (Tontonoz et al., 1995). PPARγ is expressed in 
two isoforms, PPARγ1 and PPARγ2 (Fajas et al., 1997, Farmer, 2006). The 
expression of PPARγ1 is detectable in many tissues, whereas PPARγ2 is expressed 
exclusively in adipose tissue (Farmer, 2006). The function of PPARγ is to induce 
expression of a group of target genes related to lipid and glucose metabolism, 
secretion of adipokines and mitochondrial biogenesis (De Pauw et al., 2009). The 
C/EBPs (α, β and δ) are induced during adipocyte differentiation but the expression 
of the three members is different in mRNA levels (Cao et al., 1991). The early 
expression of two members of the C/EBP family including C/EBPβ and C/EBPδ 
stimulates the expression of C/EBPα and PPARγ during adipocyte differentiation 
(Cao et al., 1991). A study using C/EBPα-deficient mice showed a reduced adipocyte 
ability to store lipid and reduced adipose mass (Wang et al., 1995). Moreover, both 
C/EPBα and PPARγ positively regulate each other and then activate adipocyte 
protein 2 (aP2) factor which is involved in lipid metabolism, leading to lipogenic 
capacity of the cells (Gregoire et al., 1998).  
 
1.4 Metabolism of adipocytes  
In mammals, the major physiological role of WAT is to act as a metabolic buffering 
system for storing energy as TGs and releasing energy in the form of glycerol and 
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FFAs when needed by other tissues (Frayn, 2002). This role is in particular regulated 
by two major metabolic processes known as lipogensis (fat storing/synthesis) and 
lipolysis (fat breakdown/release) both of which regulate whole-body metabolism 
(Langin, 2006a).    
 
1.4.1 Lipogenesis 
Lipogenesis is the anabolic process for de novo synthesis of fat from glucose or other 
substrate (Lafontan, 2008). The process occurs through two physiological steps 
which are FAs synthesis followed by TGs synthesis in WAT particularly in 
adipocytes the postprandial period which  then stored in cytoplasmic inclusions 
called lipid droplets (Martin and Parton, 2006). However, lipogenesis can mainly 
take place in the liver (Kersten, 2001). Fat synthesis is mediated by many different 
factors including nutritional, hormonal and transcriptions factors (Kersten, 2001). 
For example, consumption of high carbohydrate food leads to stimulated lipogenesis 
whereas consumption of polyunsaturated fatty acids inhabits lipogenesis (Jump et al., 
1994). Fat can either be synthesized de novo from glucose or be recycled from the 
excess circulating FFAs; glucose also increases lipogenesis by stimulating the 
pancreas to release insulin.  
 
In mammalian cells, lipid droplets contain a neutral lipid (TGs or cholesterol esters) 
which is enclosed by a phospholipid monolayer and associated proteins (Martin and 
Parton, 2006). One of these proteins is PAT-domain protein (Perilipin/APRP/TIP47) 
which is involved in stabilizing TGs' storage in adipocytes (Martin and Parton, 
2006).  There are also trafficking proteins such as Rab GTPase proteins which 
participate in the intracellular trafficking and storage of lipids in lipid droplets 
(Martin and Parton, 2006).    
 
During lipogenesis adipocytes release lipoprotein lipase (LPL), which acts on the 
surface of endothelial cells in the WAT where it hydrolyses the lipoprotein bound 
TGs to FFAs (Abumrad et al., 1999). FFAs subsequently are taken up the adipocyte 
by both fatty acid transporter proteins (FATPs) (Abumrad et al., 1999) and by 
passive diffusion (Hamilton and Kamp, 1999). Inside the adipocyte, FAs are 
esterified into TGs in the endoplasmic reticulum (ER) and stored in the lipid droplet, 
16 
 
and become chaperoned by aP2 that functions to solubilize and transport FAs via the 
aqueous cellular environment (Thompson et al., 2009).   
   
1.4.2 Lipolysis 
Lipolysis is the catabolic process for hydrolysing stored TGs in adipocytes into FFAs 
and glycerol in times of energy deprivation, when energy is required by other tissues 
such as muscle, heart and liver (Langin, 2006b). Lipolysis is a highly regulated 
process which is stimulated by catecholamines and inhibited by insulin (Duncan et 
al., 2007). During lipolysis, catecholamine mediates stimulation of β-adrenergic 
receptors (β1, β2 and β3) on the cell surface of adipocyte, which in turn activates 
adenylate cyclase (Lafontan, 2008). Therefore, the intracellular cAMP level is 
increased leading to the activation of cAMP-dependent protein kinase A (PKA) 
(Duncan et al., 2007). PKA activates two protein targets including hormone-sensitive 
lipase (HSL) and perilipin and consequently, TGs are released from adipocytes by 
the action of the two main enzymes which are adipose triglycerides lipase (ATGL) 
and HSL (Duncan et al., 2007). PKA stimulates perilipin activation by 
phosphorylation of at least 5 different serine residues (Carmen and Víctor, 2006). 
Perilipin is required for translocation of HSL from the cytosol compartment to the 
lipid droplet in adipocytes; this translocation is essential to the admission of HSL 
into lipid droplet where HSL catalyzes the hydrolysis of TGs (Holm, 2003).  For a 
long period, HSL was thought to be the only TGs lipase that could hydrolyse TGs 
but in 2004, the ATGL was discovered to be an additional TGs lipase with specific 
activity for TG hydrolysis (Zimmermann et al., 2004). ATGL acts as TGs hydrolyse 
in WAT and is responsible for the first step of the lipolytic activity and this activity 
is increased in the absence of HSL (Zimmermann et al., 2004). Lipolysis can be 
supressed by insulin through the activation of its downstream kinase cascad  
(PI3K/Akt) leading to the reduction of cAMP levels and thus reduced PKA activity 
(Choi et al., 2010).  
 
1.5 Function of WAT 
The traditional view of the role of WAT was limited to lipid storage as a fuel reserve 
(Trayhurn and Beattie, 2001). In addition to fuel storage, WAT can act as a thermal 
insulator by helping to reduce heat loss through the skin such as in marine mammals 
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(seals and whales) (Trayhurn and Beattie, 2001). It also has a protective function by 
providing mechanical support (padding) and protection around some of the major 
organs (Trayhurn and Wood, 2004). Furthermore, WAT is involved in many cellular 
and molecular processes such as immune response, lipid metabolism, blood pressure 
control, haemostasis, appetite and energy balance, inflammation and insulin 
sensitivity (Trayhurn and Wood, 2004).  
 
WAT is also as an active endocrine organ (Figure 1.3) (Mohamed-Ali et al., 1998). 
In 1987, Siiteri discovered that adipose tissue played an endocrine role especially 
once it produced steroid hormone (Siiteri, 1987). Subsequently in WAT, the 
discovery of leptin expression and release by adipocytes (Zhang et al., 1994) and 
other adipose-derived factors, including cytokines, chemokines, enzymes and 
hormones and growth factors, supports the endocrine role of WAT (Fruhbeck, 2008). 
In addition, FFAs which are considered as the major products are quantitatively 
released from WAT by lipolysis (Trayhurn, 2007). It is reported that raised 
circulating levels of FFA and TGs due to obesity contribute to insulin resistance and 
other metabolic disorders (Despres et al., 1990, Reaven, 1996, Boden, 2006). 
Therefore, the connection between obesity and type 2 diabetes has promoted research 
on the endocrine link between lipid and glucose homeostasis in adipose tissue (Kahn 
and Flier, 2000). Another major product that is directly produced from adipocytes 
termed adipokines are leptin, adiponectin, cytokines, chemokines and growth factors 
(Trayhurn and Wood, 2004). Currently, a large number of adipokines have been 
identified (Jung and Choi, 2014) that are produced by white adipocytes and released 
into circulation to act in an autocrine or paracrine manner in adipose tissue and also 
in endocrine manner in other insulin sensitive tissue (muscle and liver) to modulate 
energy metabolism, insulin sensitivity, immune response and inflammation (Gong et 
al., 2003, Trayhurn and Wood, 2004).    
 
In WAT, the endocrine role is in response to altered physiologic, metabolic and 
pathologic states, particularly due to the expansion of adipose tissue which is 
characterized by low grade inflammation and increase in a wide range of pro-
inflammatory factors probably due to an increase in the accumulation of 
macrophages during obesity (Hotamisligil, 2003, Weisberg et al., 2003). In addition, 
macrophages-derived factors have been found to potently stimulate the production of 
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pro-inflammatory cytokines and chemokines by human preadipocytes and adipocytes 
(Gao and Bing, 2011, Flower et al., 2003). These pro-inflammatory cytokines and 
chemokines are significantly increased in obesity and considered as potent inducers 
for insulin resistance and the development of type 2 diabetes (Pradhan et al., 2001, 
Festa et al., 2002, Trayhurn, 2007). Consequently, the increased pro-inflammatory 
factors including TNF-α, IL-1β, IL-6 and IL-8, C reactive proteins, CMP-1, 
plasminogen inhibitor activator (PIA-1) and acute phase proteins contributes in the 
obese state to a range of metabolic disorders such as insulin resistance and type 2 
diabetes (Jung and Choi, 2014).   
 
 
Figure 1-3: WAT as an endocrine organ 
 
 
 
 
Figure shows that white adipocytes-secreted factors can play various roles in the 
whole body homeostasis. 
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1.6 The insulin signalling pathway in adipose tissue 
It was well recognized that insulin signalling is initiated by a complex and highly 
integrated network that controls specialized cell functions (White, 1997, Avruch, 
1998, Taniguchi et al., 2006). The main trigger for this signalling pathway starts once 
insulin is bound to its receptor (insulin receptor). There are two major signalling 
pathways which are known: the metabolic and mitogenic pathways. The metabolic 
pathway is activated through phosphatidylinositol 3-kinase (PI3K) with the 
downstream effector being the protein kinase B (PKB) or Akt pathway. The 
metabolic pathway is involved in most of the metabolic actions of insulin. The 
mitogenic pathway occurs throughout the Ras–mitogen-activated protein kinase 
(MAPK) pathway, which regulates the expression of some genes and collaborates 
with the PI3K/Akt pathway to control cell growth and differentiation (Saltiel and 
Kahn, 2001, Avruch, 1998).  
 
1.6.1 Insulin action in adipose tissue 
Since the discovery of insulin, considerable scientific studies have attempted to gain 
understanding of the mechanism of insulin action by focusing on the metabolic 
changes that occur during insulin stimulation (White, 1997). Insulin is an anabolic 
hormone, secreted from the pancreatic β-cells. At a cellular level, insulin has 
pleiotropic effects to control numerous metabolic processes (Saltiel and Pessin, 
2002). Insulin is the most important hormone involved in whole body homeostasis, 
in particular glucose homeostasis, by increasing peripheral tissue glucose uptake and 
decreasing hepatic glucose production (Saltiel and Kahn, 2001, Gual and Tanti, 
2005). Interestingly, glucose uptake only occurs in a small proportion in adipose 
tissue (10-15%) in comparison to skeletal muscle that takes up to 75% of whole 
circulating glucose (Saltiel and Kahn, 2001, DeFronzo et al., 1992). However, 
experimental study using murine model with a knockout of the insulin-sensitive 
glucose transporter protein-4 (GLUT-4) in adipose tissue whereas GLUT-4 
expression was preserved in muscle, led to hyper-insulinaemia and impaired glucose 
tolerance, suggesting that decreased GLUT-4 expression in adipose tissue is 
important in inducing insulin resistance in muscle and liver (Abel et al., 2001). Other 
actions of insulin include promoting FFAs uptake into adipocytes (lipogenesis) and 
inhibiting lipolysis (Saltiel and Kahn, 2001). Additionally, insulin is also considered 
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as a key regulator for adipose tissue development and differentiation by inducing 
gene expression of several fat-specific transcription factors in preadipocytes, such as 
SREBP-1 and PPARγ during preadipocytes differentiation (Le Lay et al., 2002, 
Vidal-Puig et al., 1997). 
 
1.6.2 The insulin receptor and its role in insulin signalling  
The insulin receptor (IR) is abundant in all mammalian tissues but the highest 
expression has been observed in the major metabolic organs such as the liver and 
adipose tissue (adipocytes) (White, 1997). Skeletal muscle has a relatively low level 
of IR expression (Caro et al., 1987). In adipose tissue, the IR is localised in caveolae 
or flask-like invaginations of the plasma membrane (Karlsson et al., 2004, 
Gustavsson et al., 1999). The IR is a transmembrane glycoprotein which is composed 
of two extracellular α-subunits (130 kDa), and two intracellular β-subunits (96 kDa). 
These two parts of IR are linked to each other by disulphide bonds. The α-subunits 
are found outside of the cell and have insulin binding sites whereas β-subunits are 
located inside the cell and contain tyrosine kinase residues (Hubbard et al., 1993, 
Saltiel and Kahn, 2001, Cheatham and Kahn, 1995, Gual and Tanti, 2005). The IR is 
involved in several cellular functions including growth, differentiation, apoptosis and 
transformation (Lopaczynski, 1998). Insulin signalling is directly triggered and 
activated after insulin binds to the IR and it probably causes a conformational change 
by bringing the two α-subunits closer together; this allows Adenosine triphosphate 
(ATP) to bind to the intracellular β-subunit which in turn activates receptor leading 
to its auto-phosphorylation (Hubbard et al., 1993, Kido et al., 2001). Subsequently, 
auto-phosphorylation of IR leads to an increase in its tyrosine kinase activity by 
recruiting and phosphorylating intracellular docking proteins (IR’s substrate), 
including insulin receptor substrate-1 (IRS-1), insulin receptor substrate-2 (IRS-2), 
Src homology collagen (Shc) and adaptor protein with a pleckstrin homology domain 
(PH) and Src Homology 2 (SH2) domain (APS) (White, 1997, White and Kahn, 
1994). As a result, these phosphorylated molecules are able to activate different 
signalling pathways such as metabolic and mitogenic signalling pathways (Gual and 
Tanti, 2005, Saltiel and Kahn, 2001). Both IR and IRS have been known as “critical 
nodes” due to their crucial role in the insulin signalling pathway (Taniguchi et al., 
2006).   
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1.6.3 The insulin receptor substrates (IRSs) 
The family of IRSs has nine protein members of which IRS-1 and IRS-2, in both the 
humans and mice genome, are widely expressed in insulin target tissue (White, 
2002). Studies using IRS1 and IRS2 knockout mice have found that IRS1 may play a 
predominate role in insulin resistance in adipocytes and skeletal muscle whereas 
IRS-2 may be more important in hepatic cells (Rondinone et al., 1997, Kido et al., 
2000). IRS-3 has only been expressed in mice and is largely restricted to adipose 
tissue but it might not be expressed in human tissue (White, 2002). Considering the 
role of IRS1-4 isomers, they are mainly expressed in thymus and hypothalamus and 
for completing insulin signal transduction (White, 1997). IRS-4 deficient mice have 
mild negative effects in growth and glucose homeostasis (Fantin et al., 2000).  
 
The IRS family has low intrinsic catalytic activities but they have multiple 
interaction domains and phosphorylation motifs as part of their composition (White, 
2002), characterized by the existence of N-terminal PH domain adjacent to a 
phosphotyrosine-binding (PTB) domain, followed by a C-terminal tail that contains 
several tyrosine and serine phosphorylation sites (Copps and White, 2012). 
 
Regarding IRS-1, the N-terminal in PH domain helps to anchor the protein to the 
membrane close to the IR. Subsequently, PTB acts as a binding site for the 
phosphorylated tyrosine in the juxta membrane NPXY motif of the IR (Keller et al., 
1993). IRS1 is known as a docking protein because C-terminal of the IRS proteins 
contain multiple tyrosine phosphorylation sites that link the activated IR to other 
signalling proteins (Sun et al., 1991). These signalling proteins contain SH2 domains 
such as p85α regulatory subunit of the PI3K, Grb2, and SHP-2, which propagate and 
regulate insulin signalling within the cell. Activation of IRS-1 through IR leads to 
generation of over 20 potential tyrosine phosphorylation binding sites for SH2 
domain proteins (Myers and White, 1993, Sun et al., 1991). These binding sites 
include six in YMXM motifs, three in YXXM motifs, and with remaining sites found 
in several hydrophobic motifs (Myers and White, 1993). The PI3K p85 binds to 
phosphorylated IRS1 on YMXM motifs in SH2 domain (Backer et al., 1992). This 
binding site is very important for the metabolic signalling pathway which is 
responsible for growth and metabolism in mammalian cells (Cantley et al., 1991). 
The Grb2 also binds to IRS1 but on a YVNI motif and the binding site is also 
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essential for the metabolic signalling pathway (Lowenstein et al., 1992). Besides 
several tyrosine phosphorylation residues on IRS-1, there are 50 potential 
serine/threonine phosphorylation sites on IRS-1 such as Ser612 and Ser632 which 
are found near to the tyrosine residues that are involved in the binding of PI3K (Sesti 
et al., 2001, White, 2002). All tyrosine and serine residues are directly activated 
through IR by insulin (Gual and Tanti, 2005). Tyrosine phosphorylation residues of 
IRS-1 positively regulate and further propagate insulin signalling within the cells; 
however, serine/threonine phosphorylation of IRS may work mainly as important 
regulators with dual role either to reduce or enhance insulin signalling in response to 
feedbacks and crosstalk with other signalling pathways (Gual and Tanti, 2005). 
Previous animal studies have found that a group of serine phosphorylation residues at 
629 and 1223 on IRS-1 have been shown to enhance phosphorylation of tyrosine 
residues in the insulin signalling pathway (Luo et al., 2007). 
 
Previous studies have shown that phosphorylation of serine residues on IRS-1 also 
have negative effect on insulin signalling. For example, phosphorylation of Ser307 
significantly inhibited the binding between IRS1 and the IR especially when IRS-1 
associated with JNK (Aguirre et al., 2000), whereas Ser612 phosphorylation 
inhibited tyrosine residues close to the PI3K binding with IRS-1; PI3K activation is 
needed for insulin-stimulated glucose uptake (Gual and Tanti, 2005). In addition to 
insulin, there are wide ranges of agents that have the ability to stimulate serine 
phosphorylation on IRS-1. These agents include FFAs (Shulman, 2000), TNF-α 
(Kanety et al., 1995), amino acids (Tremblay and Marette, 2001), cellular stress and 
hyperinsulinemia (Schmitz‐Peiffer and Whitehead, 2003).  
 
1.6.4 The metabolic signalling pathway 
Activation IR happens through phosphating multiple tyrosine residues within the 
receptor β-subunits (Cheatham and Kahn, 1995). Subsequently, IR activation 
generates other docking sites of intracellular proteins including the IRS proteins 
(IRS-1 and IRS-2) which signal to both metabolic and mitogenic pathways (Laviola 
et al., 2006). The metabolic signalling starts after IRS proteins, particularly IRS-1, 
activate SH-2 domains with other several regulatory proteins which identify the 
specific downstream effectors (Sun et al., 1991). Among these, the major 
downstream effector seems to be PI3K which has a regulatory subunit (p85) and 
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catalytic subunit (p110). PI3K p85 is activated by binding to phosphorylated YMXM 
motifs in IRS-1 (Sun et al., 1993). PI3K p110 then catalyses the phosphorylation of 
phosphatidylinositol 4,5-bisphosphate (PIP2) into phosphatidylinositol 3, 4, 5-
trisphosphate (PIP3). Subsequently, PIP3 regulates the activation of phosphoinositide 
dependent kinase (PDK), leading to the activation of Akt/PKB (Song et al., 2005).  
 
Phosphorylation of Akt at both Ser473 and Thr308 is required to allow the kinase 
reach its full activity (Sarbassov et al., 2005), which in turn regulates cell growth, 
cell survival, differentiation and glucose uptake (Whiteman, Cho et al. 2002). 
Following Akt activation, phosphorylation was occurred at Ser9 leading to 
phosphorylate glycogen synthase kinase-3 (GSK-3), resulted in glycogen synthesis 
(Maedler et al., 2011). Akt has many substrates such as AS160 which is known to 
regulate GLUT-4 translocation in adipocytes (Thong et al., 2007). GLUT-4 is then 
translocated from the intra-cellular compartment to the plasma membrane of the cell 
mediating glucose uptake (Watson and Pessin, 2001) (Figure 1.4). 
 
1.6.5 The mitogenic signalling pathway  
In mammalian cells, mitogen-activated protein kinases (MAPKs) belong to a large 
family of serine/threonine kinases, including the ERK1/2, p38 and JNK.  MAPKs are 
common contributors to the intracellular signal transduction that starts from the cell 
surface receptors and reaches to the nucleus (Lewis et al., 1998). The mitogenic 
signalling pathway or MAPK cascade is a highly integrated network, and has a 
central role in immune-induced inflammatory responses (Hommes et al., 2003). 
Moreover, the MAPK pathway is involved in many aspect of specialised cell 
functions including cell proliferation, cell differentiation and cell death (Kyriakis and 
Avruch, 2001) (Figure 1.5). 
 
As part of the insulin signalling network in adipocytes, the mitogenic signalling 
pathway (MAPK cascade) is mainly initiated by insulin that is bound to its receptor 
and causes enhanced tyrosine kinase auto-phosphorylation, creating docking sites for 
prtoeins such as IRS and Shc proteins for signal transducers and adapters (Parpal et 
al., 2001, Stenkula et al., 2004). The adaptor molecules such as Grb2 was recruited to 
Shc and/or IRS-1 after bound to the guanine nucleotide exchange protein son of 
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sevenless (SOS) (Pawson and Scott, 1997, Li et al., 1993). The SOS catalyses GDP 
into GTP then binds to Ras; the activated Ras-GTP binds to its downstream effector 
which is protein kinase Raf (Jelinek et al., 1996). This then mediates the 
phosphorylation of the MAPK cascade and this signalling pathway is  attached to 
mitogenic effects of insulin (Pelicci et al., 1992) leading to the phosphorylation of 
the extracellular signal regulated kinases (ERK1/2) (Avruch et al., 2001).  ERK 
activation is linked to pro-survival signals in the cells (Chang and Karin, 2001). 
Moreover, the ERK pathway regulates gene transcription (Pelicci et al., 1992) and 
stimulates preadipocytes proliferation through growth factors (Boney et al., 2000).  
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Figure 1-4: The metabolic insulin signalling pathway 
 
 
Figure shows that the insulin signals from the insulin receptor are transmitted 
through the insulin receptor substrate (IRS)-1. The phosphorylation of IRS-1 
activates PI3kinase. The activation downstream effectors of PI3K, such as protein 
kinase B (PKB or Akt), leads to glucose transporter-4 (GLUT-4) translocation to the 
plasma membrane and subsequent glucose uptake.  
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Figure 1-5: The mitogenic insulin signalling pathway 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure shows that the insulin signals from the insulin receptor are transmitted 
through the adaptor molecules such as Grb2 was recruited to Shc and/or IRS-1 after 
bound to the SOS.  The SOS catalyses GDP into GTP then binds to Ras. The 
downstream effector which is protein kinase Raf which mediates the phosphorylation 
of the MAPK cascade leading to the phosphorylation of the extracellular signal 
regulated kinases (ERK1/2).   
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1.7 Dysfunction of adipose tissue in obesity:  
1.7.1 Adipose tissue storage dysfunction  
Although, adipose tissue only represents approximately 10% of glucose disposal 
from the whole body compared with muscle and liver which represent 60% and 30% 
of glucose uptake respectively (Smith, 2002), adipose tissue has been considered as 
an intrinsic inducer to initiate insulin resistance in muscle and hepatic tissue (Xu et 
al., 2003, Cancello and Clement, 2006). Functionally, increased and expanded 
adipose tissue mass, (either by hyperplasia or hypertrophy) results in increased 
storage capacity for lipids (Jo et al., 2009). However, in the obese state the lipid 
storage capacity of adipose tissue is reduced due to dysfunctional cells 
(hypertrophied adipocyte) (Le Lay et al., 2001). Thus, excess energy due to chronic 
nutritional overload may not be properly stored by the expansion of the adipose 
tissue, consequently inducing insulin resistance (Danforth, 2000). Furthermore, 
excess (triglycerides) TGs stored in muscle and liver tissues (as ectopic fat) 
contribute to  the accumulation of various metabolic products which over time impair 
insulin action in both tissues, leading to insulin resistance by inhibiting insulin-
stimulated glucose uptake and reducing glycogen synthesis (Lewis and Steiner, 1996, 
McGarry, 2002). Interestingly, ectopic lipid accumulation, particularly in the liver, is 
reduced with either improving lifestyle or drug-induced improvement of insulin 
sensitivity (Lettner and Roden, 2008).  
 
1.7.2 The role of macrophages infiltration 
As previously mentioned, adipose tissue expansion is a normal cellular process to 
help maintain healthy adipose tissue function, and this process relies on the capacity 
of preadipocytes to differentiate into new adipocytes (adipogenesis). However, in 
obesity either a decrease in preadipocyte number or their capacity to differentiate, in 
the presence of chronic positive energy balance due to energy intake exceeding 
energy expenditure, leads to expand adipose tissue by increasing adipocyte size 
(hypertrophied adipocytes) (Gesta et al., 2007). 
 
In obese adipose tissue, hypertrophied adipocytes endure molecular and cellular 
changes which influences systemic metabolism (Greenberg and Obin, 2006). First, 
an increase circulating FFAs and glycerol from adipocytes in obese individuals is 
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observed compared to lean individuals (Horowitz and Klein, 2000). Moreover, 
elevated FFAs are positively linked to inducing insulin resistance in insulin target 
tissues (Shulman, 2000). Hypertrophied adipocyte is also associated with an increase 
in release pro-inflammatory adipokines such as leptin, TNF-α, IL-6 and IL-1β but a 
decrease in adiponectin release (Gutierrez et al., 2009). There are other alterations in 
companion with adipocyte hypertrophy such as rarefaction of vasculature and neural 
function and structure in adipose tissue (Coppack, 2005). For example, capillary 
diffusion capacity for glycerol is reduced in obesity (Coppack et al., 2005). 
 
One fundamental cause for the increased release of FFAs is probably due to the 
impairment of insulin action such as to suppress lipolysis (Sorisky, 1999, Jensen et 
al., 1989). A second cause could be due to changes in perilipin expression which has 
protective role against natural enzymes that hydrolysis lipid droplet, even in obese 
individuals whose hypertrophied adipocyte, perilipin inhibiting lipases from 
hydrolysing triacylglycerol to facilitate the release of FFAs (Wang et al., 2003, 
Zhang et al., 2003). Consequently, this causes a cluster of metabolic disorders, 
including dyslipidaemia, increased hepatic glucose production and impaired insulin 
stimulated peripheral tissue glucose uptake (Despres et al., 1990, Reaven, 1996, 
Boden, 2006). One of the most crucial change which occurs in adipose tissue during 
obesity is due to mononuclear cells (such as monocytes and macrophages) 
infiltration. Previous studies in obese mice and humans have found that macrophage 
infiltration is increased in both species and macrophages infiltration is proportionally 
associated with BMI and to hypertrophic adipocytes (Weisberg et al., 2003, Wellen 
and Hotamisligil, 2003).   
 
1.7.3 The mechanisms of macrophage infiltration in adipose tissue in obesity 
Factors which induce infiltration and activation of macrophages in WAT are most 
likely multifactorial. Mechanical alterations of hypertrophied adipocytes may link 
with consequences, including altered adipokine secretion, local adipose hypoxia and 
adipocyte death together with alterations in paracrine, autocrine and endocrine 
signals which are considered as potential factors leading to macrophage infiltration 
(Bourlier and Bouloumié, 2009, Cancello and Clement, 2006).  
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1.7.3.1 Alterations of adipokine production 
The size of the adipocyte is considered as a key factor of the alteration in producing 
several adipokines. Leptin, one of the major adipokines, is increased in obesity while 
it can also be produced by preadipocytes after stimulation with cytokines (Simons et 
al., 2007). Leptin has direct effects on endothelial cells through increasing of 
oxidative stress, activation of the NF-kB pathway, and increased expression of 
chemokines and adhesion molecules, which may induce macrophage infiltration in 
adipose tissue (Curat et al., 2004, Bouloumie et al., 1999). Furthermore, increased 
release of numerous chemoattractant chemokines such as MCP-1 and IL-8 from the 
expanded WAT markedly increased infiltration of monocytes which differentiated 
later into macrophages and eosinophils in WAT (Christiansen et al., 2005). Increased 
infiltration of macrophages and other immune cells in adipose tissue may constitute 
the major sources of adipose-derived pro-inflammatory factors, leading to a low 
grade of inflammation (Lumeng et al., 2007d, Weisberg et al., 2003).  
 
1.7.3.2 Cell death  
In addition, hypertrophied adipocyte in both obese mice and humans leads to 
increased cell death, a major contributor implicated in infiltration of macrophages in 
obese adipose tissue (Cinti et al., 2005). Cinti and Mitchell reported that over 90% of 
macrophages located in WAT of obese mice and humans formed crown-like 
structures (CLS) that envelopes and ingests the pool of dead or dying adipocytes and 
its cytotoxic residue lipid droplet (Cinti et al., 2005). The CLS of macrophages acts 
as scavenging to remove adipocyte debris due to necrotic cell death; this action is 
considered as a beneficial and essential process in physiology (Cinti et al., 2005). 
During necrosis adipocyte contents are released into the extracellular space which 
induces host inflammatory response (Rock and Kono, 2008). The clearance of dead 
adipocytes possibly enhances the activation of pro-inflammatory macrophages 
(Strissel et al., 2007). Therefore, adipocyte death has potentially important effects for 
the development of obesity-related inflammation.  
 
1.7.3.3 Hypoxia 
Local hypoxia (reduced tissue oxygenation) in obese adipose tissue may play a major 
role in macrophage infiltration (Bourlier and Bouloumié, 2009). Hypoxia causes 
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adipocyte death which has been suggested to increase macrophage infiltration into 
adipose tissue. This is supported by findings that macrophages are located around 
dead adipocytes formed CLS (Cinti et al., 2005).  In obese adipose tissue of human, 
there was an increase in expression levels of hypoxia-inducible factor-1α (HIF-1α) 
(Hosogai et al., 2007), leading to induce fibrotic program which is characterized with 
a abundantly expressed secreted protein acidic and rich in cysteine (SPARC), 
profibrotic protein, which is linked to obesity induced insulin resistance (Kos and 
Wilding, 2010). However, expression levels of HIF-1α were decreased by weight 
loss (Cancello et al., 2005). In preadipocytes and adipocytes, leptin gene expression 
is stimulated by hypoxia and HIF-1 α thus leptin is considered as a hypoxia-sensitive 
gene (Grosfeld et al., 2002, Wang et al., 2008). Previous studies using several obese 
mouse models including Lep ob/ob, DIO and KKAy have demonstrated that hypoxia 
took places in obese adipose tissue (Hosogai et al., 2007, Ye et al., 2007). Hypoxia is 
also considered as a determinant factor that might connect obesity with altered 
adipokine production (Trayhurn et al., 2008). According to in vitro studies using 
different models of cultured adipocytes showed that expression levels of adiponectin 
were reduced by hypoxia whereas expression levels of pro-inflammatory factors, 
including, TNF-α, IL-6, IL-1, MCP-1 and PAI-1, were increased in parallel with 
hypoxia response genes (HIF-1α, glucose transporter 1, Vascular endothelial growth 
factor (VEGF)) (Wang et al., 2007, Hosogai et al., 2007). Alteration in adipokine 
production, in particular change in pro-inflammatory cytokine production under 
hypoxic conditions, is as a sign for responding to hypoxia (Lewis et al., 1999, Oda et 
al., 2006). Hypoxia has also been found to evoke cell necrosis in murine 3T3-L1 
adipocytes (Ye, 2009). Collectively, hypoxia is involved in macrophage recruitment 
in obese rodents through several initiating factors including increased leptin 
production, adipocyte death and upregulation of pro-inflammatory genes. However, 
recent research has reported that obese insulin resistant subjects had significantly 
higher adipose tissue oxygen partial pressure (AT PO2) compared to lean insulin 
sensitive individuals (Goossens and Blaak, 2015). Further clinical studies are 
required to clarify whether hypoxia is present in adipose tissue in obese humans. 
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1.7.4 The consequence of macrophage infiltration: alteration of adipokine release 
and insulin sensitivity  
The accumulation of macrophages in obese adipose tissue contributes to increased 
systemic concentrations of the pro-inflammatory cytokines/chemokines (Cancello 
and Clement, 2006). Interestingly, similarities in the expression of pro-inflammatory 
gene profiles between macrophages and mature adipocytes and their precursors have 
been reported, indicating that both preadipocytes and adipocytes could have some 
macrophage properties (Charrière et al., 2003, Cancello and Clement, 2006). In 
addition, adipokines including pro-inflammatory factors, growth factors and other 
proteins are very important in the regulation of lipid metabolism, glucose 
homeostasis, blood pressure, vascular haemostasis and angiogenesis (Trayhurn, 
2007). The altered production of adipokines in obese adipose tissue, especially those 
with pro-inflammatory properties, is associated proportionally with the degree of 
obesity (Weisberg et al., 2003, Maury and Brichard, 2010). However, some 
adipokines with anti-inflammatory or insulin-sensitizing properties such as 
adiponectin are reduced in obese subjects (Arita, 2012). The dysregulation of 
adipokine production is implicated to induce a chronic low grade inflammation status 
in adipose tissue that which contributes to obesity associated complications such as 
triglyceridemia and insulin resistance (Weisberg et al., 2003, Constant et al., 2006, 
Constant et al., 2008). Studies in mouse and humans have shown that the 
macrophage crosstalk with adipocytes can lead to the alteration of adipocyte 
function, such as inhibition of preadipocyte differentiation (Constant et al., 2006, 
Gao et al., 2010), stimulating inflammatory responses (Lacasa et al., 2007) and 
reducing insulin sensitivity (Lumeng et al., 2007c). Therefore, identification of the 
key factors that mediate the effect of macrophages on adipose cells is important as it 
may provide potential therapeutic targets for obesity-related insulin resistance 
(Figure 1.6). 
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Figure 1-6: Adipose tissue remodelling in obesity 
 
 
 
 
 
 
 
 
 
Edited_version 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure shows unhealthy adipose expansion with massive enlargement of existing 
adipocytes (hypertrophied adipocytes), increased infiltration of macrophages and 
other immune cells.  Hypertrophied adipocytes lead to structural and functional 
changes in adipose tissue including adipokine alteration, elevated FFAs release, 
limited angiogenesis, and subsequent hypoxia. All of which propagate an overall 
systemic inflammation associated with the development of obesity-related insulin 
resistance, adapted from Sun, K., et al. (2011).   
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1.7.4.1 Tumour Necrosis Factor α (TNF-α) 
In adipose tissue, TNF-α is mostly produced by monocytes and macrophages and 
plays a central role in inflammatory and autoimmune diseases (Trayhurn and Wood, 
2004). TNF-α is a 26-KDa transmembrane protein which is cleaved to produce a 17-
kDa as the active form of TNF-α. In WAT, TNF-α expression was firstly recognized 
in rodents and found to be significantly increased in obese models; therefore, it was 
proposed as the first molecular link between obesity and insulin resistance 
(Hotamisligil et al., 1993). TNF-α has also been found to be secreted by human 
preadipocytes and adipocytes (Coppack, 2001). TNF- α is considered as a key 
regulator that plays an important role in the expression of a range of adipokines 
(Coppack, 2001), in particular pro-inflammatory factors such as interleukin 6, C 
reactive protein, neurotrophin, haptoglobin and nerve growth factor (Trayhurn and 
Wood, 2004). In WAT, both levels of gene expression and protein secretion of TNF-
α are increased in obese individuals whereas TNF-α plasma levels decreased in same 
obese individuals upon weight loss (Kern et al., 1995, Dandona et al., 1998). 
Consistently, a community-based cohort study has found that the circulating levels of 
TNF-α were positively correlated with markers of insulin resistance (Hivert et al., 
2008). A previous study using TNF-α deficient mice fed with a high fat diet showed 
that mice were protected from obesity-induced insulin resistance (Uysal et al., 1997).     
  
Studies using adipocytes from murine and human adipose tissue showed that 
treatment with TNF-α inhibits  insulin action by inhibiting insulin-stimulated 
phosphorylation of  the IR, and subsequent inhibits phosphorylation of IRS-1 
(Hotamisligil, 1999, Liu et al., 1998). In addition, an in vitro study demonstrated that 
TNF-α treatment induced phosphorylation of IRS-1 but at serine residues, which in 
turn inhibited IR activity and downstream signalling of PI3K activation in human 
adipocytes (Sykiotis and Papavassiliou, 2001). A growing body of evidence shows 
that role of TNF-α in inhibiting lipogenesis occurred through decreased FFA uptake 
and  stimulation of lipolysis, impairing insulin signalling through induction of serine 
phosphorylation of IRS-1, inhibiting preadipocyte differentiation by suppressing 
expression of adipocyte-specific genes and stimulate an inflammatory response 
(Sethi and Hotamisligil, 1999). Lumeng et al found that TNF-α neutralizing 
antibodies partially reversed insulin resistance in 3T3-L1 adipocytes produced by 
MC medium collected from J774A.1 and RAW264 (Lumeng et al., 2007c). 
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Furthermore, thiazolidinediones (TZDs) which are used as oral hypoglycaemic agent,  
have inhibitory effect on gene expression of TNF-α and prevent TNF-α-induced 
insulin resistance (Quinn et al., 2008). 
1.7.4.2 Monocyte Chemoattractant Protein-1 (MCP-1) 
Adipose cells produce several chemoattractant proteins that facilitate monocyte 
infiltration from blood circulation into adipose tissue; monocytes then differentiate to 
macrophages (Rasouli and Kern, 2008). MCP-1, also named as chemokine (C-C 
motif) ligand 2 (CCL2) with molecular weight approximately 11-KDa. MCP-1 is 
expressed in several cell types including adipose cells, skeletal and smooth muscle 
cells and endothelial cells (Deshmane et al., 2009). MCP-1 plays an important role in 
the recruitment of immune cells (macrophages and lymphocytes), triggered through 
binding MCP-1 ligand to its target receptor on the cell surface that is termed C-C 
motif receptor 2 (CCR2) (Deshmane et al., 2009). Expression of MCP-1 increases 
with obesity in most fat tissue types, especially in visceral fat, and reduces after 
weight loss (Christiansen et al., 2005). Insulin, growth hormone, TNF-α and IL-6 
induce MCP-1 expression in 3T3-L1 cells (Fasshauer et al., 2004). In humans, MCP-
1 in adipose tissue is expressed predominantly in non-adipose cells (SVF) such as 
resident macrophages (Bourlier and Bouloumié, 2009). However, a recent an in vitro 
study by our group showed that expression and release of MCP-1 are low in human 
adipocytes but upon MC medium treatment MCP-1 levels are markedly increased 
(Gao et al., 2014).   
 
Some in vitro and in vivo studies using obese and insulin resistant mouse models 
showed that increased expression and circulating levels of MCP-1 in adipose tissue is 
positively associated with obesity which may contribute to the development of 
insulin resistance and impair adipocyte differentiation (Di Gregorio et al., 2005, 
Sartipy and Loskutoff, 2003). In contrast, MCP-1 or its receptor (CCR2) knockout in 
mice reduces macrophage infiltration in adipose tissue (Tsou et al., 2007a, Kanda et 
al., 2006a). Overexpression of MCP-1 in WAT of mice increased infiltration of 
macrophages into adipose depot and reduced systemic insulin sensitivity assessed by 
insulin tolerance and hyperinsulinemic-euglycemic clamp tests (Kamei et al., 2006). 
In addition, MCP-1 overexpression in WAT affected insulin-stimulated tyrosine 
phosphorylation of IR and IRS proteins and decreased Akt phosphorylation in 
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muscle and liver, which in turn led to insulin resistance in both tissues (Kamei et al., 
2006). Previous studies revealed that circulating levels of MCP-1 were increased in 
type 2 diabetes patients compared to non-diabetic individuals (Ezenwaka et al., 2009, 
Nomura et al., 2000). In addition, a case-cohort study based on human population 
found that raised circulating levels of MCP-1 were associated with the incidence of 
type 2 diabetes (Herder et al., 2006). Taken together, previous results suggest that 
MCP-1 could link obesity-related inflammation with the development of insulin 
resistance. 
 
1.7.4.3 RANTES (CCL5) 
RANTES, a member of the chemokine family and also known as (C-C motif) ligand 
5 (CCL5), is a 8-KDa protein (Proudfoot et al., 1996). RANTES is released by a 
range of cells such as macrophages, eosinophils, platelets, fibroblasts, endothelium 
and epithelial cells (Marques et al., 2013). It is also classified as a chemotactic 
chemokine; an in vitro study has shown that RANTES induces recruitment of a range 
of different cells types including T cells, dendritic cells, eosinophils, NK cells, mast 
cells and basophils (Marques et al., 2013). RANTES binds with its receptors, on the 
cell surface, such as CCR1, CCR3 and CCR5 to mediate its biological effects 
(Murphy, 2002). 
 
RANTES is a crucial pro-inflammatory factor in obesity-related adipose tissue 
inflammation (Matter and Handschin, 2007). A recent study has found that gene 
expression of RANTES in adipose tissue was increased in obese humans, and its 
secretion induced monocyte migration and macrophage survival in human adipose 
tissue (Keophiphath et al., 2010). Consistently, obese subjects with metabolic 
syndrome have higher mRNA levels of RANTES and CCR5 in visceral adipose 
tissue than in other depots (Wu et al., 2007). Moreover, obese mice with CCR5 
knockout are protected from obesity-induced insulin resistance and this is related to 
reduced adipose tissue macrophage content and a M2 type-dominant polarization 
(Kitade et al., 2012a). It suggests that CCR5 plays a critical role in obesity-induced 
inflammation and insulin resistance.  
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1.7.4.4 Leptin  
The mechanisms underlying the development of obesity and its metabolic disorders 
and complications have been studied intensively, particularly, after the discovery of 
leptin in 1994 (Zhang et al., 1994). Leptin is a mature hormone is a protein of the 
molecular weight 16 KDa encoded by (ob) gene. Due to the discovery of leptin, 
adipose tissue has been recognized as an endocrine organ (Zhang et al., 1994, 
Leopold et al., 1994). Leptin is considered as a major adipokine with multiple 
physiological roles such as regulating food intake, energy expenditure, body weight 
and neuro-endocrine functions (Otero et al., 2005, Howard et al., 2004). The 
hypothalamus is considered as the major site of leptin action (Kahn and Flier, 2000). 
Leptin action is triggered through binding to its receptors (obR) which are expressed 
in most tissues (Galic et al., 2010). Obesity is highly correlated with increased leptin 
production and increased plasma leptin concentrations (Flier, 2004, Considine et al., 
1996), which may reflect leptin resistance (Ahima and Osei, 2008). Mice with leptin 
deficiency have obesity development such as in the phenotype of ob/ob mice 
(Zabolotny et al., 2002). Consistently, by giving recombinant leptin to morbid obese 
children suffering from a lack of leptin function, weight loss is successfully achieved 
(Shimabukuro et al., 1997). 
 
White adipocytes in both human and rodents are considered as the main source of 
leptin from adipose tissue (Montague et al., 1998). However, leptin is also 
recognized to be produced at low levels in other places including  BAT, muscles, 
stomach, placenta, and and fetal tissues (such as heart and bones) (Trayhurn and 
Beattie, 2001). In addition, an in vitro human study using preadipocytes has reported 
that small levels of leptin was produced following stimulation with TNF-α and IL-1β 
(Simons et al., 2007, Simons et al., 2005). Leptin has a structure similar to helical 
cytokines like IL-2 and growth hormone 1, and is thought to have pro-inflammatory 
activities by increasing production of IL-6 and TNF-α from monocytes and 
stimulating the production of CC-chemokine ligands (Deng and Scherer, 2010, 
Santos-Alvarez et al., 1999, Kiguchi et al., 2009). Therefore, it was suggested that 
leptin production is altered during inflammation and infection period, which could be 
a part of the cytokine cascade which organizes (Simons et al., 2005) the host defense 
mechanisms and innate immune response (Faggioni et al., 2001, Pecoits‐Filho et al., 
2002).  
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Leptin was suggested to be a central player in glucose homeostasis as a previous 
study has shown that leptin appeared as a major insulin-sensitizing adipokine by 
reversing insulin resistance and diabetes mellitus in mice (Shimomura et al., 1999). 
In addition, studies on two groups of rodents (leptin deficient and obese with leptin 
resistance) demonstrated that both groups have severe insulin resistance which was 
rapidly improved by administration of leptin; thus leptin has insulin sensitizing effect 
on both groups (Farooqi et al., 2002). Further supporting evidence suggests that fatty 
acid oxidation is promoted by leptin and leptin can reduce ectopic fat accumulation 
in non-adipose tissues, as a result of increased insulin sensitivity (Muoio et al., 
1997). Leptin acts to activate adenosine monophosphate-activated protein kinase 
(AMPK) which is a key mediator of fatty acid oxidation (Minokoshi et al., 2002). 
The effect of activation could be seen in certain skeletal muscles as a direct effect 
and also in the hypothalamus as an indirect effect (Minokoshi et al., 2002). 
Furthermore, in the obesity state, resistance to leptin could promote ectopic lipid 
storage, which may in turn further impair insulin sensitivity (Ahima et al., 2006). 
However, several murine studies have showed that leptin impairs insulin action in 
different cell types such as adipocytes (Müller et al., 1997), skeletal muscle cells 
(Sweeney et al., 2001) and hepatocytes cells (Cohen et al., 1996). Leptin has ability 
to increase oxidative stress, activation of the NF-kB pathway, and increased 
expression of chemokines and adhesion molecules, which may induce macrophage 
infiltration in adipose tissue (Curat et al., 2004, Bouloumie et al., 1999). 
Macrophage-derived factors significantly alter adipose cells function, inducing 
inflammatory responses, reducing insulin sensitivity and impairing differentiation 
capability which may contribute to obesity-related metabolic disorder such as insulin 
resistance and type 2 diabetes (Bing, 2015). 
 
1.7.4.5 Adiponectin  
In the mid1990s adiponectin was originally discovered by four independent research 
groups through different experimental approaches (Hu et al., 1996, Scherer et al., 
1995, Maeda et al., 1996, Nakano et al., 1996). Adiponectin is considered as the most 
abundant adipokine produced from adipocytes (Chandran et al., 2003). Adiponectin 
is a 30 KDa protein and its gene expression takes place from the middle stage of 
differentiation onwards (Scherer et al., 1995, Hu et al., 1996, Ouchi et al., 2011). The 
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circulating levels of adiponectin are present at high concentrations (3 to 30 µg/ml) in 
plasma (Pajvani et al., 2003, Ouchi et al., 2003a). Human adiponectin is recognized 
in different three forms as low molecular weight (trimer isoform), middle molecular 
weight and high molecular weight (hexamer isoform) (Kadowaki and Yamauchi, 
2005). The high molecular weight isoform is reported as the most active form of 
adiponectin and considered as a better marker for the prediction of insulin resistance 
and metabolic syndrome than plasma total adiponectin level (Hara et al., 2006). 
Adiponectin is also detected in many different places such as the pituitary gland, 
brain and cerebrospinal fluid which is triggered by fasting (Steinberg and Kemp, 
2007). Structurally, full-length of adiponectin is composed of a collagen-like domain 
(tail) and a globular domain head (Kadowaki and Yamauchi, 2005), that is similar to 
complement factor C1q (Wong et al., 2004).   
 
An important difference between adiponectin and most adipokines is that adiponectin 
production and its plasma concentrations are decreased in extremely obese and 
insulin-resistant subjects (Hotta et al., 2001, Hu et al., 1996). Previous studies using 
obese/diabetic mice and human models have demonstrated that plasma adiponectin 
levels are significantly reduced (hypoadiponectinemia) (Arita, 2012, Hu et al., 1996, 
Yamauchi et al., 2001). In addition, circulating levels of adiponectine have also been 
found to be decreased in patients with metabolic disorders (Trujillo and Scherer, 
2005) including type 2 diabetes, lipodystrophy, nonalcoholic hepatic steatosis (Deng 
and Scherer, 2010), cardiovascular diseases (Hotta et al., 2000, Kumada et al., 2003), 
hypertension (Ouchi et al., 2003b), and mutations in  the adiponectin gene (Kondo et 
al., 2002). However, a number of studies in both mice and humans have confirmed 
that adiponectin expression and secretion are increased with weight loss and 
improved insulin sensitivity (Milan et al., 2002, Yang et al., 2001, Hulver et al., 
2002). Adiponectin is essential for PPARγ agonists, such as TZD, to improve their 
anti-diabetic activities (Fasshauer and Paschke, 2003), mainly during exposure to a 
high fat diet (Nawrocki et al., 2006). Vice versa, PPARγ is found to be important to 
increase expression and plasma concentrations of adiponectin (Maeda et al., 2001). 
Thus, adiponectin has known to possess an anti-diabetic property that is proposed to 
treat obesity-related insulin resistance (Lindsay et al., 2002). Two case-control 
studies have demonstrated that individuals, who have high adiponectin circulating 
levels, are less likely to develop type 2 diabetes than individuals with low 
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adiponectin circulating levels (Lindsay et al., 2002, Spranger et al., 2003a, Yu et al., 
2002b). Consistently, adiponectin has been shown to improve hepatic insulin action 
which suppressed hepatic glucose production and increased glucose utilization and 
fatty acids oxidation in adipose tissue through activation of AMPK (Berg et al., 
2001, Rasmussen et al., 2006, Yamauchi et al., 2002).   
 
Adiponectin is also commonly considered to have anti-inflammatory, pro-angiogenic 
and anti-apoptotic properties (Rajala and Scherer, 2003, Deng and Scherer, 2010, 
Landskroner-Eiger et al., 2009). An interesting observation of a study using murine 
pre-adipocytes (3T3-L1) was shown that adiponectin overexpression enhanced 
adipocyte differentiation and lipid accumulation (Fu et al., 2005). There are a range 
of therapeutic managements or interventions, such as weight loss, caloric restriction 
and TZDs treatment, which can improve adiponectin expression and secretion (Yu et 
al., 2002b, Bruun et al., 2003a, Combs et al., 2003). On the other hand, several 
studies have shown that TNFα treatment can inhibit gene expression and secretion of 
adiponectin in murine adipocytes (3T3-L1) and human primary adipocytes 
(Fasshauer et al., 2003, Kappes and Löffler, 1999). Furthermore, an in vitro study 
using murine adipocytes (3T3-L1) found that IL-6 treatment led to a reduction in 
adiponectin gene expression (50%) and secretion (75%) (Fasshauer et al., 2003).  
Thus, it was suggested that adiponectin expression and secretion are reduced due to 
pro-inflammatory cytokines which mainly increased   in obesity. 
 
1.7.5 Interleukins (ILs) 
ILs are a cluster of polypeptides which are made up of a number of members with 
both pro and anti-inflammatory properties. ILs are cytokines that act on leukocytes 
and other tissue targets such as adipose tissue cells including preadipocytes, 
adipocytes and adipose tissue macrophages (Khadka, 2014). These cells also express 
and release a number of ILs such as IL-1 ( IL-1α and IL-1β), IL-6 and IL-8 (Gao and 
Bing, 2011). Several ILs have been considered as potential effectors in the pathology 
of insulin resistance associated with type 2 diabetes (Fève and Bastard, 2009). 
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1.7.5.1 Interleukin-6 (IL-6) 
IL-6 is a cytokine mostly associated with the immune system response (Torres-Leal 
et al., 2012). During the innate immune response IL-6 is mainly involved in the 
production of acute phase reactants such as C-reactive protein (CRP) from the liver 
(Steel and Whitehead, 1994). Unlike TNF-α, IL-6 has both pro-inflammatory and 
anti-inflammatory properties. This makes it play dual roles; at some level it provides 
a defence mechanism by promoting synthesis of anti-inflammatory cytokines which 
reduce inflammatory response where at other level such as in chronic inflammation it 
acts as pro-inflammatory cytokine (Kamimura et al., 2004). IL-6 is secreted in 
humans by a wide range of cells including monocytes, macrophages, endothelial 
cells, β pancreatic cells, osteoblasts, myocytes, adipocytes  (Kamimura et al., 2004, 
Carey and Febbraio, 2004) as well as preadipocytes (Gao and Bing, 2011).  
 
In humans, the expression and secretion of IL-6 was observed in adipocytes and 
preadipocytes (Sopasakis et al., 2004, Bastard et al., 2000, Vicennati et al., 2002, 
Krogh-Madsen et al., 2004). Substantial amounts of IL-6 are produced by WAT 
especially from the visceral depot where IL-6 may constitute 10-35% of circulating 
levels (Mohamed-Ali et al., 1997). However, non-adipose cells are considered as 
major source of IL-6 which may constitute about 60-90% of IL-6 secretion 
(Sopasakis et al., 2004). The circulating levels of IL-6 have been reported to be 
increased in obese individuals and also increased in individuals with type 2 diabetes 
(Vozarova et al., 2001b). Furthermore, evidence suggests that IL-6 directly plays a 
role in insulin resistance in 3T3-L1 adipocytes and primary mouse hepatocytes by 
altering insulin signalling through reduced gene and protein expression of IRS-1 and 
GLUT-4, and impaired insulin-induced glycogenesis in hepatocytes (Senn et al., 
2002, Rotter et al., 2003). Another explanation for the role of IL-6 in insulin 
resistance is that several members of suppressor of cytokine signaling-3 (SOCS-3) in 
insulin target tissues are induced by IL-6 which in turn inhibits phosphorylation of 
insulin-stimulated IR, IRS-1 PI3K p85 and Akt (Senn et al., 2003). It appears from 
the literature that IL-6 is one of several pro-inflammatory cytokines implicated in 
insulin resistance and obesity. 
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1.7.5.2 Interleukin 8 (IL-8) 
IL-8 is a member of the C-X-C motif chemokine family, a chemoattractant protein, 
which facilitates neutrophil and lymphocytes chemotaxis (Mackay, 2001) and also 
induces chemotaxis of macrophages (Waugh and Wilson, 2008). It is involved in 
many inflammatory diseases such as asthma, inflammatory bowel disease, sepsis and 
adult respiratory disease. IL-8 has commonly been recognized for its association with 
different inflammatory processes (Baggiolini et al., 1995, Roebuck, 1999). A 
previous in vitro study using human adipose tissue has found that IL-8 production 
was increased in dose dependent manner after stimulation with two pro-
inflammatory cytokines treatment including IL-1β and TNF-α (Bruun et al., 
2001).Therefore, IL-8  may be involved in obesity-related complications.  
 
Similar to MCP-1, IL-8 has four conserved cysteine residues at N-terminus but its 
residues are separated by one amino acid (CXC chemokines) (Roebuck, 1999). IL-8 
chemokine plays a key role in activation of multiple intracellular signalling pathways 
downstream through binding IL-8 ligand to its target G protein–coupled receptors on 
the cell surface that termed CXCR1and CXCR2 (Waugh and Wilson, 2008). IL-8 is 
secreted by a variety of cells including adipose cells (Gerhardt et al., 2001) and its 
circulating levels are increased in obesity (Rotter et al., 2003, Straczkowski et al., 
2002).  A research conducted to study the link between insulin sensitivity and plasma 
levels of IL-6, IL-8 and TNF-α, found that circulating levels of IL-8 and IL-6 were 
upregulated and associated with measures of insulin resistance in the abdominal 
depot of obese subjects. The circulating levels of these cytokines/chemokines were 
influenced by weight loss (Bruun et al., 2003b). Gene expression of IL-8 is 
upregulated in mammary adipose tissue of obese women, in parallel with increased 
macrophage infiltration (Sun et al., 2012). A previous study showed that IL-8 
receptor (CXCR2) knockout in diet-induced obese mice prevents insulin resistance 
and macrophage recruitment into adipose tissue (Neels et al., 2009). Furthermore, an 
in vitro study using human adipocytes has found that IL-8 has an inhibitory effect on 
insulin action by reducing insulin-stimulated phosphorylation of Akt whereas it has a 
stimulatory effect on Akt mRNA expression (Kobashi et al., 2009).   
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1.7.5.3 Interleukin 1 family 
IL-1 family is considered to be involved in several cellular activities such as 
regulating host defence and immune responses (Auron et al., 1984) and also 
implicated in the acute-phase response and is responsible for many alterations that 
are linked with the onset of a number of medical conditions  (Di Iorio et al., 2003). 
The interleukin-1 family (IL-1) consists of 11 cytokines (Di Iorio et al., 2003).  
However, the two major cytokines are IL- 1α and IL-1β (Dinarello, 2009).  
Structurally, IL-1α and IL-1β have similar biological properties with slight sequence 
homology and they are different in several regulation aspects such as localization, 
maturation, and secretion (Tack et al., 2012). Both major forms of IL-1 bind to 
common receptors, type I (signalling) and type II (decoy), that are present on a 
variety of target cells (Dinarello, 1998a, Mantovani et al., 2001, Fibbe and Willemze, 
1991). Another member of the IL-1 family is an interleukin-1 receptor antagonist 
(IL-1 RA) which has similar sequence homology to IL-1β and binds to human IL-1 
receptors without activating them and antagonizes both IL-1 subtypes by controlling 
their production and biological activity (Arend, 1990). 
 
1.7.5.3.1 Interleukin 1β (IL-1β) 
IL-1β is produced largely by macrophages (Sims and Smith, 2010), and also by 
several immune cells including dendritic cells, B lymphocytes and NK cells 
(Dinarello, 2009). Moreover, IL-1β can also be expressed and released by adipose 
cells (preadipocytes and adipocytes) (Xu et al., 2003, Weisberg et al., 2003) and its 
expression and release has been found to be enhanced in obesity (Fain, 2006). IL-1β 
plays an important role in mediating the inflammatory response (Arend, 2002). 
Furthermore, IL-1β has a role in development of systemic and local responses to 
injury, infection, and other immunological events and is the main cause of acute and 
chronic inflammation by inducing the production of cytokines and chemokines from 
epithelial, endothelial and immunocompetent cells (Dinarello, 1998b, Dinarello et 
al., 2010). For example, intravenous injection into humans with a small amount of 
IL-1β induces fever, thrombocytosis, leukocytosis, hypotension and the release of 
adrenal corticotropin hormone (Smith et al., 1993, Crown et al., 1993, Crown et al., 
1991). IL-1β plays also a role in a range of cellular processes, including cell 
proliferation, differentiation and apoptosis (Arend, 2002) as well as a role in normal 
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homeostasis such as metabolism, hematopoiesis, regulation of blood pressure, renal 
and hepatic function and sleep (Dinarello, 1993). 
 
Unlike IL-1α which is produced in an active form, IL-1β is firstly formed as pro–IL-
1β (inactive form) which accumulates in the cytosol, and then it is cleaved and 
processed by the cysteine protease caspase-1 (also named interleukin converting 
enzyme (ICE) to produce the active form of IL-1β (p17). Caspase-1 has been known 
to be controlled by a multi-protein complex termed the nucleotide-binding 
oligomerization domain receptors (NLRP3) inflammasome (Figure 1.7) (Agostini et 
al., 2004). Once mature active form of IL-1β is released, it can increase its signals 
through binds to the IL-1 receptor I leading to a vicious cycle of inflammation, which 
in turn increase the activation and infiltration of macrophages into inflamed tissues, 
such as the islet and adipose tissue (Dinarello et al., 2010).   
 
In the unhealthy state, IL-1β is expressed upon stimulation by stress-related 
pathways and the initial translation product is an inactive precursor. In vitro, 
stimulated human blood monocytes release less than 10% of the intracellular pool of 
IL-1β into the extracellular compartment (Schindler et al., 1990). Stienstra and et al 
reported elevated caspase-1 and increased levels of IL-1β from adipocytes isolated 
from mice that fed a high fat diet or obese ob/ob mice. However, adipose tissue from 
caspase-1-deficient mice is histologically distinct compared to fat from wild type 
mice; differentiation of preadipocytes isolated from caspase-1-deficient mice resulted 
in more metabolically active fat cells and are more insulin sensitive as compared to 
wild-type mice (Stienstra et al., 2010). Studies have shown that IL-1β upregulates the 
expression of inflammation–related genes in adipocytes and preadipocytes (Gao and 
Bing, 2011, Permana et al., 2006). Furthermore, a study showed that IL-1β induced a 
significant increase in pro-inflammatory cytokine (IL-6) in adipocytes and peripheral 
blood cells (Flower et al., 2003), consistently, a recent study conducted by our group 
showed that the release of a range of pro-inflammatory factors from human 
adipocytes including IL-6, MCP-1, IL-8 and RANTES were induced after treatment 
with IL-1β (Gao et al., 2014). 
 
IL-1β is considered as a key pro-inflammatory cytokine which produced mainly by 
monocytes and macrophages (Agostini et al., 2004). Accordingly, an in vitro study 
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using murine and human adipocytes reported that long term treatment with IL-1β 
inhibited insulin stimulated phosphorylation of the p-IR β subunit, IRS-1 and 
Akt/protein kinase B. In addition, IL-1β changed adipocyte differentiation by 
reducing adipogenic factors such as C/EPBα and PPARγ (Lagathu et al., 2006) 
.However, a recent study by Gagnon and other using an in vitro human cell models 
(THP-1 macrophage and human primary preadipocytes) reported that IL-1β was 
sufficient to inhibit preadipocytes adipogenesis but IL-1β is not required for the 
ability of macrophage CM to inhibit adipogenesis in human preadipocytes (Gagnon 
et al., 2013). Growing evidence based on mouse models suggests that IL-1β is 
essentially involved in the translation of obesity-associated inflammation into insulin 
resistance. However, little is known whether IL-1β mediates the effect of 
macrophages on insulin signalling in human preadipocytes and adipocytes.   
 
Figure 1-7: Schematic illustration of inflammasome activation that 
leads to IL-1β release 
 
 
 
 
Edited_version 
 
 
 
 
 
 
 
 
Figure shows inflammasome activation is induced by a group of stimuli including 
(LPS, ceramides, glucose and uric acid). Inflammasome activation leads increased 
caspase-1-dependent cleavage of pro-IL-1β into mature IL-1β, which is subsequently 
released from the cells, adapted from (Tack et al., 2012).   
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1.7.5.3.2 Targeting IL-1β in obesity and diabetes  
Recent studies suggest that IL-1β may be a candidate in the development of insulin 
resistance and type 2 diabetes (Tack et al., 2012, Wen et al., 2011). Therefore, 
clarifying whether IL-1β mediate the effect of macrophages on the human adipose 
cells is important as it may provide potential therapeutic targets for obesity-related 
insulin resistance. Currently, most therapeutic agents used for inhibiting TNF-α 
activity are using neutralization approaches. However, there are several approaches 
for inhibiting interleukin IL-1β activities (Dinarello, 2004). Interestingly, the 
development of anti-IL-1β neutralizing antibody in humans is considered to be more 
beneficial as a therapeutic strategy than in IL-1α. This is because some studies using 
animal and human models demonstrated that IL-1β is released and found in 
pathological fluids while IL-1α remains an intracellular cytokine (Dinarello, 1996).  
 
The IL-1RA (interleukin-1 receptor antagonist), also known as anakinra, is presently 
approved after used in clinical trials to treat diseases in human such as rheumatoid 
arthritis (Dinarello, 2004). At molecular level, IL-1RA binds to the IL-1 receptor I 
with high affinity and stops the binding of IL-1 to its receptor via a mechanism of 
competitive receptor antagonism (Dinarello, 2004). In studies using rodent models of 
obesity and diabetes (GK rats), blocking IL-1β by a neutralizing antibody or IL-1RA 
reduced hyperglycemia and tissue inflammation (Owyang et al., 2010, McGillicuddy 
et al., 2011, Ehses et al., 2009). Recently, several of studies conducted in patients 
with type 2 diabetes have shown that the IL-1β neutralizing antibody or IL-1RA 
(anakinra) have beneficial effects on glucose control and β-cell function, with a 
reduction in circulating pro-inflammatory markers (Larsen et al., 2007, Cavelti-
Weder et al., 2012, Sloan-Lancaster et al., 2013).  
 
As mentioned above, obese adipose tissue has been found to produce significant 
amounts of IL-1β via NLRP3 activation, which in turn is linked to inflammation and 
insulin resistance (Vandanmagsar et al., 2011, Stienstra et al., 2011). However, 
caspase-1-deficient mice have decreased body fat and improved insulin sensitivity 
(Stienstra et al., 2010). Therefore, reducing IL-1β production by inhibition of 
caspase-1 (ICE) has become a promising therapeutic strategy as well to reduce IL-β 
role in many inflammatory diseases (Randle et al., 2001).  
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This thesis was conducted as one of the studies on the tissue specific effects of IL-1β 
inhibition in humans. IL-1β inhibition might decrease macrophage infiltration and 
inflammatory response in adipose tissue, thus improving adipose tissue function such 
as insulin sensitivity and differentiation of preadipocytes. 
 
 
1.8 Aims of the study  
1.8.1 Hypothesis 
WAT is a heterogenous organ containing multiple depots and several cell types 
including preadipocytes, adipocytes and macrophages. These cells are able to 
produce and release a wide range of cytokines and other compounds. It has been 
shown that adipocytes are able to secrete adipokines. Therefore, adipose tissue is a 
key endocrine organ. Macrophages are considered to be the major source of pro-
inflammatory cytokines in obese adipose tissue. IL-1β, a pro-inflammatory cytokine, 
is a major product of macrophages. Therefore, it is hypothesized that IL-1β could 
mediate the effects of macrophage-induced impairment of the insulin signalling 
pathway and induce inflammation in human adipose cells (preadipocytes and 
adipocytes).  
   
1.8.2 Aims and objectives 
Identification of the major factors that mediate detrimental effects of macrophages on 
adipocytes may offer potential therapeutic targets. IL-1β, a proinflammatory 
cytokine, is suggested to be involved in the development of insulin resistance. In this 
context, several invitro human cell models were used, including  primary 
preadipocytes, adipocytes, THP-1 macrophages (cell line) and peripheral blood 
monnuclear cells-derived macrophages (PBMCs), to establish the effect of cross talk 
between them on insulin signalling of adipocytes and their precursors 
(preadipocytes).  
 
The specific objectives are listed below: 
1. Characterize the key insulin signalling molecules in human primary 
preadipocytes in comparison with adipocytes;  
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2. Investigate the role of IL-1β in macrophage-predipocyte crosstalk, and 
whether this crosstalk modulates the insulin signalling pathway in human 
preadipocytes; 
3. Examine the role of IL-1β in modulating pro-inflammatory factors expression 
and release by preadipocytes; 
4. Investigate the effect of long-term treatment with IL-1β on lipid storage 
functions and adipogenesis in human adipocytes;    
5. Investigate whether IL-1β mediating macrophage-induced lipolysis in human 
adipocytes through blocking IL-1β activity;  
6. Investigate the role of IL-1β in macrophage-adipocyte crosstalk, and whether 
this cross-talk modulates insulin signalling molecules and pro-inflammatory 
factors expression and release  in human adipocytes; 
7. Investigate whether inhibiting the effect of IL-1β by different approaches 
reduces the inflammatory response involved in adipose tissue dysfunction. 
 
The results obtained after completing the experimental studies may provide some 
answers to above mentioned hypothesis. This may contribute to filling the gap in our 
knoweledge and provide a better understanding of the role of the macrophage-
derived factors, in particular IL-1β, in the development of insulin resistance and type 
2 diabetes.   
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CHAPTER 2:  
Material and Methods 
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2 Material and Methods 
2.1 Reagents, materials and equipment  
2.1.1 Chemical reagents 
Reagents      Suppliers reagents                                                                           
3-isobutyl-1-methylxanthine (IBMX) Sigma 
Acrylamide/Bisacrylamide  Bio-rad 
Ammonium persulphate Bio-rad 
Anti-PI3Kinase p85 pAB                                                                Cell Signaling   
 
Anti- Total AKT pAB                                                                     Cell Signaling   
 
Anti- Phospho-Akt (Ser473) mAb                                                  Cell Signaling   
 
Anti-Glut-4 pAB Millipore 
Anti-GAPDH pAB                                                                          Abcam 
 
Anti-insulin receptor (phospho Y1158) mAB Abcam 
Anti-insulin receptor substrate-1 (IRS-1) mAB                              Cell Signaling 
 
Anti-Phospho-IRS-1 (Ser-612) mAB                                              Cell Signaling 
 
Anti-rabbit IgG HRP-linked AB Cell Signaling 
Bicinchoninic acid Sigma    
Biotin  Sigma 
Bisacrylamide  Bio-rad 
Bovine Serum Albumin Sigma 
Bromphenole blue Sigma 
β-Mercaptoethanol  SERVA 
IL-1β converting enzyme (ICE) Caspase-1 inhibitor II                 Calbiochem 
 
Il-1β human recombinant                                                               Sigma 
 
Chloroform  Fisher Scientific 
Coomassie Brillian Blue dye                 Fisher Scientific 
Copper sulphate Sigma     
Dexamethasone  Sigma 
Dulbecco’sModefied Eagle’s Medium/ Ham’s Nutrient
  
 
Mixture F12 Sigma 
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Ethidium bromide                                                                          Sigma       
Fetal Calf serum Sigma 
Formaldehyde solution                                                                  BDH  
 
Glycerol Sigma 
Glycine Sigma 
Hydrochloric acid  Fisher Scientfic 
Insulin  Sigma 
Interleukin-1β (IL-1β) Human recombinant  Sigma 
Interleukin- receptor antagonist (IL-1RA)  
Human recombinant  Sigma 
Isopropanol  Sigma 
Human Interleukin-1β neutralizing AB R&D Systems 
L-Thyroxine  Sigma 
Methanol Fisher Scientific 
Oil Red O stain     Sigma 
PageRular prestained protein ladder  Fermentas 
Penicillin/Streptomycin mix Sigma 
Pencillin/Streptomycin/Fungizone mix Sigma 
Phorbol-12-myristate-13-acetate Sigma 
Phoshate- buffered saline tablets Sigma 
Ponceau S Sigma 
Protease inhibitor cocktail   Sigma 
Phosphatase inhibitor cocktail Sigma 
Pure-ethanol  Sigma 
RNase AWAY Molecular 
BioProducts,Inc. 
Rosiglitazone  Enzo Life Sciences   
Roswell Park Memorial Institue medium (RPMI-1640) Sigma 
Sodium dodecyl sulphate (SDS) Sigma 
Sodium Chloride Sigma 
Taqman primers Eurogentec 
Taqman probes Eurogentec 
Tetramethylethylenediamine (TEMD) Sigma 
Total AKT Rabbit antibody New England Biolabs 
Tricine Sigma 
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Trizma BASE Sigma 
TRIzol ® reagent Sigma 
Trypsine-EDTA solution Sigma 
Water, molecular biology reagent (DEPC-treated,ultra 
 
 
Pure water) Sigma 
                  
2.1.2 Kits                          
Kits Supplier 
Free glycerol determination kit                                                                Sigma 
Human IL-1β DuoSet® ELISA development System R& D Systems 
Human IL-8 DuoSet® ELISA development System  R& D Systems 
Human CCL-5 DuoSet® ELISA development System R& D Systems 
Human IL-6 DuoSet® ELISA development System  R& D Systems 
Human MCP-1 DuoSet® ELISA development System R& D Systems 
Human Adiponectin DuoSet® ELISA development System  R& D Systems 
Insulin receptor substrate Antibody sampler Kit Cell Signaling 
Pierce LHD Cytotoxicity Assay Kit                                                          Thermo Scientific   
 
qPCR Core kit Eurogetec 
SuperSignal® West Pico ECL kit  Thermo Scientific 
iScrip cDNA synthesis kit Bio-Rad 
 
2.1.3 Equipment and system                                                                                     
Equipment and system                                                                   Supplier
6/12/24 well tissue culture plates Techno Plastic Products 
96-well real time PCR plates Starlab 
Block- Digital dry path Labent International 
Benchmark™ Plus Microplate Spectrophotometer  Bio-rad 
Bio-Rad Mini-PROTEAN™ Tetra System  Electrophoresis Bio-rad 
Biophotometer Eppendorf 
Bottle top 0.2 µm filters Techno Plastic Products 
ChemiDoc™ XRS+System  Bio-Rad 
Disposable serological pipette tips Starlab 
Dynatech Orbital shaker Vari-Shaker   Labexchange 
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Eppendorff centrifuge 5415C  Eppendrof 
Fisherbrand Scale Fisher Scientific 
Hybridizer hybridization oven UVP 
LABNET Multigene Gradient thermal cycler  Labnet Intennational 
Mx3005P QPCR system Stratagene 
Nikon Diaphot inverted microscope/D50 camera Nikon 
Hybond ECL nitrocellulose membrane Amersham 
Platform shaker STR6 Stuart 
Vortex mixer SA8 Stuart 
                 
2.1.4 Software 
Software   Supplier 
Molecular Imager ChemiDoc XRS+ System                                  BioRad
GraphPad Prism 5                                                                            GraphPad Software 
Microplate Spectrophotometer                                                        BioRad
Microsoft Excel 2007                                                                      Microsoft  
MxPro
TM 
  QPCR software                                                              Stratage
 
2.1.5 Supplier’s addresses and URLs    
Supplier Address and URLs 
Abcam Abcam plc,330 Cambridge Science Park Cambridge CB4 
0FL,United Kingdom,  http ://www.Abcam.com 
Amersham Amersham Pl,Little Chalfront, Buckinghamshire, United 
Kingdom,  http:// www.amershambiosciences.com 
Bio-Rad Bio-Rad Laboratories Ltd,Bio-Rad House.Maxted Road, 
Hemel Hempstead,    Hertfordshire HP2 7DX,United 
Kingdom, http:// www.bio-rad.com   
Cell Signaling                          Cell Signaling Technology, New England Biolabs (UK) Ltd.  
75-77 Knowl Piece, Wilbury Way, Hitchin, Hertfordshire SG4 
0TY   United Kingdom,  http:// www.cellsignaling.com     
Enzo Life Sciences Enzo Life Sciences (UK) LTD, Palatine House, Matford 
Court, Exeter EX2 8N, United Kingdom,  
http://www.enzolifesciences.com 
Eppendorf Eppendorf UK Limited, Endurance House, Vision 
Park,Chivers Way, Histon, Cambridge CB24 9ZR, United 
Kingdom,  http://www.eppendorf.co.uk 
Eurogentec Eurogentec Ltd. Old Headmasters House, Unit 1, Building 
1,Forest Business Centre, Fawley Road, 
Fawley,Southampton,Hampshire SO45 1FJ, United Kingdom,   
http:// www.fermentas.de 
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Fermentas European Head Office Germany. Fermentas GmbH, 
Opelstrasse 968789 St. Leon-Rot,Germany, 
http://www.fermentas.de 
Fisher Scientific Fisher Scientific UK Ltd.Bishop Meadow Road, 
Loughborough,Leicestershire, LE11 5RG, United Kingdom, 
http://www.fisher.co.uk 
Labnet International Labnet International.PO Box 841,Woodbridge,NJ07095,USA, 
http://www.labent.com 
Molecular 
BioProducts,Inc. 
Molecular BioProducts,Inc.B399389 Waples Street, San 
Diego, CA 92121-3903, http:// www.mbpinc.com 
Millipore Millipore UK Ltd, Croxley Green Business Park, Watford, 
WD18 8YH, United Kingdom, http:// www.millipore.com    
New England 
Biolabs 
New England Biolabs (UK) Ltd. 75/77 Knowl Piece, Wilbury 
Way, Hitchin, Herts. SG4 0TY, United Kingdom,   
http:// www.neb.com 
Nikon Nikon UK Limited.380 Richmond Road, Kingston upon 
Thames,Surrey KT2 5PR, United Kingdom,  
http: // www.europe-nikon.com 
PromoCell PromoCell GmbH, Sickingenstraße 63/65, D-69126 
Heidelberg, Germany, www.promocell.com 
R & D Systems R & D Systems Europe Ltd.19 barton lane, Abingdon Science 
Park,Abingdon, OX14 3NB, U niited Kingdom,  
http:// www.rndsystems.com 
SERVA SERVA Electrophoresis GmbH.Carl-Benz-Str.7P.O.B.10 52 
60,69115 Heidelberg, Germany, http///www.serva.de 
Sigma Sigma-Aldrich Company Ltd. Fancy Road, Dorset BH12 
4QH, United Kingdom, http:// www. Sigmaaldriche.com 
/united kingdom.html   
Starlab STARLAB (UK),Ltd.Unit4 Tanners Drive,Blakelands, Milton 
Keynes MK14 5NA, United Kingdom, http:/ / www.starlab.de    
Stratagene (Agilent) Algilent Technologies,Inc.Life Sciences and Chemical 
Analysis, Group 5301,Stevens Creek Boulevard, Santa 
Clara,CA 95051-7201,USA 
Techno plastic 
products 
TPPTechno Plastic AG,Zollstrasse 155,CH-8219,Trasadingen, 
Switzerland 
Thermo Scientific                   Thermo Fisher Scientific Inc. Unit 9 Altey Way North Nelson 
Industrial Estate Cramlington, Northumberland, NE23 1WA, 
http://wwwthermoscientific.com  
 
UVP Ultra-Violet Products Ltd, Unit 1,Trinity Hall Farm Estate, 
Nuffield Road, Cambridge CB4 1TG,United kingdom,  
http://www.UVP.com  
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2.2 Cell Culture system 
2.2.1 Cell culture basis  
One of the most important and widely used methods to study cell biology and the 
effects of biologically active molecules on living organisms is cell culture. Cell 
culture systems provide excellent models that allow understanding of cellular and 
molecular basis of cells in both physiological and pathological conditions. Cell 
culture refers to the cell removal from human, animal or plant and their consequent 
expansion in an encouraging artificial environment (Aschner et al., 2011). Cells are 
contained mainly in a humidified atmosphere of 5% CO2/ 95% air at 37 ºC 
incubators unless specified otherwise to achieve successful cell cultivation. 
Moreover, cell culture can be performed using the cells which may be taken directly 
from the tissue as primary cells and disaggregated by mechanical or enzymatic 
methods before cultivation, or it can be achieved by cells derived from a cell line or 
cell strain that has already been established (Aschner et al., 2011). 
 
2.2.2 Method 
In this research project, there were three cell types used, namely primary human pre-
adipocytes, human THP-1 monocytes (cell line) and peripheral blood mononuclear 
cell-derived macrophages (PBMCs). All were used as model systems to study the 
effects of the crosstalk between macrophages and adipose cells, and to demonstrate 
how adipose tissue dysfunction, such as the impairment of insulin signalling might 
occur during the development of obesity.  
 
In culture of primary human pre-adipocytes and THP-1 cells, all appropriate bio-
safety practices were followed to reduce and eliminate exposure to laboratory 
workers, and all required precautions were taken to avoid any contamination and 
infection into the candidate cells. Firstly, all glassware was well washed and 
autoclaved, and all plastic ware used was sterilized. Secondly, the UV-C lamp in the 
laminar flow hood or cell culture hood was used and surfaces were exposed to UV 
light for a minimum of 15 minutes before use. In addition, the cell culture hood was 
wiped by 1% Vircon solution, followed by 70% ethanol, to make sure a clean 
environment for cell culture was obtained. All items that were to be used in the hood 
were sprayed with 70% ethanol before entering the hood. This was to reduce the risk 
55 
 
of infection which may occur to cells. All medium components were mixed together 
by using single-use serological pipette (Starlab, Milton Keynes, UK) inside the hood 
and medium was filtered through a 0.22 µm filter membrane (TechnoPlastic 
Products, Trasadigen,Switzerland).    
 
The culture growth medium and feeding medium were prepared, and they were kept 
at 4 ºC until use. They were then warmed in HB-1000 a hybridization incubator 
(Cambridge,UK) prior to use.  Induction medium (Differentiation medium) (see 
below) was also prepared in the same way; however it had to be freshly prepared 
prior to the time of use and any extra medium was discarded afterwards. 
 
2.3 Human preadipocytes culture and differentiation  
2.3.1 Reagents and mediums  
        Preadipocytes growth medium  
        1x Preadipocytes Growth Medium (Promocell) 
        1x Preadipocytes supplementMix (Promocell) 
        100 ml pencillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericine mix 
 
   Differentiation medium 
       1x Dullbecco’s Modified Eagle’s Medium-Ham’s F12 (DMEM) (1:1, vol/vol) 
        Biotin 32 µM 
        Insulin 100 nM 
        Rosiglitazone 8 µM 
        Dexamethasone 1 µM 
        3-isobutyl-1-methylxanthine 200µM 
        L-Thyroxine 11 nM  
        100 U/ml penicillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericine mix 
 
         Human primary adipocyte feeding medium (post differentiation) 
         1x Dullbecco’s Modified Eagle’s Medium-Ham’s F12 (DMEM) (1:1, vol/vol)  
         Fetal calf serum 3% 
         Insulin 100 nM 
         Dexamethasone 1 µM 
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       Biotin 32 µM  
       100 U/ml pencillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericine mix 
 
2.3.1.1 Cell culture reagents  
          Phosphate- buffered saline (Autoclaved) 
          Trypsin 0.05% -EDTA 0.2% solution  
 
2.3.1.2 Cell culture equipment 
          Autoclaved Pasture pipettes 
          Filter and filter collection bottle 
          150 cm² and 75 cm
2
 cell culture flasks 
          Seriological pipette and sterile pipette tips 
          50 ml centrifuge tubes  
          Haemocytometer 
          6 /12 and 24 well plates 
 
2.3.2 Human preadipocytes storage  
For all experiments, PromoCell (Heidelberg, Germany) provided our lab with the 
human primary white preadipocytes that were originally derived from subcutaneous 
adipose tissue of a female Caucasian subject (age 44 years; BMI 21). Cryopreserved 
cells were stored in liquid nitrogen immediately after arrival, or were directly seeded. 
Cells could not be stored at - 80 ºC because this temperature was not sufficient for 
cell preservation and causes irreversible cell damage. 
 
2.3.3 Resuspension of preadipocytes from cryopreservation   
For suspending and culturing the human preadipocyte cells, Promocell’s protocol 
was followed in all cell culture experiments.  An appropriate amount of culture 
growth medium was freshly prepared and warmed in 1000-HB a hybridization 
incubator (Cambridge, UK) to 37 ºC. Forty ml of growth medium was poured into a 
150 cm² flask. A vial of preadipocytes was removed from a liquid nitrogen store and 
the vial lid was loosened to help release pressure then quickly transferred in a box of 
ice. The vial was then placed in a water bath at 37 ºC continuously swirled for 90 
seconds to defrost cells. After defrosting, 1 ml of the warm culture growth medium 
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was added into the vial to ensure all cells were thawed completely, and mixed gently 
up and down using a pipette. The cell suspension was added to the 150 cm² flask 
contained growth medium and immediately incubated at 37 ºC with a humidified 
atmosphere of 5% CO2 /95% air for 24 hr, and the lid of flask was released a half 
turn. In the following, cells viability was directly checked under a phase contrast by 
Diaphot inverted microscope (Nikon, Surrey, UK) after which cells were removed 
from incubator. The culture medium was replaced with fresh growth medium and the 
cells were incubated for 3 to 4 days.  Cells were observed during these days to see if 
the cells had become 70 to 90% confluent, but not reached 100% confluence to make 
sure cells will not undergo growth arrest.  
 
2.3.4 Preadipocytes subculture  
Once preadipocytes reached 70%-90% confluence, medium was discarded by 
aspirating it aseptically, after which attached cells were washed 2 times with 
autoclaved phosphate-buffered saline (PBS) by adding 10 ml each time from the 
non-layered side to avoid removing the cells. The PBS was removed and 6 ml of 
trypsin was added to the flask and placed in the incubator at 37ºC for 3 to 5 minutes 
or placed at room temperature inside the laminar flow for detaching cells. The cells 
were inspected under a light microscope, and the flask gently shaken, to check if all 
cells had become completely detached. Once all the cells were fully detached, 10 ml 
of culture growth medium was added to the flask with swirling it to neutralize the 
trypsin solution and prevent toxic effects of trypsin that may cause cells death. The 
number of cells was counted using a haemocytometer. Flask suspension aliquot was 
used in both sides of haemocytometer by pipetting 10 µl of cell suspension to each 
side. The total cell number was used to determine the volume of cells' suspension 
which was needed to reach 40,000 cells per ml/well as the cell plating density. 
Remaining cell suspension was poured into a 30 ml centrifuge tube then spun at 250 
x g for 5 minutes. The supernatant was aspirated aseptically from the tube and 5 ml 
of growth medium and Cryo-Stem Freezing Medium (Cryo-SFM) with ratio 4:1 were 
added to pellet of cells to obtain homogeneity.  To store cells in liquid nitrogen with 
a new passage number put each 1 ml of cells suspension in separate vial. 
Alternatively, 1 vial of cells suspension was added to original flask (150 cm²) with 
adding 40 ml of growth medium to continue in experiment. The flask was then 
placed back into the incubator at 37 ºC and 5% CO2/95% air for 3 days. Once 
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preadipocytes  reached proper confluence (70%-90%) the cells would  be plated  out  
and then placed back into an incubator at 37 ºC and 5% CO2/95% air until cells had 
become 90% confluent. Depending on the experimental deign, preadipocytes could 
be used at this point for experiment or cells would be induced to differentiate into 
mature adipocytes.  
 
2.3.5 Human preadipocytes differentiation 
The growth medium was discarded from all wells, and preadipocytes were washed 
two times with sterile PBS that had been pre-warmed to 37 ºC in 1000-HB a 
hybridization incubator (Cambridge, UK). PBS was then removed, and the induction 
medium was added to each well. This time point was defined as day 0 (zero).  The 
plates were then incubated at 37 ºC and 5% CO2/95% air for four days. 
Differentiation of the cells was checked using a light microscope under phase 
contrast, where small lipid droplets could be recognized within the cells. The 
Differentiation medium was then aspirated, and the feeding medium was replaced 
every three days with fresh feeding medium until day 12 post differentiation.  
 
2.4 HumanTHP-1 monocytes culture  
2.4.1 THP-1 cell culture medium and equipment 
1x Roswell Park Memorial Institute 1640 medium (RPMI-1640) 
10% Fetal calf serum 
100 nM phorbol 12-myristate 13-acetate (PMA) 
100 U/ml penicillin and 100 µg/ ml streptomycin mix  
Pipette and sterile pipette tips 
75 cm
2 
culture flasks  
 
2.4.2 Human THP-1 monocytes   
The human THP-1 acute monocytic leukemia cell line was purchased from Health 
Protection Agency Culture Collections (Porton Down, Salisbury UK). Liquid 
nitrogen storage was used to store all vials of cells until the day of use. 
 
2.4.3 Human THP-1 monocytes generation and maintenance  
To start a cell subculture experiment, a frozen vial of human THP-1 monocytes 
(1x10
6
) was taken from the liquid nitrogen store and immediately defrosted in a water 
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bath at 37 ºC or by holding in hand until completely thawed. One ml of pre-warmed 
THP-1 culture medium was added to the vial to facilitate defrosting and the cells 
were suspended gently being pipetted up and down a few times. The thawed aliquot 
was then poured into a 75 cm
2
 flask containing 20 ml of THP-1 culture medium and 
then placed in an incubator at 37 ºC in a humidified atmosphere of 5% CO2/ 95% air 
for 24 hr with the flask’s lid released a half turn. After 24 hr of incubation, cells were 
poured into a 50 ml centrifuge tube and spun down at 200 x g for 5 minutes, and then 
the supernatant was discarded aseptically. The pellet of cells was mixed with 5 ml of 
fresh cell culture medium. Once again, the suspension of cells was decanted into 75 
cm² flask, and 20 ml of THP-1 culture medium was added to the flask. Cells could be 
passaged every 3 to 4 days when cell density reached 10
6
/ml. For culturing, THP-1 
cells (1X10
6
) were cultured in 24-well plates in Roswell Park Memorial Institute 
(RPMI-1640) medium with 10% FCS, 100 U/ml penicillin and 100µg/ml 
streptomycin at 37 ºC. 
 
2.4.4 Human THP-1 monocytes differentiation and macrophage-conditioned 
medium preparation 
To prepare macrophage-conditioned (MC) medium, THP-1 monocytes were 
differentiated by the addition of PMA 100 nM (Sigma) for 48 hr. The culture 
medium was  replaced with serum-free RPMI-1640 medium (without PMA) for 24 h. 
the MC medium was then collected and stored at -80 ºC until needed. 
 
2.4.5 Human Peripheral blood mononuclear cells (PBMCs) culture  
2.4.5.1 PBMCs culture medium and equipment 
1x Roswell Park Memorial Institute 1640 medium (No phenol red) 
10% Fetal bovine serum 
2 mM L-glutamine 
20 Mm 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
100 nM phorbol 12-myristate 13-acetate (PMA)  
1 µg/ml Lipopolysaccharides (LPS; Sigma, UK)  
1 mM Adenosine triphosphate (ATP; Sigma, UK) 
Pipette and sterile pipette tips 
Cell culture flasks (Corning, Amsterdam, Holland) 
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Cell culture plates (Corning, Amsterdam, Holland)  
 
2.4.5.2 Generation of human primary macrophage-conditioned medium   
Peripheral blood-derived macrophages were obtained from six healthy male and 
female donors BMI: (20-28). Blood sampling was approved by local and national 
ethics committees (UK National Research Ethics Service). PBMCs were 
differentiated into macrophages and macrophage-conditioned medium was collected, 
which was kindly provided by Dr Christopher Ford (Liverpool University, UK). All 
vials of medium were stored in -80 ºC until the day of use.  
 
2.5 Cell treatment  
According to the specific experimental design, the cells were treated with different 
agents and various concentrations as described in more details in each result chapter.  
 
2.6 Cell and medium collection 
All precautions needed were taken to avoid any contamination of the candidate cells 
and collected medium. Firstly, all glassware was well washed and autoclaved and all 
plastic ware used was as a brand new and sterile. Secondly, the UV-C lamp in the 
laminar flow hood was turned on to sterilise the surfaces for at least 15 minutes. 
Thirdly, the cell culture hood was wiped by1% Vircon solution, and wiped by 70% 
ethanol as well, to make sure a clean environment for cell and medium collection 
was obtained. Fourthly, collection tubes were completely sprayed with 70% ethanol 
and opened inside a sterile cell culture hood. In aseptic way, cell lysate or extract and 
medium were transferred into RNase-free 2 ml centrifuge tubes or sterile 1.5 ml 
Eppendorf tubes (Eppendorf, UK). 
 
2.6.1 Cell culture medium collection 
2.6.1.1 The practical basis 
Cell culture medium was collected prior to cell collection for measurement of 
secreted proteins as conditioned medium is a good source of secreted proteins by the 
cells. ELISA was used to measure secreted protein concentrations after a given 
treatment to study changes in the secretion pattern.  
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2.6.1.2 Medium collection method  
 Equipment   
Pipette and sterile pipette tips 
RNase-free 2ml centrifuge tubes 
Sterile 1.5 ml Eppendorf tubes  
Sterile centrifuge tubes  
 
The steps were carried out as follows: once the cells were ready to study, Either the 
preadipocytes or adipocytes conditioned medium was collected into 1.5 ml 
Eppendorf or RNase-free 2 ml centrifuge tubes by taking just 1 ml from each well. 
The collected medium was stored at -80 ºC until further use. 
 
2.6.2 Cell collection for Total RNA extraction 
2.6.2.1 The practical basis 
A strong denaturing chemical compound used to denature protein is guanidinium 
thiocyanate, which is able to efficiently breakdown cells, denature protein and 
inactivate RNase. Guanidinium thiocyanate is a key reagent in the TRIzol® solution 
(Invitrogen, Paisley, UK). To extract total RNA from preadipocytes or adipocytes, 
guanidinium thiocyanate-phenol-chloroform extraction was used based on the 
method described by Chomczynski and his colleague (Chomczynski and Sacchi, 
2006). Chloroform, as detergent, binds to protein and lipids of the cell membrane 
dissolving them as non-aqueous compounds. Thus, it disrupts cell membrane by 
breaking bonds that hold the membrane together. RNA and DNA are aqueous 
compounds. As for phenol, it is used for separating the RNA aqueous supernatant 
from other phases that contain DNA and non-aqueous compounds. 
 
2.6.2.2 Reagent and equipment   
Cell culture in plates  
TRIzol® reagent (Contains phenol and guanidine isothiocyanate) 
RNase-free 2ml centrifuge tubes 
Pipette and sterile pipette tips  
Rocking platform 
 
62 
 
After the cell medium were collected or discarded, 500 µl of TRIzol® solution was 
added into each well of the plate which was then shaken by using a rocking platform 
for 5 minutes to detach cells. After cells have detached, the cells suspension was 
pipetted up and down to ensure that all cells were mechanically dislodged. Then 
from each well the mixture was collected into RNase tubes and stored at -80 ºC until 
further investigation. The collected cells were used for RNA extraction (See section 
2.9). 
 
2.6.3 Collection of cell lysate  
2.6.3.1 The practical basis 
The cell collection was carried out for measuring biological molecules (intracellular 
proteins) through breakdown of candidate cells to allow isolation and extraction of 
the proteins which could be used for investigation. Lysis buffer was used to disrupt 
the cell membrane together with mechanical disruption by using pipetting for 
enhanced breakage.  Most of the mammalian cells are generally fragile and can be 
disrupted by lysis buffer that contains sodium dodecyl sulphate detergent (SDS). 
SDS is considered as the main component of cell lysis buffer, where its function, in 
addition to lysing action, is to denature proteins into their primary structure. Protein 
extracts need to be collected as quickly as possible and stored at -80 ºC until use to 
reduce degradation. Therefore, it is highly recommended to add protease and 
phosphatase inhibitor cocktails to lysis buffer. Protease inhibitor acts to inhibit 
endogenous proteases which are released during cell disruption and degrade other 
proteins (Deutscher, 1990). The phosphatase inhibitor acts to inhibit the action of 
exogenous and endogenous phosphatases (Deutscher, 1990). These phosphatases 
may remove phosphate group from proteins which are phosphorylated by protein 
kinases, most likely at tyrosine or serine residues, during cell signal transduction 
episodes that are involved in several cellular processes such as cell growth, 
proliferation and cell apoptosis (Alberts et al., 2015). Moreover, there are many 
methods for lysing cells to extract total protein carried out depending on the protein 
of interest. 
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2.6.3.2 Reagent and equipment  
  Cell lysis buffer 
  50 mM Tris-HCl, pH 6.7 
  5% glycerol 
  2% SDS  
  Protease inhibitor cocktail (1:100) 
  Phosphatase inhibitor cocktail (1:100) 
  Cold autoclaved PBS  
  Pipette and sterile pipette tips 
  RNase-free centrifuge tubes  
 
2.6.3.3 Method  
After the cell medium was aspirated, the monolayer of cells was washed two times 
with 1 ml of cold autoclaved PBS per well. 300 µl or 150 µl of lysis buffer was 
added into each well of a 6 well plate or 12 well plate respectively. Tapping the plate 
on the bench was needed to remove the attached cells from the bottom of the wells. 
The cells/lysis mixture was pipetted up and down to ensure that the maximum 
number of cells were collected and then transferred into RNase-free 2 ml centrifuge 
tubes and stored at -80 ºC to prevent protein degradation until further investigation. 
 
2.7 Analysis of lipid accumulation in adipocytes  
2.7.1 Oil Red O Staining assay 
2.7.1.1 Reagent and equipment  
Autoclaved PBS 
Oil Red O stain  
10% formaldehyde  
Isopropanol  
96-wells microplate  
Shaker platform 
Inverted microscope/D50 camera (Nikon,UK) 
Benchmark™ Plus Microplate Spectrophotometer (Bio-Rad, UK) 
Lysis buffer 
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2.7.1.2 Method  
Post differentiation, mature adipocytes have neutral lipid droplets that were stained 
with Oil Red O as described previously (Ramirez-Zacarias et al., 1992) with some 
modifications. The cell culture medium was discarded from wells and monolayer 
cells were washed two times with PBS. Cells in each well of a 6 well plate were 
fixed in 0.5 ml 10% formaldehyde (BDH, UK) in PBS for 1 hr at room temperature. 
Freshly prepared Oil Red O solution (six ml 0.5% Oil Red O in isopropanol with 4 
ml water mixed), then 375µl of Oil Red O solution was added into each wells of 
plates for 1 hour at room temperature. Cells subsequently were washed with PBS to 
remove excess Oil Red O stain, and cells were observed and images were taken by 
using a phase contrast microscope (Figure 2.1). The dye retained in cells was 
removed with 300 µl of isopropanol after that 200 µl of isopropanol from each well 
of plate was transferred into a new 96 well plate for measuring lipid content through 
the absorbance wave at 510 nm by a Benchmark™ Plus Microplate 
Spectrophotometer (Bio-rad, UK). Lipid levels were then correlated to total protein 
amount by using BCA protein assay (As described in section 2.13.2).    
 
Figure 2-1: Oil Red O Staining to determine neutral lipid content in 
mature adipocytes 
 
a                                                                      b   
 
 
 
 
 
The figure shows the phase contrast photos of human preadipocytes post 
differentiation. (a) Differentiated adipocytes without staining as control; (b) 
Differentiated adipocytes stained with Oil Red O. 
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2.8 Determination of glycerol release in cell culture medium 
Glycerol, release during lipolysis, was determined in adipocyte culture medium using 
a colorimetric method as described previously (Mracek et al., 2011). 
  
2.8.1 Reagent and equipment  
Glycerol standard solution (0.26 mg/ml) (Sigma,UK) 
Reconstitution free glycerol reagent (Sigma,UK) 
Double distilled water  
96-wells microplate 
Shaker platform 
Benchmark™ Plus Microplate Spectrophotometer (Bio-rad, UK)  
 
2.8.1.1 Method 
Briefly, a 1:1 of reconstituted free glycerol and double distilled water was prepared 
and mixed well. Serial dilutions of glycerol standard solution were prepared as 
follows: 1(blank), 1:5, 1:10, 1:20, 1:40, 1:80, 1:160. Medium (25 µl) or serial 
dilutions of glycerol standard solution were incubated with a free glycerol reagent 
(200 µl, Sigma) in a 96-well microplate at room temperature on a shaker platform to 
mix thoroughly for 15 min. The absorbance of the samples and standard were then 
measured using Benchmark
™
 Plus Microplate Spectrophotometer (Bio-rad, UK) at a 
wavelength of 540 nm. The concentrations of glycerol in samples were calculated by 
a glycerol standard curve constructed from the glycerol standard or alternatively by 
using the following formula:  
         [(A sample – A blank) / (A standard – A blank)] x Concentration of standard  
 
2.9 Total RNA isolation 
 
2.9.1 Reagents and equipment   
RNase AWAY
®
 
TRIzol
®
/Cells mixture  
Cholorform 
Isoprpanol  
75% pure ethanol 
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Refrigeration centrifuge 
Sterile pipette tips and pipette  
Ultra-pure water– molecular biology reagent, RNase and DNase-free (Sigma) 
 
2.9.2 Method 
To prevent any RNase and DNase contamination, all lab ware including glass, plastic 
ware, gloves and all surfaces around the RNA isolation work must be sprayed with 
RNase AWAY
® 
as precaution. Cells were collected in TRIzol
®
 as a mixture as 
mentioned in section 2.9.1. The TRIzol
®
/Cells mixture was placed in the box of ice 
and thawed at room temperature and homogenised by passing them through a 23 
gauge needle three times, separate needles were used for each sample. 100 µl of 
cholorform reagent was added into each tube of the Trizol
®
/cells mixture and the 
tubes were vigorously shaken for 15 to 20 second after which the mixture was left to 
stand for 10 mins at room temperature.  All mixture tubes were then centrifuged at 
14000 rpm for 15 mins at 4 ºC. Three phases were created and seen in the tubes; a 
lower red colour containing protein, a white interphase containing DNA and 
colourless upper aqueous containing RNA. The colourless upper aqueous RNA layer 
was moved into a new RNase-free tube with extra care taken when pipetting to avoid 
any contamination from any of the other two layers. 250 µl of isopropanol was added 
to each aqueous tube which was then vortexed and left to stand at room temperature 
for 10 minutes.  All tubes were then centrifuged once more at 4 ºC for 10 mins at 
14000 rpm. Following this, the supernatant was aspirated away, making sure that 
pellets were not dislodged and still remained in the tubes.  100 µl of 75% ethanol 
was added into each tube, which were gently shaken up side down, after which tubes 
were centrifuged at 4 ºC for 10 minutes at 14000 rpm again.  The supernatant was 
discarded by using a pipette (taking care not remove the RNA pellet ) and the pellets 
were allowed to air dry for 5 minutes before being dissolved in 12 µl of RNase-free 
water (Sigma); the RNA samples were then be stored at -80 ºC until required for 
RNA quantification. 
 
2.9.3 RNA quantification 
To measure RNA concentration and purity, RNA samples were first thawed at room 
temperature on ice and then the RNA samples were diluted 1:70 in RNase-free water. 
A spectrophotometer (Biophotometer Eppendorf, Cambridge, UK) was set to read 
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diluted RNA samples. 70 µl of RNase-free water was added into a 10 mm cuvette 
tube and then measured as a blank. The sample was prepared by adding 1 µl of RNA 
to 69 µl of the RNase-free water in a cuvette tube. The absorbance reading was taken 
at 260 nm (A260) and 280 nm (A280) and then the RNA concentration (µg/µl) was 
automatically calculated by the spectrophotometer. At 260 nm, the nucleic acids can 
reach to their maximum absorbance, and RNA has an extinct coefficient of 
approximately 44.19 at that wavelength. The concentration of RNA can be calculated 
by the spectrophotometer using the Beer-Lambert law: 
Concentration of RNA µg/µl = A260 x 44 x Dilution factor/1000 
 
This quantified the RNA purity to discover if there were any protein contaminations 
from the extraction. Therefore, if the value 260:280 ratio = 2 that would indicate a 
pure sample, where a value < 1.6 would show poor RNA quality with contamination 
which is probably from protein. RNA extracts were diluted to a concentration of 0.1 
µg/ µl by using this formula:  
          Concentration of RNA extract x 1 µl = 0.1 µg/ µl x total volume of dilution  
  
2.10 Reverse-transcription polymerase chain reaction 
 
2.10.1 The practical basis     
This technique was used for generating single-strand DNA complementary to the 
mRNA sequences in total RNA samples. An RNA-dependent DNA polymerase 
enzyme (reverse transcriptase enzyme, RT) is not normally found in prokaryotic and 
eukaryotic cells, but is found in few types of viruses including retrovirus.  In this 
reaction, reverse transcriptase enzyme derived from Monloney Murine Leukaemia 
Virus (MMLV) was used (Pelt-Verkuil et al., 2008). In addition, the iScript first 
strand cDNA Synthesis Kit (Bio-Rad, Hertfordshire, UK), including oligo (dT) and 
random hexamer primers, was used in the reaction mix. The poly (A) tail at the 3' 
end of the mRNA acts as a starting point for the reverse transcriptase to which a 
short complementary synthetic oligonucleotide (oligo dTprimer) is hybridised to 
form a poly (dT/dA) hybrid. Random hexamers primers are synthesized completely 
randomly to provide a various range of cDNA sequences. Random hexamers primers 
were combined to allow priming all over the length of mRNA for uniform 
68 
 
representation of all RNA sequences ensures transcription of 5' ends of long mRNA 
and allows for reverse transcription of RNAs without poly (A) tails (Figure 2.2). The 
cDNA synthesis on the mRNA template needs essential conditions and resources 
which are available and maintained in the kit buffer including all four 
deoxynucleotide triphosphates (dNTPs), MgCl2  supplies Mg
2+
 as cofactors and a 
neutral pH.   
 
2.10.2 Method 
Reagent and equipment 
5xcDNA synthesis kit buffer  
iScript reverse transcriptase (Bio-Rad, UK) 
0.1 µg/µl RNA sample 
Thermal cycler (Eppendorf, UK)         
   
After the total RNA was quantified, reverse transcription (RT) was performed to 
make DNA strands that are complementary to the mRNA. These strands are single 
stranded DNA (ssDNA) referred to as complementary DNA (cDNA).  
 
Based on the manufacture’s protocol (Bio Rad), the total RNA was diluted 1:10 for 
use in RT-PCR. The RT procedure was performed in 0.5 ml sterile RNase-free tubes, 
with the total reaction volume of 10 µl.  The Master mix was prepared in a RNase 
free tube using 2µl of 5XiScripit reaction (Bio-Rad, UK) mix,  0.5 µl of iScript 
reverse transcriptase, 2.5 µl of nuclease free water and the volume was made up to 
10 µl by adding a 1:10 RNA template volume to give a concentration of 0.5 µg  of  
RNA.  
 
A master mix of 5xiScripit reaction mix and iScript reverse transcriptase was made 
up to carry out the required amount of reaction, plus two more reactions volume were 
needed in case any error happened in the pipetting. 5 µl of the master mix was then 
added to the 1.5 ml tubes containing water and RNA template, mixed by vortexing, 
and then centrifuged to spin the sample down. The RT reaction was carried out in a 
thermal cycler (PCR express). The tubes were incubated at 25 ºC for 5 minutes, 
followed by 42 ºC for 30 minutes, 85 ºC for 5 minutes and finally held at 4 ºC for 10 
minutes to cool the tubes. Once the reaction was completed, cDNA was diluted 1:4 
69 
 
by adding 30 µl of ultra-pure water into each PCR tube for use in quantitative PCR 
(qPCR) and standard PCR. The samples were stored at -20 ºC to prevent degradation 
until required for use.  
 
Figure 2-2: First strand cDNA synthesis 
 
 
 
The figure shows the traditional first strand cDNA synthesis by using oligo-(dT) 
primer and reverse transcriptase enzyme which hybrids to the mRNA sequences. 
 
 
2.11 Real-time polymerase chain reaction (RT-qPCR) 
 
2.11.1 The practical basis  
RT-qPCR is a reproducible and sensitive method for quantifying genes of interest 
(DNA and RNA target) in biological samples. It is considered to be a fundamental 
progress of the PCR technology that allows reliable detection and measurement of 
mRNA levels generated during each cycle of PCR process (Fraga et al., 2008). Its 
procedure follows the general principles of PCR and quantifies a targeted DNA 
molecule during the exponential phase based on amplification of DNA. In the 
exponential phase, the amount of PCR product approximately doubles in each cycle 
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as the reaction proceeds until the  reaction slows and enters a non-exponential phase 
(cycles 28–40) (Figure 2.3). Therefore, the exponential phase is considered to be a 
very efficiently phase that occurs early in the reaction process and gives reliable 
quantification of the starting DNA by correlating the measurement to the amount of 
specific starting DNA. Primarily, intercalating dyes such as SYBRGreen
®
 was used 
by PCR product detection. After that qPCR systems were improved by the 
introduction of fluorogenic probes such as Taqman
®
. Taqman
®
 system was used in 
this project (Eurogentec, UK). 
 
2.11.2 Taqman
®
 system principles  
In this project, the Taqman
®
 system was used to measure specific PCR product 
accumulation by using a pair of primers (sense and anti-sense) and a dual-labelled 
fluorogenic oligonucleotide probe (Fraga et al., 2008). The probe is a short 
oligonucleotide sequence which is labelled with two different fluorescent dyes. The 
reporter dye (fluorophore usually FAM) is covalently linked to the 5' terminus end 
and a quenching dye (usually TAMRA) at the 3' terminus end. A probe homologous 
to primers that is designed to anneal within cDNA regions by binding to specific 
area. The probe will be excited by energy emitted from the PCR cycler’s light 
source, and when the reporter and quencher are in close proximity, energy is 
transferred between the two fluorophores and emission from the reporter is quenched 
by the quencher by a process called FRET (Forster or fluorescence resonance energy 
transfer). As the reaction proceeds, the primes are extended toward the probe and 
synthesis the nascent strand by Taq polymerase that cleaves the probe, releasing the 
reporter from the oligonucleotide quencher. The activity of FRET is consequently 
reduced and the reporter emits fluorescence (518 nm or FAM) which increases 
during each cycle proportional to the rate of probe cleavage. As the reaction 
proceeds, the increased numbers of PCR products can be observed when the amount 
of fluorescence (ΔR) is increased. The Mx3005P qPCR software measures the 
florescent emission of reporter by using a reference dye (usually ROX), and a 
software algorithm is used to calculate and normalise the increase of reporter signal 
intensity over the extension phase (ΔRN) to the reference dye (ROX). Normalization 
is essential to correct for difference in reaction mix volumes between samples. The 
amplification plot is examined at an early point in the log phase of product 
accumulation. This is done when fluorescence from a sample crosses the threshold, 
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and permits the fluorescence to be plotted on a graph against the cycle number 
(Figure 2.3).    
 
2.11.3 Preparation of 96 well plates for real-time PCR 
2.11.3.1 Taqman assay reagent and equipment 
           qPCR core kit consisting of: 
           10 x reaction buffer 
           50 mM magnesium chloride  
           5 mM dNTP mix  
           Forward and reverse primers 
           Taqman probe 
           RNase- free water  
  Strategne Mx3005P instrument (Thermal cycler) 
 
2.11.3.2 Method 
A master mix for each gene of interest without cDNA was made up to give a final 
volume of 11.5 µl per well, with a 2-well excess to allow for pipetting errors. 1 µl of 
the synthesised cDNA (equivalent to 12.5 ng of cDNA) was added into each well of 
a 96 well plate. Real-time amplification was performed in a final volume of 12.5 µl 
made up of cDNA, optimised concentration of primers, Taqman probe (FAM-
TAMRA) and a master mix made from a qPCR core kit (Euroentech, Seraing, 
Belgium). Real-time PCR amplification was performed in duplicates using a 
Strategene Mx3005P instrument. A non-template control was incubated in each 
plate. The plate was spun at 500 x g for 1 minute to gather the contents to the bottom 
of the wells. The plate was then inserted into the heat block of the Mx3005P qPCR 
instrument with an optical pad placed on top and aligned with the well position. PCR 
cycling conditions were as follows: 95 ºC denaturation step for 10 minutes followed 
by 40 cycles (95 ºC denaturation step for 15 seconds and annealing-cum-extension 
step at 60 ºC) for 1 min. Data was collected automatically in real-time by MxPro 
software and analysed at the end of the run.  
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Figure 2-3: Amplification plot; Baseline-subtracted fluorescence 
against number of PCR cycles 
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The figure shows an amplification plot of cycle numbers on the X axis against 
fluorescence units (dRn) on the Y axis for each reaction. The blue line represents an 
amplification plot, while the exponential phase highlighted by the green arrow and 
the non-exponential phase is highlighted by the yellow arrow. The Ct (threshold 
cycle) value defined as the number of cycles required for the fluorescent signal to 
cross the threshold level. 
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2.11.3.3 Taqman assay reagents  
Working solutions of primers and probes were reconstituted to produce a 100 µM 
stock.                 
                          Each 12.5 µl reaction contained the following: 
 
    
                        
   
  
  
    
  
  
  
    
  
   
                          
  
                                 
 
2.11.3.4 Analysis of real-time PCR data 
When data had been collected, the results were analysed by the Mx3005P software.   
Amplification plots were shown on log scale, and the threshold was manually 
adjusted for each plate to remove any background noise.  The software automatically 
recalculated the Ct value for each well (Ct defined as the cycle number at which the 
fluorescence emitted from the well crossed the threshold). All samples were 
normalised to the value of the housekeeping gene (β-actin), the difference of Ct 
values between the control and treated samples were calculated and the relative fold 
changes obtained between the two groups. The formula used for calculation is as 
previously reported (Livak and Schmittgen, 2001):  
 
                                   ΔCt=Ct (Target gene)-Ct (Reference gene) 
ΔΔCt=Mean ΔCt (Treated sample)-Mean ΔCt (Control samples)  
 Fold change= 2 
-ΔΔCt
 
Component Amount (µl) per well 
10x buffer 1.25 
MgCl2 1.25 
dNTP   0.5 
Forward Primer 0.038 
Reverse Primer          0.038 
Probe                                  0.063 
Hot Goldstar Enzyme 0.0625 
Ultra-pure water  8.3 
Total master mix volume per 
well  
11.5 
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2.11.3.5 Primer and probe sequences  
The sequences of primers and probes for human ß-actin, adiponectin, Leptin, IL-6, 
IL-8, MCP-1, C/EBPα, aP2 and PPARγ are described in Table (2.1) as previously 
reported (Bing et al., 2006, Wang et al., 2005a, Bao et al., 2005). The primers and 
probes for RANTES (CCL5) and IL-8were obtained commercially (Applied 
Biosystems, Applera; Hs99999048-m1 and Hs00174103-m1).   
 
Table 2-1: Primer sequence of human target genes 
 
Transcript     Primer sequence  
 
Human β-actin 
Forward             5'-GGATGCAGAAGGAGATCACTG-3' 
Reverse             5'-CGATCCACACGGAGTACTTG-3' 
Probe                            5'-FAM-CCCTGGCACCCAGCAATG-TAMRA-3' 
Human Adiponectin  
Forward             5'-CCCAAAGAGGAGAGAGGAAGCT-3' 
Reverse             5'-GCCAGCAATGAGATGCAA-3' 
Probe             5'-FAM-TTCCCAGATGCCCCAGCAAC-TAMRA-3' 
Human Leptin                         
Forward                                            5'-CCAAAACCCTCATCAAGACAATT-3'   
Reverse                                             5'-AGTCCAAACCGCTGTCTTTCTG-3' 
Probe                                            5'-TGACATTTCACACGCAGTCAGTCTCCT-3' 
Human IL-6 
Forward             5'-GGTACATCCTCGACGGCATCT-3' 
Reverse             5'-GTGCCTCTTTGCTGCTTTCAC-3' 
Probe                                           5'-FAMTGTTACTCTTGTTACATGTCTCCTTT CTCAGGGCTTAMRA-3'                                                                      
Human MCP-1 
Forward                            5'-CATAGCAGCCACCTTCATTCC-3' 
Reverse                            5'-TCTGCACTGAGATCTTCCTATTGG-3' 
Probe             5'-FAM-ACCTGGACCTCTGCCCTCCGGATGGTAMRA-3' 
C/EBPα 
Forward                                             5'-AGAGCCGAGATAAAGCCAAACA-3' 
Reverse                                              5'-CGGTCATTGTCACTGGTCAACT-3'  
Probe                                                 5'-AACGTGGAGACGCAAGGTGCT-3'   
PPARϒ 
Forward                                             5'-AGTGGAGACCGCCCAGG-3' 
Reverse                                              5'-GCAGCAGGTTGTCTTGGATGT-3' 
Probe                                              5'-TTGCTGAACGTGAAGCCCATCGAG-3' 
AP2 
Forward                                            5'-GTCAAGAGCACCATAACCTTAGATG-3' 
Reverse                                             5'- TCGTGGAAGTGACGCCTTTC-3'                                                                     
Probe                                                5'-ACGCATTCCACCACCAGTTTATCATCCTCT-3' 
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2.12 Enzyme-linked immunosorbent assay (ELISA) 
2.12.1 The practical basis  
Enzyme-linked immunosorbent assay (ELISA) is a biochemical assay used to detect 
the presence of proteins that are released from cells and measure their concentrations 
in the biological solution (usually in liquid or wet sample) (Engvall and Perlmann, 
1971). ELISA is done by adding a specific antibody (Capture and detection) to the 
sample solution to attach to the antigen which can then be detected.  
 
In this research, proteins released from primary human preadipocytes and adipocytes 
into the cell culture medium were measured after treating cells with many different 
treatments. The ELISA kits used in this research were all commercially available 
(R&D system), and were suited for the measurement of natural proteins produced by 
human cells. As mentioned in the ELISA procedure (Section 2.12.2.4), a microtiter 
plate was used and coated overnight with capture antibody (monoclonal) against the 
target protein.  After the coating of the plate, unbound antibodies were washed and 
were blocked using reagent diluent or blocking buffer to block non-specific binding 
sites for 1 hr before adding cell culture medium into the plate for 2 hr. The wells 
were aspirated and then washed with washing buffer three times and incubated with 
the detection antibody (anti-human target protein antibody) for 2 hr to bind with the 
antigens. Washing steps were repeated before adding streptavidin–horseradish 
peroxide conjugate which binds to the biotin on the detection antibody for 20 
minutes. Once again washing steps were repeated and then substrate solution 
consisting of equal volumes of hydrogen peroxide and tetramethylbenzidine (TMB) 
(usually called A and B substrate) was added for 20 minutes. The horseradish 
peroxide (HRP) enzyme oxidises TMB and providing a visible blue colour by 
catalyzing the electron transfer from TMB to the peroxide. Stop solution was added 
to stop colour development, which resulted in a yellow solution to appear. The 
absorbance is afterward measured at 450 nm with a wavelength correction set to 570 
nm. Note, all wells were incubated at room temperature. IL-1β, IL-8, IL-6, MCP-1, 
RANTES (CCL5) and adiponectin, in cell culture medium were measured using 
DuoSet ELISA development kits purchased from R&D (Abingdon, UK) according to 
their protocols.   
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2.12.2 Method  
2.12.2.1 Measurement of MCP-1, IL-6, IL-1β, RANTES (CCL5) and adiponectin  
Reagents and equipment  
Phosphate-buffered saline (PBS) 
Reagent diluent (1% BSA in filtered PBS) as blocking buffer 
Capture monoclonal antibody (Diluted to working concentration with PBS) 
Detection monoclonal antibody (Diluted to working concentration with reagent 
diluent) 
Recombinant human standard (Diluted in various 2-fold serial dilution for 7 points 
standard curve, excluding blank)  
Wash buffer (0.05% Tween-20 in PBS)  
Streptavidin-HRP  
Substrate solution mixture (1:1 in volume) 
Stop solution (2MSulphric acid) 
96-well MaxiSorp
®
 flat-bottom microplate  
Benchmark
™
 Plus Microplate Spectrophotometer 
Multi-channel pipette 
Shaker plate form (Fisher Scientific, UK) 
 
2.12.2.2 Measurement of IL-8 
Reagents and equipment  
Phosphate-buffered saline (PBS) 
Tris-buffered Saline (20 mM Trizma base and 150 mM NaCl) 
Blocking buffer (1% BSA in PBS with 0.05% sodium azide (NaN3)) 
Reagent diluents (0.1% BSA and 0.05% Tween-20 in PBS in Tris-buffered Saline) 
Capture monoclonal antibody (Diluted to working concentration with PBS) 
Detection monoclonal antibody (Diluted to working concentration with reagent 
diluent) 
Recombinant human standard (Diluted in various 2-fold serial dilution for 7 points 
standard curve, excluding blank)  
Wash buffer (0.05% Tween-20 in PBS) 
Streptavidin-HRP  
Substrate solution mixture (1:1 in volume) 
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Stop solution (2MSulphric acid) 
96-well MaxiSorp
®
 flat-bottom microplate  
Benchmark™ Plus Microplate Spectrophotometer 
Multi-channel pipette 
 
2.12.2.3 Plate preparation 
1. The capture antibody was diluted with PBS to make a working solution (Table 
2.2). A 96-well MaxiSorp
®
 flat–bottom microplate was immediately coated with 100 
µl of diluted antibody per well, sealed and incubated overnight.  
2. The following day, each well was aspirated and washed 3 times with washing 
buffer by using a multi-channel pipette. To avoid excess wash buffer in the wells, 
plates were turned upside down and gently tapped against a clean paper towel.  
3. The plate was blocked with 300 µl of reagent diluent for one hr at room 
temperature. Again, the aspiration and washing as mentioned in step 2 was repeated. 
The plate was then ready to use. 
 
2.12.2.4 Assay procedure 
1. 100 µl of sample or standard were added into wells after they were diluted in 
Reagent Diluent. The wells were covered with an adhesive film and left to incubate 
at room temperature for 2 hr. 
2. Repeat the aspiration and wash as mentioned above, and 100 µl of detection 
antibody as added into wells after being diluted in reagent diluent. The wells were 
incubated for 2 hr and with a new adhesive film to cover them. 
3. Repeat the aspiration and wash, after which 100 µl working solution of 
Streptavidin-HRP was added to each well and the plate was incubated for 20 minutes 
at room temperature. 
4. The wells were aspirated and washed. 100 µl of substrate solution was then added 
to each well and incubated for at least 20 minutes in the dark until a blue colour 
developed. 50 µl of Stop solution was added to each well to stop colour development 
and the plate was gently tapped to ensure thorough mixing.   
5. The optical density was determined using a microplate spectrophotometer at 450 
nm with a reference wavelength at 570 nm to correct any optical imperfections if 
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found in the plate.  The concentrations of proteins were calculated using the standard 
curve. 
Samples treated with or without MC medium and several treatments according to the 
experimental design were diluted and some samples were used neat based on the 
pilot studies. The optical density of the samples were obtained using a Benchmark™ 
Plus microplate spectrophotometer (Bio-Rad). The Microplate Manger v5.2 software 
was used to collect and analyse the data. A standard curve was made and plotted to 
achieve a best-fit line and correlation coefficient of > 0.96 by applying the equation 
of the best-fit curve or line to calculate the concentration of protein. 
 
 
Table 2-2: Antibodies and standard concentrations used for ELISAs 
 
Protein measured Captured 
antibody  
working 
solution 
concentration 
Detection 
antibody   
working solution 
 concentration 
Concentration of 
S1 (first point) 
 
Human adiponectin 
 
2 µg/ml 
 
2  µg/ml 
 
4000 pg/ml 
Human IL-6 2 µg/ml 50   ng/ml  600  pg/ml 
Human MCP 1 µg/ml 100 ng/ml 1000 pg/ml 
Human IL-8 4 mg/ml 4 mg/ml 2000 pg/ml 
Human RANTES  1 mg/ml  20  ng/ml                     1000 pg/ml 
Human IL-1β              4 µg/ml                               200 ng/ml                     250  pg/ml 
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Figure 2-4: Schematic illustration of ELISA 
 
 
The figure shows briefly the procedure of the enzyme-linked immunosorbent assay 
(ELISA).    
 
2.13 Western blotting  
2.13.1 Western blotting principles  
In 1979, the Western blotting method also known as protein immunoblot was 
introduced by Towbin and his colleagues (Towbin et al., 1979). It has become one of 
the most common techniques in the molecular biology field, which is used to 
separate and identify proteins’ expression within many different human cells 
including primary adipose cells. In this study, cell lysates were collected with lysis 
buffer that contained protease and phosphatase inhibitor cocktails (both from Sigma, 
UK). Tissue or cell lysate preparation is often carried out at cold temperatures to 
avoid protein denaturing and degradation as mentioned with more detail in section 
2.6.3. After cell lysates were collected, the bicinchoninic acid (BCA) method was 
used to quantify protein concentrations. These values were used to calculate the 
volume of lysate with a protein concentration 30 µg/lane that will be loaded per lane 
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of the acrylamide gel. Lysate was diluted 1:10 into a loading buffer. Loading buffer 
contains glycerol, SDS, β-mercaptoethanol and bromophenol blue dye.  Glycerol 
helps samples sink easily into the gel’s wells. SDS offers the protein a negative 
charge and β-mercaptoethanol prevents the reformation of disulphide bonds. The 
bromophenol blue helps to visualise how far the protein separation through gel has 
progressed. The lysate was heated immediately after being diluted, to denature the 
higher protein structure; by denaturing the high structure it ensures that the negative 
charge of amino acids is not neutralized, enabling the protein to move during 
electrophorosis. Diluted lysates were then equally loaded into each well of sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) gel.  
 
After the protein mixtures were separated, they were transferred to a nitrocellulose 
membrane. The transfer is done using an electric field oriented vertical to the surface 
of the gel, causing proteins to move out of the gel onto the membrane. The 
membrane was then probed using antibodies binding-specifically to a protein of 
interest. To detect the protein of interest from total protein, an appropriate primary 
antibody was used. Firstly, the nitrocellulose membrane was blocked with bovine 
serum albumin solution (5% BSA) for 1 hr prior to addition of a primary antibody 
overnight at 4 ºC. Secondly, a secondary antibody-HRP conjugate was then added to 
bind to the primary antibody for 1 hour. Finally, a luminol substrate was added to the 
secondary antibody which converted to a chemiluminescent substance due to the 
effect of HRP conjugate in the secondary antibody. The signal intensity was then 
detected with the camera of the ChemiDoc™ XRs+ molecular imager. Notably, 
Western blotting was used in this project to measure the relative expression of 
proteins and is considered as a semi-quantitative method.   
 
2.13.2 Protein quantification by the Bicinchoninic acid (BCA) method 
2.13.2.1 The principle of the BCA protein assay 
This assay is used to measure total cellular proteins concentrations (from 0.2 to 1.0 
mg/ml). It is completely reliant on the reduction process, where the reduction amount 
is proportional to the protein amount present in samples (Smith et al., 1985). By 
mixing bicinchoninic acid and copper with proteins this will provide Cu
+
-protein 
complex in alkaline environments. BCA forms a purple-coloured complex with Cu
+ 
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in alkaline conditions. This happens due to the reduction of the Cu
2+
 to Cu
+
. 
Consequently, the amount of Cu
2+
 reduced is proportional to the amount of protein 
present in the solution. BCA assays are routinely performed at 37ºC (Smith et al., 
1985). It is always favourable to prepare the standard and the sample in the same 
buffer to reduce any interference effects. 
 
2.13.2.2 Reagent and equipment  
1 mg/ml bovine serum albumin (BSA-protein standard) 
Bicinchoninic acid solution  
Copper (II) sulphate solution  
Double distilled water  
96-well microplate  
Orbital microplate shaker 
Benchmark
™
 Plus Microplate Spectrophotometer 
 
2.13.2.3 Method   
Cell samples were diluted in lysis buffer that contained (25 mM Tris-HCl, pH 6.7, 10 
% Glycerol, 2% SDS) with freshly added protease inhibitor and phosphatase 
inhibitor cocktail to form cell lysates. A standard curve was plotted by using serial 
dilution of bovine serum albumin (BSA) with final concentrations of 0.2, 0.4, 0.6, 
0.8, 1.0 mg/ml. Cell lysates were diluted 1:4 into wells by pipetting 7.5 µl of double 
distilled water to 2.5 µl of cell lysate. A 50:1 bicinchoninic acid to copper sulphate 
solution was made and 200 µl of this mixture was added to each well of diluted 
standard or samples by using a multichannel pipette. The plate was gently tapped to 
ensure thorough mixing, and then incubated for 30 minutes in a hybridization oven. 
The plate was read using a spectrophotometer at 570 nm. The concentrations of 
protein were determined using the standard curve generated (Figure.2.5) and 
multiplying it by a dilution factor of 4. Data was collected and schemed using the 
Microplate Manager V5.2 software. A standard curve was created relative to the 
obtained protein concentration of the samples that were determined. A standard 
curve was made and plotted to achieve a best-fit line and correlation coefficient of > 
0.99 by applying the equation of the best-fit curve or line to calculate the 
concentration of protein, whereas the ideal correlation coefficient is equal 1. Samples 
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were then diluted 10 times with loading buffer and heated at 95 ºC to denature 
proteins for 10 minutes. Samples can be stored at -80 ºC or used directly in western 
blotting. 
 
Figure 2-5: Standard curve generation for Bicinchoninic acid (BCA) 
method 
 
 
                  
 
 
 
 
 
 
 
 
 
 
The figure shows a standard curve for measuring protein concentration by using BSA 
as standar. 
 
 
2.13.3 Sodium dodecyl sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
2.13.3.1 Reagent and equipment 
PageRular protein marker (Fermentas) 
Loading buffer 
1 ml 0.5 M Tris-HCL, pH 6.8  
1.6 ml 10% SDS 
1 ml Glycerol  
0.4 ml β-mercaptoethanol  
0.01 g Bromophenol blue  
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3x Gel Buffer  
18.16g Trizma base  
10 ml 5M hydrochloric acid   
0.75 ml 20% SDS  
Double-distilled water (made up to 50 ml in total volume) 
 
Separating gel (10 ml) (10%) 
2 ml 48 % acrylamide/1.5 % bisacrylamide mixed with 36.4 ml double distilled 
water  
3.3 ml 3x gel buffer  
1 ml glycerol 
50 µl ammonium persulphate  
6 µl tetramethylethylenediamine (TEMED) 
 
Stacking gel (5 ml) (4%) 
0.4 ml 48% acrylamide/1.5% bisacrylamide mixed with 3.36 ml double distilled 
water  
1.2 ml 3x gel buffer  
40 µl ammonium persulphate  
4 µl TEMD  
 
Cathode buffer (PH 8.25) 
12.11 g Trizma base (100 mM) 
17.92 g Tricine (100 mM) 
5 ml 20% SDS (0.1%) 
Double distilled water (made up to 1000 ml of total volume) 
 
Anode buffer (PH 8.9) 
24.22 Trizma base  
6 ml 1M hydrochloric acid  
Double distilled water (made up to 2000 ml total volume) 
 
Gel electrophesis equipment 
Bio-Rad Mini-PROTEAN™ Tetra System  
2.0 mm notched plates  
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2.0 mm plain glass plates 
1.0 mm comb, 10 or 15 well  
Casting base with silicone seals 
2.13.3.2 Method  
All gel electrophoresis components were cleaned with ethanol, dried and assembled 
according to the manufacturer’s instructions (Bio Rad). Once assembled and locked 
into position onto the casting base, distilled water was first poured between the glass 
plates to check for leak. The water was then poured and dried by using filter paper. 
Secondly, the separating gel was prepared and added between the glass plates by 
using a pipette and leaving a third of the space for the stacking gel. Then, 1x gel 
buffer or distilled water was added to the top of the gel to avoid gel from dehydrating 
while it sets.  Once the gel had set, 1x gel buffer or distilled water was poured out. 
Thirdly, the stacking gel was prepared and pipetted into remaining third of space 
between glass plates.  The combs were quickly inserted and the gel was stacked to 
set for 30 minutes. The combs were then removed from the gel’s top, and gels were 
removed from the casting base and placed into the gel tank. The tank was filled with 
Cathode buffer until the brim of the gel was completely submerged.  30 µg/lane of 
each sample was loaded slowly to each lane to avoid overflow and a PageRuler™ 
protein marker was added to the first lane. Anode buffer was then added to the tank 
to the labelled mark. The electrodes were run at 45v for 30 minutes to separate 
proteins, and increased to 85v until the blue dye migrated out of the gel. Finally, the 
electrophoresis system was disassembled and the gel was ready to be transferred.  
 
2.13.4 Electroblotting  
2.13.4.1 Reagents and equipment 
Transfer buffer 
3.03 g Tris-base (25 mM) 
14.4 g Glycine (192 mM) 
200 ml methanol (20%) 
Double distilled water (made up to 1000 ml volume) 
Electroblotting equipment 
Compression cassettes  
Fibre pads (foam pad) 
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Thick blotting paper (Filter paper) 
Hybond ECL nitrocellulose membrane 
Bio-Rad Mini-PROTEAN™ Tetra System 
 
Tris-base buffered saline (TBS) PH 7.2 -7.6  
2.42 g Tris-base   
29. 24 g sodium chloride  
 0.1% Tween-20 
Double distilled water (made up to 1000 ml volume) 
 
In the electroblotting step, all components; nitrocellulose membrane and thick filter 
paper were soaked in distilled water for 5 minutes and then transfer buffer for 10 
minutes. The blotting unit was assembled by placing components in the following 
order: 
Cassettes were opened, from the bottom: foam pad- blotting paper- transfer 
membrane- gel- blotting paper-foam pad. It was necessary to ensure there were no 
bubbles between the components within cassettes. The cassettes were then placed 
into the adapter.  The system was run at 100v for 80 minutes, with cold water or ice 
bag to keep the tank cool. 
 
2.13.5 Immunological detection of proteins  
2.13.5.1 Reagent and equipment  
0.1% Ponceau S 
Tris-base buffered saline (TBS) PH 7.2 -7.6  
0.1% TTBS (TBS and 0.1% Tween-20) 
Blocking solution (5% BSA in 0.1% TTBS) 
Primary antibodies 
Secondary antibodies 
Luminol enhancer and stable peroxide buffer (Supersignal® West Pico ECL kit) 
ChemiDoc™ XRS+ System (Bio-Rad) 
2.13.5.2 Ponceau S staining  
As soon as the transfer step was completed, the membrane was taken out and placed 
in a container and washed with 0.1% TTBS for 3 minutes. Detection procedure 
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began by submerging the membrane into Ponceau S stain for 5 minutes until the 
protein bands could be seen. The ponceau S was then discarded and the membrane 
was immediately washed with 0.1% TTBS to remove the red stain.  
 
2.13.5.3 Signal detection  
After the red stain was removed, the membrane was placed and incubated in a small 
container containing 5 ml of blocking solution at room temperature for 1 hour on a 
shaker. Primary antibody was added to the blocking solution to a ratio depending on 
the instructions supplied and optimization test. The container was incubated on a 
shaking platform overnight at 4 ºC. From experience, monoclonal antibodies were 
favoured than polyclonal ones, because they had less background on blot due to their 
high specificity. In the following day, the membrane was placed on a shaking 
platform and washed 4 times each for 10 minutes with fresh 0.1% TTBS. The 
membrane was submerged in blocking solution and the secondary antibody 
conjugated with HRP was added to a ratio depending on the instructions supplied and 
incubated for 1 hour at room temperature on a shaking platform. Repeat washing step 
again for 4 times in fresh 0.1%TTBS for 10 minutes each time. The membrane was 
finally washed in TBS (without Tween-20) to reduce the signal induced by Tween-
20, before moving on to the development step. The enhanced chemiluminescence 
(ECL) solution was added in a 1:1 ratio, incubated for 5 minute and the membrane 
was taken out with forceps and placed in a transparent plastic folder; gently 
removing any bubbles that might be introduced into the folder. The membrane was 
scanned using the ChemiDoc™ XRS+ System and the accumulative signals were 
read over a period of 40 minutes. The antibody concentrations and conditions 
presented in Table 2. 3 were used for each probe.  
2.13.5.4 Determination of the optimal primary antibody dilution  
Although the primary and secondary human antibodies concentrations were usually 
recommended by the manufacturers, it was also essential to define the optimal 
primary antibodies concentrations for detection which provides clean blots with low 
background. For this, a series of spot blots were carried out.  Several dilutions of 
protein sample were applied directly onto the nitrocellulose membrane, then each 
blot of the protein sample being prepared for specific antibody dilution to be tested. 
The membranes were then blocked with 5% BSA and washed exactly as mentioned 
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above. A dilution of primary antibody was then prepared as described in Table 2.3 
and incubated with the membrane overnight at 4Cº. 
2.13.5.5 Relative quantification of proteins 
To determine the optical density of band images created by the molecular imager, 
densitometry was used for this purpose by the Image Lab software provided along 
with the ChemiDoc™ XRS+ System. The volume/density values were exported to 
Excel and the relative densities were obtained by the normalization of the optical 
density for GAPDH which was used as a housekeeping protein.  
 
Table 2-3: Antibody dilution and condition used for western blots 
 
Primary Antibodies         Provider           Dilution      Molecular weight   
 
 GAPDH 
   
 
 IRS-1 
 
 
 PI3K p85 
 
 
GLUT-4 
 
 Total AKT   
 
 
 p-Akt (Ser473) 
 
 
 p-IR(Y-1185) 
 
 p-IRS-1(Ser-612) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abcam 
 
 
 
Cell signalling 
 
 
Cell signalling 
 
 
Millipore 
 
 
Cell signalling 
 
 
Cell signalling 
 
  
 
Abcam 
 
Cell signalling 
 
 
 
  
1:2000 
 
 
 
 1:1000 
 
 
 1:1000 
 
 
 1:2500 
 
 
 1:1000 
 
  
1:1000 
 
  
 
 1:1000 
 
1:1000 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 43 KDa 
  
  
 
170 KDa 
60 KDa 
55 KDa 
50 KDa 
50 KDa 
95 KDa 
170 KDa 
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2.14 Cell viability assessment 
Cell viability was determined by using a colorimetric method for measuring cellular 
cytotoxicity from the release of lactate dehydrogenase (LDH) into cell culture 
medium. After treatment with THP-1 MC medium, IL-1β, IL-1RA, Caspas-1 
inhibitor and IL-1β neutralizing antibody, the viability of preadipocytes and 
adipocytes were determined by using the LDH cytotoxicity assay (Thermo 
Scientific
TM 
Pierce
TM
, USA). Cell culture medium was collected for measuring LDH 
activity. LDH levels were measured using a spectrophotometer at 490 and 680 nm at 
room temperature. The LDH activity in the medium was determined once reducing 
of NADH was occurred as explained in the following reaction:  
 Lactate + NAD
+
    ----------> Pyruvate + NADH
 
For calculation of cytotoxicity: 
Cytotoxicity (%) = (Experimental value – Low control) / High control – Low control) x 100 
Low control was defined as the sample cell culture medium (not-treated cells) only while 
high control containing 1x LDH positive control solution. All samples were measured in 
triplicate. 
2.15 Statistical analysis 
All results are presented as mean ± SEM or mean ± SD and group size varied 
between experiments. Differences between two groups were analysed by Student’s 
unpaired t-test, while differences among more than two groups were assessed by one-
way ANOVA coupled with Bonferroni’s t-test. Differences were considered as 
statistically significant when p< 0.05. Statistical tests were performed using 
Graphpad Prism version 5.03 (Graphpad software Inc., California, USA).  
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CHAPTER 3: 
 Characterization of insulin signalling molecules in 
human preadipocytes 
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3 Characterization of insulin signalling molecules in human 
preadipocytes   
 
3.1 Introduction  
Obesity, defined as an abnormal increase in WAT accumulation in the body, is a 
global health problem (Berry et al., 2014). Obesity is characterised by chronic low-
grade inflammation, which contributes to the development of insulin resistance and 
type 2 diabetes (Lumeng and Saltiel, 2011a, Odegaard and Chawla, 2013). The 
development of obesity induces marked changes in WAT morphology and functions 
(Sun et al., 2011); WAT becomes inflamed with a significant increase in infiltration 
of macrophages and other immune cells (Lolmède et al., 2011, Weisberg et al., 
2003). Macrophage-derived factors potently stimulate the production of pro-
inflammatory cytokines and chemokines by human preadipocytes and adipocytes 
(Lacasa et al., 2007, Coppack, 2001). 
 
Insulin as an anabolic hormone has crucial biological actions, mainly regulating 
glucose homeostasis by the stimulation of glucose uptake on insulin sensitive organs 
including adipose tissue, muscle and liver through the insulin signalling pathway 
(Gual and Tanti, 2005, Saltiel and Kahn, 2001). The insulin action is triggered by 
binding of insulin to the insulin receptor which induces auto-phosphorylation of 
intrinsic amino acids, including tyrosine and serine residues (Kido et al., 2001, Paz et 
al., 1999). The auto-phosphorylation leads to the activation of two major signalling 
pathways including the metabolic (PKB/Akt) and the mitogenic (MAPKs) cascades. 
In the metabolic cascade, insulin controls circulating glucose level through 
coordination of two processes: inhibition of glucose production by hepatic cells and 
stimulation of insulin target cells (muscle and adipose tissues) to uptake glucose 
(Cheatham and Kahn, 1995). To complete this metabolic function, phosphorylation 
of the IRS-1 and/or IRS-2 at tyrosine residues is considered as critical and required 
step to bind and activate PI3-kinase. The PI3-kinase has downstream effectors such 
as protein kinase B (PKB), also known as Akt. Akt mediates the metabolic actions of 
insulin through the phosphorylation of several substrates including several kinases 
and, leading to an increase in glucose uptake by inducing GLUT-4 translocation from 
intracellular vesicles to the plasma membrane (Taniguchi et al., 2006).  
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Interestingly, insulin sensitive organs have been shown to display insulin resistance 
particularly in the obese state (Hotamisligil, 2000). Although, adipose tissue only 
represents approximately 10% of glucose disposal from the whole body compared 
with muscle and liver which represent 60% and 30% of glucose uptake respectively 
(Smith, 2002), adipose tissue has been considered as an intrinsic inducer to initiate 
insulin resistance in muscle and hepatic tissue. This could be due to a decreased 
response to insulin in hypertrophied adipocytes, which may stimulate FFAs release 
into the blood circulation leading to systemic insulin resistance (Smith, 2002). This 
notion has been supported by the study of Krebs and his colleague Roden who found 
that insulin resistance is positively correlated with high circulating levels of FFAs 
which are released during the lipolysis process (Krebs and Roden, 2005).   
 
Considering the importance of insulin action, firstly, it regulates cellular mechanisms 
in adipose cells by stimulating several operations, including glucose and FFAs 
uptake, increasing de novo fatty acid synthesis in adipocytes and inhibiting lipolysis 
(Saltiel and Kahn, 2001). Moreover, insulin modulates the development of adipose 
tissue by regulating the expression of a number of adipokines and adipogenic 
transcription factors including PPARγ and SREBP-1c (Vidal-Puig et al., 1997, Dif et 
al., 2006). Secondly, WAT is approximately composed of 50% adipocytes and 50% 
SVF cells which include preadipocytes, macrophages and other immune cells (Eto et 
al., 2009). Therefore, preadipocytes appear to be a major cellular component of the 
SVF. However, the characteristics of insulin signalling and the molecules involved in 
human preadipocytes are largely unknown.   
 
A previous study using murine preadipocytes cell lines (3T3L-1 and 3T3-F442A)  
has shown that insulin signalling molecules including IR, IRS-1 and PI3K-p85α were 
increased during the differentiation of adipocytes but the auto-phosphorylation levels 
of IR and IRS-1 were decreased after chronic treatment with dexamethasone or 
insulin (Saad et al., 1994). Wortmannin has been shown to inhibit PI3K-p85α which 
in turn inhibits adipogenesis of 3T3L-1 (Tomiyama et al., 1995), activation of PKB 
is adequate to induce adipocyte differentiation (Magun et al., 1996). Wnt signaling is 
essential for healthy growth through promotes muscle and bone development and 
blocks the development of fat (Wright et al., 2007, Glass et al., 2005, Day et al., 
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2005). Interestingly, it has also reported that Wnt signalling  interaction with insulin 
signalling in preadipocytes led to phosphorylation of key insulin signalling proteins 
through Wnt co-receptor LRP5 (Palsgaard et al., 2012).  
 
Previous study on human preadipocytes has reported that insulin sensitization of 
preadipocytes by glucocorticoid, are produced in adipose tissue and contribute to 
metabolic disorders, may improve human preadipocyte differentiation and enhance 
components of the insulin signalling pathway (Tomlinson et al., 2010). Overall, it is 
still unclear whether insulin alone modulates the insulin signalling molecules in 
human preadipocytes. Therefore, this chapter will investigate and characterize the 
insulin signalling molecules and their response to insulin in human preadipocytes. 
The knowledge obtained would provide a basis for understanding the mechanisms 
that underlie how adipose tissue, as insulin target organ, contributes to insulin 
sensitivity or insulin resistance occurred in the physiological or pathological 
conditions. 
 
3.2 Aim of the study  
The aim of this study was to characterize the insulin signalling molecules, including 
IR (Y1185), IRS-1 (Ser612), PI3K p85α, GLUT-4 and Akt (Ser473), in human 
primary preadipocytes in comparison with adipocytes. By using in vitro human cell 
models, the specific objectives were set below:  
 Basal expression of insulin signalling molecules in human primary 
preadipocytes; 
 Expression of glucose transporter-4 (GLUT-4) during preadipocytes 
differentiation;  
 Expression of insulin-stimulated phosphorylation of IR, IRS-1 and Akt in 
preadipocytes; 
 Expression of insulin-stimulated phosphorylation of IR, IRS-1 and Akt in 
adipocytes. 
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3.3 Material and methods  
3.3.1 Culture of human preadipocytes and adipocytes  
Human white preadipocytes cell cultured based on the protocol from PromoCell 
(Heidelberg, Germany). Cells were cultured in preadipocyte growth medium 
supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, and 0.25 µg/ml 
amphotericin B (Lonza, Tewkesbury, UK) at 37°C in a humidified atmosphere of 5% 
CO2-95% air. Preadipocytes were seeded at 40,000/cm
2
 and divided into two groups. 
In the first group, preadipocytes were grown until confluence and then harvested as 
cell lysates for investigating the insulin signalling molecules. In the second group, 
preadipocytes were induced to differentiate (day 0) by incubation for 3 days in 
Dulbecco’s modified Eagle’s medium (DMEM)-Ham’s F-12 (1:1) medium 
containing 32 µM biotin, 1 µM dexamethasone, 200 µM 3-isobutyl-1-
methylxanthine, 100 nM insulin, 11 nM L-thyroxine (all from Sigma, Poole, Dorset, 
UK), 8 µM rosiglitazone (GlaxoSmithKline, Uxbridge, UK), and 100 U/ml 
penicillin, 100 µg/ml streptomycin, and 0.25 µg/ml amphotericin B. After induction, 
cells were cultured in maintenance medium containing 3% fetal calf serum (FCS, 
Sigma), 100 nM insulin, 32 µM biotin, 1 µM dexamethasone and antibiotics until 
full differentiation into adipocytes. Adipocytes were then harvested as cell lysates for 
investigating the insulin signalling molecules. 
 
3.3.2 Cell treatment 
According to a time course experiment that was previously performed by our group, 
the optimal time point of maximum response to insulin was verified as at 5 min 
following the  stimulation with insulin (data not shown). Therefore, preadipocytes 
and adipocytes were treated with 100 nM of insulin for 5 miutes to stimulate the 
autophosphorylation of insulin signalling molecules. Separate groups of 
preadipocytes and adipocytes were not treated with insulin and served as controls. 
 
3.3.3 Western blotting 
Protein concentrations in cell lysates were determined by the BCA assay as described 
in section 2.13.2. Protein samples (20µg/lane) were resolved by 10% Tricine-SDS 
polyacrylamide slab gels (Mini Protean Tetra, Bio-Rad, Hemel Hempstead, UK) and 
transferred onto a nitrocellulose membrane. For immunodetection, the membrane 
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was blocked for 1 h at room temperature with TBS containing 0.1% Tween-20 and 
5% BSA and then incubated overnight at 4°C with the primary antibodies, including 
IRS-1(diluted at1:1000), PI3K p85α (diluted at1:1000) and GLUT4(diluted at1:2500) 
in 5% BSA and 0.1% Tween-20.  For insulin response study, primary antibodies 
phospho-insulin receptor (Y1185), phospho-IRS-1 (Ser612) and phospho-Akt (S473) 
were diluted at 1:1000. GAPDH (diluted at 1:20000). After four washes with 
1xTTBS, the membranes were incubated with a HRP-conjugated secondary antibody 
(diluted at 1:2000). Signals were detected by enhanced chemiluminescence and 
scanned using Molecular Imager ChemiDoc XRS+ System (Bio-Rad). The size of 
the protein bands detected was estimated with PageRuler protein markers 
(Fermentas, York, UK). The membranes were further probed with GAPDH (1:20000 
dilution) or total Akt (1:1000 dilution) as a loading control.    
 
3.3.4 Statistical analysis 
Data are expressed as means ± SEM. Differences between two groups were analysed 
by Student’s unpaired t-test. Differences were considered as statistically significant 
when p< 0.05. 
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3.4 Results 
3.4.1 Basal and insulin-stimulated expression of the insulin signalling proteins in 
human primary preadipocytes and adipocytes 
 
3.4.1.1 Basal expression of the insulin signalling proteins (IRS-1, PI3K-p85α and 
GLUT-4) in human primary preadipocytes and adipocytes    
This experiment was to investigate whether preadipocytes would express any of the 
insulin signalling proteins at basal level in comparison with mature human 
adipocytes. One group of human primary preadipocytes was grown until confluence 
and then cells were harvested as cell lysates for investigating the basal expression of 
insulin signalling molecules, including total IRS-1, total PI3K-p85α and GLUT-4. 
The second group of preadipocytes was differentiated and maintained until became 
mature adipocytes (at day 12 post-differentiation), and then they were harvested as 
cell lysates for investigating the basal expression of insulin signalling proteins as 
positive controls.  
 
3.4.1.1.1 Protein abundance of insulin receptor substrate-1 (IRS-1) in human 
preadipocytes and adipocytes   
Basal IRS-1 protein expression was detected in preadipocytes and mature adipocytes. 
However, the basal level of IRS-1 expression was significantly higher (1.8-fold, p˂ 
0.05) in adipocyte compared with preadipocytes (Figure 3.1 a-b).   
 
3.4.1.1.2 Protein abundance of phosphatidylinositol 3-kinase-p85α (PI3K-p85α) in 
human preadipocytes and adipocytes 
Total PI3K-p85α protein expression in was also detected preadipocytes but it was 
significantly higher in adipocytes (1.4-fold, p˂ 0.01) compared with preadipocytes 
(Figure 3.1 a, c).     
 
3.4.1.1.3 Protein abundance of glucose transporter 4 (GLUT-4) in human 
preadipocytes and adipocytes 
In preadipocytes, the expression of GLUT-4 protein was barely detectable. However, 
GLUT-4 expression was significantly increased (12-fold, p< 0.001) at day 12 post 
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differentiation (mature adipocytes) in comparison with preadipocytes (Figure 3.1 a, 
d).  
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 Figure 3-1: Basal expressions of the insulin signalling protein (IRS-
1, PI3K-p85α and GLUT-4) in human preadipocytes and adipocytes 
             
                a     
        
 
 
                                                                              
                
               b                  
  
 
 
 
 
 
 
     c      
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                d  
 
 
 
 
 
 
 
 
 
 
Basal expression of insulin signalling proteins of IRS-1, PI3K-p85 and GLUT-4 in 
human preadipocytes were compared with mature human adipocytes. Both 
preadipocytes and adipocytes were unstimulated. (a) Western blotting was used for 
measuring protein expression in cell lysates, and GAPDH was used as a loading 
control. The relative protein expression of insulin signalling proteins including IRS-1 
(b), PI3K-p85α (c) and GLUT-4 (d) were quantified and analysed by using 
densitometric analysis of signal intensity. Data are means ± SEM (n=3 per group). 
*p< 0.05, **p< 0.01, ***p<0.001 
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3.4.2 Expression of glucose transporter 4 (GLUT-4) during preadipocytes 
differentiation 
 
GLUT-4 was largely expressed in mature adipocytes (Figure 3.1); its expression 
during the adipocyte development was then examined. Consistently, the level of 
GLUT-4 expression was barely detected at day 0 but interestingly, GLUT-4 
expression was significantly increased from day 3 to day 12 post differentiation in 
human adipocytes  (3.2-fold, p< 0.01) (Figure 3.2). 
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Figure 3-2: Time course of glucose transporter 4 (GLUT-4) 
expressions during preadipocyte differentiation 
 
 
 a 
 
 
 
b 
 
 
 
 
 
 
 
Expression of GLUT-4 protein during the development of human adipocytes. (a) 
Western blotting was used for measuring GLUT-4 protein expression in cell lysates, 
and GAPDH was used as a loading control. (b) The relative protein expression of 
GLUT-4 was quantified and analysed by using densitometric analysis of signal 
intensity. Data are means ± SEM (n=3 per group). *p< 0.05, **p< 0.01 between 
groups indicated; ND, none detected  
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3.4.3 Phosphorylation of the insulin signalling proteins p-IR, p-IRS-1(Ser612) and 
p-Akt (Ser473) in human preadipocytes in response to insulin  
Insulin can trigger auto-phosphorylation events which act as signals in the cells 
(Taniguchi et al., 2006). This experiment was performed to investigate whether any 
of the key insulin signalling molecules expressed by preadipocytes are modulated 
after insulin stimulation. Western blotting was used to detect phosphorylated insulin 
receptor (p-IR-Y1185), phosphorylated insulin receptor substrate-1(p-IRS-1Ser612) 
and phosphorylated Akt (Ser473).  
 
3.4.3.1 Protein abundance of insulin-stimulated phosphorylation of IR (Y1185) in 
human preadipocytes  
In this experiment, it was observed that basal levels of p-IR were detectable and they 
were significantly increased (6-fold, p˂ 0.002) in preadipocytes which were 
stimulated with 100 nM insulin, compared with unstimulated preadipocytes (Figure 
3.3). 
 
3.4.3.2 Protein abundance of insulin-stimulated phosphorylation of IRS-1 
(Ser612) in human preadipocytes  
Protein level of the p-IRS-1(Ser612) in unstimulated preadipopcytes was also 
detectable but at very low levels.  In line with the result of insulin-stimulated p-IR, p-
IRS-1(Ser612) was significantly increased (p˂ 0.001) in preadipocytes that were 
stimulated with 100 nM insulin (Figure 3.4). 
 
3.4.3.3 Protein abundance of insulin-stimulated phosphorylation of Akt (Ser473) 
in human preadipocytes  
The results have shown that basal protein level of p-Akt (Ser473) was not detectable 
in unstimulated preadipopcytes (Figure 3.5). However, p-Akt (Ser473) was 
significantly increased (p˂ 0.001) in preadipocytes which were stimulated with 100 
nM insulin. 
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Figure 3-3: Expression of insulin-stimulated phosphorylation of IR 
(Y1185) in human preadipocytes 
 
 
              a    
  
 
 
 
                 b   
               
 
 
 
 
 
 
 
 
Preadipocytes were treated with or without insulin (100nM) for 5 min. (a) The 
representative western blot is shown for p-IR and GAPDH was used a loading 
control (b) The relative protein expression of p-IR was quantified by using 
densitometric analysis of signal intensity. Data is shown as mean ± SEM (n=3 per 
group). **p< 0.01  
 
 
 
 
 
103 
 
Figure 3-4: Expression of insulin-stimulated phosphorylation of 
IRS-1 (Ser612) in human preadipocytes 
 
 
             a  
 
 
 
 
 
          b 
 
                 
 
              
 
 
 
 
 
 
 
Preadipocytes were treated with or without insulin (100nM) for 5 min. (a) The 
representative western blot is shown for p-IRS-1(Ser612) which was normalised to 
the loading control GAPDH. (b) The relative protein expression of p-IRS-1(Ser612) 
was quantified by using densitometric analysis of signal intensity. Data is shown as 
mean ± SEM (n=3per group). ***p< 0.001    
 .    
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Figure 3-5: Expression of insulin-stimulated phosphorylation of Akt 
(Ser473) in human preadipocytes 
 
 
 
            a      
  
 
 
 
 
 
            b   
                       
 
 
 
 
 
 
                       
 
Preadipocytes were treated with or without insulin (100nM) for 5 min. (a) The 
representative western blot is shown for p-Akt (Ser473) which was normalised to the 
loading control, GAPDH. (b) The relative protein expression of p-Akt (Ser473) was 
quantified by using densitometric analysis of signal intensity. Data is shown as mean 
± SEM (n= 3 per group). ***p< 0.001, ND, none detected   
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3.4.4 Phosphorylation of the insulin signalling proteins p-IR (Y1185), p-IRS-
1(Ser612) and p-AKT (Ser473) in human adipocytes in response to insulin 
  
This experiment was performed in adipocytes to examine the phosphorylation of the 
key insulin signalling proteins, which served as controls to preadipocytes. Proteins 
including p-IR (Y1185), p-IRS-1(Ser612) and p-Akt (Ser473) were measured by 
using western blotting. Human primary preadipocytes were differentiated and 
maintained until they became mature adipocytes (at day 12 post-differentiation). The 
cells were then treated with or without 100 nM insulin. Cell lysates were collected 
for examining the expression of the phosphorylated insulin signalling proteins.  
 
3.4.4.1 Protein abundance of insulin-stimulated phosphorylation of IR (Y1185) in 
human adipocytes 
As shown by figure 3.6, phosphorylated IR (Y1185) was expressed at low levels in 
adipocytes; it was significantly increased (4.2-fold, p˂ 0.01) in response to insulin in 
comparison with unstimulated adipocytes. 
 
3.4.4.2 Protein abundance of insulin-stimulated phosphorylation of IRS-1 
(Ser612) in human adipocytes 
A significant increase was observed in abundance level of phosphorylated IRS-1 
(Ser612) (2.9-fold, p˂ 0.01) in insulin-stimulated adipocytes in comparison to 
unstimulated adipocytes (Figure 3.7)  
 
3.4.4.3 Protein abundance of insulin-stimulated phosphorylation of Akt (Ser473) 
in human adipocytes 
In agreement with the results of p-IR and p-IRS-1 (Ser612), phosphorylated Akt 
(Ser473) was expressed at low levels in adipocytes; its expression was significantly 
increased (1.7-fold, p˂ 0.05) in insulin-stimulated adipocytes in comparison to 
unstimulated adipocytes (Figure 3.8). 
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Figure 3-6: Expression of insulin-stimulated phosphorylation of IR 
(Y1185) in mature human adipocytes 
 
                  
                a    
 
 
 
 
              b              
  
 
 
 
 
 
 
 
 
Adipocytes were treated with or without insulin (100nM) for 5 min. (a) The 
representative western blot is shown for p-IR (Y1185) which was normalised to the 
loading control, total Akt. (b) The relative protein expression of p-IR was quantified 
by using densitometric analysis of signal intensity. Data is shown as mean ± SEM 
(n=3 per group), **p< 0.01    
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Figure 3-7: Expression of insulin-stimulated phosphorylation of 
IRS-1 (Ser612) in mature human adipocytes 
                           
          a                           
       
 
 
 
 
          b           
                            
 
 
  
 
 
 
 
 
 
 
Adipocytes were treated with or without insulin (100nM) for 5 min. (a) The 
representative western blot is shown for p-IRS-1(Ser612) which was normalised to 
the loading control GAPDH. (b) The relative protein expression of p-IRS-1 (Ser612) 
was quantified by using densitometric analysis of signal intensity. Data is shown as 
mean ± SEM (n=3 per group), *p< 0.05 
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Figure 3-8: Expression of insulin-stimulated phosphorylation of Akt 
(Ser473) in mature human adipocytes 
 
              a  
 
 
 
 
 
  
             b 
                              
                                         
 
 
 
 
 
 
Adipocytes were treated with or without insulin (100nM) for 5 min. (a) The 
representative western blot is shown for p-Akt (Ser473) which was normalised to the 
loading control total Akt.  (b) The relative protein expression of p-Akt (Ser473) was 
quantified by using densitometric analysis of signal intensity. Data is shown as mean 
± SEM (n=3 per group), **p< 0.01   
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3.5 Discussion 
Adipose tissue is one of the main target tissues for insulin action and a major 
contributor to insulin resistance during obesity development (Smith, 2002b). There is 
clear evidence that preadipocytes and adipocytes, as the main adipose cells in the 
organ, secrete a range of bioactive proteins including hormones, pro-inflammatory 
factors and other signalling molecules that have a role in glucose and lipid 
homeostasis (Van Tienen et al., 2011). It is suggested that insulin modulates 
adipocyte development and differentiation (Le Lay et al., 2002, Vidal-Puig et al., 
1997) but also acts as a key metabolic regulator (Saltiel and Kahn, 2001, Gual and 
Tanti, 2005). Moreover, preadipocytes are important in adipose tissue remodelling in 
obesity but their role in the development of insulin resistance is largely unknown. 
Therefore, the aim of the present study was to investigate whether insulin signalling 
molecules, particularly in the metabolic insulin cascade, are present and modulated 
by insulin in human preadipocytes.   
 
To our knowledge the basal levels of insulin signalling proteins in human 
preadipocytes with a direct comparison with human mature adipocytes have not yet 
been fully investigated before. The primary objective of this study was to examine 
whether the key insulin signalling molecules (IRS-1, PI3K- p85α and GlUT-4) are 
present at the basal level in human preadipocytes.  Results from this study showed 
that basal levels of insulin signalling proteins IRS-1 and PI3K-p85α were detected in 
human preadipocytes. Furthermore, these two insulin signalling molecules have 
significantly increased in mature adipocytes compared with preadipocytes (Figure3.1 
a-c). These results are in agreement with previous studies in murine adipocytes (Saad 
et al., 1994). It suggests that the expression levels of insulin signalling molecules for 
both IRS-1and PI3K-p85α in preadipocytes were increased during the course of the 
differentiation process, which may have importance in adipose tissue functions as 
well as development. 
 
IRS-1 is a member of the insulin receptor substrate family of signalling molecules, 
and is considered as one of the main insulin receptor substrates in the insulin 
signalling pathway in muscle and fat cells (Schmitz‐Peiffer and Whitehead, 2003). 
IRS-1 is a crucial mediator that plays a key role in insulin signalling particularly 
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once subsequently phosphorylated via activated IR (Sesti et al., 2001). IRS-1 
function is positively regulated once phosphorylation occurs at its tyrosine residue 
which is required for insulin-stimulated responses. However, IRS-1 at 
serine/threonine residues has double roles which in turn leading to stimulate or 
inhibit the insulin action through its signalling pathway (Paz et al., 1997). Evidence 
has suggested that insulin signalling in an individual with insulin resistance and type 
2 diabetes is often inhibited at the level of IRS-1 of tyrosine residues 
(Schmitz‐Peiffer and Whitehead, 2003, Sesti et al., 2001).  
 
PI3K is considered to be a downstream effector of IRS proteins (Cantley, 2002). 
After tyrosine phosphorylation, IRS proteins activate PI3K, where p85-α appears to 
be the subunit that links PI3-kinase activity in p110 to the tyrosine-phosphorylated 
proteins (Hara et al., 1994) leading to insulin-stimulated glucose transport and 
translocation through activation its downstream effector such as Akt (Cheatham and 
Kahn, 1995). Moreover, PI3K also plays an important role in insulin-reduced 
lipolysis in murine adipocytes (Okada et al., 1994). However, inhibition of PI3-
kinase using a specific inhibitor such as wortmannin totally impairs insulin-
stimulated glucose uptake in adipocytes (Okada et al., 1994). Collectively, it is 
suggested that increase in insulin signalling molecules including IRS-1 and PI3K is a 
prerequisite to promote the link of insulin signal transduction in adipose cells with 
glucose and lipid metabolism.  
 
The GLUT-4 is the major glucose transporter in adipose tissue and one of the final 
molecules in the process by which insulin mediates cellular glucose uptake (Olson 
and Pessin, 1996). The present study also showed that GLUT-4 protein level was 
barely detectable in preadipocytes compared to mature adipocytes. A previous study 
that used crude membrane fractions of undifferentiated human preadipocytes showed 
that GLUT-4 protein expression was detectable in a very small amount while its 
expression was increased by 16.7-fold at 16 day post differentiation (Hauner et al., 
1998). Interestingly, in preadipocytes there are repressor sequences in the 5'-flanking 
region of the GLUT-4 gene between positions -200 and -100 bp but not in adipocytes 
(Yokomori et al., 1999). Therefore, it has been suggested GLUT-4 protein is only 
abundantly expressed once preadipocytes differentiate into mature adipocytes. This 
study also performed a time course experiment to examine the levels of GLUT-4 
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protein expressions at several time points during preadipocytes differentiation. 
Results showed that GLUT-4 protein expression gradually increased from day 3 up 
to day 12 post differentiation (Figure 3.2). This is in agreement with previous studies 
using murine adipocytes (3T3L-1) in which several types of glucose transporter 
proteins are progressively expressed during the differentiation of adipocytes as 
demonstrated by kinetic studies (Weiland et al., 1990, Tordjman et al., 1989). Taken 
together, these results suggest that an increase in abundance of GLUT-4 expression 
in mature adipocytes could be responsible for the appearance of insulin 
responsiveness in adipose tissue to achieve metabolic function, such as insulin-
stimulated glucose transport.  
 
Another objective of the present study was to investigate whether the insulin 
signalling molecules, IR (Y1185), IRS-1 (Ser612) and Akt (Ser473) in human 
preadipocytes are modulated by insulin in comparison with mature adipocytes. The 
result showed that in both preadipocytes and mature adipocytes, exposure to insulin 
(100nM) led to the phosphorylation of IR (Y1185). Following insulin stimulation, 
there was a significant increase in the protein abundance of IR and this would be due 
to increased phosphorylation activity. This result is in agreement with the reports that 
once insulin binds to IR conformational changes are made (Kido et al., 2001, Sun et 
al., 1991), which in turn activates IR leading to its auto-phosphorylation (Hubbard et 
al., 1993).  
 
Considering the regulation of IRS-1 function is crucial in insulin signalling, this 
study examined whether insulin affects the IRS-1 (Ser612), as one of the IRS’ 
inhibitory residues in insulin signalling, in preadipocytes compared with adipocytes. 
The result showed that the level of phosphorylated IRS-1(Ser612) was significantly 
increased in both cells following insulin stimulation. Previous studies have found 
that phosphorylation of IRS-1 at serine residues has an inhibitory effect on insulin 
signalling pathway that may contribute to insulin resistance (Tanti et al., 1994, Gual 
and Tanti, 2005, Paz et al., 1997).   
 
Akt is known to serve as an important regulator of cell survival and proliferation 
(Song et al., 2005). The full activation of Akt needs phosphorylation on serine 473 of 
Akt by insulin or growth factors (Alessi et al., 1996). The present study also 
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examined whether Akt (Ser473) is modulated by insulin in preadipocytes in 
comparison with mature adipocytes. Result of the present study showed that insulin 
significantly stimulated the protein abundance of phosphorylated Akt (Ser473) in 
both adipose cells. These results suggested that treatment of adipose cells with 
insulin markedly induces the insulin signalling molecules that may have stimulatory 
or inhibitory roles on several biological processes such as proliferation, 
differentiation and development of adipose cells. 
 
In summary, our data provides some evidence that the key insulin signalling 
molecules were detected in both human adipose cells (preadipocytes and adipocytes).  
Both IRS-1and PI3K-p85α were expressed whereas Glut4 was barely detected in 
preadipocytes. The levels of insulin molecules (IRS-1, PI3K-p85α and GLUT-4) 
were significantly higher in differentiated adipocytes. Furthermore, insulin 
significantly stimulated the level of phosphorylated insulin signalling molecules, 
including IR (Y1185), IRS-1(Ser612) and Akt (Ser473), in human preadipocytes as 
well as mature adipocytes.  
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CHAPTER 4:  
IL-1β modulates insulin signalling proteins and 
mediates macrophage-induced production of pro-
inflammatory factors in human pre-adipocytes 
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4 IL-1β modulates insulin signalling proteins and mediates 
macrophage-induced production of pro-inflammatory 
factors in human pre-adipocytes 
 
4.1 Introduction 
In this chapter, it is investigated whether IL-1β plays a major role in mediating the 
effect of MC medium on insulin signalling pathways, and on cytokines/chemokines 
expression and release in human preadipocytes.  
As mentioned in previous sections, obesity is now accepted to be a state of chronic 
low-grade inflammation (Hotamisligil, 2006, Rosen and Spiegelman, 2006b). 
Growing evidence from the studies in obese mice and human suggests that increased 
macrophage accumulation in adipose tissue during obesity might provide a causative 
link between inflammation and metabolic disorders such as insulin resistance and 
type 2 diabetes (Cancello and Clement, 2006, Weisberg et al., 2003, Xu et al., 2003). 
In addition, macrophages-derived factors have been found to potently stimulate the 
production of pro-inflammatory cytokines and chemokines by human preadipocytes 
and adipocytes (Flower et al., 2003, Gao and Bing, 2011). 
WAT is made up of a number of different cell types including mature adipocytes,  
and the cells of the SVF which include fibroblast, preadipocytes, macrophages and 
other immune cells (T-Lymphocytes and neutrophils) (Lee et al., 2012, Fruhbeck, 
2008). These cells produce cytokines/chemokines and growth and complement 
factors (Fruhbeck, 2008, Yang et al., 2006). The alteration in the release of pro-
inflammatory factors by adipose cells has been associated with the metabolic 
disorders of obesity (Weisberg et al., 2003). Therefore, it is reasonable to expect that 
crosstalk will occur between these cells, possibly mediated by pro-inflammatory 
factors.     
Several studies have provided evidence that some pro-inflammatory factors including 
TNF-α, IL-6, MCP-1 and IL-1β, are directly involved in obesity-associated 
pathologies, particularly insulin resistance and type 2 diabetes (Spranger et al., 
2003c, Hotamisligil, 1999, Lagathu et al., 2003, Böni-Schnetzler and Donath, 2011, 
Sartipy and Loskutoff, 2003). An in vitro study using primary culture of human 
preadipocytes has shown that chemokines including IL-8, MIP-1 and MCP-1 were 
115 
 
highly produced, whereas their level of release was low in mature adipocytes 
(Gerhardt et al., 2001). This suggests that preadipocytes may have a central role in 
the recruitment of macrophages in comparison with mature adipocytes. 
Identification of the key factors that mediate the effect of macrophages on human 
preadipocytes is challenging but it may provide better understanding for obesity-
related insulin resistance in adipose tissue. IL-1β is considered as a key pro-
inflammatory cytokine which produced mainly by monocytes and macrophages 
(Agostini et al., 2004). In adipose tissue, gene expression of IL-1β is upregulated in 
obese mice and humans. IL-1β is also released by human adipose tissue explants but 
by non-fat cells (Fain, 2006, Koenen et al., 2011) and the levels released are 
enhanced in obesity (Nov et al., 2010). Some studies suggested that adipocytes also 
release IL-1β with much less amount as compared to macrophages (Lagathu et al., 
2006, Juge-Aubry et al., 2004, Wen et al., 2011, Tack et al., 2012). Previous studies 
also suggested a link between circulating IL-1β levels and metabolic disorders, such 
as insulin resistance and type 2 diabetes (Lagathu et al., 2006, Xie et al., 2010).       
Recently, researchers have started to study the crosstalk between macrophages and 
preadipocytes by establishing in vitro models from human and rodents’ origin 
(Sorisky et al., 2013, Lacasa et al., 2007, Gagnon et al., 2013). Using the crosstalk 
models, some studies have demonstrated that macrophages-derived factors inhibit 
preadipocyte differentiation in human abdominal stromal as well as 3T3-L1 
preadipocytes and stimulate inflammation in preadipocytes (Constant et al., 2006, 
Suganami et al., 2005).  In addition, a recent study by our group revealed that 
macrophage-derived factors induce expression and release of matrix metalloproteins 
in human preadipocytes (MMP1 and MMP3) which are involved in the inflammatory 
response and adipose tissue remodelling in obesity (Gao and Bing, 2011). 
Furthermore, two studies suggest that pro-inflammatory factors from macrophages 
induce profound changes in human preadipocytes that may stimulate a fibrotic 
phenotype via modification of extracellular matrix (ECM) in adipose tissue (Lacasa 
et al., 2007, Keophiphath et al., 2009). Interestingly, it has been shown that 
macrophages-derived factors protect 3T3-L1 preadipocytes from apoptosis via 
activation the survival signalling that phosphorylates Akt and Erk molecules in the 
presence of ROS (Molgat et al., 2011). However, there is a lack of studies using 
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human primary preadipocytes as an in vitro model to demonstrate the effect of 
macrophages or IL-1β on insulin signalling pathway. 
From the above, it has become clear that macrophages crosstalk with preadipocytes 
may influence preadipocytes differentiation, survival and proliferation. Insulin 
signalling is crucial and required for metabolic health (Fischer-Posovszky et al., 
2012, Taniguchi et al., 2006). Beside the studies on direct effect of macrophages on 
preadipocytes, a number of cytokines/chemokines (TNF-α, IL-6, IL-1β and MCP-1) 
have been considered as candidates to impair insulin signalling in mature adipocytes. 
However, little is known whether macrophages-derived factors modulate insulin 
signalling pathways in human primary preadipocytes. Moreover, whether IL-1β 
mediates the effect of macrophages on insulin signalling in human preadipocytes has 
not been reported. 
4.2 Aim of the study 
The aims of this study were to investigate the role of IL-1β in macrophage-
preadipocyte crosstalk, and how this crosstalk modulates the insulin signalling 
pathway in human preadipocytes. The specific objectives were set below: 
 Effect of treatment with IL-β (2 ng/ml) for 4 and 24 hr on the insulin 
signalling pathway in preadipocytes;  
 Effect of MC medium on expression of the insulin signalling molecules 
in preadipocytes; 
 Effect of blocking IL-1β activity on MC medium-modulated expression 
of the insulin signalling molecules; 
 Effect of blocking IL-1β activity on MC medium-induced gene 
expression of pro-inflammatory factors; 
 Effect of blocking IL-1β activity on MC medium-induced release of 
pro-inflammatory factors including IL-6, MCP-1, IL-8 and RANTES. 
 
4.3 Material and methods 
4.3.1 Culture of human preadipocytes    
Human white preadipocytes derived from subcutaneous adipose tissue of a female 
Caucasian subject (BMI 21kg/m
2
; age 44 yr) were obtained from PromoCell 
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(Heidelberg, Germany). Cells were cultured in preadipocyte growth medium 
supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, and 0.25 µg/ml 
amphotericin B (Lonza, Tewkesbury, UK) at 37 °C in a humidified atmosphere of 
5% CO2-95% air. Preadipocytes were seeded at 40,000/cm
2
. Subsequently, 
preadipocytes were grown until confluence. At confluence, preadipocytes were 
harvested to use for the studies below.    
4.3.2 Generation of THP-1 macrophages-conditioned medium 
The human THP-1 monocytes were cultured in (RPMI-1640) medium with 10% 
FCS, 100 U/ml penicillin and 100µg/ml streptomycin and then placed in an incubator 
at 37 ºC in humidified atmosphere of 5% CO2/ 95% air for 24 hr until cell density 
reached 10
6
/ml (see section 2.4.3). THP-1 monocytes were then differentiated by the 
addition of PMA 100 nM (Sigma) for 48 hr. The culture medium was replaced with 
serum-free RPMI-1640 medium (without PMA) for 24 h. the MC medium was then 
collected as previously mentioned in section 2.4.4.   
4.3.3 Cell treatment  
To assess whether IL-1β affects the insulin signalling pathway, human preadipocytes 
were treated with RPMI-1640 medium and with or without IL-1β (2 ng/ml) for 4 and 
24 hr. Preadipocytes were also treated with 100 nM of insulin for 5 minutes to 
stimulate the autophosphorylation of insulin signalling molecules. Separate groups of 
preadipocytes were not treated with insulin and served as controls. To investigate 
whether IL-1β mediates the effects of MC medium, MC medium was pre-incubated 
with a human IL-1β neutralizing antibody (2 μg/ml) for 1 hr at 37 °C to block IL-1β 
activity; preadipocytes were then incubated with either RPMI-1640 medium 
(control), MC medium or MC medium neutralized by IL-1β antibody for 24 hr. 
4.3.4 Western blotting  
For assessing protein expression Western blotting method was used. For insulin 
response study, primary antibodies inducing phospho-insulin receptor (Y1185) 
(abcam, UK), phospho-IRS-1 (Ser612) and phospho-Akt (S473) (New England 
BioLabs Ltd, Hitchin, UK) were used and diluted at 1:1000. GAPDH (abcam, UK) 
diluted at 1:2000 or Akt (Cell Signalling) diluted at 1:1000 was used as a loading 
control. After 4 washes with 1xTTBS, anti-rabbit secondary antibody (New England 
BioLabs Ltd, Hitchin, UK) at 1:2000 dilution (or 1:20000 for GAPDH) were used. 
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Signals were detected by chemiluminescence (West Pico kit, Pierce, Loughborough, 
UK) and scanned using Molecular Imager ChemiDoc XRS+ System (Bio-Rad). The 
size of the protein bands detected was estimated with PageRuler protein markers 
(Fermentas, York, UK). The membrane was further probed with GAPDH (Abcam, 
Cambridge, UK) or total Akt (New England BioLabs Ltd). 
4.3.5 Measurement of cytokine/chemokine release (ELISA) 
The release levels of IL-1β by THP-1 macrophages and of IL-6, MCP-1, IL-8 and 
RANTES by preadipocytes were determined as the protein concentrations in cell 
culture medium, using ELISA kits (See section 2.12).  
4.3.6 Real-time PCR 
Total RNA was extracted from cells using Trizol as previously mentioned in section 
2.9. RNA concentration was determined from the absorbance at 260 nm. First strand 
cDNA was reverse transcribed from 0.5 µg of total RNA using an iScript first strand 
synthesis kit in a final volume of 10 µl (Section 2.10). Real-time PCR amplification 
was performed in a final volume of 12.5 µl, containing cDNA (equivalent to 12.5 ng 
of RNA), optimized concentrations of primers, TaqMan probe (FAM-TAMRA) and 
a master mix made from qPCR core kit (Section 2.11). The sequences of primers and 
probes for human β-actin, IL-6, MCP-1 and IL-8 were as described previously (Table 
2.1). Real-time PCR amplification was performed using a Stratagene Mx3005P 
instrument and the PCR cycling conditions were as follows:( 95 ºC for 10 minutes 
followed by 40 cycles (95 ºC for 15 sec, 60 ºC) for 1 minute. The results were 
expressed as fold changes of Ct value relative to controls using the data analysis 
software from the manufacturer. 
4.3.7 Cell viability assay 
Cell viability was determined by using a colorimetric method for measuring cellular 
cytotoxicity from the release of lactate dehydrogenase (LDH) into cell culture 
medium (See section 2.14). 
4.3.8 Statistical analysis 
Data are expressed as means ± SEM or means ± SD. Differences between two groups 
were analysed by Student’s unpaired t-test; one-way ANOVA coupled with 
Bonferroni’s t-test was employed for comparison of multiple-groups. Differences 
were considered as statistically significant when p < 0.05. 
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4.4 Effects of IL-1β on expression of the insulin signalling molecules 
in human primary preadipocytes 
4.4.1 Effect of 4 hr treatment with IL-1β on insulin-stimulated phosphorylation of 
insulin signalling molecules in human preadipocytes 
This experiment was to investigate whether IL-1β, one of the major cytokines 
produced by macrophages, could affect insulin signalling molecules in human 
preadipocytes in response to insulin stimulation. It was first assessed that the effect 
of 4 hr treatment with IL-1β on response of insulin signalling molecules that includes 
p-IR, p-IRS-1 and p-Akt with or without insulin stimulation.   
4.4.1.1 Effect of 4 hr treatment with IL-1β on protein expression of p-IR (Y1185) 
As shown in figure 4.1, the basal protein abundance of phosphorylated IR was barely 
detectable in cells with or without IL-1β (2 ng/ml) treatment; there was no significant 
difference between the groups. However, there was a significant increase in insulin-
stimulated p-IR abundance in untreated and IL-1β treated preadipocytes (p˂ 0.01 and 
p˂ 0.05) respectively in comparison with unstimulated cells. Interestingly, 
preadipocytes exposed to IL-1β resulted in a significant reduction in insulin-
stimulated phosphorylation of IR at Y1185 (by 3.2-fold, p< 0.05) compared with the 
corresponding controls (Figure 4.1).     
4.4.1 .2 Effect of 4 hr treatment with IL-1β on protein expression of p-IRS-1 
(Ser612)   
As shown in figure 4.2, low levels of basal protein abundance for p-IRS-1 (Ser612) 
were detected in both untreated and treated preadipocytes with IL-1β (2 ng/ml) 
treatment; there was no significant difference between the groups. In addition, there 
was a significant increase in insulin-stimulated p-IRS-1 in untreated and treated 
preadipocytes with IL-1β in comparison with unstimulated cells (p˂ 0.001and p˂ 
0.05). However, preadipocytes exposed to IL-1β resulted in a significant reduction in 
insulin stimulated phosphorylation of IRS-1 at ser612 (by 1.8-fold, p< 0.05) 
compared with corresponding controls (Figure 4.2).    
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4.4.1.3 Effect of 4 hr treatment with IL-1β on protein expression of p-Akt (Ser473)   
As shown in figure 4.3, the basal protein abundance of Akt phosphorylation at serine 
473 in both untreated and treated preadipocytes with IL-1β were undetectable. 
However, there was a significant increase in insulin-stimulated p-Akt abundance in 
untreated and treated preadipocytes with IL-1β in comparison with unstimulated cells 
(both p˂ 0.001). Another observation was that a slight reduction in p-Akt abundance 
level in preadipocytes after exposed to the effect of IL-1β, but this was not 
statistically significant (Figure 4.3).   
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Figure 4-1: Effect of 4 hr treatment with IL-1β on insulin-stimulated 
phosphorylation of IR in human preadipocytes 
 
         a  
        
 
 
       b  
      
 
 
 
 
 
Preadipocytes were either untreated or treated with 2 ng/ml IL-1β for 4 hr and then 
stimulated with or without 100 nM insulin. (a) The representative western blot is 
shown for p-IR, which was normalised to the loading control, GAPDH. (b) The 
quantification and measurement for the protein bands from p-IR was performed by 
using densitometric analysis of signal intensity. Data is shown as mean ± SEM (n=3 
per group). *p< 0.05, **p< 0.01 
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Figure 4-2: Effect of 4 hr treatment with IL-1β on insulin-stimulated 
phosphorylation of IRS-1(Ser612) in human preadipocytes 
  
      a 
          
 
 
   b  
  
 
 
 
 
 
Preadipocytes were either untreated or treated with 2 ng/ml IL-1β for 4 hr and then 
stimulated with or without 100 nM insulin. (a) The representative western blot is 
shown for p-IRS-1(Ser612), which was normalised to the loading control, GAPDH. 
(b) The quantification and measurement for the protein bands from p-IR was 
performed by using densitometric analysis of signal intensity. Data is shown as mean 
± SEM (n=3 per group). *p< 0.05, ***p< 0.001  
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Figure 4-3: Effect of 4 hr treatment with IL-1β on insulin-stimulated 
phosphorylation of Akt in human preadipocytes 
 
    a       
  
 
  
   b       
  
 
 
 
 
 
Preadipocytes were either untreated or treated with 2 ng/ml IL-1β for 4 and then 
stimulated   with or without100 nM insulin. (a) A representative western blot is 
shown for p-Akt, which was normalised to the loading control, GAPDH. (b) The 
quantification and measurement for the protein bands from p-IR was performed by 
using densitometric analysis of signal intensity. Data is shown as mean ± SEM (n=3 
per group). ***p< 0.001. ND = non detectable. NS= Non significant  
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4.4.2 Effect of 24 hr treatment with IL-1β on insulin-stimulated phosphorylation of 
insulin signalling molecules in human preadipocytes  
Although 4 hr treatment with IL-1β affected the expression of insulin signalling 
molecules under insulin stimulation, it is unknown whether IL-1β has a longer time 
effect. The aim of this experiment was to study the effect of IL-1β treatment for 24 hr 
on insulin signalling molecules in response to insulin stimulation in human 
preadipocytes. 
4.4.2 .1 Effect of 24 hr treatment with IL-1β on protein expression of p-IR (Y1185)   
There was a significant reduction in p-IR abundance level in preadipocytes treated 
with IL-1β for 24 hr (by 2-fold, p˂ 0.01) in comparison with untreated cells (Figure 
4.4). In addition, there was a significant reduction in insulin-stimulated p-IR level in 
cells exposed to IL-1β in comparison to control (p˂ 0.05) (Figure 4.4).   
4.4.2 .2 Effect of 24 hr treatment with IL-1β on protein expression of p-IRS-1 
(Ser612)   
There was no difference in protein abundance of p-IRS-1 (Ser612) in untreated or IL-
1β treated preadipocytes without stimulation with insulin (Figure 4.5). Furthermore, 
there was a significant increase in insulin–stimulated p-IRS-1 abundance level in 
both untreated or treated preadipocytes with IL-1β treatment (3.1-fold, p˂ 0.01 and 
3.8-fold, p˂ 0.05) respectively, in comparison with unstimulated corresponding 
controls. However, this stimulatory effect was induced by insulin with slight effects 
caused by IL-1β.  
4.4.2.3 Effect of 24 hr treatment with IL-1β on protein expression of p-Akt 
(Ser473)  
Consistent with the results of 4 hr treatment with IL-1β, the basal abundance level of 
Akt phosphorylation at serine 473 was undetectable in both untreated and IL-1β 
treated preadipocytes (Figure 4.6). However, a significant increase in p-Akt 
abundance was observed in untreated and treated preadipocytes (p˂ 0.001 and p˂ 
0.001) respectively, once stimulated with insulin in comparison with corresponding 
unstimulated cells. Interestingly, a 24 hr exposure showed a significant increase in 
insulin-stimulated p-Akt abundance (2.8-fold, p˂ 0.05) in preadipocytes treated with 
IL-1β compared to untreated cells (Figure 4.6). 
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Figure 4-4: Effect of 24 hr treatment with IL-1β on insulin-
stimulated phosphorylation of IR in human preadipocytes 
 
      a             
 
 
 
      b    
                 
 
 
 
 
 
Preadipocytes were either untreated or treated with 2 ng/ml IL-1β for 24 hr then 
stimulated with or without 100 nM insulin. (a) The representative western blot is 
shown for p-IR, which was normalised to the loading control, GAPDH. (b) The 
quantification and measurement for the protein bands from p-IR was performed by 
using densitometric analysis of signal intensity. Data is shown as mean ± SEM (n=3 
per group). *p< 0.05, **p< 0.01  
 
 
126 
 
Figure 4-5: Effect of 24 hr treatment with IL-1β on insulin-
stimulated phosphorylation of IRS-1(Ser612) in human 
preadipocytes 
 
     a   
 
 
 
      b  
         
 
 
 
 
 
 
Preadipocytes were either untreated or treated with 2 ng/ml IL-1β for 24 hr and then 
stimulated with or without 100 nM insulin. (a) The representative western blot is 
shown for p-IRS-1(Ser612), which was normalised to the loading control, GAPDH. 
(b) The quantification and measurement for the protein bands from p-IRS-1 was 
performed by using densitometric analysis of signal intensity. Data is shown as mean 
± SEM (n=3 per group). *p< 0.05, **p< 0.01 
127 
 
Figure 4-6: Effect of 24 hr treatment with IL-1β on insulin-
stimulated phosphorylation of Akt in human preadipocytes 
     
 
     a  
 
 
 
     b  
  
 
 
 
 
 
 
Preadipocytes were either untreated or treated with 2 ng/ml IL-1β for 24 hr and then 
stimulated with or without 100 nM insulin. (a) The representative western blot is 
shown for p-Akt, which was normalised to the loading control, GAPDH. (b) The 
quantification and measurement for the protein bands from p-Akt were performed by 
using densitometric analysis of signal intensity. Data is shown as mean ± SEM (n=3 
per group). ***p< 0.001 vs unstimulated cells, *p˂ 0.05 vs stimulated control cells. 
ND = none detectable levels   
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4.4.3 Influence of IL-1β on the effect of macrophage-derived factors on insulin 
signalling molecules in response to insulin in human preadipocytes 
The presence of inflammatory mediators in MC medium may reduce and/or 
modulate insulin signalling proteins in adipose tissue (Lumeng et al., 2007c). To 
investigate whether IL-1β is a major factor which mediates the effects of MC 
medium, an IL-1β neutralising antibody was used to block IL-1β activity and the 
expression levels of insulin signalling molecules in human predipocytes was 
determined by western blotting. 
4.4.3.1 Effect of IL-1β neutralising antibody on MC medium-induced expression 
of p-IRS-1 (Ser612) 
Upon insulin (100 nM) stimulation, significant increases in the phosphorylated level 
of IRS-1 (Ser612) in control (3.7 fold increase, p< 0.01), MC medium (2.9 fold 
increase, p< 0.05) and MC with IL-1β blocking antibody (2.1 fold increase, p<0.01) 
groups compared with unstimulated cell groups. Preadipocytes exposed to MC 
medium without insulin stimulation showed a significant increase (2.4-fold, p< 0.01) 
in protein expression of pIRS-1(Ser612) compared with the corresponding controls. 
However, MC medium-induced protein abundance of basal pIRS-1 was slightly 
reduced by IL-1β antibody but not statistically significant (Figure 4.7). 
4.4.3.2 Effect of IL-1β neutralising antibody on MC medium-induced p-Akt 
(Ser473) 
Insulin (100 nM) stimulation induced a significant increase in phosphorylation of 
Akt (Ser473) in control preadipocytes (6.4 fold increases, p< 0.01) compared with 
corresponding unstimulated group (Figure 4.8). However, MC medium increased the 
basal abundance of p-Akt (2.8-fold, p< 0.05) compared with control group but 
suppressed the induction of p-Akt in response to insulin (Figure 4.8). In contrast, IL-
1β neutralising antibody reversed the inhibitory effect of MC medium on p-Akt as it 
significantly increased p-Akt abundance in response to insulin (Figure 4.8).   
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Figure 4-7: Effect of IL-1β neutralising antibody on macrophage-
induced p-IRS-1 (Ser612) 
 
    a  
 
 
 
    b   
      
         
 
 
 
 
Preadipocytes were treated with RPMI (control), MC medium or MC medium with 2 
µg/ml IL-1β neutralising antibody and then stimulated with or without 100 nM 
insulin. The representative western blot is shown (a). The relative protein bands from 
p-IRS-1 (Ser612) were quantified and normalised to the loading control, total Akt 
(b). Data is shown as mean ± SD (n= 4 per group). *p< 0.05, **p< 0.01 and +p˂ 0.05 
vs indicated group 
 
 
130 
 
Figure 4-8: Effect of IL-1β neutralising antibody on macrophage-
modulated p-Akt (Ser473) 
 
  a          
 
 
       
  b     
  
  
 
 
 
 
Preadipocytes were treated with RPMI (control), MC medium or MC medium with 2 
µg/ml IL-1β neutralising antibody and then stimulated with or without 100 nM 
insulin. The representative western blot is shown with relevant molecular weight 
markers from the protein ladder (a). The relative protein bands from p-Akt (Ser473) 
was quantified and normalised to the loading control, GAPDH (b). Data is shown as 
mean ± SD (n= 4. Per group), **p< 0.01 and +p˂ 0.05 vs indicated group  
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4.4.4 Blocking IL-1β activity reverses the induction effect of macrophage-derived 
factors on mRNA levels of the pro-inflammatory factors in human 
preadipocytes   
Several cytokines/chemokines have been shown to promote insulin resistance by 
influencing insulin signalling pathway (Tack et al., 2012). Cytokines/chemokines can 
also be produced by preadipocytes and potently induced by MC medium (O’Hara et 
al., 2012, Gao and Bing, 2011). The next experiments were carried out to verify the 
role of IL-1β in mediating the effects of MC medium on the gene expression of the 
cytokines/chemokines by preadipocytes. In this experiment, preadipocytes were 
incubated with either RPMI-1640 medium (control), MC medium, MC medium 
neutralized by the IL-1β antibody (2 μg/ml) for 24 hr. Gene expression of IL-6, 
MCP-1 and IL-8 was determined using real-time PCR   
4.4.4 .1 IL-1β neutralisation reversed the effect of MC medium-induced gene 
expression of IL-6  
As shown in figure 4.9 a, the gene expression of IL-6 by preadipocytes was barely 
detectable in the control group; MC medium potently increased the mRNA levels of 
IL-6 (85-fold increase, p˂ 0.001). However, this induction was blunted by IL-1β 
neutralization (p< 0.001) in preadipocytes (Figure 4.9 a).   
4.4.4.2 IL-1β neutralisation blocked the effect of MC medium-induced gene 
expression of MCP-1 
 The gene expression of MCP-1 was detected in the control group of preadipocytes. 
MC medium strongly stimulated gene expression of MCP-1 (10-fold, p˂ 0.001) but 
this induction was totally reversed by IL-1β neutralization (p< 0.001) (Figure 4.9 b). 
4.4.4 .3 IL-1β neutralisation reversed the effect of MC medium-induced gene 
expression of IL-8 
The gene expression of IL-8 was detectable in the control group of preadipocytes, 
and MC medium potently stimulated gene expression of IL-8 (17-fold increase, p˂ 
0.001). However, this induction was partially blunted by IL-1β neutralization (p< 
0.001) (Figure 4.9 c). 
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Figure 4-9: Blocking IL-1β activity reverses the effect of 
macrophage-induced gene expression of cytokines/chemokines in 
human preadipocytes 
 
a                                                  b 
       
                                           c                 
 
 
 
 
 
 
Inhibition of IL-1β activity reverses macrophage-induced gene expression of pro-
inflammatory factors by human preadipocytes. Preadipocytes were incubated with 
either RPMI-1640 medium (control), MC medium or MC medium neutralized by IL-
1β antibody (2 μg/ml) for 24 hr. The mRNA levels of IL-6 (a), MCP-1 (b) and IL-8 
(c) were measured by real-time PCR. Data are means ± SEM (n=6 per group); *** 
p< 0.001 vs indicated groups    
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4.4.5 Blocking IL-1β activity reverses the effect of macrophage-derived factors on 
cytokine and chemokine release by human preadipocytes 
In the present study, whether blocking IL-1β activity inhibits the effects of MC 
medium-induced release of cytokines/chemokines by preadipocytes was examined. 
The secretion levels of the cytokine/chemokines were determined using ELISA.  
4.4.5.1 IL-1β neutralisation reverses the effect of MC medium-induced IL-6 
release 
As shown in figure 4.10 a, IL-6 was barely detectable in the medium of 
preadipocytes with a mean value of 8 pg/ml in the control group. Notably, MC 
medium potently stimulated the release of IL-6 (up to 11158 pg/ml) but this 
induction was largely blunted by IL-1β neutralisation (all p< 0.001). To distinguish 
the production of cytokine by preadipocytes from macrophages, the basal levels of 
IL-6 in THP-1 macrophage medium were shown as MC alone (72± 18 pg/ml) 
(Figure 4.10 a). 
4.4.5 .2 IL-1β neutralisation reverses the effect of MC medium-induced MCP-1 
release  
As shown by figure 4.10 b, the preadipocytes medium MCP-1 was detected with a 
mean value of 85 pg/ml in the control group of preadipocytes.  MC medium also 
potently stimulated the release of MCP-1 (up to 3077 pg/ml) but this stimulation was 
markedly reduced by IL-1β neutralisation (all p< 0.001). To distinguish for the 
production of MCP-1 by preadipocytes from that by macrophages, the basal levels of 
MCP-1 in THP-1 macrophage medium were shown as MC alone (216 ± 56 pg/ml) 
(Figure 4.10 b).   
4.4.5 .3 IL-1β neutralisation reverses the effect of MC medium-induced IL-8 
release 
Further results have been observed to be in a similar pattern as IL-6 and MCP-1 
release from preadipocytes. The release of IL-8 at basal level was detected with a 
mean value of 646 pg/ml in the control group of preadipocytes. MC medium strongly 
stimulated the release of IL-8 (up to 7081 pg/ml) but this induction was reversed by 
IL-1β neutralisation (all p< 0.001). The basal levels of IL-8 in THP-1 macrophage 
medium were shown as MC alone (762 ± 53 pg/ml) (Figure 4.10 c). 
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4.4.5 .4 IL-1β neutralisation partially reverses the effect of MC medium-induced 
RANTES release 
Lastly, the basal level of RANTES were determined and detected with a mean value 
of 88 pg/ml in the control group of preadipocytes. Consistent with the above data, 
MC medium strongly stimulated the release of RANTES (up to 3649 pg/ml) but this 
induction was significantly reduced by IL-1β neutralisation (all p< 0.001). The basal 
levels of RANTES in THP-1 macrophage medium were shown as MC alone (1014 ± 
51 pg/ml) (Figure 4.10 d). 
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Figure 4-10: Blocking IL-1β activity reverses the effects of MC 
medium on cytokine/chemokines release in human preadipocytes 
   a                                            b          
 
  c                                             d                                                                
 
Inhibition of IL-1β activity reverses macrophage-induced cytokine/chemokine 
release by human preadipocytes. Preadipocytes were incubated with either RPMI-
1640 medium (control), MC medium, MC medium neutralized by IL-1β antibody (2 
μg/ml), MC medium alone (without cells) for 24 hr. The releases of IL-6 (a), MCP-1 
(b), IL-8 (c) and RANTES (d) by preadipocytes were measured as protein 
concentrations in cell culture medium by ELISA. Data are means ± SEM (n=6 per 
group); ***p< 0.001 vs indicated groups     
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4.4.6 Cytotoxicity assessement 
It is not known whether the effects of both MC medium and recombinant human IL-
1β on insulin signalling molecules in preadipocytes could be caused by cytotoxicity. 
To assess this possibility, cell viability was determined as LDH release by 
preadipocytes treated with MC medium, IL-1β and IL-1β neutralising antibody.  
4.4.6.1 MC medium and an IL-1β neutralising antibody do not induce cytotoxicity 
As observed in figure 4.11 there were no significant differences in LDH release by 
preadipocytes treated with MC or MC medium pre-treated with IL-1β neutralising 
antibody for 24 hr, compared with controls. However, there was a significant 
increase in LDH release (p˂ 0.001) in the LDH positive control group compared with 
all other groups. Therefore, there was no indication of increased cytotoxicity 
following the treatment with THP-1 MC medium or IL-1β neutralizing antibody. 
4.4.6.2 Human recombinant IL-1β at several concentrations (2, 5, 10 ng/ml) does 
not induce cytotoxicity 
As shown in figure 4.12, In the same manner with MC medium there were no 
significant differences in LDH release by preadipocytes treated with IL-1β at several 
concentrations (2, 5, 10 ng/ml) for 24 hr, compared with controls. However, there 
was a significant increase in the LDH release (p˂ 0.001) in LDH positive control 
group compared with all other groups. Therefore, there was no indication of 
increased cytotoxicity induced by IL-1β (Figure.4.12). 
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Figure 4-11: MC medium and IL-1β neutralizing antibody do not 
induce cytotoxicity in human preadipocytes 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
Human preadipocytes were either untreated (control) or treated with MC medium or 
MC medium pre-treated with IL-1β neutralizing antibody for 24 hr.  Cell viability 
was assessed by measuring LDH release into the cell culture medium of 
predipocytes. Data are means ± SEM (n=6 per group); ***p< 0.001 vs all other 
groups   
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Figure 4-12: Human recombinant IL-1β at different doses (2, 5, 10 
ng/ml) do not induce cytotoxicity in human preadipocytes 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
Human preadipocytes were either untreated (control) or treated with IL-1β at 
different doses (2, 5, 10 ng/ml) for 24 hr. Cell viability was assessed by measuring 
LDH release into the cell culture medium of preadipocytes. Data are means ± SEM 
(n=6 per group); ***p< 0.001 vs all other groups    
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4.5 Discussion  
As mentioned in Chapter 1, both insulin resistance and type 2 diabetes are related to 
inflammation which is characterized by increasing a wide range of pro-inflammatory 
cytokines/chemokines probably due to an increase in the accumulation of 
macrophages during adipose tissue expansion in obesity (Hotamisligil, 2003, 
Weisberg et al., 2003). Preadipocytes at the non-differentiation state have capability 
to express pro-inflammatory factors that may contribute to the induction of 
inflammation (Poulain-Godefroy and Froguel, 2007). In the light of recent studies, 
some in vitro models have been used to study the crosstalk between macrophages 
and adipocytes and their precursors (preadipocytes). However, there is no study 
using human primary preadipocytes as an in vitro cell model to demonstrate the 
direct effect of macrophages-derived factors on the insulin signalling pathway. 
Furthermore, the key factors that mediate the effect of macrophages on the 
chemokines/cytokines expression and release by human primary preadipocytes 
which in turn may alter insulin signalling pathways are not well investigated.   
In the present study, in vitro model of primary human preadipocytes and human 
recombinant IL-1β were used to investigate the acute and sustained effects of IL-Iβ 
at time points (4 and 24 hr) respectively on several insulin signalling molecules, 
including the key molecules which are involved in the metabolic pathway (PI3K-
p85/Akt) in response to insulin stimulation. The activation of this pathway is also 
widely involved in conveying survival signals in response to a range of stimuli in 
many different cell types (Scheid et al., 1995, Yao and Cooper, 1995, Kennedy et al., 
1997, Khwaja et al., 1997). Additionally, the present study also investigated whether 
IL-1β mediates the effects of MC medium on the insulin signalling molecules by 
using a neutralizing antibody to block IL-1β activity. Lastly, whether IL-1β mediates 
the effect of MC medium on the expression and release of pro-inflammatory factors 
by human preadipocytes was explored.     
The activation and phosphorylation of the insulin signalling network is a prerequisite 
process for physiological insulin action in target tissues and cells. The first key 
protein in the insulin signalling pathway is the IR. IR is a tyrosine kinase that 
catalyses the phosphorylation of its substrates (Saltiel and Pessin, 2002). IRS-1 is 
one of the major IR substrates in insulin signalling pathway (Taniguchi et al., 2006). 
A previous study using human adipocytes from individuals with type 2 diabetes 
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showed that IRS-1 is the main docking protein for the activation of PI 3K in response 
to insulin (Rondinone et al., 1997).  
The present study has demonstrated that in human preadipocytes, IL-1β strongly 
decreased the protein abundance of insulin-stimulated phosphorylation of insulin 
signalling molecules.  The results showed that upon insulin stimulation, exposure of 
human preadipocytes to a human recombinant IL-1β (2 ng/ml for 4 and 24 hr) has led 
to significantly reduced insulin-stimulated phosphorylation of IR at tyrosine residues 
compared with untreated cells. This finding was in agreement with previous studies 
that observed IL-1β can reduce the ability of insulin to increase the tyrosine 
phosphorylation of IR (Lagathu et al., 2006). It is noted that both previous studies 
have used differentiating preadipocytes and differentiated adipocytes and high 
concentrations of mouse recombinant IL-1β (10 and 20 ng/ml). Taken together, it 
suggestes that IL-1β could impair the initial and critical node of the insulin signalling 
pathway by acting on tyrosine phosphorylation of IR in adipose cells.   
In insulin signalling pathways, IRS proteins are involved in regulate glucose uptake 
and, protein synthesis, lipogenesis and cell survival (Cheatham and Kahn, 1995).  
IRS-1 function is positively regulated once phosphorylation occurs at its tyrosine 
residues which are required for insulin-stimulated responses. However, upon insulin 
stimulation IRS-1 at serine/threonine kinases has dual roles which increase or inhibit 
the insulin action through its signalling pathway (Gual and Tanti, 2005). More 
specifically, activation of IRS-1 at inhibitory serine 612 is involved in the negative 
regulation of insulin signalling through IRS-1 by increasing its serine/threonine 
phosphorylation, which triggers dissociation with its downstream effector (PI3K) 
(Schmitz‐Peiffer and Whitehead, 2003).  
In the present study, treatment of preadipocytes with insulin significantly induced 
serine phosphorylation of IRS-1. This result was in agreement with a previous study 
that phosphorylation on several residues of serine/threonine kinases are also due to 
insulin stimulation (Mothe and Van Obberghen, 1996). Moreover, treatment of 
preadipocytes with IL-1β (2 ng/ml) for 4 hr in the presence of insulin has 
significantly increased p-IRS-1 (Ser612). However, the increase was less than 
controls (Figure 4.2).  It has been shown that insulin; pro-inflammatory factors and 
activation of cellular stress pathways increased serine phosphorylation of IRS-1 
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(Schmitz‐Peiffer and Whitehead, 2003, Gual and Tanti, 2005). A previous study 
using Fao hepatoma cells has found that TNF-α induces serine phosphorylation of 
IRS-1 through activation of serine kinases. This increased serine phosphorylation 
interferes with tyrosine phosphorylation of IRS-1 and impairs insulin action through 
impairing the association of IRS-1 with PI3K (Kanety et al., 1995). In the current 
study, IL-1β treatment for 24 hr showed a slight increase in  p-IRS-1 (Ser612) in 
preadipocytes but the strongest stimulatory effect was induced by insulin, suggesting 
that a possible  effect of IL-1β on the induction of serine phosphorylation of IRS-1, 
which in turn inhibiting the insulin signalling transduction at tyrosine 
phosphorylation. Consistently, it has been shown that pro-inflammatory cytokine 
TNF-α has led to a decrease in tyrosine phosphorylation of IRS-1 on tyrosine 
residues through increased serine phosphorylation of IRS-1 (Kanety et al., 1995, Rui 
et al., 2001).    
The activation of Akt was evaluated by investigating the phosphorylation of Ser473, 
one of two sites on Akt serine residues (Alessi et al., 1996). In the present study, 
preadipocytes exposed to IL-1β (2 ng/ml) for 4 hr showed an increase in insulin-
stimulated phosphorylation of Akt but the level of increase was slightly lower 
compared with controls (Figure 4.3). On the other hand, IL-1β treatment for 24 hr led 
to a significant induction in the protein abundance of insulin–stimulated 
phosphorylation of Akt; the increase was higher compared with controls stimulated 
with insulin.   
Previous studies using human and murine mature adipocytes have demonstrated that 
IL-1β has the inhibitory effect on insulin-stimulated phosphorylation of Akt (Lagathu 
et al., 2006). However, a previous study in human endothelial cells has shown a 
stimulatory effect of TNF-α or IL-1β on p-Akt in a time-dependent manner (Madge 
and Pober, 2000). Furthermore, previous studies have reported similar observations 
but in different cell types using a range of cytokines including IL-3, IL-4 and TNF-α 
(Hinton and Welham, 1999, Ozes et al., 1999), which showed that induced insulin-
stimulated phosphorylation of Akt occurred due to the link between Akt activation 
and proliferation/survival function in response to these cytokines. Taken together, 
these results suggest that IL-1β could serve as a stimulus depending on cell type 
and/or specific function of the protein kinase such as Akt.  Interestingly, it was 
observed that 4 hr exposure to IL-1β has led to decreases in insulin-stimulated 
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phosphorylation of IRS-1 and Akt, whereas a 24 hr exposure to IL-1β increased 
phosphorylation of IRS-1 and Akt. These results suggest that the stimulatory effect 
of IL-1β on phosphorylation of IRS-1 and Akt at serine residues is possibly in a 
time-dependent manner.  
The above data led us to further investigate whether IL-1β is responsible for 
mediating the effect of MC medium on the insulin signalling molecules in human 
preadipocytes. The present study showed that there were significant increases in 
insulin-stimulated phosphorylation of IRS-1(Ser612) in all groups (Figure 4.7). 
Furthermore, the basal p-IRS-1 was induced by MC medium. This result is in 
agreement with some previous studies which showed that serine/threonine 
phosphorylation of IRS-1 is induced by a range of inducers such as okadaic acid on 
3T3-L1 adipocytes (Tanti et al., 1994), PMA on 3T3-L1 adipocytes (Jiang et al., 
2004), free fatty acids on muscle cells (Yu et al., 2002a), TNF-α on Fao hepatoma 
cells (Kanety et al., 1995) and amino acids on  3T3-L1 adipocytes (Gual and Tanti, 
2005, Haruta et al., 2000). In the present study, blocking the activity of IL-1β using a 
neutralizing antibody did not alter the effect of MC medium on insulin-stimulated 
phosphorylation of IRS-1. The result suggests that other macrophage-derived factors 
in MC medium could contribute to the activation of p-IRS-1 at serine 612. 
Regarding, the basal p-Akt data, a recent study showed that the phosphorylation of 
Akt was significantly increased upon treatment with MC medium (derived from 
murine J774A macrophages), and that MC medium-induced murine preadipocytes 
survival through Akt/Erk pathway mediated via PDGFR (Molgat et al., 2011). 
Similarly, the current study observed that basal p-Akt was induced by MC medium 
in human preadipocytes (Figure 4.8). However, MC medium suppressed the effect of 
insulin on p-Akt, whereas, IL-1β neutralisation reversed inhibitory effect of MC 
medium on p-Akt expression in response to insulin (Figure 4.8). Therefore, it is 
suggested that IL-1β may contribute to some of the effect of MC medium on the 
activation of Akt in preadipocytes. It might be claimed that the modulating effects of 
IL-1β on the insulin signalling molecules in preadipocytes could be due to 
cytotoxicity. However, the current study has shown that there was no cytotoxicity 
after treatment with high doses of IL-1β as shown in figure 4.12. 
The mechanisms of IL-1β in the modulation of macrophage-preadipocytes crosstalk 
on insulin signalling in adipose tissue are poorly understood. It is suggested that local 
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inflammation enhanced by macrophage infiltration in adipose tissue could be crucial 
leading to the impairment of insulin sensitivity (Lumeng & Saltiel, 2011). IL-1β has 
been particularly implicated in the inflammatory response (Gao and Bing, 2011) and 
the modulation of insulin sensitivity (Lagathu et al., 2006). Therefore, the second 
major aim of the present study was to examine the role of IL-1β in mediating 
macrophages-induced expression and release of pro-inflammatory factors by 
preadipocytes.  The present study showed that MC medium potently induced gene 
expression and protein release of the pro-inflammatory factors including IL-6, MCP-
1 and IL-8 in human predipocytes. These results are in agreement with previous 
studies (Lacasa et al., 2007, Gao and Bing, 2011), suggesting that macrophages are 
strong inducers of an inflammatory state in preadipocytes which in turn could 
promote macrophages recruitment and maintenance in adipose tissue.  Furthermore, 
inhibiting IL-1β activity in MC medium with a neutralizing antibody led to a 
significant reduction in gene expression of IL-6, MCP-1 and IL-8 (Figure 4.9). 
Consistent with the gene expression results, the release of pro-inflammatory factors 
including IL-6, MCP-1, IL-8 and RANTES by preadipocytes was markedly 
decreased by blocking IL-1β activity (Figure 4.10).Taken together; these results 
suggest that IL-1β is considered to be a key mediator for the pro-inflammatory 
activity of adipose tissue macrophages. The deleterious effect of macrophages on 
insulin signalling could be modulated by IL-1β through upregulation of the 
inflammatory response in preadipocytes.     
In summary, this study demonstrates that IL-1β may modulate the protein expression 
of the insulin signalling molecules in human preadipocytes. IL-1β also mediates 
macrophage-induced modulation of the insulin signalling molecules in human 
preadipocytes.  Blocking IL 1β activity partially reverses the effect of MC medium 
on protein expression of p-Akt in human preadipocytes. IL-1β blockade also protects 
against macrophage-stimulated expression and release of the pro-inflammatory 
cytokines/chemokines including IL-6, RENTS, MCP-1 and IL-8 by preadipocytes. 
These results suggest that inhibition of IL-1β may reduce macrophage accumulation-
associated inflammation and dysregulation of insulin signalling molecules in human 
adipose tissue. 
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CHAPTER 5:  
Effect of long-term treatment with IL-1β on 
preadipocyte differentiation and adipocyte functions 
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5 Effect of long-term treatment with IL-1β on preadipocyte 
differentiation and adipocyte functions 
 
5.1 Introduction 
Based on the results from Chapter 3 and 4,  it is  suggested that macrophage derived 
factors, in particular IL-1β, may play a detrimental role on human adipose cell 
development such as preadipocytes differentiation (adipogenesis), consequently 
leading to adipose tissue dysfunction. Adipose tissue has many functions; the 
traditional function, which is similar in all mammals, is storing energy in adipocytes 
in the form of TGs and this is important for the regulation of energy homeostasis 
(Korner et al., 2009, Symonds, 2012, Langin et al., 2009).  
As mentioned earlier, adipose tissue releases energy, through cellular processes 
namely lipolysis, in the forms of glycerol and FFAs, when needed by other organs 
during exercise or fasting periods (physiological conditions) (Cinti, 2007, Trayhurn 
and Beattie, 2001, Langin et al., 2009). However, adipose tissue released FFAs are 
elevated in the circulation especially in the obese state which in turn induces adipose 
tissue remodelling (Sun et al., 2011, Lee et al., 2010, Boden, 2008). Increased FFAs 
release in obesity is probably due to the impairment of insulin action such as the 
suppression of lipolysis (Sorisky, 1999, Jensen et al., 1989). Consequently, this 
causes a cluster of metabolic disorders, including dyslipidaemia, increased hepatic 
glucose production and impaired peripheral glucose uptake (Despres et al., 1990, 
Reaven, 1996, Boden, 2006). 
In addition to the traditional role, adipose tissue has also been discovered as an 
endocrine organ producing various bioactive proteins, known as adipokines that have 
both actions at local (autocrine/paracrine) and systemic (endocrine) levels (Kershaw 
and Flier, 2004, Mohamed-Ali et al., 1998). Moreover, these adipokines are involved 
in complex pathways to maintain metabolic and vascular functions, and many of 
which are linked to immunity and the inflammatory response (Kershaw and Flier, 
2004). However, the overexpression and secretions of inflammation related-
adipokines in adipose tissue, such as TNF-α, IL-1, IL-6 and MCP-1, have been found 
to link with a number of metabolic disorders including inflammation and insulin 
resistance (Tilg and Moschen, 2006).   
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In obesity, WAT expands through two processes including hypertrophy and 
hyperplasia. Hypertrophy, an increase in the volume of existing adipocytes prevails 
in obesity (Lacasa et al., 2007, Hirsch et al., 1989). When adipocytes become 
terminal cells, they have a lipid buffering capacity of ∼3 μg lipid/cell (Danforth, 
2000). This capacity may vary dramatically based on the physiological or 
pathological conditions. In the obese state this capacity is reduced due to 
dysfunctional cells (hypertrophied adipocyte) (Le Lay et al., 2001). Thus, excess 
energy may not be properly stored by the expansion of the adipose tissue (Danforth, 
2000). Several studies have shown that a deficit in adipogenesis due to hypertrophied 
adipocytes is characterized by reduced lipid storage capacity. This in turn leads to the 
release of FAs into the circulation and favours accumulation of lipids in the liver and 
muscle with detrimental effects on insulin action in these tissues (Danforth, 2000, 
Weyer et al., 2000, Heilbronn et al., 2004). Furthermore, studies on obese animals 
and humans have shown that enlarged adipocytes are less responsive to insulin 
compared to lean adipocytes, developing insulin resistance (Friedman, 2000, Molina 
et al., 1989). 
Hyperplasia (an increase in the number of new adipocytes) occurs by the 
proliferation and then differentiation of preadipocytes into adipocytes (Sun et al., 
2011). Differentiation of preadipocytes is directed by serial expression of a range of 
important transcription factors including members of the C/EBP and the PPAR 
families (Tontonoz et al., 1995). C/EPBα and PPARγ are important during 
proliferation-differentiation conversion and terminal differentiation; aP2 is an 
adipocyte marker and its relative abundance reflects the terminal differentiation of 
the adipose cells (Yang et al., 2004). Moreover, both C/EPBα and PPARγ 
transcription factors positively regulate each other and then activate aP2 (Gregoire et 
al., 1998). Adiponectin and leptin are also considered as mature adipocyte markers 
(Yang et al., 2004).  
During adipose tissue expansion there is an increase in infiltration of macrophages 
and other immune cells; these cells may constitute the major sources of adipose-
derived pro-inflammatory cytokines/chemokines (Lumeng et al., 2007c, Weisberg et 
al., 2003). In addition to the pro-inflammatory role of macrophages and other 
immune cells in adipose tissue, preadipocytes and adipocytes can produce a large 
range of cytokine/chemokine such as TNF-α, IL-6, IL-8, MCP-1 and RANTES; 
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moreover, the production of these pro-inflammatory factors by preadipocytes and 
adipocytes can be markedly induced by macrophage-derived factors (Coppack, 2001, 
Weisberg et al., 2003, Gao and Bing, 2011). It appears that adipose cells and 
macrophages communicate each other through paracrine crosstalk or direct cellular 
processes (Bourlier and Bouloumié, 2009). Most previous studies have suggested 
that increased macrophage infiltration in adipose tissue in obesity could have an anti-
adipogenic action (Xu et al., 2003, Sorisky et al., 2013). Recently, two in vitro 
studies using murine and human preadipocytes showed that MC medium strongly 
inhibited adipogenesis in both models by suppressing lipid accumulation as well as 
inhibiting fatty acid synthase, PPARγ, CEBPα, leptin and adiponectin (Lacasa et al., 
2007). Adiponectin is produced primarily by adipocytes (Scherer et al., 1995), and 
has many functions such as anti-diabetic and anti-inflammatory properties (Trujillo 
and Scherer, 2005). However, pro-inflammatory cytokines including TNF-a, IL-6, 
IL-1β, IFN-γ, or TGF-β have been found to suppress in vitro preadipocytes 
differentiation into adipocytes, and  also to increase lipolytic activity in adipocytes 
(Gregoire et al., 1998, Coppack, 2001). 
IL-1β has been shown to play an important role in mediating the inflammatory 
response as well as being involved in a range of cellular processes, including cell 
proliferation, differentiation and apoptosis (Arend, 2002). Previous studies mostly 
using murine adipocytes reported that IL-1β inhibits adipogenesis (Lagathu et al., 
2006, Xie et al., 2010). However, the precise molecular mechanisms of the anti-
adipogenic action of IL-1β in human predipocytes differentiation are still unclear. 
More importantly, whether IL-1β mediates macrophages-induced alteration of lipid 
storage in human adipocyte remain to be established. 
5.2 Aim of the study  
This chapter was therefore aimed to investigate the role of IL-1β in mediating 
macrophage-induced adipose tissue remodelling. By using in vitro human cell 
models, the specific objectives were set below:  
 The effect of long-term treatment with IL-1β on the lipid storage functions of 
adipose tissue by influencing lipid accumulation in human adipocytes; 
 The effect of long-term treatment with IL-1β on expression of  adipogenic 
factors that are involved in the development of human mature adipocytes, and 
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also on expression of pro-inflammatory factors that are involved in adipose 
tissue remodelling and insulin resistance such as IL-6, MCP-1, IL-8 and 
RANTES; 
 The effect of long-term treatment with IL-1β on expression of the key 
adipokines:  
 The effect of IL-1β blockade on the effect of MC medium-induced lipolysis 
in human adipocytes. 
5.3 Method and materials  
5.3.1 Culture of human preadipocytes    
Human primary preadipocytes were grown and induced to undergo adipogenesis (as 
described in section 2.3).  
5.3.2 Generation of THP-1 macrophages-conditioned medium  
The human THP-1 monocytes were cultured in RPMI-1640 medium as mentioned in 
details in section 2.4.3. Macrophage-conditioned (MC) medium was then prepared 
and harvested as previously mentioned in section 2.4.4.  
5.3.3 Cell treatment 
To investigate whether the long-term treatment of IL-1β inhibits human 
preadipocytes differentiation and impairs lipid storage function of adipose tissue by 
influencing lipolysis and lipid accumulation in human adipocytes, human 
preadipocytes were used and then treated with RPMI-1640 medium (control), IL-1β 
(1 ng/ml) or (5 ng/ml) from the induction day (Day 0) to day 12 post induction. To 
investigate whether IL-1β mediates macrophage-induced lipolysis in human 
adipocytes, the following experiments were carried out: firstly, MC medium was pre-
incubated with a human IL-1β neutralizing antibody (2 μg/ml) for 1 hr at 37 °C to 
block IL-1β activity; adipocytes were then incubated with either RPMI-1640 medium 
(control), MC medium, MC medium neutralized by IL-1β antibody or  mouse IgG 
(as a negative control) for 24 hr. Secondly, differentiated adipocytes were pre-treated 
with a recombinant human IL-1β receptor antagonist (IL-1RA; Sigma) at 1 µg/ml for 
2 hr and then incubated with MC medium in the presence or absence of IL-1RA or 
IL-1RA alone for 24 hr. 
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5.3.4 Measurement of lipid accumulation in adipocytes  
Lipid content in adipocytes was measured using Oil Red O stain as detailed in 
section 2.7.1.2. The dye retained in cells was removed with isopropanol and pipetted 
into a 96 well-plate. After measuring the absorbance by a Benchmark™ Plus 
Microplate Spectrophotometer (Bio-rad, UK) at 550 nm, lipid levels were associated 
to total protein amount by BCA protein assay as described in section 2.13.2. 
5.3.5 Measurement of glycerol release 
Lipolysis was determined as the levels of glycerol in adipocyte culture medium using 
a colorimetric method as described in section 2.13.2. The absorbance of the samples 
and standard were then measured using a spectrophotometer (Bio-Rad) at a 
wavelength of 540 nm. The concentration of glycerol was calculated by a glycerol 
standard curve. 
5.3.6 Real-time PCR  
Total RNA was extracted from cells using Trizol as previously mentioned in section 
2.9. RNA concentration was determined from the absorbance at 260 nm. First strand 
cDNA was reverse transcribed from 0.5 µg of total RNA using an iScript first strand 
synthesis kit in a final volume of 10 µl (Section 2.10). Real-time PCR amplification 
was performed in a final volume of 12.5 µl, containing cDNA (equivalent to 12.5 ng 
of RNA), optimized concentrations of primers, TaqMan probe (FAM-TAMRA) and 
a master mix made from qPCR core kit (Section 2.11). The sequences of primers and 
probes for human β-actin (control), inflammation factors (IL-6, MCP-1, IL-8 and 
RANTES), adipogenic factors (C/EPBα, PPARγ and aP2), and hormonal factors 
(adiponectin and leptin) were as described previously (Table 2.1). Real-time PCR 
applications were performed using a Stratagene Mx3005P instrument and the PCR 
cycling conditions were as follows: 95 ºC for 10 minutes followed by 40 cycles (95 
ºC for 15 sec, 60 ºC) for 1 minutes. The results were expressed as fold changes of Ct 
value relative to controls using the data analysis software from the manufacturer 
(section 2.11). 
5.3.7 Cell viability assay 
Cell viability was determined by using a colorimetric method for measuring cellular 
cytotoxicity from the release of lactate dehydrogenase (LDH) into cell culture 
medium as previously detailed in section 2.14. 
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5.3.8 Statistical analysis 
Data are expressed as means ± SEM or means ± SD. Differences between two groups 
were analysed by Student’s unpaired t-test; one-way ANOVA coupled with 
Bonferroni’s t-test was employed for comparison of multi-groups. Differences were 
considered as statistically significant when p< 0.05. 
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5.4 Long-term treatment with IL-1β affects preadipocyte 
differentiation and lipid levels during adipocyte development  
This study aimed to investigate whether long-term treatment of IL-1β impairs human 
preadipocyte differentiation and alters lipid accumulation during adipocyte 
development. Human primary preadipocytes were induced to undergo differentiation, 
and then treated with or without IL-1β (control) (from day 0 to day 12). Cells were 
collected, and lipid content was morphologically and quantitatively determined 
5.4.1 Chronic treatment with IL-1β reduces lipid levels during the differentiation 
of primary human preadipocytes  
 As shown by figure 5. 1 a-b, treatment with IL-1β (1 and 5 ng/ml) led to reduced 
lipid levels in differentiated adipocytes (Day 12) as evaluated morphologically by 
microscopy and Oil red O staining. Although treatment with IL-1β at both doses (1 
and 5 ng/ml) reduced lipid levels during adipocytes development the significant 
reduction was seen at 5 ng/ml (37 %, p˂ 0.01) compared with controls.  These results 
showed that inhibitory effects were in a dose dependent manner (Figure 5.1 a-b).  
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Figure 5-1: Effect of long-term treatment with IL-1β (1ng and 
5ng/ml) on lipid levels in human mature adipocytes 
 
   a            No staining                                       Oil red O staining 
                                                                                                 
 
 
 
 
 
                        Control                                                           Control   
                                                                                                                   
                                   
                            
 
 
 
                        IL-1β (1 ng/ml)                              IL-1β (1 ng/ml)   
                                                                                                                             
                                 
 
 
                                             
                   IL-1β (5 ng/ml)                                                IL-1β (5 ng/ml) 
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Human preadipocytes were induced to undergo differentiation. Mature adipocyte 
samples were collected at day 12 post induction after long treatment with IL-1β (12 
days) at two concentrations (1ng/ml and 5ng/ml). The effect of IL-1β on cell 
morphology, IL-1β inhibits differentiation of human preadipocytes, as assessed by 
morphology: using Oil Red O staining of neutral lipids (a) at day 12, cultures were 
photo-graphed and images shown are representative of two experiments. IL-1β 
induces lipid reduction in a dose-dependent manner. Lipid levels were determined at 
510 nm and linked to total protein amount by BCA protein assay (b). Results are 
expressed as means ± SEM (n=3 per group). **p< 0.01 vs control    
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5.4.2 Long-term treatment with IL-1β downregulates mRNA levels for key 
adipogenic factors in human adipocytes   
To study whether long-term treatment with IL-1β at various concentrations (1 ng/ml, 
5 ng/ml and 20 ng/ml) inhibits gene expression of key adipogenic factors including 
C/EPBα, PPARγ and aP2, preadipocytes were treated from the onset of induction 
(day 0) until cells became lipid-laden mature adipocytes (day 12 post induction) as 
seen in Figure 5.1.a. Total RNA was extracted from cells (day 12) and mRNA levels 
were determined using real time PCR.       
As shown by Figure 5.2. Long-term treatment with IL-1β at all concentrations 
significantly downregulated mRNA levels of C/EBPα (81%, 81 % and 82 %, all p< 
0.001) compared with controls. In Figure 5.2.b, PPARγ mRNA levels were 
significantly decreased by 1ng/ml IL-1β (38%, p< 0.05), 5 ng/ml IL-1β (37%, 
p<0.01) and 20 ng/ml IL-1β (40 %, p< 0.01). In addition, the expression profile of 
aP2 was also significantly downregulated by 5 and 20 ng/ml IL-1β (40%, p< 0.05 
and 43%, p< 0.01) compared with controls (Figure 5.2.c).  However, the inhibitory 
effect of the IL-1β was not dose-dependent for the three genes studied. The greatest 
reduction was observed in C/EBPα gene compared with other adipogenic factors.  
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Figure 5-2: Long-term treatment with IL-1β reduces mRNA levels of 
the key adipogenic factors in human adipocytes 
 a                                                    b         
  
                                                               
                          c  
 
                                        
 
 
 
 
Mature adipocytes were collected at day 12 post induction after long-term treatment 
with IL-1β at various concentrations (1ng/ml, 5 ng/ml and 20 ng/ml).  IL-1β 
treatment decreased (a) C/EBPα, (b) PPARγ and (c) aP2 mRNA levels in human 
adipocytes compared with controls. Gene expression levels were measured by real-
time PCR and normalised to β-actin. Data are expressed as mean ± SEM (n=6 per 
group). * p< 0.05, **p< 0.01, ***p< 0.001 vs controls   
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5.4.3 Long-term treatment with IL-1β upregulates mRNA levels of the pro-
inflammatory factors (IL-6, MCP-1, IL-8 and RANTES) in human 
adipocytes   
Since pro-inflammatory factors are expressed and secreted by several types of cells 
in adipose tissue, this study examined whether long-term treatment with IL-1β at 
various concentrations (1 ng/ml, 5 ng/ml and 20 ng/ml) during differentiation of 
preadipocytes induces gene expression of the key pro-inflammatory factors including 
IL-6, MCP-1, IL-8 and RANTES in adipocytes. In this experiment, cells were treated 
from the onset of induction (day 0) until cells became lipid-laden mature adipocytes 
(day 12) and mRNA levels were measured in adipocytes at day 12 post-induction.  
As shown in figure 5.3.a-d, in contrast with the effect of IL-1β on adipogenic factors, 
long-term treatment with IL-1β at all concentrations induced a significant 
upregulation in gene expression of the pro-inflammatory factors. IL-6 mRNA levels 
were significantly increased by 1ng/ml IL-1β (186-fold, p< 0.001), 5 ng/ml IL-1β 
(273-fold, p< 0.001) and 20 ng/ml IL-1β ( 256-fold, p< 0.001); MCP-1 mRNA levels 
were significantly increased by 1ng/ml IL-1β (23-fold, p< 0.001), 5 ng/ml IL-1β (23-
fold, p< 0.001) and 20 ng/ml IL-1β  (25-fold, p< 0.001);  IL-8 mRNA levels were 
also significantly increased (243-fold,p˂0.001),  (414-fold,p˂ 0.001) and (372-fold, 
p< 0.001) and RANTES (722-fold,p˂ 0.001), (1469-fold, p< 0.001) and (1260-
fold,p˂  0.001) compared with controls.  Interestingly, the stimulatory effect of IL-1β 
for both IL-8 and RANTES was dose-dependent and this appeared obvious at 1 and 5 
ng/ml concentrations (P˂ 0.05 and p˂ 0.01) respectively. The greatest upregulation 
was observed in RANTES gene expression compared with other pro-inflammatory 
factors (Figure 5.3).    
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Figure 5-3: Long-term treatment with IL-1β increases mRNA levels 
of pro-inflammatory factors (IL-6, MCP-1, IL-8 and RANTES) in 
human adipocytes 
         a                                                         b                                               
                                                      
       c                                              d 
                                                                                                                
 
Adipocytes were collected at day 12 post inductions after long-term treatment with 
IL-1ß at various concentrations (1 ng/ml, 5 ng/ml and 20 ng/ml). IL-1β treatment 
increased mRNA of the key pro-inflammatory factors (a) IL-6, (b) MCP-1, (c) IL-8 
and (d) RANTES (CCL5) in human adipocytes. Gene expression levels were 
measured by real-time PCR and normalised to β-actin. Data are expressed as mean ± 
SEM n=6 per group***p< 0.001 vs controls; +p< 0.05 and ++p˂ 0.01 vs 1 ng/ml of 
IL-1β  
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5.4.4 Long-term treatment with IL-1β downregulates mRNA level of adiponectin in 
human adipocytes 
This experiment investigated whether long-term treatment with IL-1β at various 
concentrations (1 ng/ml, 5 ng/ml and 20 ng/ml) affects gene expression level of 
adiponectin in adipocytes. Figure 5.4 has shown that long-term treatment with IL-1β 
at all three concentrations (1 ng/ml, 5 ng/ml and 20 ng/ml) significantly decreased 
mRNA levels of adiponectin (38%, p< 0.05, 37%, p< 0.01 and 40%, p< 0.01) when 
compared with controls. However, the inhibitory effect was not dose-dependent 
(Figure 5.4).    
 
5.4.5 Long-term treatment with IL-1β upregulates mRNA level of leptin in human 
adipocytes 
The present experiment investigated the long-term effect of IL-1β at various 
concentrations (1 ng/ml, 5 ng/ml and 20 ng/ml) on gene expression level of leptin in 
adipocytes. As shown by figure 5.5, in contrast to adiponectin result, long-term 
treatment with IL-1β at all concentrations (1 ng/ml, 5 ng/ml and 20 ng/ml) 
significantly upregulates mRNA levels of leptin (8-fold, 13-fold and 9-fold, all p< 
0.001) when compared with controls.  
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Figure 5-4: Long-term treatment with IL-1β downregulates mRNA 
levels of   adiponectin in human adipocytes 
 
 
 
 
 
 
 
 
Adipocytes were collected at day 12 post induction after long-term treatment with 
IL-1β at various concentrations (1 ng/ml, 5 ng/ml and 20 ng/ml). IL-1β treatment 
decreased adiponectin mRNA level in human adipocytes. Gene expression levels 
were measured by real-time PCR and normalised to β-actin. Data are expressed as 
mean ± SEM n=6 per group. * p< 0.05, **p < 0.01 vs controls 
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Figure 5-5: Long-term treatment with IL-1β upregulates mRNA 
level of leptin in human adipocytes 
 
 
 
 
 
 
 
 
Adipocytes were collected at day 12 post inductions after long-term treatment with 
IL-1β at various concentrations (1 ng/ml, 5 ng/ml and 20 ng/ml). IL-1β treatment 
increased leptin mRNA level in human adipocytes. Gene expression levels were 
measured by real-time PCR and normalised to β-actin. Data are expressed as mean ± 
SEM n=6 per group. ***p< 0.001 vs controls   
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5.4.6 MC medium and IL-1β stimulate lipolysis in human adipocytes 
To determine whether macrophage-derived factors or IL-1β exposure alters lipid 
mobilization in differentiated human adipocytes, cells at day 12 post-induction were 
treated either with TPH-1 MC medium (25%) or with IL-1β (2ng/ml) for 24 hr. 
Lipolysis was determined as glycerol release from adipocytes into cell culture 
medium.    
It was shown that both MC medium and IL-1β significantly increased glycerol 
release from differentiated adipocytes into culture medium (>2-fold, p˂ 0.001) 
(Figure 5.6.a) and (˂1.5-fold, p< 0.001) (Figure 5.6. b) respectively.  
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Figure 5-6: MC medium and IL-1β stimulate lipolysis in human 
adipocytes 
  
             a   
 
 
  
  
 
 
 
            b                     
                  
  
                
 
 
 
Adipocytes were treated with either (a) RPMI-1640 medium (control) or THP-1 MC 
medium for 24 hr or (b) RPMI-1640 medium (control) or RPMI-1640 medium with 
IL-1β (2 ng/ml) for 24 hr. Lipolysis was determined as glycerol release into the 
culture medium in (a) and (b). Data are means ± SEM (n=6 per group); **p< 0.01, 
***p< 0.001 vs indicated groups  
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5.4.7 IL-1ß neutralizing antibody reverses MC medium-induced lipolysis in 
adipocytes  
As macrophage-derived factors and IL-1β enhance adipocyte lipolysis, we next 
investigated whether IL-1β mediates macrophages-induced lipolysis in human 
adipocytes. MC medium was pre-incubated with a human IL-1β neutralizing 
antibody (2μg/ml) for 1 hr to block IL-1β activity. Differentiated adipocytes (day 12) 
were then incubated with either RPMI-1640 medium (control), MC medium or MC 
medium neutralized by IL-1β antibody or mouse IgG for 24 hr. The results showed 
that adipocytes treated with MC medium for 24 hr significantly increased glycerol 
release (>2-fold, p< 0.001) compared with controls; however, MC medium-
stimulated lipolysis was completely abolished by blocking IL-1β activity with a 
neutralizing antibody (p< 0.001) (Figure 5.7). However, treatment with IgG 
(negative control) had no effect on MC medium-induced lipolysis in adipocytes 
(Figure5.7). 
5.4.8 Blocking IL-1 receptor binding in human adipocytes partially reverses MC 
medium- induced lipolysis. 
The second experimental approach was to block IL-1β receptor binding in 
adipocytes. Differentiated adipocytes were pre-treated with an IL-1β receptor 
antagonist (IL-1RA) for 2 hr and then incubated with MC medium in the presence or 
absence of IL-1RA for 24 hr.  As shown in Figure 5.8, adipocytes treated with MC 
medium significantly increased lipolysis (6.5-fold, p< 0.001) compared with 
controls. Consistent with the results of the IL-1β neutralizing antibody, MC medium-
stimulated lipolysis was partially reversed by blocking IL-1β receptor with an IL-1Ra 
(p< 0.001). Adipocytes treated with IL-1RA alone (negative control) did not show 
any difference in glycerol release compared with controls (Figure 5.8). 
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Figure 5-7: IL-1β neutralizing antibody reverses MC medium-
induced lipolysis 
 
 
 
 
 
  
  
 
 
 
 
Adipocytes treated with MC medium for 24 hr showed a marked increase in glycerol 
release compared with controls. This upregulation was abolished by the pre-
treatment of MC medium with an IL-1β neutralizing antibody (2 μg/ml). Data are 
mean ± SEM (n= 6 per group).***p< 0.001 vs control; +++p< 0.001 vs MC 
medium group and MC+IgG group   
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Figure 5-8: Blocking IL-1 receptor binding in human adipocytes 
partially reverses MC medium-induced lipolysis 
 
 
   
 
 
 
 
 
 
 
Treatment with MC medium significantly increased lipolysis in adipocytes compared 
with controls. This up-regulation was abolished by the pre-treatment of adipocytes 
with a recombinant IL-1RA (1 µg/ml) for 2 hr to block IL-1 receptor binding in 
adipocytes; adipocytes were then incubated with MC medium in the presence or 
absence of IL-1RA for 24 hr. Data are mean ± SEM, n= 6 per group. *** p< 0.001 
vs control; +++ p< 0.001 vs MC medium group   
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5.5 Discussion  
As reported in previous studies, certain pro-inflammatory cytokines known to be 
mainly produced by macrophages including, TNF-α and IL-16, may have inhibitory 
effects on adipogenesis. TNFα has been documented earlier as a strong cytokine that 
inhibits 3T3-L1 and human preadipocyte differentiation (Torti et al., 1989, 
Petruschke and Hauner, 1993, Ruan et al., 2002) and induces lipolysis in human 
adipocytes (Rydén et al., 2004). IL-6 may have paracrine effect which inhibits 
differentiation of preadipocytes obtained from subcutaneous adipose tissue 
(Sopasakis et al., 2004). Recently, IL-1β has also been reported as a key anti-
adipogenic factor (Lagathu et al., 2006). However, there were conflicting 
observations about the effect of IL-1β and it is unclear whether IL-1β mediates the 
effect of macrophage-derived factors on adipogenesis (Simons et al., 2007, Gagnon 
et al., 2013).       
The present study investigated the long-term effect of IL-1β on adipocyte 
development, including lipid accumulation and the expression of the key adipogenic 
factors. The study also examined the long-term effect of IL-1β on the expression of 
the pro-inflammatory cytokines/chemokines and the key adipokines by adipocytes. 
Finally, whether IL-β acts to mediate the effect of MC medium on lipid mobilization 
was explored.  
The results have shown that exposure of human preadipocytes to IL-1β (1 and 5 
ng/ml) during the 12-day period of differentiation impaired adipogenesis. The 
inhibition with a 5 ng/ml of IL-1β occurred with a significant reduction in the 
cellular lipid content in human adipocytes. Consistently, cell morphology exhibited a 
significant inhibition of lipid accumulation in differentiated adipocytes after 
incubated with IL-1β (Figure 5.1). These results are consistent with a previous study 
which found that 6-10 days of treatment of murine adipocytes with IL-1β (10 or 20 
ng/ml) decreased cellular lipid content (Lagathu et al., 2006). The same study also 
shown that mature human adipocytes (day 22 post-induction) treated with IL-1β for 7 
days had reduced cellular lipid content. These results suggest that IL-1β exposure 
inhibits the adipogenic process and impairs lipid storage function of adipocytes.  
The present study also examined the long-term effect of IL-1β at several 
concentrations (1, 5 and 20 ng/ml) on the gene expression of the key adipogenic 
167 
 
factors. The results from this study showed that prolonged IL-1β exposure during 
preadipocytes differentiation has inhibitory effects on the expression of the key 
adipogenic genes. IL-1β has significantly downregulated mRNA levels of C/EBPα, 
PPARγ and aP2, suggesting that IL-1β has an inhibitory effect on preadipocyte 
differentiation.  
In contrast to the inhibitory effects of IL-1β on adipogenic factors, the present study 
showed that IL-1β had a stimulatory effect on pro-inflammatory factors. Prolonged 
IL-1β treatment significantly upregulated gene expression of pro-inflammatory 
factors, including IL-6, IL-8, MCP-1 and RANTES in adipocytes.  Previous studies 
have suggested that IL-1β may play a role in the increased production of MCP-1 in 
adipocytes (Bruun et al., 2005, Fain and Madan, 2005). MCP-1 is a chemokine 
produced by a variety of adipose cells, including macrophages and human adipocytes 
(Gerhardt et al., 2001, Gao et al., 2012) and is responsible to recruit macrophages 
into tissues (Christiansen et al., 2005). A recent study from our group has shown that 
24 hr treatment with IL-1β also stimulates IL-6, IL-8 and RANTES production in 
adipocytes (Gao et al., 2014).  Collectively, it is suggested that IL-1β could have a 
role in inducing pro-inflammatory responses that may be responsible for adipose 
tissue dysfunction in obesity (Arvin et al., 1996, Di Iorio et al., 2003). Taken 
together, these results suggest that IL-1β could be a major factor that has linked an 
adipogenic deficit and an increase in the production of pro-inflammatory factors in 
obese adipose tissue (Heilbronn et al., 2004, Le Lay et al., 2001).  
 
Macrophages, adipocytes and preadipocytes within adipose tissue have been shown 
to produce various pro-inflammatory protein factors including but not limited to 
TNF-α, IL-6, IL-1β, MPC-1 and RANTES (Gao and Bing, 2011, Coppack, 2001, 
Weisberg et al., 2003, Strissel et al., 2007). Other adipokines such as adiponectin and 
leptin are mainly produced by adipocytes (Yadav et al., 2013); leptin can also be 
produced by preadipocytes after stimulation with cytokines (Simons et al., 2007). 
Both adiponectin and leptin are considered as adipocyte markers in terminal 
adipocyte differentiation (Yang et al., 2004). Both are important in the regulation of 
energy homeostasis and insulin action (Havel, 2002). Previous studies have shown 
that macrophage-secreted factors influence adipokine expression by adipocytes, such 
as increasing the expression of a wide range of pro-inflammatory genes (O’Hara et 
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al., 2009) and stimulating leptin expression (Hirasaka et al., 2007) while decreasing 
adiponectin (Constant et al., 2006). In addition, several in vitro studies demonstrated 
that adiponectin expression and secretion levels were reduced by pro-inflammatory 
factors such as TNF-α (Kappes and Löffler, 1999, Bruun et al., 2003a, 
Degawa‐Yamauchi et al., 2005, Wang et al., 2005a) and IL-6 (Fasshauer et al., 2003, 
Bruun et al., 2003a). However, there are few studies on the long-term effect of IL-1β 
on the expression of adiponectin and leptin. Therefore, the present study examined 
the effect of long-term treatment with IL-1β at several concentrations (1, 5 and 20 
ng/ml) on gene expression of adiponectin and leptin in differentiated adipocytes. 
Results in the current study have shown that prolonged exposure to IL-1β had an 
inhibitory effect on adiponectin mRNA levels. However, the inhibitory effect of IL-
1β was not in a dose dependent manner. Adiponectin has been considered as a 
positive regulator of insulin sensitivity through regulating glucose and lipid 
metabolism in insulin target tissues (Berg et al., 2002). Adiponectin also possesses 
anti-inflammatory and antidiabetic properties (Ouchi et al., 2001). Considering the 
antagonistic actions between the role of adiponectin and IL-1β (Lagathu et al., 2006, 
Lihn et al., 2004, Simons et al., 2007), reduced adiponectin expression by IL-1β may 
enhance inflammation and insulin resistance in obesity. 
In contrast to adiponectin, the expression of leptin is increased with the increase in 
body weight (Yadav et al., 2013). In addition to inhibiting food intake and increasing 
energy expenditure (Mantzoros, 1999), leptin is involved in the inflammatory 
response (Bernotiene et al., 2006). Leptin is generally considered as a pro-
inflammatory factor (cytokine) due to the similarity in protein structure between 
leptin and its receptors with some cytokines such as IL-6 (Dessolin et al., 1997). In 
this study, our results showed that prolonged treatment with IL-1β had stimulatory 
effect on leptin gene expression, suggesting that IL-1β may act together with leptin 
to stimulate inflammation in obesity. In agreement with the effect of IL-1β on 
adipogenesis, previous in vitro and in vivo studies demonstrated that leptin increased 
lipolysis and inhibited adipocyte lipogenesis (Harris, 2014) .It could be suggested 
that IL-1β and leptin may work synergistically to mediate the inhibition of 
adipogenesis and stimulation of lipolysis. 
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The present study observed that MC medium reduces the lipid storage function of 
human adipocytes through increased lipolysis. Interestingly, IL-1β at 2 ng/ml 
concentration was shown to have a similar potency as the MC medium to induce 
lipolysis in differentiated adipocytes (Figure 5.6 a-b). However, it is not known 
whether IL-1β acts as a key factor in mediating the effect of MC medium. In the 
present study, our data showed that the induction of lipolysis by MC medium was 
completely attenuated by IL-1β neutralization that blocks IL-1β activities. Therefore, 
the current study provides evidence for the role of IL-1β in mediating macrophage-
induced lipolysis. This is further supported by the observation from the current study 
that the effect of MC medium was reduced by an IL-1RA which blocks IL-1 receptor 
binding in adipocytes (Figure 5.8).  
In summary, this study has focused on the effect of IL-1β, as a major cytokine 
produced by macrophages, on adipogenesis and function of human adipocytes. 
Prolonged exposure to IL-1β reduced lipid accumulation and the expression of the 
adipogenic factors by human adipocytes. This is associated with an increase in the 
expression of pro-inflammatory factors (IL-6, IL-8, MCP-1, RANTES and leptin) 
and a downregulation of adiponectin. Furthermore, this study has used two IL-1β 
blocking approaches to confirm that IL-1β could be a key player that mediates 
macrophage-induced reduction in lipid storage ability of human adipocytes. 
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CHAPTER 6: 
 IL-1β mediates macrophage-induced impairment of 
insulin signalling in human primary adipocytes 
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6 IL-1β mediates macrophage-induced impairment of 
insulin signalling in human primary adipocytes 
 
6.1 Introduction 
Based on the results from Chapters 3, 4 and 5, it is suggested that macrophage- 
derived factors particularly IL-1β may induce impairment of insulin signalling by 
affecting the key insulin signalling molecules in human primary adipocytes. In 
addition to skeletal muscle and liver, adipose tissue develops insulin resistance in 
obesity (Hotamisligil, 2000). The reduced insulin sensitivity in adipocytes may 
increase FFAs release into the circulation inducing hepatic and muscle insulin 
resistance (Smith, 2002a). Therefore, obese adipose tissue plays a crucial role in 
initiating systemic insulin resistance and the development of type 2 diabetes (Xu et 
al., 2003, Cancello and Clement, 2006). 
 
In obesity, adipose tissue is remodelled and the infiltration of macrophages is 
increased (Suganami and Ogawa, 2010). These cells may constitute the major 
sources of adipose-derived pro-inflammatory cytokine/chemokines (Cinti et al., 
2005, Lumeng et al., 2007b, Fain, 2010, O'Rourke et al., 2009). Macrophage 
infiltration in excess fat has been reported in both mice and humans, and is 
implicated in the development of insulin resistance (Bourlier and Bouloumié, 2009). 
It is estimated that over 20-30 million macrophages accumulate per kilogram of 
excess fat in obese human individuals (Lumeng and Saltiel, 2011b).  
 
Studies in murine and human have shown that macrophages crosstalk with 
adipocytes  and can lead to the alteration of adipocyte function, such as inhibiting of 
preadipocyte differentiation (Constant et al., 2006, Gao et al., 2010), stimulating 
inflammatory responses (Lacasa et al., 2007) and reducing insulin sensitivity 
(Lumeng et al., 2007c). Therefore, identification of the key factors that mediate the 
effect of macrophages on adipocytes is important as it may provide potential 
therapeutic targets for obesity-related insulin resistance. IL-1β, a key pro-
inflammatory cytokine, is produced mainly by monocytes and macrophages, which is 
then activated through caspase-1 via the NLRP3 inflammasome complex (Agostini et 
al., 2004). Recent studies suggest that IL-1β may be a candidate in the development 
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of insulin resistance and type 2 diabetes (Tack et al., 2012a, Wen et al., 2011). An 
increase in circulating levels of IL-1β together with IL-6 has been shown to increase 
the risk of type 2 diabetes (Spranger et al., 2003b). Studies in obese mice and 
diabetic rats showed that IL-1β inhibition reduces hyperglycemia and tissue 
inflammation (Owyang et al., 2010, McGillicuddy et al., 2011, Ehses et al., 2009, 
Sauter et al., 2008).  
 
In the insulin signalling pathway, IR is a core node protein activated by insulin and 
other polypeptide growth factors (Taniguchi et al., 2006). Once insulin is bound to 
the IR auto-phosphorylation occurs and the IR auto-phosphorylation leads to 
subsequent phosphorylation of its substrates including IRS-1 (Cheatham and Kahn, 
1995). IRS-1, as major substrate of the insulin receptor, is required to activate PI3K 
in response to insulin, which promotes the phosphorylation of protein kinase B (also 
known as Akt) and subsequent glucose uptake (Taniguchi et al., 2006, 
Schmitz‐Peiffer and Whitehead, 2003). It has been reported that gene expression of 
IL-1β in adipose tissue is upregulated in obese mice and humans (Juge-Aubry et al., 
2004, Lagathu et al., 2006). IL-1β is also released by human adipose tissue explants 
mainly by non-fat cells (Fain, 2006, Koenen et al., 2011b), and the release is 
increased in obesity (Nov et al., 2010). Previous studies mostly using murine 3T3-L1 
adipocytes have shown that IL-1β at a very high dose (20 ng/ml) reduced IRS-1 
protein expression and GLUT-4 mRNA levels, and prolonged treatment abolished 
insulin-stimulated phosphorylation of IRS-1 and Akt (Lagathu et al., 2006, Xie et al., 
2010). However, the effect of macrophage-adipocyte crosstalk on insulin signalling 
in human adipose tissue is largely unknown. Furthermore, whether IL-1β mediates 
macrophage-induced insulin resistance in human and rodent adipocytes has not been 
reported.  
 
 
6.2 Aim of the study 
The aim of this study was therefor to investigate the role of IL-1β in the macrophage-
adipocyte crosstalk which affects insulin signalling in human adipocytes. By using in 
vitro human cell models including primary adipocytes, THP-1 macrophages (cell 
line) and primary macrophages, the specific objectives were set below:   
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 To investigate whether THP-1 macrophage-derived factors, using MC 
medium, induce the impairment of insulin signalling pathways in human 
primary adipocytes;  
 To examine whether IL-1β induces impairment of the insulin signalling 
pathway in human primary adipocytes;  
 To examine whether blocking IL-1β activity reverses the effects of MC 
medium on the insulin signalling pathway, and on cytokine/chemokine and 
adiponectin release in human primary adipocytes; 
 To examine whether blocking the IL-1 receptor binding in human adipocytes 
reverses the effect of MC medium on the insulin signalling pathway, and also 
on cytokine/chemokine and adiponectin release in adipocytes; 
 To examine whether inhibiting IL-1β production by macrophages reverses the 
effects of MC medium on expression of  insulin signalling molecules, and 
also on cytokine/chemokine release in adipocytes 
 To investigate whether human primary macrophage-derived factors, using 
MC medium, impair the insulin signalling pathway and induce pro-
inflammatory factors release in human primary adipocytes.  
 
6.3 Material and methods  
6.3.1 Culture of human adipocytes  
Human primary preadipocytes were grown and induced to undergo differentiation 
until cells became lipid-laden mature adipocytes (day 12 post induction) (as 
described in section 2.3).    
 
6.3.2 Cell treatment 
According to the specific experimental design, the cells were treated with different 
agents as detailed below.  
 
6.3.2.1 Effect of THP-1 macrophage conditioned medium  
To assess the effect of macrophage-derived factors on insulin signalling, 
differentiated adipocytes were incubated with RPMI-1640 medium (control) or THP-
1 MC medium for 24 hr as previously described in Chapter 2. 
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6.3.2.2  Effects of Human recombinant IL-1β  
To assess the effect of IL-1β on insulin signalling, differentiated adipocytes were 
treated with RPMI-1640 medium or IL-1β (2 ng/ml) for 24 hr.  
 
6.3.2.3 Effect of IL-1β inhibition   
To investigate whether IL-1β mediates the effects of MC medium on insulin 
signalling, three of the following experiments were carried out. Firstly, MC medium 
was pre-incubated with a human IL-1β neutralizing antibody (2 μg/ml) for 1 h at 37 
°C to inactivate IL-1β activity. Differentiated adipocytes were then incubated with 
either RPMI 1640 medium (control), MC medium or MC medium neutralized by IL-
1β antibody or mouse IgG for 24 hr. Secondly, to block the IL-1β receptor in 
adipocytes, differentiated adipocytes were pre-treated with human recombinant IL-1β 
receptor antagonist (IL-1RA) at 1 µg/ml for 2 h and then incubated with MC medium 
in the presence or absence of IL-1RA for 24 hr. Finally, to inhibit IL-1β production 
by macrophages, THP-1 cells were incubated with RPMI 1640-medium (serum free) 
as controls or the 50 µM caspase1 inhibitor (Ac-YVAD-CMK) in RPMI 1640 
medium (serum free) for 48 hr, with fresh medium replenished at 24 hr; the medium 
was collected from macrophages without treatment (MC medium) or treated with 
caspase 1 inhibitor (MC medium + caspase 1 inhibitor). Differentiated adipocytes 
were then incubated with either RPMI-1640 medium (control), MC medium or the 
MC medium + caspase 1 inhibitor for 24 hr. 
 
6.3.2.4 Effects of primary macrophage conditioned medium 
To further examine whether IL-1β mediates the effect of primary macrophages on 
adipocyte insulin signaling and the inflammatory response, MC medium generated 
from human PBMC-derived macrophages was used (kindly provided by Dr. Chris 
Ford). Differentiated human adipocytes were incubated with either RPMI 1640 
medium (control), MC medium, MC medium neutralized by an IL-1β antibody, MC 
medium neutralized by an IL-1β antibody and a TNFα antibody, mouse IgG or MC 
medium with an IL-1RA for 24 hr. At the end of each experiment, cells and the 
culture media were collected and stored at -80C until analysis.  
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6.3.3 Western blotting 
For assessing protein expression Western blotting method was used. For the insulin 
response study, primary antibodies for IRS-1, PI3Kp85α (both from Cell Signalling), 
Phospho-insulin receptor (Y1185) (Abcam, UK) and phospho-Akt (S473) (New 
England BioLabs Ltd, Hitchin, UK) were used and diluted at 1:1000. GLUT-4 
(Millipor, UK) was used and diluted at 1:2000. GAPDH (Abcam, UK) diluted at 
1:2000 or Akt (Cell Signalling) diluted at 1:1000 were used as a loading controls. 
After 4 washes with 1xTTBS, anti-rabbit secondary antibody (New England BioLabs 
Ltd, Hitchin, UK) at 1:2000 dilution (or 1:20000 for GAPDH) were used. Signals 
were detected by chemiluminescence (West Pico kit, Pierce, Loughborough, UK) 
and scanned using the Molecular Imager ChemiDoc XRS+ System (Bio-Rad). The 
size of the protein bands detected was estimated with PageRuler protein markers 
(Fermentas, York, UK). The membrane was further probed with GAPDH (Abcam, 
Cambridge, UK) or total Akt. 
 
6.3.4 Measurement of cytokine/chemokine and adiponectin release 
The secretion levels of IL-1β by THP-1 macrophages or PBMC-derived 
macrophages and of IL-6, MCP-1, IL-8, RANTES and adiponectin by adipocytes 
were determined as the protein concentrations in cell culture medium, using ELISA 
kits (R&D Systems, Abingdon, UK). 
 
6.3.5 Cell viability assay 
Cell viability was determined by using a clolorimetric method for measuring cellular 
cytotoxicity from the release of lactate dehydrogenase (LDH) into cell culture 
medium (See section 2.14). 
 
6.3.6 Statistical analysis  
Data are expressed as means ± SEM or means ± SD. Differences between two groups 
were analyzed by Student’s unpaired t-test; one-way ANOVA coupled with 
Bonferroni’s t-test was employed for comparison of multiple-groups. Differences 
were considered as statistically significant when p< 0.05. 
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6.4 Macrophage-derived factors induce the impairment in the 
insulin signalling pathway in human primary adipocytes 
  
6.4.1 Macrophage-derived factors inhibit the expression of insulin signalling 
molecules 
To study the effects of macrophage-derived factors on the insulin signalling pathway 
in human adipocytes, human primary adipocytes (at day 12 post-differentiation) were 
incubated with RPMI medium or MC medium for 24 hr and the effect of 
macrophage-derived factors on protein expression of  IRS-1, PI3K p85 and GLUT-4 
as the key insulin signalling molecules was examined. Results have shown that 
treatment with MC medium for 24 hr led to a significant reduction in protein 
abundance of all the proteins;  IRS-1 protein was reduced by 40% (p< 0.01), PI3K 
p85 was reduced by 28 % (p< 0.05) and GLUT-4 was reduced by 51% (p< 0.01) in 
human primary adipocytes (Figure 6.1 a-e). 
 
6.4.2 Macrophage-derived factors inhibit insulin-stimulated phosphorylation of IR 
(Y1185) and Akt (Ser473)   
In this study, human adipocytes were incubated with RPMI medium (control) or MC 
medium for 24 hr before stimulation with 100nM insulin. In control groups, insulin 
stimulated phosphorylation of IR level was significantly increased (by 3.5-fold, 
p˂0.001) in insulin-treated adipocytes compared with unstimulated adipocytes 
(Figure 6.2 a-b). In contrast, adipocytes exposed to MC medium, had a reduction in 
insulin-stimulated phosphorylation of IR (by 2-fold, p< 0.001) compared with the 
corresponding controls (Figure 6.2 a-b). The level of serine phosphorylation of Akt 
was also examined and results showed that the p-Akt level was also increased but not 
statistically significant in response to insulin compared with basal levels in controls. 
However, adipocytes exposed to MC medium resulted in a significant reduction in 
phosphorylation of Akt at ser473 (p< 0.05) compared with the corresponding 
controls (Figure 6.3 a-b).  
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Figure 6-1: Protein expression of the insulin signalling molecules 
(IRS-1, PI3K p85α and GLUT-4) in human adipocytes is reduced by 
MC medium 
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MC medium reduces protein expression of insulin signalling molecules in human 
adipocytes. Adipocytes (at day 12 post-differentiation) were treated with RPMI-1640 
medium (control) or THP-1 MC medium for 24 hr. Cell lysates were collected and  
analysed by western blotting and densitometry, using antibodies to IRS-1 and PI3K 
p85 (a, b, c) and GLUT-4 (d, e). Data are means ± SEM (n=3 or 4 per group). *p< 
0.05, **p< 0.01 vs controls   
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Figure 6-2: Insulin-stimulated phosphorylation of IR in human 
adipocytes is reduced by MC medium 
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For measuring basal and insulin-stimulated phosphorylation of IR, adipocytes were 
incubated with RPMI-1640 or MC medium for 24 hr before stimulation with 100 nM 
insulin; IR phosphorylation was analysed by western blotting and densitometry. Total 
Akt and GAPDH were used as loading controls (a, b). Data are means ± SEM (n=3 
per group). ***p< 0.001 vs indicated group   
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Figure 6-3: Insulin-stimulated phosphorylation of Akt (Ser473) in 
human   adipocytes is reduced by MC medium 
 
 
 a   
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For measuring basal and insulin-stimulated Akt phosphorylation, adipocytes were 
incubated with RPMI-1640 or MC medium for 24 hr before stimulation with 100nM 
insulin; Akt phosphorylation at Ser473 (p-Akt) was analysed by western blotting and 
densitometry. Total Akt and GAPDH were used as loading controls (a, b). Data are 
means ± SEM (n=3 per group). *p< 0.05 vs controls.  
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6.4.3 IL-1β induces impairment in the insulin signalling pathway in human 
primary adipocytes 
 
6.4.3 .1 IL-1β inhibits the protein expression of insulin signalling molecules 
To determine the effects of IL-1β on the expression of insulin signalling molecules in 
human adipocytes, human primary adipocytes (at day 12 post-differentiation) were 
incubated with or without 2 ng/ml of IL-1β for 24 hr and the effect of IL-1β on 
protein expression of IRS-1, PI3K p85 and GLUT-4 in adipocytes was examined. 
Consistent with the results  of MC medium treatment which potently reduced the 
insulin signaling molecules, IL-1β significantly reduced protein abundance of IRS-1 
(by 20 %), PI3K p85 (by 28 %) and GLUT-4 (by 21 %) (All p< 0.01) (Figure 6.4 a-
e).   
 
6.4.3.2 IL-1β inhibits insulin-stimulated phosphorylation of IR and Akt   
Because IL-1β inhibits insulin signalling molecules, it becomes important to study 
the effect of IL-1β on proximal insulin signaling steps involved in this process. 
Adipocytes were treated as described above and then stimulated with or without 
insulin (100 nM/ml) for 5 minutes. IL-1β significantly decreased insulin-stimulated 
phosphorylation of IR at Y1185 (by 60%, p˂ 0.05) (Figure 6.5 a-b) and insulin-
stimulated phosphorylation of Akt at ser473 (by 50%, p< 0.001) (Figure 6.6 a-b) 
compared with the corresponding controls.  
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Figure 6-4: Protein expression of the insulin signalling molecules 
(IRS-1, PI3K p85α and GLUT-4) in human adipocytes is reduced by 
IL-1β 
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IL-1β impairs the insulin signaling pathway in human adipocytes. Differentiated 
adipocytes were cultured in the presence of IL-1β (2 ng/ml) or RPMI-1640 (control) 
for 24 hr. Protein expression of IRS-1 and PI3K p85α (a-c), and GLUT-4 (d,e) were 
determined in cell lysates by western blotting and densitometry.  Data are expressed 
as means ± SEM (n= 5 or 6 per group). **p< 0.01vs controls 
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Figure 6-5: IL-1β inhibits insulin-stimulated phosphorylation of IR 
in human   adipocytes 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Adipocytes were treated with IL-1β (2 ng/ml) or RPMI-1640 (control) for 24 hr 
followed by stimulation with 100 nM insulin; IR phosphorylation was analysed by 
western blotting and densitometry. Total Akt and GAPDH were used as loading 
controls (a, b). Data are expressed as means ± SEM (n= 3 per group). *p< 0.05, 
***p< 0.001vs indicated groups   
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Figure 6-6: IL-1β inhibits insulin-stimulated phosphorylation of Akt 
in human adipocytes 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Adipocytes were treated with IL-1β (2 ng/ml) or RPMI-1640 (control) for 24 hr 
followed by stimulation with 100 nM insulin; Akt phosphorylation at Ser473 (p-Akt) 
was analysed by western blotting and densitometry. Total Akt and GAPDH were 
used as loading controls (a, b). Data are expressed as means ± SEM (n=3 per group). 
*p< 0.05, ***p< 0.001vs indicated groups   
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6.4.4 Blocking IL-1β activity reduces the effects of the MC medium on the insulin 
signalling pathway in human primary adipocytes  
 
6.4.4.1 Blocking IL-1β activity reverses the effects of MC medium on protein 
expression of insulin signalling molecules.  
A recent pilot study of our lab has shown that blocking IL-1β activity reduced effects 
of MC medium on expression of genes involved in insulin signalling pathway (data 
not shown), this study was aimed to examine whether it is effective at the protein 
levels. The results showed that MC medium significantly reduced protein abundance 
of IRS-1 (46%, p< 0.01), PI3K p85α (31%, p< 0.01) and GLUT-4 (53%, p< 0.05) in 
adipocytes (Figure 6.7 a-f); however, blocking IL-1β activity with a neutralizing 
antibody abolished the effect induced by MC medium on IRS-1 ( p< 0.001) and 
GLUT-4 (p< 0.05)  (Figure 6.7 a-f). Treatment with IgG (as a negative control) did 
not alter the effect of MC medium  
 
6.4.4.2 Blocking IL-1β activity reverses the effects of MC medium on insulin-
induced phosphorylation of Akt. 
It was shown that MC medium also led to a reduction in insulin-stimulated 
phosphorylation of Akt at ser473 compared with controls (>3-fold, p< 0.001) but this 
effect was blunted by IL-1β neutralization (p< 0.05) (Figure 6.8 a-b). Treatment with 
IgG (as a negative control) did not affect the action of MC medium (Figure 6.8 a-b). 
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Figure 6-7: Blocking IL-1β activity reverses the effects of MC 
medium on protein expression of the insulin signalling molecules in 
human adipocytes 
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Inhibition of IL-1β activity abolishes the inhibitory effect of macrophages on protein 
expression of IRS-1, PI3K p85α and GLUT-4 by human adipocytes. Differentiated 
adipocytes were incubated with either RPMI-1640 medium (control), MC medium, 
MC medium neutralized by IL-1β antibody (2 μg/ml) or mouse IgG (2 μg/ml, as 
negative control) for 24 hr. Cell lysates were analysed by western blotting and 
densitometry, using antibodies to IRS-1 (a, b), PI3K p85α (c, d) and GLUT-4 (e, f). 
Data are means ± SEM (n=3 per group). *p< 0.05, **p< 0.01, ***p< 0.001 vs 
indicated groups   
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Figure 6-8: Blocking IL-1β activity reverses the effects of MC 
medium on insulin-stimulated phosphorylation of Akt in human 
adipocytes 
 
 
 
  
 
 
 
  
 
 
 
  
  
 
 
 
 
Differentiated adipocytes were incubated with either RPMI-1640 medium (control), 
MC medium, MC medium neutralized by IL-1β antibody (2 μg/ml) or mouse IgG (2 
μg/ml, as negative control) for 24 hr followed by stimulation with or without insulin 
(100 nmol/ml) for 5 min; Akt phosphorylation at Ser473 (p-Akt) was analysed by 
western blotting and densitometry. Total Akt and GAPDH were used as loading 
controls (a, b). Representative blots are shown; data are means ± SEM (n=3 per 
group). ***p< 0.001 vs indicated groups   
191 
 
6.4.4.3 Blocking IL-1β activity reverses the stimulatory effect of MC medium on 
cytokine/chemokine release by human adipocytes. 
 
In addition, we evaluated whether blocking IL-1β activity inhibits the effect of MC 
medium on the release of pro-inflammatory factors which are known to impair 
insulin signalling in adipocytes.  
 
As shown in Figure 6.9 a-d, basal secretion of cytokine and chemokines by 
adipocytes was barely detectable (IL-6, IL-8 and RANTES) or very low (MCP-1 
with a mean value of 140 pg/ml). MC medium potently stimulated the release of IL-6 
(up to 19623 pg/ml), MCP-1 (42776 pg/ml), IL-8 (88806 pg/ml) and RANTES (5618 
pg/ml) but this induction was blunted by IL-1β neutralization (all p< 0.001). 
Treatment with IgG did not affect the action of MC medium in comparison with IL-
1β neutralization groups for all IL-6, IL-8 and RANTES and MCP-1 releases (p˂ 
0.001). To distinguish the production of pro-inflammatory factors by adipocytes and 
macrophages, the basal levels of the cytokines in the THP-1 macrophage medium 
were shown as ‘MC alone’ (mean ± SEM): IL-6 (42 ± 2 pg/ml), MCP-1 (127±40 
pg/ml), IL-8 (31623 ± 1937 pg/ml) and RANTES (1902 ± 237pg/ml) (Figure 6.9 a-
d). 
 
6.4.4.4 Blocking IL-1β activity reduces the inhibitory effect of MC medium on 
adiponectin release by human adipocytes 
This study also evaluated whether blocking IL-1β activity inhibits the effect of MC 
medium on the release of adiponectin (adipokine). As shown in Figure 6.10, basal 
secretion of adiponectin was significantly higher with a mean value of 22343 pg/ml 
in control group. MC medium potently inhibited the release of adiponectin with a 
mean value of 6448 pg/ml but this inhibition was reduced by IL-1β neutralization 
(p< 0.001). Treatment with an IgG did not affect the effect of MC medium.   
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Figure 6-9: Blocking IL-1β activity reverses the stimulatory effects 
of MC medium on cytokine/chemokine release by human adipocytes 
 
Inhibition of IL-1β activity reverses macrophage-induced cytokine release by human 
adipocytes. Differentiated adipocytes were incubated with either RPMI-1640 
medium (control), MC medium, MC medium neutralized by IL-1β antibody (2 
μg/ml), mouse IgG (2 μg/ml, as negative control) or MC medium alone (without 
cells) for 24 hr. The release of IL-6 (a), MCP-1 (b), IL-8 (c) and RANTES (d) by 
adipocytes was measured as protein concentrations in cell culture medium by 
ELISAs. Data are means ± SEM (n=6 per group). ***p< 0.001vs indicated groups 
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Figure 6-10: Blocking IL-1β activity reduced the inhibitory effect of 
MC medium on adiponectin release by human adipocytes 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inhibition of IL-1β activity partially reverses macrophage-reduced adiponectin 
release by human adipocytes. Differentiated adipocytes were incubated with either 
RPMI-1640 medium (control), MC medium, MC medium neutralized by IL-1β 
antibody (2 μg/ml), mouse IgG (2 μg/ml, as negative control) for 24 hr. The release 
of adiponectin by adipocytes was measured as protein concentrations in cell culture 
medium by ELISA. Data are means ± SEM (n=6 per group). *p< 0.05, ***p< 
0.001vs indicated groups 
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6.4.5 Blocking IL-1 receptor binding in human primary adipocytes  
 
6.4.5.1 Blocking IL-1 receptor binding in human adipocytes reverses the inhibitory 
effect of MC medium on expression of insulin signalling molecules    
To further examine whether IL-1β has a key role in macrophage-induced impairment 
of insulin signalling, a recombinant IL-1RA was used to block IL-1 receptor binding 
in adipocytes. Adipocytes treated with MC medium significantly reduced protein 
expressions of IRS-1 (p< 0.001), PI3K p85α (p<0.05) and GLUT-4 (p<0.001) 
compared with controls. However, blocking IL-1receptor binding by the IL-1RA 
blunted the inhibitory effect of MC medium on IRS-1 (p< 0.01), PI3K p85α (p< 
0.05) and GLUT-4 (p< 0.01) in adipocytes (Figure 6.11 a-f).  
 
6.4.5 .2 Blocking IL-1 receptor binding reverses the stimulatory effect of MC 
medium on cytokine/chemokine release by human adipocytes 
 
This study also evaluated whether blocking the IL-1 receptor binding inhibits the 
effect of MC medium on the release of pro-inflammatory factors which are known to 
impair insulin signaling by adipocytes. Consistent with data shown in section 6.4.4.3, 
basal secretion of cytokines/chemokines was barely detectable (IL-6 and IL-8) or 
very low (MCP-1 with a mean value of 275 pg/ml) by adipocytes; MC medium 
potently stimulated the release of IL-6 (up to 10934 pg/ml), IL-8 (46572 pg/ml) and 
MCP-1 (26282 pg/ml). This induction was largely reversed by blocking IL-1β 
receptor binding as there were marked decreases in  protein release of IL-6 (97%), 
MCP-1 (93%) and IL-8 (90%) by human adipocytes (all p< 0.001; Figure 6.12 a-c). 
 
6.4.5.3 Blocking IL-1 receptor binding reverses the inhibitory effects of MC 
medium on adiponectin release by human adipocytes 
This study next evaluated whether blocking the IL-1 receptor binding inhibits the 
effects of MC medium on the release of adiponectin which is known to enhance 
insulin signaling by adipocytes. Consistent with data shown in section 6.4.4.4, basal 
secretion of adiponectin was markedly high with a mean value of 17638 pg/ml in 
control adipocytes; MC medium potently inhibited the release of adiponectin with a 
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mean value 6162 pg/ml. This inhibition was largely reversed by blocking IL-1β 
receptor binding as there was a marked increase in protein release of adiponectin 
(56%, p˂ 0.001) (Figure 6.13). 
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Figure 6-11:  Blocking IL-1 receptor binding reverses the effects of 
MC medium on protein expression of insulin signalling molecules in 
human adipocytes 
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Blocking IL-1 receptor with IL-1 receptor antagonist reverses the effects of MC 
medium on protein expression of IRS-1, PI3K p85α and GLUT-4 in human 
adipocytes. Differentiated adipocytes were incubated with either RPMI-1640 
medium (control), MC medium or MC medium with a recombinant IL-1 receptor 
antagonist (IL-1RA, 1 µg/ml) for 24 hr. Cell lysates were analysed by western 
blotting and densitometry, using antibodies to IRS1 (a, b), PI3K p85α (c, d) and 
GLUT-4 (e, f). Data are expressed as means ± SEM (n=3 per group). **p< 0.01, 
***p< 0.001vs indicated groups 
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Figure 6-12: Blocking IL-1 receptor binding reverses the stimulatory 
effects of MC medium on cytokine/chemokines release by human 
adipocytes 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Differentiated adipocytes were 
incubated with either RPMI-1640 medium (control), MC medium or MC medium 
with a recombinant IL-1 receptor antagonist (IL-1RA, 1 µg/ml) for 24 hr. The release 
of IL-6 (a), MCP-1 (b), and IL-8 (c) by adipocytes was measured as protein 
concentrations in cell culture medium by ELISA. Data are means ± SEM (n=6 per 
group). ***p< 0.001 vs indicated groups    
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Figure 6-13: Blocking IL-1 receptor binding reverses the inhibitory 
effect of MC medium on adiponectin release in human adipocytes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Differentiated adipocytes were incubated with either RPMI-1640 medium (control), 
MC medium or MC medium with a recombinant IL-1 receptor antagonist (IL-1RA, 1 
µg/ml) for 24 hr. The release of adiponectin by adipocytes was measured as protein 
concentrations in cell culture medium by ELISA. Data are means ± SEM (n=6 per 
group). ***p< 0.001 vs indicated groups   
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6.4.6 Inhibiting IL-1β production by macrophages protects insulin signalling 
pathway and reduced cytokines/chemokines release in human adipocytes.  
 
6.4.6 .1 Inhibiting IL-1β production by macrophages reduces the inhibitory effects 
of MC medium on the protein expression of insulin signalling molecules     
 
To further examine the role of IL-1β in mediating the effects of MC medium on 
insulin signalling pathway, IL-1β release by THP-1 macrophages was suppressed 
with an inhibitor of caspase 1 (IL-1β converting enzyme). Caspase-1 inhibitor (50 
µM) significantly reduced IL-1β production by THP-1 macrophages by 84% (317 ± 
56 vs 1936 ±190 pg/ml, p< 0.001). Adipocytes were then incubated with RPMI 
medium (control) or the medium from THP-1 macrophages treated with or without 
the caspase-1 inhibitor for 24 hr. As shown in Figure 6.12 a-d, MC medium treatment 
significantly decreased protein expression of IRS-1, PI3K p85α and GLUT-4 in 
adipocytes (all p< 0.001); however, this inhibition was partially (for IRS-1 and PI3K 
p85α) or totally (GLUT-4) abolished in adipocytes exposed to MC medium derived 
from THP-1 macrophages treated with the caspase-1 inhibitor (Figure 6.14 a- d).  
 
6.4.6.2 Inhibiting IL-1β production by macrophages reduces the stimulatory effects 
of MC medium on the cytokine/chemokines release by human adipocytes 
The effect of blocking IL-1β production by macrophages on the release of pro-
inflammatory factors was also examined in this study. The MC medium with 
inhibited IL-1β production reduced protein release of IL-6 (29%, p< 0.05), IL-8 
(86%, p< 0.001), MCP-1 (19%, p< 0.05) and RANTES (66%, p< 0.001) by 
adipocytes compared with the corresponding group treated with MC medium (Figure 
6. 15 a-d).    
 
 . 
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Figure 6-14: Inhibiting IL-1β production by macrophages reduces 
the effects of MC medium on protein expression of IRS-1, PI3K 
p85α and GLUT-4 in human adipocytes 
 
 
 
 
 
 
 
      
 
                
   b 
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    d 
 
      
               
 
 
            
Inhibition of IL-1β production by THP-1 macrophages reduces the effect of MC 
medium on protein expression of IRS-1, PI3K p85α and GLUT-4 by adipocytes. 
THP-1 macrophages were incubated with RPMI-1640 medium (control) or the 
caspase 1 inhibitor (50 µM) for 48 hr (with freshly changed medium at 24 hr) and the 
culture medium was collected. Differentiated adipocytes were then treated with 
either RPMI-1640 medium (control), MC medium or MC medium in the presence of 
caspase 1 inhibitor for 24 hr. Cell lysates were analysed by western blotting and 
densitometry, using antibodies to IRS-1, PI3K p85α and GLUT-4 (a, b, c, d). Data are 
expressed as means ± SEM (n=6 per group). *p< 0.05, **p< 0.01, ***p< 0.001 vs 
indicated groups   
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Figure 6-15: Inhibiting IL-1β production by macrophages reduces 
the effects of MC medium on cytokine/chemokine release by human 
adipocytes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inhibition of IL-1β production by THP-1 macrophages using a caspase 1 inhibitor 
reduces the effect of MC medium on cytokine/chemokine release including IL-6 (a), 
MCP-1 (b), IL-8 (c) and RANTES (d) by adipocytes. The levels of 
cytokine/chemokines were measured by ELISA. Data are expressed as means ± SEM 
(n=6 per group). *p< 0.05, ***p< 0.001 vs indicated groups.  
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6.5 Human primary macrophage-derived factors inhibit insulin 
signalling and stimulate cytokine/chemokines release by human 
adipocytes and the effect of blocking IL-1β 
 
6.5.1 Human primary macrophage-derived factors inhibit the protein expression of 
IRS-1 and GLUT-4, and the effect of blocking IL-1β  
To further examine whether IL-1β mediates the effect of primary macrophages on 
adipocyte insulin signalling and the inflammatory response, MC medium generated 
from human PBMC-derived macrophages were used. MC medium significantly 
reduced protein expression of IRS-1 (Figure 6.16 a-b) and GLUT-4 (Figure 6.17 a-b) 
in adipocytes (all p< 0.01).  This inhibition was reversed by IL-1β neutralization 
(both p<0.05) or by both IL-1β and TNFα neutralization (p< 0.05 for IRS-1 and p< 
0.01 for GLUT-4) or an IL-1β RA (all p< 0.01).  
 
6.5.2 Human primary macrophage-derived factors inhibit insulin-stimulated 
phosphorylation of Akt  
In line with the result from the THP-1 MC medium that reduced phosphorylation of 
Akt,  human primary MC medium also led to a reduction in insulin-stimulated 
phosphorylation of Akt at ser473 compared with controls (>2-fold, p< 0.001)  
(Figure 6.18 a-b). 
 
6.5.3 Human primary macrophage-derived factors stimulate cytokine/chemokine 
release by human adipocytes and the effect of blocking IL-1β. 
As shown in Figure 6.19 a-d, protein release of IL-6, MCP-1, IL8 and RANTES 
from adipocytes was significantly induced by MC medium compared with the 
control group. This substantial release of pro-inflammatory factors was significantly 
reduced by blocking IL-1β activity in MC medium by IL-1β neutralization (90%, 
55%, 65% and 26%, all p<0.001). This up-regulation was also partially reversed by 
both IL-1β and TNF-α neutralization (92%, 67%, 63% and 21%) or by blocking the 
IL-1 receptor  binding with an IL-RA (95%, 89%, 67% and 32%), respectively (all 
p< 0.001). Consistent with the effect of TPH-1 MC medium, human primary 
macrophage MC medium showed a similar induction effect on adipocytes to release 
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pro-inflammatory proteins. Moreover, the effect of primary macrophage-derived 
factors was also inhibited by blocking IL-1β activity and IL-1 receptor binding. 
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Figure 6-16: Human primary macrophage-derived factors inhibit 
IRS-1 protein expression and the effect of blocking IL-1β 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Differentiated human adipocytes were treated with either RPMI-1640 medium 
(control), MC medium, MC medium neutralized by IL-1β antibody (15 μg/ml), MC 
medium neutralized by IL-1β antibody (7.5 μg/ml) and TNF-α (7.5 μg/ml), mouse 
IgG (15 μg/ml) or an IL-1β receptor antagonist (IL-1RA, 1 µg/ml) for 24 hr. Cell 
lysates were analysed by western blotting (a) and densitometry (b), using antibodies 
to IRS-1; GAPDH was used as a loading control. Representative blots are shown; 
data are means ± SEM (n=3 per group). **p< 0.01 vs controls; + p< 0.05, ++ p< 0.01 
vs MC group 
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Figure 6-17: Human primary macrophage-derived factors inhibit 
GLUT-4 protein expression and are reversed by the effect of 
blocking IL-1β 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Differentiated human adipocytes were treated with either RPMI-1640 medium 
(control), MC medium, MC medium neutralized by IL-1β antibody (15 μg/ml), MC 
medium neutralized by IL-1β antibody (7.5 μg/ml) and TNF-α (7.5 μg/ml), mouse 
IgG (15μg/ml) or an IL-1β receptor antagonist (IL-1RA, 1 µg/ml) for 24 hr. Cell 
lysates were analysed by western blotting (a) and densitometry (b), using antibodies 
to GLUT-4; GAPDH was used as a loading control. Representative blots are shown; 
data are means ± SEM (n=3 per group).*p< 0.05 vs controls; + p< 0.05, ++ p< 0.01 
vs MC group 
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Figure 6-18: Human primary macrophage-derived factors inhibit 
insulin-stimulated phosphorylation of Akt at (Ser 473) in human 
adipocytes 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Differentiated human adipocytes were treated with RPMI-1640 or MC medium for 
24 hr before stimulated with 100 nM insulin; Akt phosphorylation at Ser473 (pAkt) 
(a, b) was analysed by western blotting (a) and densitometry (b); GAPDH was used 
as loading control. Representative blots are shown; data are means ± SEM (n=3 per 
group). **p< 0.01, ***p< 0.001 vs indicated group  
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Figure 6-19: Human primary macrophage-derived factors induce 
cytokine/chemokine release by human adipocytes and the effect of 
blocking IL-1β 
 
                                                                     
Blocking of IL-1β reduces the effect of MC medium on protein release of IL-6 (a), 
MCP-1 (b) and IL-8 (c) and RANTES (d) by adipocytes. The levels of 
cytokine/chemokine were measured by ELISA. Data are expressed as means ± SD 
(n=6 per group); +++p˂ 0.001 vs control group; ***p< 0.001 vs MC group 
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6.6 Cell viability assessment  
To assess the possibility that the reduction of insulin signaling molecules by several 
treatments, including THP-1 MC medium, human IL-1β neutralizing antibody (IL-1β 
Ab, 2 µg/ml), interleukin-1 receptor antagonist (IL-1RA, 1 µg/ml) and caspase-1 
inhibitor 50 µM, is due to cytotoxicity, cell viability was determined as LDH release 
by adipocytes treated with these agents. There were no significant differences in 
LDH release by adipocytes treated with THP-1 MC, IL-1β Ab, IL-1RA and caspase1 
inhibitor for 24 hr compared with controls (Figure 6.20 a-c). 
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Figure 6`-20: Effect of treatment with MC medium, IL-1β Ab, IL-
1RA and caspase-1 inhibitor on the viability of human primary 
adipocytes 
 
a                                    b             
                     c 
                                  
 
                                              
                                                                                                                               
 
                                
Cell viability was assessed by measuring LDH release into the cell culture medium 
of adipocytes treated with the MC medium (a-c), IL-1β Ab (a), IL-1RA (b) and 
caspase-1 inhibitor (c) for 24 hr. Data are means ± SD (n=6 per group).***p< 0.001 
vs all the other groups 
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6.7 Discussion   
The macrophage-adipocyte crosstalk in obese adipose tissue affects adipose tissue 
biology (in both structure and function) but the molecular mechanisms and the key 
mediators, particularly in human adipose tissue, are poorly understood. This study 
used in vitro models of human macrophages (derived from a monocytic cell line and 
also PBMC) and primary fat cells to examine the influence of macrophage-derived 
factors on the insulin signalling pathway and the role of IL-1β in human adipocytes. 
In this study, MC medium significantly reduced protein abundance of insulin 
signalling molecules, including IRS1, PI3K p85α, GLUT-4 and insulin-stimulated 
phosphorylation of IR and Akt. These results are in agreement with a previous study 
in murine 3T3-L1 adipocytes (Lumeng et al., 2007a), suggesting that macrophage-
derived factors can impair insulin signalling in human adipocytes.   
 
Although major factors that mediate the detrimental effect of macrophages on 
adipocytes remain to be identified, IL-1 has been implicated as a key regulator in 
the translation of obesity-associated inflammation into insulin resistance in rodent 
models (Jager et al., 2007, Owyang et al., 2010, McGillicuddy et al., 2011, Ehses et 
al., 2009). The current study has demonstrated that in human adipocytes IL-1 
potently inhibited insulin signal transduction.  Similar to the effect of MC medium, 
IL-1β (2 ng/ml) induced a reduction in protein expression of IRS-1, PI3K p85α, 
GLUT-4 and insulin-stimulated phosphorylation of Akt. These data raise a question 
whether IL-1β is responsible for the inhibitory effect of MC medium on the insulin 
signaling pathway in human adipocytes. This study observed that blocking the 
actions of IL-1β can in part reverse the effects of MC medium on insulin signalling 
in human adipocytes. IL-1β depletion with a neutralization antibody abolished the 
inhibitory effect of MC medium on protein abundance of insulin signalling 
molecules (IRS-1, PI3K p85α and GLUT-4) and insulin-stimulated phosphorylation 
of IR and Akt, suggesting that IL-1β blockade could restore insulin signal 
transduction in human adipocytes. IL-1β therefore could be a major contributor to 
macrophage-induced inhibition on the insulin signaling pathway.  
 
To further study the role of IL-1β in mediating the effect of macrophages, in this 
study an IL-1RA was used to prevent IL-1β binding to its receptor in adipocytes. As 
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a result, protein expression of IRS-1, PI3K p85α and GLUT-4 suppressed by MC 
medium was restored. In addition, it suggested that IL-1β plays a major role in the 
macrophage-adipocyte crosstalk associated impairment of insulin signalling in 
adipose tissue. A recent study has shown that IL-1β production in macrophages (is 
caspase 1-dependent) isolated from human adipose tissue (Stienstra et al., 2010b). 
Caspase1 has also been reported to regulate IL-1β production in mouse adipose 
tissue (Vandanmagsar et al., 2011). To further examine the role of IL-1β in 
mediating the effect of MC medium, the current study assessed the effects of IL-1β 
inhibition with a caspase-1 inhibitor on insulin signalling in adipocytes. In this study, 
the reduction in protein expression of IRS-1, PI3K p85α and GLUT-4 by MC 
medium was partially or totally reversed when IL-1β production by macrophages 
was inhibited. These results further support the importance of IL-1β in mediating 
macrophage-induced inhibition of insulin signalling in human adipocytes.   
 
The mechanisms of IL-1 in the modulation of macrophage-adipocyte crosstalk on 
insulin signalling in adipose tissue are not fully understood. It is suggested that local 
inflammation exemplified by macrophage accumulation in adipose tissue could 
induce the impairment of insulin sensitivity (Lumeng and Saltiel, 2011a). The 
present study showed that MC medium potently stimulated cytokine/chemokines 
release while inhibition adiponectin release by human adipocytes. This dysregulation 
was largely reversed by inhibiting IL-1β activity in MC medium, which led to a 
significant reduction in protein release of IL-6, MCP-1, IL-8 and RENTS by 
adipocytes (Fig. 6.9). The current study also demonstrated that blocking IL-1receptor 
binding in adipocytes or IL-1β production by macrophages can reduce macrophage-
induced release of these cytokine/chemokines.  In  line with the data of using THP-1 
macrophages, conditioned medium from PBMC-derived macrophages significantly 
induced release of IL-6, MCP-1, IL-8 and RANTES by adipocytes but this can be 
largely reversed by IL-1β neutralization or blocking of IL-1 receptors (Fig.6.17). 
These results suggest IL-1β as a key mediator for the pro-inflammatory activity of 
adipose tissue macrophages. IL-6 is suggested to play a role in insulin resistance as 
its circulating levels are positively related to adiposity (Vozarova et al., 2001, 
Spranger et al., 2003b) and IL-6 is overexpressed in fat cells from insulin resistant 
subjects (Rotter et al., 2003a). In vitro, IL-6 inhibits gene transcription of IRS-1, 
GLUT-4 and PPARγ and reduces insulin-stimulated glucose uptake in 3T3-L1 
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adipocytes (Rotter et al., 2003). Recent studies suggest that RANTES (or CCL5) is 
another key player in obesity-related adipose tissue inflammation (Matter and 
Handschin, 2007); gene expression of RANTES in adipose tissue is increased in 
obese subjects which led to increased monocyte migration and macrophage survival 
in human adipose tissue (Keophiphath et al., 2010). Furthermore, obese mice with 
deletion of RANTES receptor are protected from insulin resistance and this is related 
to reduced adipose tissue macrophage content and a M2 type-dominant polarization 
(Kitade et al., 2012b). MCP-1 (or CCL2) also has a chemotactic activity for 
monocytes (Kanda et al., 2006), as MCP-1 or its receptor (CCR2) knockout in mice 
reduces macrophage infiltration in adipose tissue (Kanda et al., 2006, Tsou et al., 
2007).  
  
IL-8 a neutrophil chemotactic factor also induces chemotaxis in macrophages 
(Waugh and Wilson, 2008) and gene expression of IL-8 is upregulated in mammary 
adipose tissue of obese women, in parallel with increased macrophage infiltration 
(Sun et al., 2012). A previous study showed that IL-8 receptor (CXCR2) knockout 
prevents macrophage recruitment in adipose tissue and insulin resistance in diet-
induced obese mice (Neels et al., 2009). Taken together, these results suggest that 
mediating the deleterious effect of macrophages on insulin signalling by IL-1β could 
be through upregulating the inflammatory response in adipocytes, especially the 
production of pro-inflammatory cytokine/chemokines. In addition to the endocrine 
and autocrine effects of these cytokines, adipocyte-derived factors may affect 
macrophage function in a paracrine manner. Our group has reported recently that 
conditioned medium from human preadipocytes and adipocytes can increase THP-1 
monocytes migration and this is probably due to chemoattractants, such as MCP-1, 
secreted by preadipocytes and adipocytes (Gao et al., 2013, Ding et al., 2013). Thus, 
the enhanced macrophages-adipocyte crosstalk in adipose tissue could stimulate 
inflammation and reduce insulin sensitivity of adipose tissue in obesity.  
 
In addition, the present study showed that blocking the activity of IL-1β or blocking 
IL-1 receptor binding can reverse the effect of MC medium on release of adiponectin 
which is considered as  an insulin-sensitizing adipokine (Wellen and Hotamisligil, 
2003) that is involved  in  glucose and lipid metabolism in skeletal myocytes, 
hepatocytes and  adipocytes (Berg et al., 2002). Adiponectin and its agonists have 
216 
 
been suggested to have a role in the prevention of obesity related insulin resistance, 
diabetes and cardiovascular diseases (Lee and Kwak, 2014). Taken together, it is 
suggested that IL-1β as a major macrophage-derived factor that impairs insulin 
signaling pathway at least in part by reducing adiponectin release by adipocytes. 
 
Although IL-1β is a macrophage-derived mediator in inducing insulin resistance in 
human adipocytes, the contribution of other macrophage-derived factors cannot be 
excluded. The  present study and previous work have shown high levels of IL-6, 
TNFα, MCP-1, RANTES and IL-8 together with other factors present in the MC 
medium (Gao et al., 2010). As some of the effects of blocking IL-1β in this study 
were partial, the other mediators could contribute. TNFα can induce insulin 
resistance in rodents and decrease the expression of insulin receptor, IRS-1 and 
GLUT-4 in 3T3-L1 adipocytes (Hotamisligil et al., 1993, Uysal et al., 1997, 
Stephens et al., 1997). TNFα neutralizing antibody has been shown partially reverse 
glucose uptake inhibited by MC medium in 3T3-L1 adipocytes (Lumeng et al., 
2007a). Blocking both TNFα and IL-1β additively restore MC medium-suppressed 
Akt phosphorylation in murine liver cells (Wen et al., 2011). A recent study from our 
lab has demonstrated that simultaneous neutralization of TNFα and IL-1β additively 
inhibited MC medium-induced gene expression of MCP-1 and IL-6 by human 
preadipocytes (Gao et al., 2013). However, in the current study, a combined effect of 
the two cytokines on insulin signalling molecules and cytokine/chemokine release by 
adipocytes was not apparent that in addition to TNF-α, other factors in MC medium 
may play a role. 
 
In summary, this study demonstrates that IL-1β is a key factor in mediating 
macrophage-induced impairment of the insulin signalling pathway in human 
adipocytes. Blocking IL-1β activity, its receptor binding and production can partially 
or totally restore insulin signalling and responsiveness in human adipocytes. IL-1β 
antagonism also either protects against macrophage-stimulated release of the pro-
inflammatory cytokines/chemokines, including IL-6, TNFα, MCP-1, RANETS and 
IL-8 or protects against macrophage-inhibited release of adiponectin. These results 
suggest that IL-1β may serve as a target for reducing obesity-associated insulin 
resistance in human adipose tissue. 
 
217 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 7:  
General discussion and future directions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
218 
 
7 General discussion and future directions 
 
7.1 Introduction 
In obesity, there is correlative relationship between excess adipose tissue and a state 
of low-grade chronic inflammation and metabolic disorders (Odegaard and Chawla, 
2013, Lumeng and Saltiel, 2011a). Obesity is highly associated with insulin 
resistance which is the major risk factor for the development of type 2 diabetes 
(King, 2007, Bogardus et al., 1984). Expansion of adipose tissue during obesity 
induces marked changes in the morphology and functional properties of WAT such 
as inducing an inflammatory response, suppressing adipogenesis and desensitizing 
insulin action (Sun et al., 2011, Bing, 2015). Consequently, WAT becomes an 
inflamed tissue with a significant rise in infiltration of macrophages and other 
immune cells which together alter the secretion of adipokines (Lolmède et al., 2011, 
Weisberg et al., 2003).   In addition, both adipocytes and preadipocytes are able to 
release protein factors, and macrophage-derived factors can potently stimulate the 
production of pro-inflammatory cytokines and chemokines in human adipose cells 
(Coppack, 2001, Lacasa et al., 2007). IL-1β, a pro-inflammatory mediator, is a major 
cytokine from macrophages, and it has been implicated in the development of insulin 
resistance during obesity (Bing, 2015, Böni-Schnetzler and Donath, 2011, Fève and 
Bastard, 2009). The studies in this thesis were thus established to investigate the role 
of IL-1β in mediating macrophage-induced impairment of the insulin signalling 
pathway and adipogenesis in human adipocytes, and whether blocking the activity of 
IL-1β, its receptor binding or production improves insulin signalling in human 
adipose cells. 
7.2 Previous work 
In addition to skeletal muscle and liver, adipose tissue has also been found to develop 
insulin resistance in obesity (Hotamisligil, 2000). The reduced insulin sensitivity in 
adipocytes may increase FFAs release into the circulation inducing profound 
metabolic changes in adipose tissue (Sun et al., 2011, Lee et al., 2010, Boden, 2008). 
Previous studies in obese mice and humans suggests that increased macrophage 
accumulation in adipose tissue during obesity might provide a causative link between 
inflammation and metabolic disorders such as insulin resistance and type 2 diabetes 
(Cancello and Clement, 2006, Weisberg et al., 2003, Xu et al., 2003). Furthermore, 
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two studies have been conducted by using murine adipose tissue cells to study the 
effects of macrophages that disrupt insulin action through downregulation of the 
expression of the insulin signalling molecules (Lumeng et al., 2007c, Zhou et al., 
2008). More specifically, macrophages of the pro-inflammatory phenotype) have 
been found to be linked with insulin resistance in both humans and mice (Lumeng et 
al., 2007a, Fujisaka et al., 2009). The first documentation  showing a close link 
between obesity and insulin resistance was published by Hotamisligil and et al who 
stated that TNF-α was the first macrophage-derived factor involved in the mediation 
and development of insulin resistance (Hotamisligil et al., 1993, Hotamisligil and 
Spiegelman, 1994). Pro-inflammatory factors including TNF-α, IL-6, MCP-1 and IL-
8 are directly involved in obesity-associated pathologies, particularly inflammation, 
insulin resistance and type 2 diabetes (Hotamisligil, 1999, Lagathu et al., 2003, 
Sartipy and Loskutoff, 2003, Spranger et al., 2003c, Neels et al., 2009). Growing 
evidence suggests that IL-1β is critically involved in the translation of obesity-
associated inflammation into insulin resistance in rodent and human models (Lagathu 
et al., 2006, Böni-Schnetzler and Donath, 2011, Bing, 2015). However, there is a 
lack of studies using human primary adipocytes and preadipocytes as in vitro models 
to demonstrate whether IL-1β mediates the effect of macrophages on the insulin 
signalling pathway.   
Another research direction has been focused on the effect of macrophage-derived 
factors on adipocyte development particularly adipocyte differentiation. The precise 
mechanisms of the anti-adipogenic action of macrophages mediated by IL-1β in 
human adipose cells are still unclear. In addition, previous studies have shown that 
adipose cells play their own roles in the inflammatory state (Chung et al., 2006, Gao 
et al., 2010). Further studies have shown that macrophage products potently induce 
the production of pro-inflammatory cytokines and chemokines by human 
preadipocytes and adipocytes (O’Hara et al., 2009, Gao et al., 2014, Gao et al., 
2012). However, the role of IL-1β in mediating the effect of macrophages that alter 
adipose tissue development (differentiation) and lipid storage function is largely 
unknown. 
7.3 Current work 
This project was aimed to study the effect of the crosstalk between macrophages and 
adipocytes/preadipocytes on adipose tissue biology and function based on the general 
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hypothesis that there is extensive cross-talk between the major cell types within 
adipose tissue. More specifically, the current thesis investigated the effects of 
macrophage-derived factors on the insulin signalling pathway and differentiation of 
human preadipocytes to adipocytes, and identified cytokine IL-1β as the potential 
mediator of the effects of macrophages.   
Chapters 3, 4, 5 and 6 showed experimental studies which were carried out in order 
to demonstrate the role of IL-1β in mediating macrophages-induced impairments of 
the insulin signalling pathway and development of the adipose tissue cells in humans. 
Therefore, human primary adipose cells (preadipocytes and adipocytes) and human 
macrophages were used in in vitro models to study the interaction between each 
other.   
7.3.1 Characterization and expression of insulin signalling molecules in human 
preadipocytes 
Although there are few studies carried out investigating the insulin signalling 
pathway and its molecules in human adipose tissue (Laviola et al., 2006, Summers et 
al., 2000), to our knowledge, little is known about the characteristics of the 
molecules involved in the insulin signalling pathway in human preadipocytes. For 
this reason, the study presented in Chapter 3 was focused on characterizing the 
insulin signalling molecules in human primary preadipocytes in comparison with 
adipocytes. The first objective was to examine whether the key insulin signalling 
molecules (IRS-1, (PI3K- p85α) and GLUT-4) are present at the basal level in human 
preadipocytes. Results showed that basal levels of insulin signalling proteins IRS-1 
and PI3K-p85α were detected in human preadipocytes. Furthermore, these two 
insulin signalling molecules were significantly increased in mature adipocytes 
compared with preadipocytes. These results are in agreement with previous studies in 
murine adipocytes (Saad et al., 1994). It suggests that the expression levels of insulin 
signalling molecules for both IRS-1 and PI3K-p85α in preadipocytes were increased 
during the course of differentiation process, which may have importance in adipose 
tissue functions as well as development.  
Expression of the glucose transporter-4 (GLUT-4) was also investigated in human 
preadipocytes and results showed that GLUT-4 protein was barely detectable in 
preadipocytes compared to mature adipocytes. A previous study that used crude 
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membrane fractions of undifferentiated human preadipocytes showed similar results 
(Hauner et al., 1998). In the following experiment, a time course study was 
conducted to examine the levels of GLUT-4 protein expression at several time points 
during preadipocytes differentiation. Results showed that GLUT-4 protein expression 
gradually increased from day 3 up to day 12 post differentiation (Figure 3.2). This is 
in agreement with previous studies using murine adipocytes (3T3L-1) in which 
GLUT-4 is progressively expressed during the differentiation of adipocytes as 
demonstrated by kinetic studies (Weiland et al., 1990, Tordjman et al., 1989). 
Therefore, it suggested GLUT-4 protein is only abundantly expressed once 
preadipocytes differentiate into mature adipocytes.  
The second objective of Chapter 3 was to examine whether the insulin signalling 
molecules, including IR (Y1185), IRS-1 (Ser612) and Akt (Ser473), in human 
preadipocytes are modulated by insulin in comparison to mature adipocytes.  The 
result showed that in both preadipocytes and mature adipocytes, exposure to insulin 
(100 nM) led to the phosphorylation of IR (Y1185), IRS-1 (Ser612) and Akt 
(Ser473). Following insulin stimulation, there were significant increases in protein 
abundance of all signalling proteins and this was due to increased phosphorylation 
activity. These results suggested that insulin markedly induces the insulin signalling 
molecules in adipose tissue that may have stimulatory or inhibitory roles on several 
biological processes such as proliferation, differentiation and development of adipose 
cells.  
7.3.2 IL-1β modulates insulin signalling proteins and mediates inflammation-
related protein in human predipocytes 
Little is known whether macrophages-derived factors modulate insulin signalling 
pathways in human primary preadipocytes. Therefore, the main aims of Chapter 4 
were to investigate whether IL-1β, one of the major cytokines produced by 
macrophages, could affect insulin signalling molecules in human preadipocytes in 
response to insulin stimulation, and affect the expression and release of pro-
inflammatory factors in human preadipocytes. To address the first objective in 
Chapter 4, in vitro model of primary human preadipocytes and human recombinant 
IL-1β were used to investigate the acute and chronic effect of IL-Iβ at two different 
time points (4 and 24 hr) respectively on several insulin signalling molecules, 
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including the key molecules involved in the metabolic pathway (PI3K-p85/Akt) in 
response to insulin stimulation. 
The finding has demonstrated that in human preadipocytes, IL-1β strongly decreased 
the protein abundance of insulin-stimulated phosphorylation of insulin signalling 
molecules.The results showed that upon insulin stimulation, exposure of human 
preadipocytes to human recombinant IL-1β (2 ng/ml for 4 and 24 hr) led to 
significantly reduced insulin-stimulated phosphorylation of IR at tyrosine residues 
compared with untreated cells. This finding was in agreement with previous studies 
which observed the IL-1β at higher doses (10 and 20 ng/ml) can reduce the ability of 
insulin to increase the tyrosine phosphorylation of IR (Lagathu et al., 2006). In 
contrast to p-IR, treatment of preadipocytes with IL-1β (2 ng/ml) in the presence of 
insulin has significantly increased p-IRS-1 (Ser612) and p-Akt although the increases 
in both signalling proteins were less than controls (Figures 4.2 and 4.3). 
Additionally, IL-1β treatment for 24 hr showed a slight increase in  p-IRS-1 (Ser612) 
in preadipocytes but the strongest stimulatory effect was induced by insulin, 
suggesting that a possible  effect of IL-1β on the induction of serine phosphorylation 
of IRS-1, which in turn inhibiting the insulin signalling transduction at tyrosine 
phosphorylation. 
 
Interestingly, there were conflicting observations about the effect of IL-1β on p-Akt 
with previous studies using human and murine mature adipocytes in which it was 
demonstrated that IL-1β has inhibitory effects on insulin-stimulated phosphorylation 
of Akt (Lagathu et al., 2006). However, other studies have reported similar results as 
in our study using different cell types and a range of cytokines including IL-3, IL-4, 
TNF-α (Hinton and Welham, 1999, Ozes et al., 1999), which showed that induced p-
Akt occurred due to the link between Akt activation and proliferation/survival 
function in response to these cytokines. A recent study showed that macrophages-
derived factors protect 3T3-L1 preadipocytes from apoptosis via activation the 
survival signalling that phosphorylates Akt and Erk molecules in the presence of 
ROS (Molgat et al., 2011). Taken together, these results suggest that IL-1β could 
serve as a stimulus agent depending on cell type and/or specific function of the 
protein such as Akt.  
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Further experiments described in Chapter 4 investigating whether IL-1β mediating 
the effect of MC medium on the insulin signalling molecules in human 
preadipocytes. The results showed that there were significant increases in p-IRS-
1(Ser612) in all groups after insulin stimulation (Figure 4.7). Furthermore, p-IRS-1 
was induced by MC medium. This result is in agreement with some previous studies 
which showed that serine/threonine phosphorylation of IRS-1 is induced by a range 
of factors as previously mentioned in section (4.7). In the present study, blocking the 
activity of IL-1β with a neutralizing antibody did not alter the effect of MC medium 
on insulin-stimulated phosphorylation of IRS-1. The result suggests that other 
macrophage-derived factors in MC medium could contribute to the activation of p-
IRS-1 at serine 612. 
Similarly, the current study observed that basal p-Akt was induced by MC medium 
in human preadipocytes (Figure 4.8). However, MC medium suppressed the effect of 
insulin on p-Akt, whereas IL-1β neutralisation reversed the inhibitory effect of MC 
medium on p-Akt expression in response to insulin (Figure 4.8). Therefore, it is 
suggested that IL-1β mediates the effect of MC medium on the activation of Akt in 
preadipocytes. 
The mechanisms of IL-1β in the modulation of the macrophage-preadipocytes 
crosstalk on insulin signalling in adipose tissue from above data are not clear enough. 
It is suggested that local inflammation enhanced by macrophage infiltration in 
adipose tissue could be crucial in leading to the impairment of insulin sensitivity 
(Lumeng and Saltiel, 2011a). IL-1β has been particularly implicated in the 
inflammatory response (Lacasa et al., 2007, Gao and Bing, 2011) and the modulation 
of insulin sensitivity (Lagathu et al., 2006). Therefore, the second major objective of 
Chapter 4 was to examine the role of IL-1β in mediating macrophages-induced 
expression and release of pro-inflammatory factors by human preadipocytes.  Results 
showed that MC medium potently induced gene expression and protein release of the 
pro-inflammatory factors including IL-6, MCP-1 and IL-8 in human preadipocytes. 
These results are in agreement with the previous studies (Lacasa et al., 2007, Gao 
and Bing, 2011), suggesting that macrophages are strong inducers of an 
inflammatory state in preadipocytes which in turn could promote macrophages 
recruitment and maintenance in adipose tissue. Furthermore, inhibiting IL-1β activity 
in MC medium with a neutralizing antibody led to a significant reduction in gene 
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expression and protein release of IL-6, MCP-1 and IL-8 by preadipocytes (Figures 
4.9 and 4.10). Taken together, these results suggest that IL-1β is considered to be a 
key mediator for the pro-inflammatory activity of adipose tissue macrophages. The 
deleterious effect of macrophages on insulin signalling could be modulated by IL-1β 
through upregulation of the inflammatory response in preadipocytes.  
7.3.3 Effect of long-term treatment with IL-1β on preadipocytes differentiation and 
adipocytes functions  
Results obtained from Chapter 4, led us to hypothesize that inflammation-related 
proteins in preadipocytes enhanced by macrophages-derived factors particularly IL-
1β could contribute to the impairment of preadipocytes differentiation (adipogenesis) 
and altering lipid storage function in human adipocytes. It has been shown in Chapter 
5 that IL-1β has adverse effects in adipocyte development and lipid levels deposition 
in adipocytes.  These results are in agreement with previous studies using murine 
adipose cell lines, where pro-inflammatory cytokines IL-1β and TNFα strongly 
suppress adipogenesis through activation of the nuclear factor kB (NF-kB) pathway 
(Petruschke and Hauner, 1993, Ruan et al., 2002).  
The results in Chapter 5 showed that exposure of human preadipocytes to IL-1β (1 
and 5 ng/ml) during the 12-day period of differentiation impaired adipogenesis. The 
inhibition with a 5 ng/ml of IL-1β occurred with a significant reduction in the 
cellular lipid content in human adipocytes. Consistently, cell morphology exhibited a 
significant inhibition of lipid accumulation in differentiated adipocytes after 
incubated with a higher dose IL-1β (5 ng/ml) (Figure 5.1). These results are 
consistent with a previous study that examined long-term treatment with IL-1β on 
murine and human adipocytes and found that IL-1β reduced cellular lipid content 
(Lagathu et al., 2006). Furthermore, the results also showed that prolonged IL-1β 
exposure during preadipocytes differentiation has inhibitory effects on the expression 
of the key adipogenic genes. IL-1β significantly downregulated mRNA levels of 
C/EBPα, PPARγ and aP2, suggesting that IL-1β has an inhibitory effect on 
preadipocyte differentiation by inhibiting the adipogenic process and impairs lipid 
storage function of adipocytes. Obtained results are also in line with previous work 
by our lab group where both MC medium and IL-1β suppressed expression of genes 
involved in adipogenesis (C/EBPα, SREBP1 and ACLY) and stimulated lipolysis in 
adipocytes (Gao et al., 2014). 
225 
 
In contrast to the inhibitory effects of IL-1β on adipogenic factors, the data in 
Chapter 5 showed that IL-1β had stimulatory effect on pro-inflammatory factors. 
Prolonged IL-1β treatment significantly upregulated gene expression of pro-
inflammatory factors, including IL-6, IL-8, MCP-1 and RANTES in adipocytes. In 
addition, a recent study from our group has shown that 24 hr treatment with IL-1β 
also stimulates IL-6, IL-8 and RANTES production in adipocytes (Gao et al., 2014). 
Collectively, it is suggested that IL-1β could have a role in inducing pro-
inflammatory responses that may be responsible for adipose tissue dysfunction in 
obesity (Arvin et al., 1996, Di Iorio et al., 2003).  
Other adipokines such as adiponectin and leptin are mainly produced by adipocytes 
(Yadav et al., 2013). Therefore, the present study examined the effect of long-term 
treatment with IL-1β at several concentrations (1, 5 and 20 ng/ml) on gene 
expression of adiponectin and leptin in differentiated adipocytes. The results in 
current study showed that prolonged exposure to IL-1β had inhibitory effect on 
adiponectin mRNA levels. Considering the antagonistic actions between the role of 
adiponectin and IL-1β (Lagathu et al., 2006, Lihn et al., 2004, Simons et al., 2007), 
reduced adiponectin expression by IL-1β may enhance inflammation and insulin 
resistence in obesity. In contrast to adiponectin, the expression of leptin is increased 
with the increase in body weight (Yadav et al., 2013), and it is known as a metabolic 
hormone affecting a range of processes such as insulin secretion, glucose transport 
and lipolysis (Trayhurn et al., 1999). The results in Chapter 5 have showed that 
prolonged treatment with IL-1β had stimulatory effect on leptin gene expression, 
suggesting that IL-1β may act together with leptin to stimulate inflammation in 
obesity. In agreement with the effect of IL-1β on adipogenesis, previous in vitro and 
in vivo studies demonstrated that leptin increased lipolysis and inhibited adipocyte 
lipogenesis (Harris, 2014). Therefore, it is suggested that IL-1β and leptin may 
provide a synergistic effect that could be responsible for the inhibition of 
adipogenesis and stimulation of lipolysis. 
The effects of MC medium and IL-1β on lipid storage function of human adipocytes 
through increased lipolysis were investigated in Chapter 5. Interestingly, IL-1β at 2 
ng/ml concentration was shown to have a similar potency as the MC medium to 
induce lipolysis in differentiated adipocytes (Figure 5.6 a-b). However, it is not 
known whether IL-1β acts as a key factor in mediating the effect of MC medium.  
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Our data showed that the induction of lipolysis by MC medium was completely 
attenuated by IL-1β neutralization that blocks IL-1β activities. Therefore, the current 
study provides evidence for the role of IL-1β in mediating macrophages-induced 
lipolysis. This is further supported by the observation from the current study that the 
effect of MC medium was reduced by an IL-1RA which blocks IL-1 receptor binding 
in adipocytes (Figure 5.8). 
7.3.4 IL-1β mediates macrophage-induced impairment of insulin signalling in 
human primary adipocytes 
Based on the results from Chapters 3, 4 and 5 and previous studies (Smith, 2002, 
Heilbronn et al., 2004, Krebs and Roden, 2005, Suganami et al., 2011), we next 
hypothesised that macrophage-derived factors particularly IL-1β may induce 
impairment of insulin signalling by affecting the key insulin signalling molecules in 
human primary adipocytes. In vitro human cell models including primary adipocytes, 
THP-1 macrophages (cell line) and primary macrophages were used to address this 
question. 
In this study, MC medium significantly reduced protein abundance of the key insulin 
signalling molecules at basal (IRS1, PI3K p85α and GLUT-4) and phosphorylated 
levels (p-IR and p-Akt). These results are in agreement with a previous study in 
murine 3T3-L1 adipocytes (Lumeng et al., 2007c), suggesting that macrophage-
derived factors can impair insulin signalling in human adipocytes. In addition, 
similarly to the MC medium effect, our results demonstrated that IL-1β (2 ng/ml) 
potently inhibits insulin signalling molecules (IRS1, PI3K p85α, GLUT-4, p-IR and 
p-Akt) in human adipocytes.  
Interestingly, the current study used three different approaches to reverse the effect 
of IL-1β in mediating MC medium. The first approach was by using an IL-1β 
neutralizing antibody to block IL-1β activity. IL-1β depletion with a neutralization 
antibody abolished the inhibitory effect of MC medium on protein abundance of 
insulin signalling molecules. The second approach was by using an IL-1RA to 
prevent IL-1β binding to its receptor in adipocytes. As a result, protein expression of 
IRS-1, PI3K p85α and GLUT-4 suppressed by MC medium was restored by an IL-
1RA action. A recent study has shown that IL-1β production is caspase 1-dependent 
in macrophages isolated from human adipose tissue (Stienstra et al., 2010). The third 
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approach was by using a caspase-1 inhibitor to inhibit IL-1β production from 
macrophages. Results showed that the reduction in protein expression of IRS-1, PI3K 
p85α and GLUT-4 by MC medium was partially or totally reversed when IL-1β 
production by macrophages was inhibited, suggesting that IL-1β blockade could 
restore insulin signal transduction in human adipocytes. IL-1β therefore could be a 
major contributor to macrophage-induced inhibition of the insulin signalling 
pathway. 
The study in Chapter 6 also showed that MC medium from both THP-1 and PBMC-
derived macrophages potently stimulated cytokine/chemokine release (IL-6, 
RANETS, MCP-1 and IL-8) by adipocytes. This finding is in agreement with our 
results in Chapter 4 and a previous study showed that MC medium stimulated pro-
inflammatory factors release by preadipocytes (Lacasa et al., 2007). It is suggested 
that increased cytokine/chemokine release by adipose cells could induce local 
inflammation enhanced by macrophages accumulation leading to the impairment of 
insulin sensitivity in adipose tissue.  
To further study the role of IL-1β in mediating the effect of macrophages, the current 
study has used the similar IL-1β blockade approaches to reverse the effect of IL-1β 
in mediating MC medium-induced cytokine/chemokine release by adipocytes. In 
contrast to the stimulatory effects of IL-1β on pro-inflammatory factors, the present 
study showed that IL-1β had inhibitory effect on adiponectin release. This 
dysregulation was largely reversed by inhibiting IL-1β activity in MC medium, 
which led to a significant increase in protein release of adiponectin (Figure 6.10). 
Interestingly, the similarity of the effect of IL-1β (1, 5 and 20 ng/ml) on 
differentiating cells in Chapter 5 and the effect of MC medium on differentiated cells 
in Chapter 6 was observed. Taken together, it suggested that IL-1β as a major 
macrophage-derived factor that impairs insulin signalling pathway may at least in 
part by reducing adiponectin release by adipocytes. 
These, results obtained are in the line with work by another researcher in our 
laboratory who using the PCR array analysis, found that IL-1β downregulated 
expression of genes involved in insulin signalling, insulin sensitivity, glucose 
metabolism and lipid metabolism, including IRS-1, IRS-2, PPARα, PPARγ, PGC-1β, 
GLUT4, GPD1, GSK-3β, ACLY and CEBPα. When IL-1β activity was inhibited 
228 
 
with a neutralizing antibody, the expression of 22 of 27 genes being downregulated 
by MC medium was partially restored, including all genes that were mentioned 
above (Gao et al., 2015).    
Collectively, these data suggest that IL-1β is appeared as a major macrophage-
derived mediator in inducing insulin resistance in human adipocytes. Therefore, IL-
1β may serve as a target for reducing obesity-associated insulin resistance in human 
adipose tissue. However, the contribution of other macrophage-derived factors 
cannot be excluded.  
The main findings in this thesis are summarized as follows: 
1. Regarding insulin signalling, basal expression of insulin signalling proteins (IR, 
IRS-1 and PI3K-p85α) was present and detectable in both human adipose cells 
(preadipocytes and adipocytes). However, the basal expression of GLUT-4 was 
barely detected in preadipocytes. Insulin as metabolic regulator has significantly 
stimulated the abundance of levels of phosphorylated insulin signalling molecules, 
including IR (Y1185), IRS-1(Ser612) and Akt (Ser473), in both human adipose cells. 
2. IL-1β was able to modulate the expression of insulin signalling protein including 
IR (Y1185), IRS-1(Ser612) and Akt (Ser473) in human preadipocytes upon insulin 
stimulation.  Furthermore, IL-1β also mediated macrophage-induced modulation of 
the insulin signalling molecules in human preadipocytes. 
3. IL-1β also mediated the macrophage-induced expression and release of the pro-
inflammatory cytokine/chemokines which contribute to local inflammation 
environment that could reduce the expression of insulin signalling proteins. 
However, IL-1β blockade has been found to protect against the effect of 
macrophage-derived factors on preadipocytes. 
4. Regarding adipose cell development, prolonged exposure of cells to IL-1β, from 
the induction of the differentiation state until full differentiated adipocytes state, has 
shown an inhibitory effect on lipid storage ability (accumulation) during adipocyte 
development through to the differentiation process. 
5. Prolonged exposure to IL-1β also has inhibited the expression of the key 
adipogenic genes which were significantly downregulated in mature adipocytes. At 
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the full stage of differentiation, prolonged exposure to IL-1β has also reduced the 
gene expression of adiponectin which is known as a mature adipocyte marker. In 
contrast, the long-term treatment which IL-1β has stimulatory effects on the 
expression of pro-inflammatory genes including IL-6, IL-8, MCP-1, RANTES and 
leptin in human adipocytes. 
6. IL-1β blockade (using IL-1β neutralizing antibody and IL-1R antagonist) has 
confirmed that IL-1β could be a key player that mediates macrophage-induced 
reduction in lipid storage ability of human adipocytes.  
7. In human primary adipocytes, IL-1β is a key factor in mediating macrophage-
induced impairment of the insulin signalling pathway. Blocking IL-β activity, IL-1 
receptor for binding and IL-β production using three different approaches (including 
IL-1β neutralizing antibody, IL-1R antagonist and caspase-1 inhibitor) either 
partially or totally protected against macrophage-induced insulin resistance by 
impairing the expression of insulin signalling proteins and reducing the release of 
adiponectin from adipocytes. 
8. IL-1β blockade protected against macrophages-initiated pro-inflammatory state by 
inducing the release of the pro-inflammatory cytokine/chemokines from adipocytes. 
 
7.4 Future directions 
Obesity alters adipose tissue function (metabolic and endocrine) and leads to a pro-
inflammatory state with immune responses that include infiltration of adipose tissue 
with macrophages. These macrophages are believed to alter insulin sensitivity in 
adipose cells that contributes to obesity-associated complications such as 
inflammation and insulin resistance leading to the development of type 2 diabetes 
(Weisberg et al., 2003). 
It has been mentioned in Chapter 1 that the mitogenic cascade is also involved in the 
insulin signalling pathway. The mitogen-activated protein kinase (MAPK) pathway 
such as c-Jun N-terminal kinases (JNK) and extracellular signal-regulated kinases 
(ERK) provides another route in insulin-mediated regulation of adipocyte 
transcription factors and adipose tissue development. Therefore, there could be an 
opportunity to explore other mediators of the insulin signalling pathway and the role 
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of IL-1β on the insulin molecules involved in mitogenic cascade in human adipose 
cells. 
As reported in previous studies, preadipocytes play a role as macrophage-like cells 
by acquiring high phagocytic activity and releasing several pro-inflammatory factors 
involved in the inflammatory response. This conversion appears in proliferating 
preadipocytes and disappears when preadipocytes differentiate into adipocytes 
(Charrière et al., 2003, Cousin et al., 1999). To increase our understanding about 
adipose tissue dysfunction and how it affects the insulin signalling pathway in 
adipose cells, further experiments will be needed to investigate whether human 
preadipocytes (using preadipocytes conditioned medium) as a new approach, show 
possible cross-talk between preadipocytes and adipocytes. This interaction between 
preadipocytes and adipocytes hypothesize that preadipocytes might be induced by 
adipose-derived factors which could impair the key insulin signalling molecules in 
the metabolic cascade such as IR, IRS-1, PI3K p85α and GLUT-4 in human 
adipocytes   
Another future direction is that freshly isolated adipose cells, as alternative 
approaches which may more challenging, taken from lean, obese and type 2 diabetes 
subjects would provide more information about the expression of genes involved in 
insulin signalling, insulin sensitivity, glucose metabolism and lipid metabolism in  
three different samples from human subjects by using PCR array analysis. In 
addition, there could be chance also to investigate the abundance of proteins involved 
in insulin signalling pathway by using western blotting methods. 
7.5 Concluding remark 
Studies undertaken for this project have demonstrated that IL-1β is a key pro-
inflammatory factor in mediating macrophage-modulated insulin resistance in human 
adipose cells. IL-1β also mediated macrophage-induced expression and release of 
pro-inflammatory cytokine/chemokines in adipose cells. Identification of IL-1β as a 
key factor that mediates detrimental effect of macrophages on human adipose cells is 
important for better understanding of obesity-related adipose tissue dysfunction and 
for developing potential targets for treatment. 
 
231 
 
 
 
 
 
 
 
 
REFERENCES: 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
232 
 
8 References list 
 
ABEL, E. D., PERONI, O., KIM, J. K., KIM, Y.-B., BOSS, O., HADRO, E., 
MINNEMANN, T., SHULMAN, G. I. & KAHN, B. B. 2001. Adipose-
selective targeting of the GLUT4 gene impairs insulin action in muscle and 
liver. Nature, 409, 729-733. 
ABUMRAD, N., COBURN, C. & IBRAHIMI, A. 1999. Membrane proteins 
implicated in long-chain fatty acid uptake by mammalian cells: CD36, FATP 
and FABPm. Biochimica et Biophysica Acta (BBA)-Molecular and Cell 
Biology of Lipids, 1441, 4-13. 
AGOSTINI, L., MARTINON, F., BURNS, K., MCDERMOTT, M. F., HAWKINS, 
P. N. & TSCHOPP, J. 2004. NALP3 forms an IL-1β-processing 
inflammasome with increased activity in Muckle-Wells autoinflammatory 
disorder. Immunity, 20, 319-325. 
AGUIRRE, V., UCHIDA, T., YENUSH, L., DAVIS, R. & WHITE, M. F. 2000. The 
c-Jun NH2-terminal kinase promotes insulin resistance during association 
with insulin receptor substrate-1 and phosphorylation of Ser307. Journal of 
Biological Chemistry, 275, 9047-9054. 
AHIMA, R. & OSEI, S. 2008. Adipokines in obesity. Front Horm Res, 36, 97-182. 
AHIMA, R. S., QI, Y., SINGHAL, N. S., JACKSON, M. B. & SCHERER, P. E. 
2006. Brain adipocytokine action and metabolic regulation. Diabetes, 55, 
S145-S154. 
AL-MALKI, J., AL-JASER, M. & WARSY, A. 2003. Overweight and obesity in 
Saudi females of childbearing age. International Journal of Obesity, 27, 134-
139. 
ALBERTS, B., JOHNSON, A., LEWIS, J., MORGAN, D., RAFF, M., ROBERTS, 
K., WALTER, P., WILSON, J. & HUNT, T. 2015. Molecular biology of the 
cell, New York, NY : Garland Science, Taylor and Francis Group, 2015. 6
th
 
ed. 
ALESSI, D. R., ANDJELKOVIC, M., CAUDWELL, B., CRON, P., MORRICE, N., 
COHEN, P. & HEMMINGS, B. 1996. Mechanism of activation of protein 
kinase B by insulin and IGF-1. The EMBO journal, 15, 6541. 
ALLISON, D. B., FONTAINE, K. R., MANSON, J. E., STEVENS, J. & 
VANITALLIE, T. B. 1999. Annual deaths attributable to obesity in the 
United States. Jama, 282, 1530-1538. 
AREND, W. P. 1990. Interleukin-1 receptor antagonist: discovery, structure and 
properties. Progress in growth factor research, 2, 193-205. 
AREND, W. P. 2002. The balance between IL-1 and IL-1Ra in disease. Cytokine & 
growth factor reviews, 13, 323-340. 
233 
 
ARITA, Y. 2012. Reprint of “Paradoxical Decrease of an Adipose-Specific Protein, 
Adiponectin, in Obesity”. Biochemical and biophysical research 
communications, 425, 560-564. 
ARVIN, B., NEVILLE, L. F., BARONE, F. C. & FEUERSTEIN, G. Z. 1996. The 
role of inflammation and cytokines in brain injury. Neuroscience & 
Biobehavioral Reviews, 20, 445-452. 
ASCHNER, M., SUÑOL, C. & BAL-PRICE, A. 2011. Cell culture techniques. 
[electronic book], New York : Humana Press, 2011. 
ASSIMACOPOULOS-JEANNET, F., BRICHARD, S., RENCUREL, F., CUSIN, I. 
& JEANRENAUD, B. 1995. In vivo effects of hyperinsulinemia on lipogenic 
enzymes and glucose transporter expression in rat liver and adipose tissues. 
Metabolism, 44, 228-233. 
AURON, P. E., WEBB, A. C., ROSENWASSER, L. J., MUCCI, S. F., RICH, A., 
WOLFF, S. M. & DINARELLO, C. A. 1984. Nucleotide sequence of human 
monocyte interleukin 1 precursor cDNA. Proceedings of the National 
Academy of Sciences, 81, 7907-7911. 
AVRUCH, J. 1998. Insulin signal transduction through protein kinase cascades. 
Insulin Action. Springer. 
AVRUCH, J., KHOKHLATCHEV, A., KYRIAKIS, J. M., LUO, Z., TZIVION, G., 
VAVVAS, D. & ZHANG, X. 2001. Ras activation of the Raf kinase: tyrosine 
kinase recruitment of the MAP kinase cascade. Recent Progress in Hormone 
Research, 127-55. 
BACKER, J. M., MYERS JR, M. G., SHOELSON, S. E., CHIN, D. J., SUN, X., 
MIRALPEIX, M., HU, P., MARGOLIS, B., SKOLNIK, E. & 
SCHLESSINGER, J. 1992. Phosphatidylinositol 3'-kinase is activated by 
association with IRS-1 during insulin stimulation. The EMBO journal, 11, 
3469. 
BAGGIOLINI, M., LOETSCHER, P. & MOSER, B. 1995. Interleukin-8 and the 
chemokine family. International journal of immunopharmacology, 17, 103-
108. 
BAO, Y., BING, C., HUNTER, L., JENKINS, J. R., WABITSCH, M. & 
TRAYHURN, P. 2005. Zinc-α< sub> 2</sub>-glycoprotein, a lipid 
mobilizing factor, is expressed and secreted by human (SGBS) adipocytes. 
FEBS letters, 579, 41-47. 
BARNES, A. S. 2012. Obesity and sedentary lifestyles: risk for cardiovascular 
disease in women. Texas Heart Institute Journal, 39, 224. 
BASTARD, J. P., JARDEL, C., BRUCKERT, E., BLONDY, P., CAPEAU, J., 
LAVILLE, M., VIDAL, H. & HAINQUE, B. 2000. Elevated levels of 
interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese 
women after weight loss. Journal of Clinical Endocrinology & Metabolism, 
85, 3338. 
234 
 
BERG, A. H., COMBS, T. P., DU, X., BROWNLEE, M. & SCHERER, P. E. 2001. 
The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. 
Nature medicine, 7, 947-953. 
BERG, A. H., COMBS, T. P. & SCHERER, P. E. 2002. ACRP30/adiponectin: an 
adipokine regulating glucose and lipid metabolism. Trends in Endocrinology 
and Metabolism, 13, 84-89. 
BERNOTIENE, E., PALMER, G. & GABAY, C. 2006. The role of leptin in innate 
and adaptive immune responses. Arthritis Research and Therapy, 8, 217. 
BERRY, R., JEFFERY, E. & RODEHEFFER, M. S. 2014. Weighing in on 
adipocyte precursors. Cell metabolism, 19, 8-20. 
BING, C. 2015. Is interleukin-1β a culprit in macrophage-adipocyte crosstalk in 
obesity? Adipocyte, 4, 149-152. 
BING, C., RUSSELL, S., BECKET, E., POPE, M., TISDALE, M., TRAYHURN, P. 
& JENKINS, J. 2006. Adipose atrophy in cancer cachexia: morphologic and 
molecular analysis of adipose tissue in tumour-bearing mice. British journal 
of cancer, 95, 1028-1037. 
BODEN, G. 2006. Obesity, insulin resistance, type 2 diabetes and free fatty acids. 
BODEN, G. 2008. Obesity and free fatty acids. Endocrinology and metabolism 
clinics of North America, 37, 635-646. 
BOGARDUS, C., LILLIOJA, S., MOTT, D., REAVEN, G., KASHIWAGI, A. & 
FOLEY, J. 1984. Relationship between obesity and maximal insulin-
stimulated glucose uptake in vivo and in vitro in Pima Indians. Journal of 
Clinical Investigation, 73, 800. 
BONEY, C. M., GRUPPUSO, P. A., FARIS, R. A. & FRACKELTON JR, A. R. 
2000. The critical role of Shc in insulin-like growth factor-I-mediated 
mitogenesis and differentiation in 3T3-L1 preadipocytes. Molecular 
Endocrinology, 14, 805-813. 
BÖNI-SCHNETZLER, M. & DONATH, M. Y. 2011. Increased IL-1β activation, the 
culprit not only for defective insulin secretion but also for insulin resistance? 
Cell research, 21, 995-997. 
BOULOUMIE, A., MARUMO, T., LAFONTAN, M. & BUSSE, R. 1999. Leptin 
induces oxidative stress in human endothelial cells. The FASEB Journal, 13, 
1231-1238. 
BOURGEOIS, F., GOLDSTEIN, A. & JOHNSON, P. 1983. Lipogenesis in primary 
cultures of adipoblasts derived from genetically obese Zucker rats. 
Metabolism, 32, 673-680. 
BOURLIER, V. & BOULOUMIÉ, A. 2009. Role of macrophage tissue infiltration in 
obesity and insulin resistance. Diabetes & metabolism, 35, 251-260. 
235 
 
BRUUN, J. M., LIHN, A. S., PEDERSEN, S. B. & RICHELSEN, B. 2005. 
Monocyte chemoattractant protein-1 release is higher in visceral than 
subcutaneous human adipose tissue (AT): implication of macrophages 
resident in the AT. The Journal of clinical endocrinology & metabolism, 90, 
2282-2289. 
BRUUN, J. M., LIHN, A. S., VERDICH, C., PEDERSEN, S. B., TOUBRO, S., 
ASTRUP, A. & RICHELSEN, B. 2003a. Regulation of adiponectin by 
adipose tissue-derived cytokines: in vivo and in vitro investigations in 
humans. American Journal of Physiology-Endocrinology And Metabolism, 
285, E527-E533. 
BRUUN, J. M., VERDICH, C., TOUBRO, S., ASTRUP, A. & RICHELSEN, B. 
2003b. Association between measures of insulin sensitivity and circulating 
levels of interleukin-8, interleukin-6 and tumor necrosis factor-alpha. Effect 
of weight loss in obese men. European Journal of Endocrinology, 148, 535-
542. 
BRUUN, J. M., PEDERSEN, S. B. & RICHELSEN, B. 2001. Regulation of 
interleukin 8 production and gene expression in human adipose tissue in 
vitro. Journal of Clinical Endocrinology & Metabolism, 86, 1267-1273. 
BUNNELL, B. A., FLAAT, M., GAGLIARDI, C., PATEL, B. & RIPOLL, C. 2008. 
Adipose-derived stem cells: isolation, expansion and differentiation. 
Methods, 45, 115-120. 
BUTTERWITH, S. 1994. Molecular events in adipocyte development. 
Pharmacology & therapeutics, 61, 399-411. 
CANCELLO, R. & CLEMENT, K. 2006. Review article: Is obesity an inflammatory 
illness? Role of low‐grade inflammation and macrophage infiltration in 
human white adipose tissue. BJOG: An International Journal of Obstetrics & 
Gynaecology, 113, 1141-1147. 
CANCELLO, R., HENEGAR, C., VIGUERIE, N., TALEB, S., POITOU, C., 
ROUAULT, C., COUPAYE, M., PELLOUX, V., HUGOL, D. & 
BOUILLOT, J.-L. 2005. Reduction of macrophage infiltration and 
chemoattractant gene expression changes in white adipose tissue of morbidly 
obese subjects after surgery-induced weight loss. Diabetes, 54, 2277-2286. 
CANNON, B. & NEDERGAARD, J. 2008. Developmental biology: Neither fat nor 
flesh. Nature, 454, 947-948. 
CANTLEY, L. C. 2002. The phosphoinositide 3-kinase pathway. Science, 296, 1655-
1657. 
CANTLEY, L. C., AUGER, K. R., CARPENTER, C., DUCKWORTH, B., 
GRAZIANI, A., KAPELLER, R. & SOLTOFF, S. 1991. Oncogenes and 
signal transduction. Cell, 64, 281-302. 
236 
 
CAO, Z., UMEK, R. M. & MCKNIGHT, S. L. 1991. Regulated expression of three 
C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes & 
development, 5, 1538-1552. 
CAREY, A. & FEBBRAIO, M. 2004. Interleukin-6 and insulin sensitivity: friend or 
foe? Diabetologia, 47, 1135-1142. 
CARMEN, G.-Y. & VÍCTOR, S.-M. 2006. Signalling mechanisms regulating 
lipolysis. Cellular signalling, 18, 401-408. 
CARO, J. F., SINHA, M. K., RAJU, S., ITTOOP, O., PORIES, W. J., 
FLICKINGER, E. G., MEELHEIM, D. & DOHM, G. L. 1987. Insulin 
receptor kinase in human skeletal muscle from obese subjects with and 
without noninsulin dependent diabetes. Journal of Clinical Investigation, 79, 
1330. 
CAVELTI-WEDER, C., BABIANS-BRUNNER, A., KELLER, C., STAHEL, M. A., 
KURZ-LEVIN, M., ZAYED, H., SOLINGER, A. M., MANDRUP-
POULSEN, T., DINARELLO, C. A. & DONATH, M. Y. 2012. Effects of 
gevokizumab on glycemia and inflammatory markers in type 2 diabetes. 
Diabetes care, 35, 1654-1662. 
CEFALU, W. T. 2001. Insulin resistance: cellular and clinical concepts. 
Experimental biology and medicine, 226, 13-26. 
CHAN, D. C., WATTS, G. F., BARRETT, P. H. R. & BURKE, V. 2003. Waist 
circumference, waist-to-hip ratio and body mass index as predictors of 
adipose tissue compartments in men. QJM : monthly journal of the 
Association of Physicians, 96, 441-447. 
CHANDRAN, M., PHILLIPS, S. A., CIARALDI, T. & HENRY, R. R. 2003. 
Adiponectin: more than just another fat cell hormone? Diabetes care, 26, 
2442-2450. 
CHANG, L. & KARIN, M. 2001. Mammalian MAP kinase signalling cascades. 
Nature, 410, 37-40. 
CHARRIÈRE, G., COUSIN, B., ARNAUD, E., ANDRÉ, M., BACOU, F., 
PÉNICAUD, L. & CASTEILLA, L. 2003. Preadipocyte conversion to 
macrophage evidence of plasticity. Journal of Biological Chemistry, 278, 
9850-9855. 
CHEATHAM, B. & KAHN, C. R. 1995. Insulin Action and the Insulin Signaling 
Network*. Endocrine Reviews, 16, 117-142. 
CHOI, S. M., TUCKER, D. F., GROSS, D. N., EASTON, R. M., DIPILATO, L. M., 
DEAN, A. S., MONKS, B. R. & BIRNBAUM, M. J. 2010. Insulin regulates 
adipocyte lipolysis via an Akt-independent signaling pathway. Molecular and 
cellular biology, 30, 5009-5020. 
237 
 
CHOMCZYNSKI, P. & SACCHI, N. 2006. The single-step method of RNA 
isolation by acid guanidinium thiocyanate–phenol–chloroform extraction: 
twenty-something years on. Nature protocols, 1, 581-585. 
CHRISTIANSEN, T., RICHELSEN, B. & BRUUN, J. 2005. Monocyte 
chemoattractant protein-1 is produced in isolated adipocytes, associated with 
adiposity and reduced after weight loss in morbid obese subjects. 
International journal of obesity, 29, 146-150. 
CHUNG, S., LAPOINT, K., MARTINEZ, K., KENNEDY, A., SANDBERG, M. B. 
& MCINTOSH, M. K. 2006. Preadipocytes mediate lipopolysaccharide-
induced inflammation and insulin resistance in primary cultures of newly 
differentiated human adipocytes. Endocrinology, 147, 5340-5351. 
CINTI, S. 2001. The adipose organ: morphological perspectives of adipose tissues. 
Proceedings of the Nutrition Society, 60, 319-328. 
CINTI, S. 2006. Functional anatomy of the ‘adipose organ’. Cachexia and Wasting: 
A Modern Approach. Springer. 
CINTI, S. 2007. The adipose organ. Adipose tissue and adipokines in health and 
disease. Springer. 
CINTI, S., MITCHELL, G., BARBATELLI, G., MURANO, I., CERESI, E., 
FALOIA, E., WANG, S., FORTIER, M., GREENBERG, A. S. & OBIN, M. 
S. 2005. Adipocyte death defines macrophage localization and function in 
adipose tissue of obese mice and humans. J Lipid Res, 46, 2347-55. 
COHEN, B., NOVICK, D. & RUBINSTEIN, M. 1996. Modulation of insulin 
activities by leptin. Science, 274, 1185. 
COLLINS, S., AHIMA, R. S. & KAHN, B. B. 2005. Biology of adipose tissue. In: 
MCALLISTER, L. (ed.) Joslin’s Diabetes Mellitus. Bostan: Joslin Diabetes 
Centre. 
COMBS, T. P., BERG, A. H., RAJALA, M. W., KLEBANOV, S., IYENGAR, P., 
JIMENEZ-CHILLARON, J. C., PATTI, M. E., KLEIN, S. L., WEINSTEIN, 
R. S. & SCHERER, P. E. 2003. Sexual differentiation, pregnancy, calorie 
restriction, and aging affect the adipocyte-specific secretory protein 
adiponectin. Diabetes, 52, 268-276. 
CONSIDINE, R. V., SINHA, M. K., HEIMAN, M. L., KRIAUCIUNAS, A., 
STEPHENS, T. W., NYCE, M. R., OHANNESIAN, J. P., MARCO, C. C., 
MCKEE, L. J. & BAUER, T. L. 1996. Serum immunoreactive-leptin 
concentrations in normal-weight and obese humans. New England Journal of 
Medicine, 334, 292-295. 
CONSTANT, V., GAGNON, A., LANDRY, A. & SORISKY, A. 2006. 
Macrophage-conditioned medium inhibits the differentiation of 3T3-L1 and 
human abdominal preadipocytes. Diabetologia, 49, 1402-1411. 
 
238 
 
CONSTANT, V. A., GAGNON, A., YARMO, M. & SORISKY, A. 2008. The 
antiadipogenic effect of macrophage-conditioned medium depends on 
ERK1/2 activation. Metabolism, 57, 465-72. 
COPPACK, S. 2005. Adipose tissue changes in obesity. Biochemical Society 
Transactions, 33, 1049-1052. 
COPPACK, S. W. 2001. Pro-inflammatory cytokines and adipose tissue. 
Proceedings of the Nutrition Society, 60, 349-356. 
COPPACK, S. W., CHINKES, D. L., MILES, J. M., PATTERSON, B. W. & 
KLEIN, S. 2005. A multicompartmental model of in vivo adipose tissue 
glycerol kinetics and capillary permeability in lean and obese humans. 
Diabetes, 54, 1934-1941. 
COPPS, K. & WHITE, M. 2012. Regulation of insulin sensitivity by serine/threonine 
phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. 
Diabetologia, 55, 2565-2582. 
COUSIN, B., MUNOZ, O., ANDRÉ, M., FONTANILLES, A., DANI, C., COUSIN, 
J., LAHARRAGUE, P., CASTEILLA, L. & ENICAUD, L. 1999. A role for 
preadipocytes as macrophage-like cells. The FASEB Journal, 13, 305-312. 
CROWN, J., JAKUBOWSKI, A. & GABRILOVE, J. 1993. Interleukin-1: biological 
effects in human hematopoiesis. Leukemia & lymphoma, 9, 433-440. 
CROWN, J., JAKUBOWSKI, A., KEMENY, N., GORDON, M., GASPARETTO, 
C., WONG, G., SHERIDAN, C., TONER, G., MEISENBERG, B. & 
BOTET, J. 1991. A phase I trial of recombinant human interleukin-1 beta 
alone and in combination with myelosuppressive doses of 5-fluorouracil in 
patients with gastrointestinal cancer. Blood, 78, 1420-1427. 
CURAT, C. A., MIRANVILLE, A., SENGENÈS, C., DIEHL, M., TONUS, C., 
BUSSE, R. & BOULOUMIÉ, A. 2004. From blood monocytes to adipose 
tissue-resident macrophages induction of diapedesis by human mature 
adipocytes. Diabetes, 53, 1285-1292. 
CYPESS, A. M. & KAHN, C. R. 2010. The role and importance of brown adipose 
tissue in energy homeostasis. Current opinion in pediatrics, 22, 478. 
DANDONA, P., WEINSTOCK, R., THUSU, K., ABDEL-RAHMAN, E., ALJADA, 
A. & WADDEN, T. 1998. Tumor necrosis factor-α in sera of obese patients: 
fall with weight loss. Journal of Clinical Endocrinology & Metabolism, 83, 
2907. 
DANFORTH, E. 2000. Failure of adipocyte differentiation causes type II diabetes 
mellitus? Nature genetics, 26, 13-13. 
DAOUSI, C., CASSON, I., GILL, G., MACFARLANE, I., WILDING, J. & 
PINKNEY, J. 2006. Prevalence of obesity in type 2 diabetes in secondary 
care: association with cardiovascular risk factors. Postgraduate medical 
journal, 82, 280-284. 
239 
 
DAVIES, P. & COLE, T. 1995. Body composition techniques in health and disease, 
Cambridge University Press. 
DAY, T. F., GUO, X., GARRETT-BEAL, L. & YANG, Y. 2005. Wnt/β-catenin 
signaling in mesenchymal progenitors controls osteoblast and chondrocyte 
differentiation during vertebrate skeletogenesis. Developmental cell, 8, 739-
750. 
DE PAUW, A., TEJERINA, S., RAES, M., KEIJER, J. & ARNOULD, T. 2009. 
Mitochondrial (dys) function in adipocyte (de) differentiation and systemic 
metabolic alterations. The American journal of pathology, 175, 927-939. 
DEFRONZO, R. A., BONADONNA, R. C. & FERRANNINI, E. 1992. Pathogenesis 
of NIDDM: a balanced overview. Diabetes care, 15, 318-368. 
DEGAWA‐YAMAUCHI, M., MOSS, K. A., BOVENKERK, J. E., SHANKAR, S. 
S., MORRISON, C. L., LELLIOTT, C. J., VIDAL‐PUIG, A., JONES, R. & 
CONSIDINE, R. V. 2005. Regulation of adiponectin expression in human 
adipocytes: effects of adiposity, glucocorticoids, and tumor necrosis factor α. 
Obesity research, 13, 662-669. 
DENG, Y. & SCHERER, P. E. 2010. Adipokines as novel biomarkers and regulators 
of the metabolic syndrome. Annals of the New York Academy of Sciences, 
1212, E1-E19. 
DESHMANE, S. L., KREMLEV, S., AMINI, S. & SAWAYA, B. E. 2009. 
Monocyte chemoattractant protein-1 (MCP-1): an overview. Journal of 
interferon & cytokine research, 29, 313-326. 
DESPRES, J.-P., MOORJANI, S., LUPIEN, P. J., TREMBLAY, A., NADEAU, A. 
& BOUCHARD, C. 1990. Regional distribution of body fat, plasma 
lipoproteins, and cardiovascular disease. Arteriosclerosis, Thrombosis, and 
Vascular Biology, 10, 497-511. 
DESSOLIN, S., SCHALLING, M., CHAMPIGNY, O., LÖNNQVIST, F., 
AILHAUD, G., DANI, C. & RICQUIER, D. 1997. Leptin gene is expressed 
in rat brown adipose tissue at birth. The FASEB journal, 11, 382-387. 
DEUTSCHER, M. P. 1990. Guide to protein purification, San Diego: Academic 
Press, 1990. 
DI GREGORIO, G. B., YAO-BORENGASSER, A., RASOULI, N., VARMA, V., 
LU, T., MILES, L. M., RANGANATHAN, G., PETERSON, C. A., 
MCGEHEE, R. E. & KERN, P. A. 2005. Expression of CD68 and 
macrophage chemoattractant protein-1 genes in human adipose and muscle 
tissues association with cytokine expression, insulin resistance, and reduction 
by pioglitazone. Diabetes, 54, 2305-2313. 
DI IORIO, A., FERRUCCI, L., SPARVIERI, E., CHERUBINI, A., VOLPATO, S., 
CORSI, A., BONAFÈ, M., FRANCESCHI, C., ABATE, G. & 
240 
 
PAGANELLI,R. 2003. Serum IL-1β levels in health and disease: a 
population-based study.‘The InCHIANTI study’. Cytokine, 22, 198-205. 
DIAMOND, J. 2003. The double puzzle of diabetes. Nature, 423, 599-602. 
DIF, N., EUTHINE, V., GONNET, E., LAVILLE, M., VIDAL, H. & LEFAI, E. 
2006. Insulin activates human sterol-regulatory-element-binding protein-1c 
(SREBP-1c) promoter through SRE motifs. Biochem. J, 400, 179-188. 
DINARELLO, C. A. 1993. The biological properties of interleukin-1. European 
cytokine network, 5, 517-531. 
DINARELLO, C. A. 1996. Biologic basis for interleukin-1 in disease. Blood, 87, 
2095-2147. 
DINARELLO, C. A. 1998a. Interleukin-1, interleukin-1 receptors and interleukin-1 
receptor antagonist. International reviews of immunology, 16, 457-499. 
DINARELLO, C. A. 1998b. Interleukin‐1β, Interleukin‐18, and the 
Interleukin‐1β Converting Enzymea. Annals of the New York Academy of 
Sciences, 856, 1-11. 
DINARELLO, C. A. 2004. Therapeutic strategies to reduce IL-1 activity in treating 
local and systemic inflammation. Current opinion in pharmacology, 4, 378-
385. 
DINARELLO, C. A. 2009. Immunological and inflammatory functions of the 
interleukin-1 family. Annual review of immunology, 27, 519-550. 
DINARELLO, C. A., DONATH, M. Y. & MANDRUP-POULSEN, T. 2010. Role of 
IL-1β in type 2 diabetes. Current Opinion in Endocrinology, Diabetes and 
Obesity, 17, 314-321. 
DING, C., WILDING, J. P. & BING, C. 2013. 1,25-dihydroxyvitamin D3 protects 
against macrophage-induced activation of NFkappaB and MAPK signalling 
and chemokine release in human adipocytes. PLoS ONE, 8, e61707. 
DUNCAN, R. E., AHMADIAN, M., JAWORSKI, K., SARKADI-NAGY, E. & 
SUL, H. S. 2007. Regulation of lipolysis in adipocytes. Annual review of 
nutrition, 27, 79. 
EDELSTEIN, S. L., KNOWLER, W. C., BAIN, R. P., ANDRES, R., BARRETT-
CONNOR, E. L., DOWSE, G. K., HAFFHER, S. M., PETTITT, D. J., 
SORKIN, J. D. & MULLER, D. C. 1997. Predictors of progression from 
impaired glucose tolerance to NIDDM: an analysis of six prospective studies. 
Diabetes, 46, 701-710. 
EHSES, J., LACRAZ, G., GIROIX, M.-H., SCHMIDLIN, F., COULAUD, J., 
KASSIS, N., IRMINGER, J.-C., KERGOAT, M., PORTHA, B. & HOMO-
DELARCHE, F. 2009. IL-1 antagonism reduces hyperglycemia and tissue 
inflammation in the type 2 diabetic GK rat. Proceedings of the National 
Academy of Sciences, 106, 13998-14003. 
241 
 
ENGVALL, E. & PERLMANN, P. 1971. Enzyme-linked immunosorbent assay 
(ELISA) quantitative assay of immunoglobulin G. Immunochemistry, 8, 871-
874. 
ETO, H., SUGA, H., MATSUMOTO, D., INOUE, K., AOI, N., KATO, H., ARAKI, 
J. & YOSHIMURA, K. 2009. Characterization of structure and cellular 
components of aspirated and excised adipose tissue. Plastic and 
reconstructive surgery, 124, 1087-1097. 
EZENWAKA, C., NWAGBARA, E., SEALES, D., OKALI, F., SELL, H. & 
ECKEL, J. 2009. Insulin resistance, leptin and monocyte chemotactic protein-
1 levels in diabetic and non-diabetic Afro-Caribbean subjects. Archives of 
physiology and biochemistry, 115, 22-27. 
FAGGIONI, R., FEINGOLD, K. R. & GRUNFELD, C. 2001. Leptin regulation of 
the immune response and the immunodeficiency of malnutrition. The FASEB 
Journal, 15, 2565-2571. 
FAIN, J. & MADAN, A. 2005. Regulation of monocyte chemoattractant protein 1 
(MCP-1) release by explants of human visceral adipose tissue. International 
journal of obesity, 29, 1299-1307. 
FAIN, J. N. 2006. Release of interleukins and other inflammatory cytokines by 
human adipose tissue is enhanced in obesity and primarily due to the nonfat 
cells. Vitamins & Hormones, 74, 443-477. 
FAIN, J. N. 2010. Release of inflammatory mediators by human adipose tissue is 
enhanced in obesity and primarily by the nonfat cells: a review. Mediators 
Inflamm, 2010, 513948. 
FAJAS, L., AUBOEUF, D., RASPÉ, E., SCHOONJANS, K., LEFEBVRE, A.-M., 
SALADIN, R., NAJIB, J., LAVILLE, M., FRUCHART, J.-C. & DEEB, S. 
1997. The organization, promoter analysis, and expression of the human 
PPARγ gene. Journal of Biological Chemistry, 272, 18779-18789. 
FANTIN, V. R., WANG, Q., LIENHARD, G. E. & KELLER, S. R. 2000. Mice 
lacking insulin receptor substrate 4 exhibit mild defects in growth, 
reproduction, and glucose homeostasis. American Journal of Physiology-
Endocrinology And Metabolism, 278, E127-E133. 
FARMER, S. R. 2006. Transcriptional control of adipocyte formation. Cell 
metabolism, 4, 263-273. 
FAROOQI, I. S., MATARESE, G., LORD, G. M., KEOGH, J. M., LAWRENCE, E., 
AGWU, C., SANNA, V., JEBB, S. A., PERNA, F. & FONTANA, S. 2002. 
Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and 
neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. 
Journal of clinical investigation, 110, 1093-1104. 
FASSHAUER, M., KLEIN, J., KRALISCH, S., KLIER, M., LOSSNER, U., 
BLUHER, M. & PASCHKE, R. 2004. Monocyte chemoattractant protein 1 
expression is stimulated by growth hormone and interleukin-6 in 3T3-L1 
242 
 
adipocytes. Biochemical and biophysical research communications, 317, 
598-604. 
FASSHAUER, M., KRALISCH, S., KLIER, M., LOSSNER, U., BLUHER, M., 
KLEIN, J. & PASCHKE, R. 2003. Adiponectin gene expression and 
secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochemical and 
biophysical research communications, 301, 1045-1050. 
FASSHAUER, M. & PASCHKE, R. 2003. Regulation of adipocytokines and insulin 
resistance. Diabetologia, 46, 1594-1603. 
FESTA, A., D’AGOSTINO, R., TRACY, R. P. & HAFFNER, S. M. 2002. Elevated 
levels of acute-phase proteins and plasminogen activator inhibitor-1 predict 
the development of type 2 diabetes the insulin resistance atherosclerosis 
study. Diabetes, 51, 1131-1137. 
FÈVE, B. & BASTARD, J.-P. 2009. The role of interleukins in insulin resistance and 
type 2 diabetes mellitus. Nature Reviews Endocrinology, 5, 305-311. 
FIBBE, W. & WILLEMZE, R. 1991. The role of interleukin-1 in hematopoiesis. 
Acta haematologica, 86, 148-154. 
FINUCANE, M. M., STEVENS, G. A., COWAN, M. J., DANAEI, G., LIN, J. K., 
PACIOREK, C. J., SINGH, G. M., GUTIERREZ, H. R., LU, Y. & 
BAHALIM, A. N. 2011. National, regional, and global trends in body-mass 
index since 1980: systematic analysis of health examination surveys and 
epidemiological studies with 960 country-years and 9· 1 million participants. 
The Lancet, 377, 557-567. 
FISCHER-POSOVSZKY, P., TEWS, D., HORENBURG, S., DEBATIN, K.-M. & 
WABITSCH, M. 2012. Differential function of Akt1 and Akt2 in human 
adipocytes. Molecular and cellular endocrinology, 358, 135-143. 
FLIER, J. S. 2004. Obesity wars: molecular progress confronts an expanding 
epidemic. Cell, 116, 337-350. 
FLOWER, L., GRAY, R., PINKNEY, J. & MOHAMED-ALI, V. 2003. Stimulation 
of interleukin-6 release by interleukin-1β from isolated human adipocytes. 
Cytokine, 21, 32-37. 
FRAGA, D., MEULIA, T. & FENSTER, S. 2008. Real‐Time PCR. Current 
Protocols Essential Laboratory Techniques, 10.3. 1-10.3. 34. 
FRAYN, K. 2002. Adipose tissue as a buffer for daily lipid flux. Diabetologia, 45, 
1201-1210. 
FRIEDMAN, J. M. 2000. Obesity in the new millennium. Nature, 404, 632-634. 
FRUHBECK, G. 2008. Overview of adipose tissue and its role in obesity and 
metabolic disorders. Methods Mol Biol, 456, 1-22. 
243 
 
FU, Y., LUO, N., KLEIN, R. L. & GARVEY, W. T. 2005. Adiponectin promotes 
adipocyte differentiation, insulin sensitivity, and lipid accumulation. Journal 
of lipid research, 46, 1369-1379. 
FUJISAKA, S., USUI, I., BUKHARI, A., IKUTANI, M., OYA, T., KANATANI, 
Y., TSUNEYAMA, K., NAGAI, Y., TAKATSU, K. & URAKAZE, M. 2009. 
Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-
induced obese mice. Diabetes, 58, 2574-2582. 
GAGNON, A., FOSTER, C., LANDRY, A. & SORISKY, A. 2013. The role of 
interleukin 1β in the anti-adipogenic action of macrophages on human 
preadipocytes. Journal of Endocrinology, 217, 197-206. 
GALIC, S., OAKHILL, J. S. & STEINBERG, G. R. 2010. Adipose tissue as an 
endocrine organ. Molecular and cellular endocrinology, 316, 129-139. 
GAO, D. & BING, C. 2011. Macrophage-induced expression and release of matrix 
metalloproteinase 1 and 3 by human preadipocytes is mediated by IL-1β via 
activation of MAPK signaling. Journal of Cellular Physiology, 226, 2869-
2880. 
GAO, D., MADI, M., DING, C., FOK, M., STEELE, T., FORD, C., HUNTER, L. & 
BING, C. 2014. Interleukin-1β mediates macrophage-induced impairment of 
insulin signaling in human primary adipocytes. American Journal of 
Physiology-Endocrinology And Metabolism, 307, E289-E304. 
GAO, D., TRAYHURN, P. & BING, C. 2010. Macrophage-secreted factors inhibit 
ZAG expression and secretion by human adipocytes. Molecular and cellular 
endocrinology, 325, 135-142. 
GAO, D., TRAYHURN, P. & BING, C. 2012. 1, 25-Dihydroxyvitamin D3 inhibits 
the cytokine-induced secretion of MCP-1 and reduces monocyte recruitment 
by human preadipocytes. International journal of obesity, 37, 357-365. 
GAO, D., TRAYHURN, P. & BING, C. 2013. 1,25-Dihydroxyvitamin D3 inhibits 
the cytokine-induced secretion of MCP-1 and reduces monocyte recruitment 
by human preadipocytes. Int J Obes (Lond), 37, 357-65. 
GERHARDT, C., ROMERO, I. A., CANCELLO, R., CAMOIN, L. & 
STROSBERG, A. 2001. Chemokines control fat accumulation and leptin 
secretion by cultured human adipocytes. Molecular and cellular 
endocrinology, 175, 81-92. 
GESTA, S., TSENG, Y.-H. & KAHN, C. R. 2007. Developmental origin of fat: 
tracking obesity to its source. Cell, 131, 242-256. 
GIMBLE, J. M., BUNNELL, B. A., CHIU, E. S. & GUILAK, F. 2011. Concise 
Review: Adipose‐Derived Stromal Vascular Fraction Cells and Stem Cells: 
Let's Not Get Lost in Translation. Stem Cells, 29, 749-754. 
GIRALT, M. & VILLARROYA, F. 2013. White, brown, beige/brite: different 
adipose cells for different functions? Endocrinology, 154, 2992-3000. 
244 
 
GLASS, D. A., BIALEK, P., AHN, J. D., STARBUCK, M., PATEL, M. S., 
CLEVERS, H., TAKETO, M. M., LONG, F., MCMAHON, A. P. & LANG, 
R. A. 2005. Canonical Wnt signaling in differentiated osteoblasts controls 
osteoclast differentiation. Developmental cell, 8, 751-764. 
GONG, D., YANG, R., MUNIR, K. M., HORENSTEIN, R. B. & SHULDINER, A. 
R. 2003. New progress in adipocytokine research. Current Opinion in 
Endocrinology, Diabetes and Obesity, 10, 115-121. 
GOOSSENS, G. H. & BLAAK, E. E. 2015. Adipose tissue dysfunction and impaired 
metabolic health in human obesity: a matter of oxygen? Frontiers in 
endocrinology, 6. 
GREEN, H. & KEHINDE, O. 1975. An established preadipose cell line and its 
differentiation in culture II. Factors affecting the adipose conversion. Cell, 5, 
19-27. 
GREENBERG, A. S. & OBIN, M. S. 2006. Obesity and the role of adipose tissue in 
inflammation and metabolism. The American journal of clinical nutrition, 83, 
461S-465S. 
GREGOIRE, F. M., SMAS, C. M. & SUL, H. S. 1998. Understanding adipocyte 
differentiation. Physiological reviews, 78, 783-809. 
GROSFELD, A., ZILBERFARB, V., TURBAN, S., ANDRE, J., GUERRE-MILLO, 
M. & ISSAD, T. 2002. Hypoxia increases leptin expression in human PAZ6 
adipose cells. Diabetologia, 45, 527-530. 
GUAL, P. & TANTI, J. 2005. Positive and negative regulation of insulin signaling 
through IRS-1 phosphorylation. Biochimie, 87, 99. 
GUH, D. P., ZHANG, W., BANSBACK, N., AMARSI, Z., BIRMINGHAM, C. L. 
& ANIS, A. H. 2009. The incidence of co-morbidities related to obesity and 
overweight: a systematic review and meta-analysis. BMC public health, 9, 88. 
GUSTAVSSON, J., PARPAL, S., KARLSSON, M., RAMSING, C., THORN, H., 
BORG, M., LINDROTH, M., PETERSON, K. H., MAGNUSSON, K.-E. & 
STRÅLFORS, P. 1999. Localization of the insulin receptor in caveolae of 
adipocyte plasma membrane. The FASEB Journal, 13, 1961-1971. 
GUTIERREZ, D. A., PUGLISI, M. J. & HASTY, A. H. 2009. Impact of increased 
adipose tissue mass on inflammation, insulin resistance, and dyslipidemia. 
Current diabetes reports, 9, 26-32. 
HAMANN, A., BENECKE, H., LE MARCHAND-BRUSTEL, Y., SUSULIC, V. S., 
LOWELL, B. B. & FLIER, J. S. 1995. Characterization of insulin resistance 
and NIDDM in transgenic mice with reduced brown fat. Diabetes, 44, 1266-
1273. 
HAMILTON, J. A. & KAMP, F. 1999. How are free fatty acids transported in 
membranes? Is it by proteins or by free diffusion through the lipids? 
Diabetes, 48, 2255-2269. 
245 
 
HANSEN, J. B., PETERSEN, R. K., LARSEN, B. M., BARTKOVA, J., ALSNER, 
J. & KRISTIANSEN, K. 1999. Activation of peroxisome proliferator-
activated receptor γ bypasses the function of the retinoblastoma protein in 
adipocyte differentiation. Journal of Biological Chemistry, 274, 2386-2393. 
HARA, K., HORIKOSHI, M., YAMAUCHI, T., YAGO, H., MIYAZAKI, O., 
EBINUMA, H., IMAI, Y., NAGAI, R. & KADOWAKI, T. 2006. 
Measurement of the high–molecular weight form of adiponectin in plasma is 
useful for the prediction of insulin resistance and metabolic syndrome. 
Diabetes care, 29, 1357-1362. 
HARA, K., YONEZAWA, K., SAKAUE, H., ANDO, A., KOTANI, K., 
KITAMURA, T., KITAMURA, Y., UEDA, H., STEPHENS, L. & 
JACKSON, T. R. 1994. 1-Phosphatidylinositol 3-kinase activity is required 
for insulin-stimulated glucose transport but not for RAS activation in CHO 
cells. Proceedings of the National Academy of Sciences, 91, 7415-7419. 
HARRIS, R. B. 2014. Direct and indirect effects of leptin on adipocyte metabolism. 
Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1842, 414-
423. 
HARUTA, T., UNO, T., KAWAHARA, J., TAKANO, A., EGAWA, K., SHARMA, 
P. M., OLEFSKY, J. M. & KOBAYASHI, M. 2000. A rapamycin-sensitive 
pathway down-regulates insulin signaling via phosphorylation and 
proteasomal degradation of insulin receptor substrate-1. Molecular 
endocrinology, 14, 783-794. 
HAUNER, H., RÖHRIG, K., SPELLEKEN, M., LIU, L. & ECKEL, J. 1998. 
Development of insulin-responsive glucose uptake and GLUT4 expression in 
differentiating human adipocyte precursor cells. International journal of 
obesity and related metabolic disorders: journal of the International 
Association for the Study of Obesity, 22, 448-453. 
HAUSMAN, D., DIGIROLAMO, M., BARTNESS, T., HAUSMAN, G. & 
MARTIN, R. 2001. The biology of white adipocyte proliferation. Obesity 
reviews, 2, 239-254. 
HAVEL, P. J. 2002. Control of energy homeostasis and insulin action by adipocyte 
hormones: leptin, acylation stimulating protein, and adiponectin. Current 
opinion in lipidology, 13, 51-59. 
HEATON, J. M. 1972. The distribution of brown adipose tissue in the human. 
Journal of anatomy, 112, 35. 
HEDLEY, A. A., OGDEN, C. L., JOHNSON, C. L., CARROLL, M. D., CURTIN, 
L. R. & FLEGAL, K. M. 2004. Prevalence of overweight and obesity among 
US children, adolescents, and adults, 1999-2002. Jama, 291, 2847-2850. 
HEILBRONN, L., SMITH, S. & RAVUSSIN, E. 2004. Failure of fat cell 
proliferation, mitochondrial function and fat oxidation results in ectopic fat 
storage, insulin resistance and type II diabetes mellitus. International Journal 
of Obesity, 28, S12-S21. 
246 
 
HERDER, C., MÜLLER-SCHOLZE, S., KOENIG, W., THORAND, B., 
HAASTERT, B., HOLLE, R., ILLIG, T., RATHMANN, W., SEISSLER, J. 
& WICHMANN, H.-E. 2006. Systemic monocyte chemoattractant protein-1 
concentrations are independent of type 2 diabetes or parameters of obesity: 
results from the Cooperative Health Research in the Region of Augsburg 
Survey S4 (KORA S4). European journal of endocrinology, 154, 311-317. 
HIMMS-HAGEN, J. 1979. Obesity may be due to a malfunctioning of brown fat. 
Canadian Medical Association Journal, 121, 1361. 
HIMMS-HAGEN J. 1989. Brown adipose tissue thermogenesis and obesity. Prog. 
Lipid Res., 28, Prog. Lipid Res. 
HINTON, H. J. & WELHAM, M. J. 1999. Cytokine-induced protein kinase B 
activation and Bad phosphorylation do not correlate with cell survival of 
hemopoietic cells. The Journal of Immunology, 162, 7002-7009. 
HIRASAKA, K., KOHNO, S., GOTO, J., FUROCHI, H., MAWATARI, K., 
HARADA, N., HOSAKA, T., NAKAYA, Y., ISHIDOH, K. & OBATA, T. 
2007. Deficiency of Cbl-b gene enhances infiltration and activation of 
macrophages in adipose tissue and causes peripheral insulin resistance in 
mice. Diabetes, 56, 2511-2522. 
HIRSCH, J., FRIED, S., EDENS, N. & LEIBEL, R. 1989. The fat cell. The Medical 
clinics of North America, 73, 83-96. 
HIVERT, M.-F., SULLIVAN, L. M., FOX, C. S., NATHAN, D. M., D'AGOSTINO 
SR, R. B., WILSON, P. W. & MEIGS, J. B. 2008. Associations of 
adiponectin, resistin, and tumor necrosis factor-α with insulin resistance. The 
Journal of Clinical Endocrinology & Metabolism, 93, 3165-3172. 
HOLM, C. 2003. Molecular mechanisms regulating hormone-sensitive lipase and 
lipolysis. Biochemical Society Transactions, 31, 1120-1124. 
HOMMES, D., PEPPELENBOSCH, M. & VAN DEVENTER, S. 2003. Mitogen 
activated protein (MAP) kinase signal transduction pathways and novel anti-
inflammatory targets. Gut, 52, 144-151. 
HOROWITZ, J. F. & KLEIN, S. 2000. Whole body and abdominal lipolytic 
sensitivity to epinephrine is suppressed in upper body obese women. 
American Journal of Physiology-Endocrinology And Metabolism, 278, 
E1144-E1152. 
HOSOGAI, N., FUKUHARA, A., OSHIMA, K., MIYATA, Y., TANAKA, S., 
SEGAWA, K., FURUKAWA, S., TOCHINO, Y., KOMURO, R. & 
MATSUDA, M. 2007. Adipose tissue hypoxia in obesity and its impact on 
adipocytokine dysregulation. Diabetes, 56, 901-911. 
HOTAMISLIGIL, G. 1999. The role of TNFα and TNF receptors in obesity and 
insulin resistance. Journal of internal medicine, 245, 621-625. 
247 
 
HOTAMISLIGIL, G. 2000. Molecular mechanisms of insulin resistance and the role 
of the adipocyte. International journal of obesity and related metabolic 
disorders: journal of the International Association for the Study of Obesity, 
24, S23-7. 
HOTAMISLIGIL, G. 2003. Inflammatory pathways and insulin action. International 
journal of obesity, 27, S53-S55. 
HOTAMISLIGIL, G. S. 2006. Inflammation and metabolic disorders. Nature, 444, 
860-867. 
HOTAMISLIGIL, G. S., SHARGILL, N. S. & SPIEGELMAN, B. M. 1993. Adipose 
expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin 
resistance. Science (New York, NY), 259, 87. 
HOTAMISLIGIL, G. S. & SPIEGELMAN, B. M. 1994. Tumor necrosis factor α: a 
key component of the obesity-diabetes link. Diabetes, 43, 1271-1278. 
HOTTA, K., FUNAHASHI, T., ARITA, Y., TAKAHASHI, M., MATSUDA, M., 
OKAMOTO, Y., IWAHASHI, H., KURIYAMA, H., OUCHI, N. & 
MAEDA, K. 2000. Plasma concentrations of a novel, adipose-specific 
protein, adiponectin, in type 2 diabetic patients. Arteriosclerosis, thrombosis, 
and vascular biology, 20, 1595-1599. 
HOTTA, K., FUNAHASHI, T., BODKIN, N. L., ORTMEYER, H. K., ARITA, Y., 
HANSEN, B. C. & MATSUZAWA, Y. 2001. Circulating concentrations of 
the adipocyte protein adiponectin are decreased in parallel with reduced 
insulin sensitivity during the progression to type 2 diabetes in rhesus 
monkeys. Diabetes, 50, 1126. 
HOWARD, J. K., CAVE, B. J., OKSANEN, L. J., TZAMELI, I., BJØRBÆK, C. & 
FLIER, J. S. 2004. Enhanced leptin sensitivity and attenuation of diet-
induced obesity in mice with haploinsufficiency of Socs3. Nature medicine, 
10, 734-738. 
HU, E., LIANG, P. & SPIEGELMAN, B. M. 1996. AdipoQ is a novel adipose-
specific gene dysregulated in obesity. Journal of Biological Chemistry, 271, 
10697-10703. 
HUBBARD, S. R., WEI, L., ELLIS, L. & HENDRICKSON, W. 1993. Crystal 
structure of the tyrosine kinase domain of the human insulin receptor. Nature, 
372, 746-754. 
HULVER, M. W., ZHENG, D., TANNER, C. J., HOUMARD, J. A., KRAUS, W. 
E., SLENTZ, C. A., SINHA, M. K., PORIES, W. J., MACDONALD, K. G. 
& DOHM, G. L. 2002. Adiponectin is not altered with exercise training 
despite enhanced insulin action. American Journal of Physiology-
Endocrinology And Metabolism, 283, E861-E865. 
JAGER, J., GREMEAUX, T., CORMONT, M., LE MARCHAND-BRUSTEL, Y. & 
TANTI, J. F. 2007. Interleukin-1beta-induced insulin resistance in adipocytes 
248 
 
through down-regulation of insulin receptor substrate-1 expression. 
Endocrinology, 148, 241-51. 
JAMES, P. T., LEACH, R., KALAMARA, E. & SHAYEGHI, M. 2001. The 
worldwide obesity epidemic. Obesity research, 9, 228S-233S. 
JELINEK, T., DENT, P., STURGILL, T. W. & WEBER, M. J. 1996. Ras-induced 
activation of Raf-1 is dependent on tyrosine phosphorylation. Molecular and 
Cellular Biology, 16, 1027-1034. 
JENSEN, M. D., HAYMOND, M. W., RIZZA, R. A., CRYER, P. E. & MILES, J. 
1989. Influence of body fat distribution on free fatty acid metabolism in 
obesity. Journal of Clinical Investigation, 83, 1168. 
JIANG, G., DALLAS-YANG, Q., BISWAS, S., LI, Z. & ZHANG, B. 2004. 
Rosiglitazone, an agonist of peroxisome-proliferator-activated receptor 
gamma (PPARgamma), decreases inhibitory serine phosphorylation of IRS1 
in vitro and in vivo. Biochem. J, 377, 339-346. 
JO, J., GAVRILOVA, O., PACK, S., JOU, W., MULLEN, S., SUMNER, A. E., 
CUSHMAN, S. W. & PERIWAL, V. 2009. Hypertrophy and/or hyperplasia: 
dynamics of adipose tissue growth. PLoS Comput Biol, 5, e1000324. 
JUGE-AUBRY, C. E., SOMM, E., CHICHEPORTICHE, R., BURGER, D., 
PERNIN, A., CUENOD-PITTET, B., QUINODOZ, P., GIUSTI, V., 
DAYER, J. M. & MEIER, C. A. 2004. Regulatory effects of interleukin (IL)-
1, interferon-beta, and IL-4 on the production of IL-1 receptor antagonist by 
human adipose tissue. J Clin Endocrinol Metab, 89, 2652-8. 
JUMP, D. B., CLARKE, S. D., THELEN, A. & LIIMATTA, M. 1994. Coordinate 
regulation of glycolytic and lipogenic gene expression by polyunsaturated 
fatty acids. Journal of lipid research, 35, 1076-1084. 
JUNG, U. J. & CHOI, M.-S. 2014. Obesity and its metabolic complications: the role 
of adipokines and the relationship between obesity, inflammation, insulin 
resistance, dyslipidemia and nonalcoholic fatty liver disease. International 
journal of molecular sciences, 15, 6184-6223. 
KADOWAKI, T. & YAMAUCHI, T. 2005. Adiponectin and adiponectin receptors. 
Endocrine reviews, 26, 439-451. 
KAHN, B. B. & FLIER, J. S. 2000. Obesity and insulin resistance. Journal of 
clinical investigation, 106, 473-481. 
KAHN, S. G. C. R. 2012 White adipose tissue. In: KLINGENSPOR, M. T. F. (ed.) 
Adipose tissue biology. New York: Springer . 
KAMEI, N., TOBE, K., SUZUKI, R., OHSUGI, M., WATANABE, T., KUBOTA, 
N., OHTSUKA-KOWATARI, N., KUMAGAI, K., SAKAMOTO, K. & 
KOBAYASHI, M. 2006. Overexpression of monocyte chemoattractant 
protein-1 in adipose tissues causes macrophage recruitment and insulin 
resistance. Journal of Biological Chemistry, 281, 26602-26614. 
249 
 
KAMIMURA, D., ISHIHARA, K. & HIRANO, T. 2004. IL-6 signal transduction 
and its physiological roles: the signal orchestration model. Reviews of 
physiology, biochemistry and pharmacology. Springer. 
KANDA, H., TATEYA, S., TAMORI, Y., KOTANI, K., HIASA, K.-I., 
KITAZAWA, R., KITAZAWA, S., MIYACHI, H., MAEDA, S. & 
EGASHIRA, K. 2006. MCP-1 contributes to macrophage infiltration into 
adipose tissue, insulin resistance, and hepatic steatosis in obesity. Journal of 
Clinical Investigation, 116, 1494. 
KANETY, H., FEINSTEIN, R., PAPA, M. Z., HEMI, R. & KARASIK, A. 1995. 
Tumor necrosis factor α-induced phosphorylation of insulin receptor 
substrate-1 (IRS-1) Possible mechanism for suppression of insulin-stimulated 
tyrosine phosphorylation of IRS-1. Journal of Biological Chemistry, 270, 
23780-23784. 
KAPPES, A. & LÖFFLER, G. 1999. Influences of ionomycin, dibutyryl-cycloAMP 
and tumour necrosis factor-alpha on intracellular amount and secretion of 
apM1 in differentiating primary human preadipocytes. Hormone and 
metabolic research= Hormon-und Stoffwechselforschung= Hormones et 
metabolisme, 32, 548-554. 
KARLSSON, M., THORN, H., DANIELSSON, A., STENKULA, K. G., ÖST, A., 
GUSTAVSSON, J., NYSTROM, F. H. & STRÅLFORS, P. 2004. 
Colocalization of insulin receptor and insulin receptor substrate‐1 to 
caveolae in primary human adipocytes. European Journal of Biochemistry, 
271, 2471-2479. 
KASUGA, M. 2006. Insulin resistance and pancreatic β cell failure. Journal of 
Clinical Investigation, 116, 1756. 
KATZMARZYK, P. T. & JANSSEN, I. 2004. The economic costs associated with 
physical inactivity and obesity in Canada: an update. Canadian journal of 
applied physiology, 29, 90-115. 
KELLER, S. R., AEBERSOLD, R., GARNER, C. W. & LIENHARD, G. E. 1993. 
The insulin-elicited 160 kDa phosphotyrosine protein in mouse adipocytes is 
an insulin receptor substrate 1: identification by cloning. Biochimica et 
Biophysica Acta (BBA)-Gene Structure and Expression, 1172, 323-326. 
KENNEDY, S. G., WAGNER, A. J., CONZEN, S. D., JORDAN, J., BELLACOSA, 
A., TSICHLIS, P. N. & HAY, N. 1997. The PI 3-kinase/Akt signaling 
pathway delivers an anti-apoptotic signal. Genes & development, 11, 701-
713. 
KEOPHIPHATH, M., ACHARD, V., HENEGAR, C., ROUAULT, C., CLÉMENT, 
K. & LACASA, D. 2009. Macrophage-secreted factors promote a profibrotic 
phenotype in human preadipocytes. Molecular Endocrinology, 23, 11-24. 
250 
 
KEOPHIPHATH, M., ROUAULT, C., DIVOUX, A., CLEMENT, K. & LACASA, 
D. 2010. CCL5 promotes macrophage recruitment and survival in human 
adipose tissue. Arterioscler Thromb Vasc Biol, 30, 39-45. 
KERN, P. A., SAGHIZADEH, M., ONG, J. M., BOSCH, R. J., DEEM, R. & 
SIMSOLO, R. B. 1995. The expression of tumor necrosis factor in human 
adipose tissue. Regulation by obesity, weight loss, and relationship to 
lipoprotein lipase. Journal of Clinical Investigation, 95, 2111. 
KERSHAW, E. E. & FLIER, J. S. 2004. Adipose tissue as an endocrine organ. 
Journal of Clinical Endocrinology & Metabolism, 89, 2548-2556. 
KERSTEN, S. 2001. Mechanisms of nutritional and hormonal regulation of 
lipogenesis. EMBO reports, 2, 282-286. 
KHADKA, A. 2014. Interleukins in Therapeutics. PharmaTutor, 2, 67-72. 
KHWAJA, A., RODRIGUEZ‐VICIANA, P., WENNSTRÖM, S., WARNE, P. H. 
& DOWNWARD, J. 1997. Matrix adhesion and Ras transformation both 
activate a phosphoinositide 3‐OH kinase and protein kinase B/Akt cellular 
survival pathway. The EMBO Journal, 16, 2783-2793. 
KIDO, Y., BURKS, D. J., WITHERS, D., BRUNING, J. C., KAHN, C. R., WHITE, 
M. F. & ACCILI, D. 2000. Tissue-specific insulin resistance in mice with 
mutations in the insulin receptor, IRS-1, and IRS-2. Journal of Clinical 
Investigation, 105, 199. 
KIDO, Y., NAKAE, J. & ACCILI, D. 2001. The Insulin Receptor and Its Cellular 
Targets 1. The Journal of Clinical Endocrinology & Metabolism, 86, 972-
979. 
KIGUCHI, N., MAEDA, T., KOBAYASHI, Y., FUKAZAWA, Y. & KISHIOKA, S. 
2009. Leptin enhances CC-chemokine ligand expression in cultured murine 
macrophage. Biochemical and biophysical research communications, 384, 
311-315. 
KIM, C., NEWTON, K. M. & KNOPP, R. H. 2002. Gestational Diabetes and the 
Incidence of Type 2 Diabetes A systematic review. Diabetes care, 25, 1862-
1868. 
KIMM, S. Y. & OBARZANEK, E. 2002. Childhood obesity: a new pandemic of the 
new millennium. Pediatrics, 110, 1003-1007. 
KING, D. 2007. Foresight report on obesity. The Lancet, 370, 1754. 
KITADE, H., SAWAMOTO, K., NAGASHIMADA, M., INOUE, H., 
YAMAMOTO, Y., SAI, Y., TAKAMURA, T., YAMAMOTO, H., 
MIYAMOTO, K.-I. & GINSBERG, H. N. 2012a. CCR5 plays a critical role 
in obesity-induced adipose tissue inflammation and insulin resistance by 
regulating both macrophage recruitment and M1/M2 status. Diabetes, 61, 
1680-1690. 
251 
 
KITADE, H., SAWAMOTO, K., NAGASHIMADA, M., INOUE, H., 
YAMAMOTO, Y., SAI, Y., TAKAMURA, T., YAMAMOTO, H., 
MIYAMOTO, K., GINSBERG, H. N., MUKAIDA, N., KANEKO, S. & 
OTA, T. 2012b. CCR5 plays a critical role in obesity-induced adipose tissue 
inflammation and insulin resistance by regulating both macrophage 
recruitment and M1/M2 status. Diabetes, 61, 1680-90. 
KLINGENSPOR, M. & FROMME, T. 2012. Brown Adipose Tissue Adipose Tissue 
Biology. In: SYMONDS, M. E. E. (ed.). Springer New York. 
KOBASHI, C., ASAMIZU, S., ISHIKI, M., IWATA, M., USUI, I., YAMAZAKI, 
K., TOBE, K., KOBAYASHI, M. & URAKAZE, M. 2009. Inhibitory effect 
of IL-8 on insulin action in human adipocytes via MAP kinase pathway. J 
Inflamm (Lond), 6, 25. 
KOENEN, T. B., STIENSTRA, R., VAN TITS, L. J., JOOSTEN, L. A., VAN 
VELZEN, J. F., HIJMANS, A., POL, J. A., VAN DER VLIET, J., NETEA, 
M. G. & TACK, C. J. 2011. The inflammasome and caspase-1 activation: a 
new mechanism underlying increased inflammatory activity in human 
visceral adipose tissue. Endocrinology, 152, 3769-3778. 
KOH, Y. J., KOH, B. I., KIM, H., JOO, H. J., JIN, H. K., JEON, J., CHOI, C., LEE, 
D. H., CHUNG, J. H. & CHO, C.-H. 2011. Stromal vascular fraction from 
adipose tissue forms profound vascular network through the dynamic 
reassembly of blood endothelial cells. Arteriosclerosis, thrombosis, and 
vascular biology, 31, 1141-1150. 
KONDO, H., SHIMOMURA, I., MATSUKAWA, Y., KUMADA, M., 
TAKAHASHI, M., MATSUDA, M., OUCHI, N., KIHARA, S., 
KAWAMOTO, T. & SUMITSUJI, S. 2002. Association of Adiponectin 
mutation with type 2 diabetes a candidate gene for the insulin resistance 
syndrome. Diabetes, 51, 2325-2328. 
KORNER, J., WOODS, S. C. & WOODWORTH, K. A. 2009. Regulation of energy 
homeostasis and health consequences in obesity. The American journal of 
medicine, 122, I-CO4. 
KOS, K. & WILDING, J. P. 2010. SPARC: a key player in the pathologies 
associated with obesity and diabetes. Nature reviews Endocrinology, 6, 225-
235. 
KREBS, M. & RODEN, M. 2005. Molecular mechanisms of lipid‐induced insulin 
resistance in muscle, liver and vasculature. Diabetes, Obesity and 
Metabolism, 7, 621-632. 
KRISKA, A. M., SAREMI, A., HANSON, R. L., BENNETT, P. H., KOBES, S., 
WILLIAMS, D. E. & KNOWLER, W. C. 2003. Physical activity, obesity, 
and the incidence of type 2 diabetes in a high-risk population. American 
Journal of Epidemiology, 158, 669-675. 
KROGH-MADSEN, R., PLOMGAARD, P., KELLER, P., KELLER, C. & 
PEDERSEN, B. K. 2004. Insulin stimulates interleukin-6 and tumor necrosis 
252 
 
factor-α gene expression in human subcutaneous adipose tissue. American 
Journal of Physiology-Endocrinology and Metabolism, 286, E234-E238. 
KUMADA, M., KIHARA, S., SUMITSUJI, S., KAWAMOTO, T., MATSUMOTO, 
S., OUCHI, N., ARITA, Y., OKAMOTO, Y., SHIMOMURA, I. & 
HIRAOKA, H. 2003. Association of hypoadiponectinemia with coronary 
artery disease in men. Arteriosclerosis, thrombosis, and vascular biology, 23, 
85-89. 
KWON, H. & PESSIN, J. E. 2013. Adipokines mediate inflammation and insulin 
resistance. Frontiers in endocrinology, 4. 
KYRIAKIS, J. M. & AVRUCH, J. 2001. Mammalian mitogen-activated protein 
kinase signal transduction pathways activated by stress and inflammation. 
Physiological reviews, 81, 807-869. 
LACASA, D., TALEB, S., KEOPHIPHATH, M., MIRANVILLE, A. & CLEMENT, 
K. 2007. Macrophage-secreted factors impair human adipogenesis: 
involvement of proinflammatory state in preadipocytes. Endocrinology, 148, 
868-877. 
LAFONTAN, M. 2008. Advances in adipose tissue metabolism. International 
journal of obesity, 32, S39-S51. 
LAGATHU, C., BASTARD, J. P., AUCLAIR, M., MAACHI, M., CAPEAU, J. & 
CARON, M. 2003. Chronic interleukin-6 (IL-6) treatment increased IL-6 
secretion and induced insulin resistance in adipocyte: prevention by 
rosiglitazone. Biochemical and biophysical research communications, 311, 
372-379. 
LAGATHU, C., YVAN-CHARVET, L., BASTARD, J.-P., MAACHI, M., 
QUIGNARD-BOULANGE, A., CAPEAU, J. & CARON, M. 2006. Long-
term treatment with interleukin-1β induces insulin resistance in murine and 
human adipocytes. Diabetologia, 49, 2162-2173. 
LANDSKRONER-EIGER, S., QIAN, B., MUISE, E. S., NAWROCKI, A. R., 
BERGER, J. P., FINE, E. J., KOBA, W., DENG, Y., POLLARD, J. W. & 
SCHERER, P. E. 2009. Proangiogenic contribution of adiponectin toward 
mammary tumor growth in vivo. Clinical Cancer Research, 15, 3265-3276. 
LANGIN, D. 2006a. Adipose tissue lipolysis as a metabolic pathway to define 
pharmacological strategies against obesity and the metabolic syndrome. 
Pharmacological Research, 53, 482-491. 
LANGIN, D. 2006b. Control of fatty acid and glycerol release in adipose tissue 
lipolysis. Comptes rendus biologies, 329, 598-607. 
LANGIN, D., FRÜHBECK, G., FRAYN, K. N. & LAFONTAN, M. 2009. Adipose 
Tissue: Development, Anatomy and Functions. Obesity. John Wiley & Sons, 
Ltd. 
253 
 
LARSEN, C. M., FAULENBACH, M., VAAG, A., VØLUND, A., EHSES, J. A., 
SEIFERT, B., MANDRUP-POULSEN, T. & DONATH, M. Y. 2007. 
Interleukin-1–receptor antagonist in type 2 diabetes mellitus. New England 
Journal of Medicine, 356, 1517-1526. 
LAVIOLA, L., PERRINI, S., CIGNARELLI, A. & GIORGINO, F. 2006. Insulin 
signalling in human adipose tissue. Archives of physiology and biochemistry, 
112, 82-88. 
LE LAY, S., KRIEF, S., FARNIER, C., LEFRÈRE, I., LE LIEPVRE, X., BAZIN, 
R., FERRÉ, P. & DUGAIL, I. 2001. Cholesterol, a cell size-dependent signal 
that regulates glucose metabolism and gene expression in adipocytes. Journal 
of Biological Chemistry, 276, 16904-16910. 
LE LAY, S., LEFRÈRE, I., TRAUTWEIN, C., DUGAIL, I. & KRIEF, S. 2002. 
Insulin and Sterol-regulatory Element-binding Protein-1c (SREBP-1C) 
Regulation of Gene Expression in 3T3-L1 Adipocytes IDENTIFICATION 
OF CCAAT/ENHANCER-BINDING PROTEIN β AS AN SREBP-1C 
TARGET. Journal of Biological Chemistry, 277, 35625-35634. 
LEAN, M., LARA, J. & HILL, J. O. 2006. Strategies for preventing obesity. Bmj, 
333, 959-962. 
LEE, M.-J., WU, Y. & FRIED, S. K. 2010. Adipose tissue remodeling in 
pathophysiology of obesity. Current opinion in clinical nutrition and 
metabolic care, 13, 371. 
LEE, M.-J., WU, Y. & FRIED, S. K. 2012. Adipose tissue heterogeneity: Implication 
of depot differences in adipose tissue for obesity complications. Molecular 
aspects of medicine. 
LEE, S. & KWAK, H.-B. 2014. Role of adiponectin in metabolic and cardiovascular 
disease. Journal of exercise rehabilitation, 10, 54. 
LEOPOLD, L., FRIEDMAN, J., ZANG, Y., PROENCA, R., MAFFEI, M. & 
BARONE, M. 1994. Positional cloning of the mouse obese gene and its 
human homologue. Nature, 372, 425-432. 
LETTNER, A. & RODEN, M. 2008. Ectopic fat and insulin resistance. Current 
diabetes reports, 8, 185-191. 
LEWIS, G. F. & STEINER, G. 1996. Acute effects of insulin in the control of VLDL 
production in humans. Implications for the insulin-resistant state. Diabetes 
care, 19, 390-393. 
LEWIS, J., LEE, J., UNDERWOOD, J., HARRIS, A. & LEWIS, C. 1999. 
Macrophage responses to hypoxia: relevance to disease mechanisms. Journal 
of leukocyte biology, 66, 889-900. 
LEWIS, T. S., SHAPIRO, P. S. & AHN, N. G. 1998. Signal transduction through 
MAP kinase cascades. Advances in cancer research, 74, 49-114. 
254 
 
LI, N. A., BATZER, A., DALY, R., YAJNIK, V., SKOLNIK, E., CHARDIN, P., 
BAR-SAGI, D., MARGOLIS, B. & SCHLESSINGER, J. 1993. Guanine-
nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine 
kinases to Ras signalling. Nature, 363, 85-88. 
LIHN, A. S., BRUUN, J. M., HE, G., PEDERSEN, S. B., JENSEN, P. F. & 
RICHELSEN, B. 2004. Lower expression of adiponectin mRNA in visceral 
adipose tissue in lean and obese subjects. Molecular and cellular 
endocrinology, 219, 9-15. 
LINDSAY, R. S., FUNAHASHI, T., HANSON, R. L., MATSUZAWA, Y., 
TANAKA, S., TATARANNI, P. A., KNOWLER, W. C. & KRAKOFF, J. 
2002. Adiponectin and development of type 2 diabetes in the Pima Indian 
population. The Lancet, 360, 57-58. 
LIU, L. S., SPELLEKEN, M., RÖHRIG, K., HAUNER, H. & ECKEL, J. 1998. 
Tumor necrosis factor-alpha acutely inhibits insulin signaling in human 
adipocytes: implication of the p80 tumor necrosis factor receptor. Diabetes, 
47, 515-522. 
LIVAK, K. J. & SCHMITTGEN, T. D. 2001. Analysis of Relative Gene Expression 
Data Using Real-Time Quantitative PCR and the 2< sup>− ΔΔCT</sup> 
Method. methods, 25, 402-408. 
LOBSTEIN, T. 2011. Prevalence and costs of obesity. Medicine, 39, 11-13. 
LOLMÈDE, K., DUFFAUT, C., ZAKAROFF-GIRARD, A. & BOULOUMIÉ, A. 
2011. Immune cells in adipose tissue: key players in metabolic disorders. 
Diabetes & metabolism, 37, 283-290. 
LOPACZYNSKI, W. 1998. Differential regulation of signaling pathways for insulin 
and insulin-like growth factor I. Acta Biochimica Polonica, 46, 51-60. 
LOWELL, B. & FLIER, J. 1997. Brown adipose tissue, beta 3-adrenergic receptors, 
and obesity. Annu Rev Med, 48, 307-316. 
LOWENSTEIN, E., DALY, R., BATZER, A., LI, W., MARGOLIS, B., 
LAMMERS, R., ULLRICH, A., SKOLNIK, E., BAR-SAGI, D. & 
SCHLESSINGER, J. 1992. The SH2 and SH3 domain-containing protein 
GRB2 links receptor tyrosine kinases to ras signaling. Cell, 70, 431-442. 
LUMENG, C. N., BODZIN, J. L. & SALTIEL, A. R. 2007a. Obesity induces a 
phenotypic switch in adipose tissue macrophage polarization. Journal of 
Clinical Investigation, 117, 175. 
LUMENG, C. N., DEYOUNG, S. M., BODZIN, J. L. & SALTIEL, A. R. 2007b. 
Increased inflammatory properties of adipose tissue macrophages recruited 
during diet-induced obesity. Diabetes, 56, 16-23. 
LUMENG, C. N., DEYOUNG, S. M. & SALTIEL, A. R. 2007c. Macrophages block 
insulin action in adipocytes by altering expression of signaling and glucose 
transport proteins. Am J Physiol Endocrinol Metab, 292, E166-74. 
255 
 
LUMENG, C. N. & SALTIEL, A. R. 2011. Inflammatory links between obesity and 
metabolic disease. The Journal of clinical investigation, 121, 2111-2117. 
LUO, M., LANGLAIS, P., YI, Z., LEFORT, N., DE FILIPPIS, E. A., HWANG, H., 
CHRIST-ROBERTS, C. Y. & MANDARINO, L. J. 2007. Phosphorylation of 
human insulin receptor substrate-1 at Serine 629 plays a positive role in 
insulin signaling. Endocrinology, 148, 4895-4905. 
LUO, M., REYNA, S., WANG, L., YI, Z., CARROLL, C., DONG, L. Q., 
LANGLAIS, P., WEINTRAUB, S. T. & MANDARINO, L. J. 2005. 
Identification of insulin receptor substrate 1 serine/threonine phosphorylation 
sites using mass spectrometry analysis: regulatory role of serine 1223. 
Endocrinology, 146, 4410-4416. 
LUSTGARTEN, M. S. & FIELDING, R. A. 2011. Assessment of analytical methods 
used to measure changes in body composition in the elderly and 
recommendations for their use in phase II clinical trials. The journal of 
nutrition, health & aging, 15, 368-375. 
MACKAY, C. R. 2001. Chemokines: immunology's high impact factors. Nature 
immunology, 2, 95-101. 
MADGE, L. A. & POBER, J. S. 2000. A phosphatidylinositol 3-kinase/Akt pathway, 
activated by tumor necrosis factor or interleukin-1, inhibits apoptosis but does 
not activate NFκB in human endothelial cells. Journal of Biological 
Chemistry, 275, 15458-15465. 
MAEDA, K., OKUBO, K., SHIMOMURA, I., FUNAHASHI, T., MATSUZAWA, 
Y. & MATSUBARA, K. 1996. cDNA cloning and expression of a novel 
adipose specific collagen-like factor, apM1 (AdiPoseMost abundant Gene 
transcript 1). Biochemical and biophysical research communications, 221, 
286-289. 
MAEDA, N., TAKAHASHI, M., FUNAHASHI, T., KIHARA, S., NISHIZAWA, 
H., KISHIDA, K., NAGARETANI, H., MATSUDA, M., KOMURO, R. & 
OUCHI, N. 2001. PPARγ ligands increase expression and plasma 
concentrations of adiponectin, an adipose-derived protein. Diabetes, 50, 
2094-2099. 
MAEDLER, K., DHARMADHIKARI, G., SCHUMANN, D. M. & STØRLING, J. 
2011. Interleukin-targeted therapy for metabolic syndrome and type 2 
diabetes. Diabetes-Perspectives in Drug Therapy. Springer. 
MAGUN, R., BURGERING, B., COFFER, P., PARDASANI, D., LIN, Y., 
CHABOT, J. & SORISKY, A. 1996. Expression of a constitutively activated 
form of protein kinase B (c-Akt) in 3T3-L1 preadipose cells causes 
spontaneous differentiation. Endocrinology, 137, 3590-3593. 
MANTOVANI, A., LOCATI, M., VECCHI, A., SOZZANI, S. & ALLAVENA, P. 
2001. Decoy receptors: a strategy to regulate inflammatory cytokines and 
chemokines. Trends in immunology, 22, 328-336. 
256 
 
MANTZOROS, C. S. 1999. The role of leptin in human obesity and disease: a 
review of current evidence. Annals of internal medicine, 130, 671-680. 
MARINOU, K., TOUSOULIS, D., ANTONOPOULOS, A. S., STEFANADI, E. & 
STEFANADIS, C. 2010. Obesity and cardiovascular disease: from 
pathophysiology to risk stratification. International journal of cardiology, 
138, 3-8. 
MARQUES, R. E., GUABIRABA, R., RUSSO, R. C. & TEIXEIRA, M. M. 2013. 
Targeting CCL5 in inflammation. Expert opinion on therapeutic targets, 17, 
1439-1460. 
MARSHALL, J. A. & BESSESEN, D. H. 2002. Dietary fat and the development of 
type 2 diabetes. Diabetes Care, 25, 620-622. 
MARTIN, S. & PARTON, R. G. 2006. Lipid droplets: a unified view of a dynamic 
organelle. Nature reviews Molecular cell biology, 7, 373-378. 
MATTER, C. M. & HANDSCHIN, C. 2007. RANTES (regulated on activation, 
normal T cell expressed and secreted), inflammation, obesity, and the 
metabolic syndrome. Circulation, 115, 946-948. 
MAURY, E. & BRICHARD, S. M. 2010. Adipokine dysregulation, adipose tissue 
inflammation and metabolic syndrome. Molecular and cellular 
endocrinology, 314, 1-16. 
MCGARRY, J. D. 2002. Banting lecture 2001 Dysregulation of fatty acid 
metabolism in the etiology of type 2 diabetes. Diabetes, 51, 7-18. 
MCGILLICUDDY, F. C., HARFORD, K. A., REYNOLDS, C. M., OLIVER, E., 
CLAESSENS, M., MILLS, K. H. & ROCHE, H. M. 2011. Lack of 
interleukin-1 receptor I (IL-1RI) protects mice from high-fat diet-induced 
adipose tissue inflammation coincident with improved glucose homeostasis. 
Diabetes, 60, 1688-98. 
MILAN, G., GRANZOTTO, M., SCARDA, A., CALCAGNO, A., PAGANO, C., 
FEDERSPIL, G. & VETTOR, R. 2002. Resistin and adiponectin expression 
in visceral fat of obese rats: effect of weight loss. Obesity research, 10, 1095-
1103. 
MINOKOSHI, Y., KIM, Y.-B., PERONI, O. D., FRYER, L. G., MÜLLER, C., 
CARLING, D. & KAHN, B. B. 2002. Leptin stimulates fatty-acid oxidation 
by activating AMP-activated protein kinase. Nature, 415, 339-343. 
MOHAMED-ALI, V., GOODRICK, S., RAWESH, A., KATZ, D., MILES, J., 
YUDKIN, J., KLEIN, S. & COPPACK, S. 1997. Subcutaneous adipose tissue 
releases interleukin-6, but not tumor necrosis factor-α, in vivo. Journal of 
Clinical Endocrinology & Metabolism, 82, 4196. 
MOHAMED-ALI, V., PINKNEY, J. & COPPACK, S. 1998. Adipose tissue as an 
endocrine and paracrine organ. International journal of obesity, 22, 1145-
1158. 
257 
 
MOLGAT, A. S., GAGNON, A. & SORISKY, A. 2011. Macrophage-induced 
preadipocyte survival depends on signaling through Akt, ERK1/2, and 
reactive oxygen species. Experimental cell research, 317, 521-530. 
MOLINA, J. M., CIARALDI, T. P., BRADY, D. & OLEFSKY, J. M. 1989. 
Decreased activation rate of insulin-stimulated glucose transport in 
adipocytes from obese subjects. Diabetes, 38, 991-995. 
MONTAGUE, C. T., PRINS, J. B., SANDERS, L., ZHANG, J., SEWTER, C. P., 
DIGBY, J., BYRNE, C. & O'RAHILLY, S. 1998. Depot-related gene 
expression in human subcutaneous and omental adipocytes. Diabetes, 47, 
1384-1391. 
MORRIS, R. D., RIMM, D. L., HARTZ, A. J., KALKHOFF, R. K. & RIMM, A. A. 
1989. Obesity and heredity in the etiology of non-insulin-dependent diabetes 
mellitus in 32,662 adult white women. American journal of epidemiology, 
130, 112-121. 
MOTHE, I. & VAN OBBERGHEN, E. 1996. Phosphorylation of insulin receptor 
substrate-1 on multiple serine residues, 612, 632, 662, and 731, modulates 
insulin action. Journal of Biological Chemistry, 271, 11222-11227. 
MRACEK, T., STEPHENS, N., GAO, D., BAO, Y., ROSS, J., RYDEN, M., 
ARNER, P., TRAYHURN, P., FEARON, K. & BING, C. 2011. Enhanced 
ZAG production by subcutaneous adipose tissue is linked to weight loss in 
gastrointestinal cancer patients. British journal of cancer, 104, 441-447. 
MUKHOPADHYAY, A., BHADRA, M. & BOSE, K. 2005. Human obesity: A 
background. Human obesity: a major health burden. Journal of Human 
Ecology special issue, 1-9. 
MÜLLER, G., ERTL, J., GERL, M. & PREIBISCH, G. 1997. Leptin impairs 
metabolic actions of insulin in isolated rat adipocytes. Journal of Biological 
Chemistry, 272, 10585-10593. 
MUOIO, D. M., DOHN, G. L., FIEDOREK, F. T., TAPSCOTT, E. B. & 
COLEMAN, R. A. 1997. Leptin directly alters lipid partitioning in skeletal 
muscle. Diabetes, 46, 1360-1363. 
MURPHY, P. M. 2002. International Union of Pharmacology. XXX. Update on 
chemokine receptor nomenclature. Pharmacological reviews, 54, 227-229. 
MYERS, M. G. & WHITE, M. F. 1993. The new elements of insulin signaling: 
insulin receptor substrate-1 and proteins with SH2 domains. Diabetes, 42, 
643-650. 
NAKANO, Y., TOBE, T., CHOI-MIURA, N.-H., MAZDA, T. & TOMITA, M. 
1996. Isolation and characterization of GBP28, a novel gelatin-binding 
protein purified from human plasma. Journal of biochemistry, 120, 803-812. 
NAO 2001. Tackling Obesity in England. UK: National Audit Office  
258 
 
NAWROCKI, A. R., RAJALA, M. W., TOMAS, E., PAJVANI, U. B., SAHA, A. 
K., TRUMBAUER, M. E., PANG, Z., CHEN, A. S., RUDERMAN, N. B. & 
CHEN, H. 2006. Mice lacking adiponectin show decreased hepatic insulin 
sensitivity and reduced responsiveness to peroxisome proliferator-activated 
receptor γ agonists. Journal of Biological Chemistry, 281, 2654-2660. 
NCMP 2015. National Child Measurement Programme operational guidance. UK: 
Public health England. 
NEELS, J. G., BADEANLOU, L., HESTER, K. D. & SAMAD, F. 2009. 
Keratinocyte-derived Chemokine in Obesity EXPRESSION, REGULATION, 
AND ROLE IN ADIPOSE MACROPHAGE INFILTRATION AND 
GLUCOSE HOMEOSTASIS. Journal of Biological Chemistry, 284, 20692-
20698. 
NG, C., POZNANSKI, W., BOROWIECKI, M. & REIMER, G. 1971. Differences in 
growth in vitro of adipose cells from normal and obese patients. 
NICHOLLS, D. G. & LOCKE, R. M. 1984. Thermogenic mechanisms in brown fat. 
Physiol Rev, 64, 1-64. 
NOMURA, S., SHOUZU, A., OMOTO, S., NISHIKAWA, M. & FUKUHARA, S. 
2000. Significance of chemokines and activated platelets in patients with 
diabetes. Clinical & Experimental Immunology, 121, 437-443. 
NOV, O., KOHL, A., LEWIS, E. C., BASHAN, N., DVIR, I., BEN-SHLOMO, S., 
FISHMAN, S., WUEEST, S., KONRAD, D. & RUDICH, A. 2010. 
Interleukin-1beta may mediate insulin resistance in liver-derived cells in 
response to adipocyte inflammation. Endocrinology, 151, 4247-56. 
O'ROURKE, R. W., METCALF, M. D., WHITE, A. E., MADALA, A., WINTERS, 
B. R., MAIZLIN, II, JOBE, B. A., ROBERTS, C. T., JR., SLIFKA, M. K. & 
MARKS, D. L. 2009. Depot-specific differences in inflammatory mediators 
and a role for NK cells and IFN-gamma in inflammation in human adipose 
tissue. Int J Obes (Lond), 33, 978-90. 
O’HARA, A., LIM, F.-L., MAZZATTI, D. J. & TRAYHURN, P. 2009. Microarray 
analysis identifies matrix metalloproteinases (MMPs) as key genes whose 
expression is up-regulated in human adipocytes by macrophage-conditioned 
medium. Pflügers Archiv-European Journal of Physiology, 458, 1103-1114. 
O’HARA, A., LIM, F.-L., MAZZATTI, D. J. & TRAYHURN, P. 2012. Stimulation 
of inflammatory gene expression in human preadipocytes by macrophage-
conditioned medium: Upregulation of IL-6 production by macrophage-
derived IL-1β. Molecular and cellular endocrinology, 349, 239-247. 
ODA, T., HIROTA, K., NISHI, K., TAKABUCHI, S., ODA, S., YAMADA, H., 
ARAI, T., FUKUDA, K., KITA, T. & ADACHI, T. 2006. Activation of 
hypoxia-inducible factor 1 during macrophage differentiation. American 
Journal of Physiology-Cell Physiology, 291, C104-C113. 
259 
 
ODEGAARD, J. I. & CHAWLA, A. 2013. Pleiotropic actions of insulin resistance 
and inflammation in metabolic homeostasis. Science, 339, 172-177. 
OKADA, T., KAWANO, Y., SAKAKIBARA, T., HAZEKI, O. & UI, M. 1994. 
Essential role of phosphatidylinositol 3-kinase in insulin-induced glucose 
transport and antilipolysis in rat adipocytes. Studies with a selective inhibitor 
wortmannin. Journal of Biological Chemistry, 269, 3568-3573. 
OLSON, A. L. & PESSIN, J. E. 1996. Structure, function, and regulation of the 
mammalian facilitative glucose transporter gene family. Annual review of 
nutrition, 16, 235-256. 
OTERO, M., LAGO, R. O., LAGO, F., CASANUEVA, F. F., DIEGUEZ, C., 
GÓMEZ-REINO, J. J. & GUALILLO, O. 2005. Leptin, from fat to 
inflammation: old questions and new insights. FEBS letters, 579, 295-301. 
OUCHI, N., KIHARA, S., ARITA, Y., NISHIDA, M., MATSUYAMA, A., 
OKAMOTO, Y., ISHIGAMI, M., KURIYAMA, H., KISHIDA, K. & 
NISHIZAWA, H. 2001. Adipocyte-derived plasma protein, adiponectin, 
suppresses lipid accumulation and class A scavenger receptor expression in 
human monocyte-derived macrophages. Circulation, 103, 1057-1063. 
OUCHI, N., KIHARA, S., FUNAHASHI, T., MATSUZAWA, Y. & WALSH, K. 
2003a. Obesity, adiponectin and vascular inflammatory disease. Current 
opinion in lipidology, 14, 561-566. 
OUCHI, N., OHISHI, M., KIHARA, S., FUNAHASHI, T., NAKAMURA, T., 
NAGARETANI, H., KUMADA, M., OHASHI, K., OKAMOTO, Y. & 
NISHIZAWA, H. 2003b. Association of hypoadiponectinemia with impaired 
vasoreactivity. Hypertension, 42, 231-234. 
OUCHI, N., PARKER, J. L., LUGUS, J. J. & WALSH, K. 2011. Adipokines in 
inflammation and metabolic disease. Nature Reviews Immunology, 11, 85-97. 
OWYANG, A. M., MAEDLER, K., GROSS, L., YIN, J., ESPOSITO, L., SHU, L., 
JADHAV, J., DOMSGEN, E., BERGEMANN, J. & LEE, S. 2010. XOMA 
052, an anti-IL-1β monoclonal antibody, improves glucose control and β-cell 
function in the diet-induced obesity mouse model. Endocrinology, 151, 2515-
2527. 
OZES, O. N., MAYO, L. D., GUSTIN, J. A., PFEFFER, S. R., PFEFFER, L. M. & 
DONNER, D. B. 1999. NF-κB activation by tumour necrosis factor requires 
the Akt serine–threonine kinase. Nature, 401, 82-85. 
PAJVANI, U. B., DU, X., COMBS, T. P., BERG, A. H., RAJALA, M. W., 
SCHULTHESS, T., ENGEL, J., BROWNLEE, M. & SCHERER, P. E. 2003. 
Structure-function studies of the adipocyte-secreted hormone 
Acrp30/adiponectin. Journal of Biological Chemistry, 278, 9073. 
PALSGAARD, J., EMANUELLI, B., WINNAY, J. N., SUMARA, G., 
KARSENTY, G. & KAHN, C. R. 2012. Cross-talk between Insulin and Wnt 
Signaling in Preadipocytes: ROLE OF WNT CO-RECEPTOR LOW 
260 
 
DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-5 (LRP5). 
Science Signalling, 287, 12016. 
PARPAL, S., KARLSSON, M., THORN, H. & STRÅLFORS, P. 2001. Cholesterol 
depletion disrupts caveolae and insulin receptor signaling for metabolic 
control via insulin receptor substrate-1, but not for mitogen-activated protein 
kinase control. Journal of Biological Chemistry, 276, 9670-9678. 
PATRICK JR, C. W. Adipose tissue engineering: the future of breast and soft tissue 
reconstruction following tumor resection. 2000. Wiley Online Library, 302-
311. 
PAWSON, T. & SCOTT, J. D. 1997. Signaling through scaffold, anchoring, and 
adaptor proteins. Science, 278, 2075-2080. 
PAZ, K., HEMI, R., LEROITH, D., KARASIK, A., ELHANANY, E., KANETY, H. 
& ZICK, Y. 1997. A molecular basis for insulin resistance Elevated 
serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to 
the juxtamembrane region of the insulin receptor and impairs their ability to 
undergo insulin-induced tyrosine phosphorylation. Journal of Biological 
Chemistry, 272, 29911-29918. 
PAZ, K., LIU, Y.-F., SHORER, H., HEMI, R., LEROITH, D., QUAN, M., 
KANETY, H., SEGER, R. & ZICK, Y. 1999. Phosphorylation of insulin 
receptor substrate-1 (IRS-1) by protein kinase B positively regulates IRS-1 
function. Journal of Biological Chemistry, 274, 28816-28822. 
PECOITS‐FILHO, R., NORDFORS, L., HEIMBÜRGER, O., LINDHOLM, B., 
ANDERSTAM, B., MARCHLEWSKA, A. & STENVINKEL, P. 2002. 
Soluble leptin receptors and serum leptin in end‐stage renal disease: 
relationship with inflammation and body composition. European journal of 
clinical investigation, 32, 811-817. 
PELICCI, G., LANFRANCONE, L., GRIGNANI, F., MCGLADE, J., CAVALLO, 
F., FORNI, G., NICOLETTI, I., GRIGNANI, F., PAWSON, T. & PELICCI, 
P. G. 1992. A novel transforming protein (SHC) with an SH2 domain is 
implicated in mitogenic signal transduction. Cell, 70, 93-104. 
PELT-VERKUIL, E. V., BELKUM, A. V. & HAYS, J. P. 2008. Principles and 
technical aspects of PCR amplification [electronic book] / by Elizabeth van 
Pelt-Verkuil, Alex van Belkum, John P. Hays, Dordrecht : Springer Science + 
Business Media, 2008. 
PERMANA, P. A., MENGE, C. & REAVEN, P. D. 2006. Macrophage-secreted 
factors induce adipocyte inflammation and insulin resistance. Biochemical 
and biophysical research communications, 341, 507-514. 
PETROVIC, N., WALDEN, T. B., SHABALINA, I. G., TIMMONS, J. A., 
CANNON, B. & NEDERGAARD, J. 2009. Chronic PPARγ activation of 
epididymally derived white adipocyte cultures reveals a population of 
thermogenically competent, UCP1-containing adipocytes molecularly distinct 
261 
 
from classical brown adipocytes. Journal of Biological Chemistry, jbc. M109. 
053942. 
PETROVIC, N., WALDEN, T. B., SHABALINA, I. G., TIMMONS, J. A., 
CANNON, B. & NEDERGAARD, J. 2010. Chronic peroxisome proliferator-
activated receptor γ (PPARγ) activation of epididymally derived white 
adipocyte cultures reveals a population of thermogenically competent, UCP1-
containing adipocytes molecularly distinct from classic brown adipocytes. 
Journal of Biological Chemistry, 285, 7153-7164. 
PETRUSCHKE, T. & HAUNER, H. 1993. Tumor necrosis factor-alpha prevents the 
differentiation of human adipocyte precursor cells and causes delipidation of 
newly developed fat cells. The Journal of Clinical Endocrinology & 
Metabolism, 76, 742-747. 
POULAIN-GODEFROY, O. & FROGUEL, P. 2007. Preadipocyte response and 
impairment of differentiation in an inflammatory environment. Biochemical 
and biophysical research communications, 356, 662-667. 
PRADHAN, A. D., MANSON, J. E., RIFAI, N., BURING, J. E. & RIDKER, P. M. 
2001. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes 
mellitus. Jama, 286, 327-334. 
PROUDFOOT, A. E., POWER, C. A., HOOGEWERF, A. J., MONTJOVENT, M.-
O., BORLAT, F., OFFORD, R. E. & WELLS, T. N. 1996. Extension of 
recombinant human RANTES by the retention of the initiating methionine 
produces a potent antagonist. Journal of Biological Chemistry, 271, 2599-
2603. 
QUINN, C., HAMILTON, P., LOCKHART, C. & MCVEIGH, G. 2008. 
Thiazolidinediones: effects on insulin resistance and the cardiovascular 
system. British journal of pharmacology, 153, 636-645. 
RAJALA, M. W. & SCHERER, P. E. 2003. Minireview: the adipocyte—at the 
crossroads of energy homeostasis, inflammation, and atherosclerosis. 
Endocrinology, 144, 3765-3773. 
RAMIREZ-ZACARIAS, J., CASTRO-MUNOZLEDO, F. & KURI-HARCUCH, W. 
1992. Quantitation of adipose conversion and triglycerides by staining 
intracytoplasmic lipids with Oil red O. Histochemistry, 97, 493-497. 
RANDLE, J. C., HARDING, M. W., KU, G., SCHÖNHARTING, M. & KURRLE, 
R. 2001. ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs. Expert 
opinion on investigational drugs, 10, 1207-1209. 
RASMUSSEN, M. S., LIHN, A. S., PEDERSEN, S. B., BRUUN, J. M., 
RASMUSSEN, M. & RICHELSEN, B. 2006. Adiponectin receptors in 
human adipose tissue: effects of obesity, weight loss, and fat depots. Obesity, 
14, 28-35. 
262 
 
RASOULI, N. & KERN, P. A. 2008. Adipocytokines and the metabolic 
complications of obesity. Journal of Clinical Endocrinology & Metabolism, 
93, s64-s73. 
REAVEN, G. 1996. Hypertension and associated metabolic abnormalities-the role of 
insulin resistance and the sympathoadrenal system. N. Engl. J. Med., 334, 
374-381. 
REAVEN, G. 2004. The metabolic syndrome or the insulin resistance syndrome? 
Different names, different concepts, and different goals. Endocrinology and 
metabolism clinics of North America, 33, 283-303. 
ROBERTS, R., HODSON, L., DENNIS, A., NEVILLE, M., HUMPHREYS, S., 
HARNDEN, K., MICKLEM, K. & FRAYN, K. 2009. Markers of de novo 
lipogenesis in adipose tissue: associations with small adipocytes and insulin 
sensitivity in humans. Diabetologia, 52, 882-890. 
ROCK, K. L. & KONO, H. 2008. The inflammatory response to cell death. Annual 
review of pathology, 3, 99. 
ROEBUCK, K. A. 1999. Regulation of interleukin-8 gene expression. Journal of 
interferon & cytokine research, 19, 429-438. 
RONDINONE, C. M., WANG, L.-M., LONNROTH, P., WESSLAU, C., PIERCE, J. 
H. & SMITH, U. 1997. Insulin receptor substrate (IRS) 1 is reduced and IRS-
2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes 
from subjects with non-insulin-dependent diabetes mellitus. Proceedings of 
the National Academy of Sciences, 94, 4171-4175. 
ROSEN, E. D. & MACDOUGALD, O. A. 2006a. Adipocyte differentiation from the 
inside out. Nature reviews Molecular cell biology, 7, 885-896. 
ROSEN, E. D. & SPIEGELMAN, B. M. 2006b. Adipocytes as regulators of energy 
balance and glucose homeostasis. Nature, 444, 847-853. 
ROSS, R. 2003. Advances in the application of imaging methods in applied and 
clinical physiology. Acta diabetologica, 40, s45-s50. 
ROTTER, V., NAGAEV, I. & SMITH, U. 2003. Interleukin-6 (IL-6) induces insulin 
resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-
alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol 
Chem, 278, 45777-84. 
RUAN, H., HACOHEN, N., GOLUB, T. R., VAN PARIJS, L. & LODISH, H. F. 
2002. Tumor necrosis factor-α suppresses adipocyte-specific genes and 
activates expression of preadipocyte genes in 3T3-L1 adipocytes nuclear 
factor-κB activation by TNF-α is obligatory. Diabetes, 51, 1319-1336. 
RUI, L., AGUIRRE, V., KIM, J. K., SHULMAN, G. I., LEE, A., CORBOULD, A., 
DUNAIF, A. & WHITE, M. F. 2001. Insulin/IGF-1 and TNF-α stimulate 
phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. Journal 
of Clinical Investigation, 107, 181. 
263 
 
RYDÉN, M., ARVIDSSON, E., BLOMQVIST, L., PERBECK, L., DICKER, A. & 
ARNER, P. 2004. Targets for TNF-α-induced lipolysis in human adipocytes. 
Biochemical and biophysical research communications, 318, 168-175. 
SAAD, M., FOLLI, F., ARAKI, E., HASHIMOTO, N., CSERMELY, P. & KAHN, 
C. R. 1994. Regulation of insulin receptor, insulin receptor substrate-1 and 
phosphatidylinositol 3-kinase in 3T3-F442A adipocytes. Effects of 
differentiation, insulin, and dexamethasone. Molecular Endocrinology, 8, 
545-557. 
SACKS, H. S. & FAIN, J. N. 2007. Human epicardial adipose tissue: a review. 
American heart journal, 153, 907-917. 
SALTIEL, A. R. & KAHN, C. R. 2001. Insulin signalling and the regulation of 
glucose and lipid metabolism. Nature, 414, 799-806. 
SALTIEL, A. R. & PESSIN, J. E. 2002. Insulin signaling pathways in time and 
space. Trends in cell biology, 12, 65-71. 
SANTOS-ALVAREZ, J., GOBERNA, R. & SÁNCHEZ-MARGALET, V. 1999. 
Human leptin stimulates proliferation and activation of human circulating 
monocytes. Cellular immunology, 194, 6-11. 
SARBASSOV, D. D., GUERTIN, D. A., ALI, S. M. & SABATINI, D. M. 2005. 
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. 
Science, 307, 1098-1101. 
SARTIPY, P. & LOSKUTOFF, D. J. 2003. Monocyte chemoattractant protein 1 in 
obesity and insulin resistance. Proceedings of the National Academy of 
Sciences, 100, 7265-7270. 
SAUTER, N. S., SCHULTHESS, F. T., GALASSO, R., CASTELLANI, L. W. & 
MAEDLER, K. 2008. The antiinflammatory cytokine interleukin-1 receptor 
antagonist protects from high-fat diet-induced hyperglycemia. 
Endocrinology, 149, 2208-2218. 
SCAFOGLIERI, A., CLARYS, J. P., CATTRYSSE, E. & BAUTMANS, I. 2014. 
Use of Anthropometry for the Prediction of Regional Body Tissue 
Distribution in Adults: Benefits and Limitations in Clinical Practice. Aging 
and disease, 5, 373. 
SCHEID, M. P., LAUENER, R. & DURONIO, V. 1995. Role of 
phosphatidylinositol 3-OH-kinase activity in the inhibition of apoptosis in 
haemopoietic cells: phosphatidylinositol 3-OH-kinase inhibitors reveal a 
difference in signalling between interleukin-3 and granulocyte-macrophage 
colony stimulating factor. Biochem. J, 312, 159-162. 
SCHENK, S., SABERI, M. & OLEFSKY, J. M. 2008. Insulin sensitivity: 
modulation by nutrients and inflammation. The Journal of clinical 
investigation, 118, 2992. 
264 
 
SCHERER, P. E., WILLIAMS, S., FOGLIANO, M., BALDINI, G. & LODISH, H. 
F. 1995. A novel serum protein similar to C1q, produced exclusively in 
adipocytes. Journal of Biological chemistry, 270, 26746-26749. 
SCHINDLER, R., MANCILLA, J., ENDRES, S., GHORBANI, R., CLARK, S. & 
DINARELLO, C. 1990. Correlations and interactions in the production of 
interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood 
mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood, 75, 40-47. 
SCHMITZ‐PEIFFER, C. & WHITEHEAD, J. 2003. IRS‐1 regulation in health 
and disease. IUBMB life, 55, 367-374. 
SEIDELL, J. C. & FLEGAL, K. M. 1997. Assessing obesity: classification and 
epidemiology. British Medical Bulletin, 53, 238-252. 
SENN, J. J., KLOVER, P. J., NOWAK, I. A. & MOONEY, R. A. 2002. Interleukin-
6 induces cellular insulin resistance in hepatocytes. Diabetes, 51, 3391-3399. 
SENN, J. J., KLOVER, P. J., NOWAK, I. A., ZIMMERS, T. A., KONIARIS, L. G., 
FURLANETTO, R. W. & MOONEY, R. A. 2003. Suppressor of cytokine 
signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin 
resistance in hepatocytes. Journal of Biological Chemistry, 278, 13740-
13746. 
SESTI, G., FEDERICI, M., HRIBAL, M., LAURO, D., SBRACCIA, P. & LAURO, 
R. 2001. Defects of the insulin receptor substrate (IRS) system in human 
metabolic disorders. The FASEB Journal, 15, 2099-2111. 
SETHI, J. K. & HOTAMISLIGIL, G. S. The role of TNFα in adipocyte metabolism.  
Seminars in cell & developmental biology, 1999. Elsevier, 19-29. 
SETHI, J. K. & VIDAL-PUIG, A. J. 2007. Thematic review series: adipocyte 
biology. Adipose tissue function and plasticity orchestrate nutritional 
adaptation. Journal of lipid research, 48, 1253-1262. 
SHIMABUKURO, M., KOYAMA, K., CHEN, G., WANG, M.-Y., TRIEU, F., LEE, 
Y., NEWGARD, C. B. & UNGER, R. H. 1997. Direct antidiabetic effect of 
leptin through triglyceride depletion of tissues. Proceedings of the National 
Academy of Sciences, 94, 4637-4641. 
SHIMOMURA, I., HAMMER, R. E., IKEMOTO, S., BROWN, M. S. & 
GOLDSTEIN, J. L. 1999. Leptin reverses insulin resistance and diabetes 
mellitus in mice with congenital lipodystrophy. Nature, 401, 73-76. 
SHULMAN, G. I. 2000. Cellular mechanisms of insulin resistance. Journal of 
Clinical Investigation, 106, 171. 
SIITERI, P. K. 1987. Adipose tissue as a source of hormones. The American journal 
of clinical nutrition, 45, 277-282. 
SIMONS, P. J., VAN DEN PANGAART, P. S., AERTS, J. M. & BOON, L. 2007. 
Pro-inflammatory delipidizing cytokines reduce adiponectin secretion from 
265 
 
human adipocytes without affecting adiponectin oligomerization. Journal of 
Endocrinology, 192, 289-299. 
SIMONS, P. J., VAN DEN PANGAART, P. S., VAN ROOMEN, C. P., AERTS, J. 
M. & BOON, L. 2005. Cytokine-mediated modulation of leptin and 
adiponectin secretion during in vitro adipogenesis: evidence that tumor 
necrosis factor-α-and interleukin-1β-treated human preadipocytes are potent 
leptin producers. Cytokine, 32, 94-103. 
SIMS, J. E. & SMITH, D. E. 2010. The IL-1 family: regulators of immunity. Nature 
Reviews Immunology, 10, 89-102. 
SLOAN-LANCASTER, J., ABU-RADDAD, E., POLZER, J., MILLER, J. W., 
SCHERER, J. C., DE GAETANO, A., BERG, J. K. & LANDSCHULZ, W. 
H. 2013. Double-blind, randomized study evaluating the glycemic and anti-
inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β 
antibody, in patients with type 2 diabetes. Diabetes Care, 36, 2239-2246. 
SMITH, J. W., LONGO, D. L., ALVORD, W. G., JANIK, J. E., SHARFMAN, W. 
H., GAUSE, B. L., CURTI, B. D., CREEKMORE, S. P., HOLMLUND, J. T. 
& FENTON, R. G. 1993. The effects of treatment with interleukin-1α on 
platelet recovery after high-dose carboplatin. New England Journal of 
Medicine, 328, 756-761. 
SMITH, P., KROHN, R. I., HERMANSON, G., MALLIA, A., GARTNER, F., 
PROVENZANO, M., FUJIMOTO, E., GOEKE, N., OLSON, B. & KLENK, 
D. 1985. Measurement of protein using bicinchoninic acid. Analytical 
biochemistry, 150, 76-85. 
SMITH, R. E. & ROBERTS, J. C. 1964. Thermogenesis of brown adipose tissue in 
cold-acclimated rats. American Journal of Physiology--Legacy Content, 206, 
143-148. 
SMITH, S. R., LOVEJOY, J. C., GREENWAY, F., RYAN, D., DE LA 
BRETONNE, J., VOLAFOVA, J. & BRAY, G. A. 2001. Contributions of 
total body fat, abdominal subcutaneous adipose tissue compartments, and 
visceral adipose tissue to the metabolic complications of obesity. Metabolism, 
50, 425-435. 
SMITH, U. 2002. Impaired ('diabetic') insulin signaling and action occur in fat cells 
long before glucose intolerance--is insulin resistance initiated in the adipose 
tissue? Int J Obes Relat Metab Disord, 26, 897-904. 
SONG, G., OUYANG, G. & BAO, S. 2005. The activation of Akt/PKB signaling 
pathway and cell survival. Journal of cellular and molecular medicine, 9, 59-
71. 
SOPASAKIS, V. R., SANDQVIST, M., GUSTAFSON, B., HAMMARSTEDT, A., 
SCHMELZ, M., YANG, X., JANSSON, P. A. & SMITH, U. 2004. High 
Local Concentrations and Effects on Differentiation Implicate Interleukin‐6 
as a Paracrine Regulator. Obesity research, 12, 454-460. 
266 
 
SORISKY, A. 1999. From preadipocyte to adipocyte: differentiation-directed signals 
of insulin from the cell surface to the nucleus. Critical reviews in clinical 
laboratory sciences, 36, 1-34. 
SORISKY, A., MOLGAT, A. S. & GAGNON, A. 2013. Macrophage-induced 
adipose tissue dysfunction and the preadipocyte: should I stay (and 
differentiate) or should I go? Advances in Nutrition: An International Review 
Journal, 4, 67-75. 
SPALDING, K. L., ARNER, E., WESTERMARK, P. O., BERNARD, S., 
BUCHHOLZ, B. A., BERGMANN, O., BLOMQVIST, L., HOFFSTEDT, J., 
NÄSLUND, E. & BRITTON, T. 2008. Dynamics of fat cell turnover in 
humans. Nature, 453, 783-787. 
SPRANGER, J., KROKE, A., MÖHLIG, M., BERGMANN, M. M., RISTOW, M., 
BOEING, H. & PFEIFFER, A. F. H. 2003a. Adiponectin and protection 
against type 2 diabetes mellitus. The Lancet, 361, 226-228. 
SPRANGER, J., KROKE, A., MOHLIG, M., HOFFMANN, K., BERGMANN, M. 
M., RISTOW, M., BOEING, H. & PFEIFFER, A. F. 2003b. Inflammatory 
cytokines and the risk to develop type 2 diabetes: results of the prospective 
population-based European Prospective Investigation into Cancer and 
Nutrition (EPIC)-Potsdam Study. Diabetes, 52, 812-7. 
SPRANGER, J., KROKE, A., MÖHLIG, M., HOFFMANN, K., BERGMANN, M. 
M., RISTOW, M., BOEING, H. & PFEIFFER, A. F. 2003c. Inflammatory 
cytokines and the risk to develop type 2 diabetes results of the prospective 
population-based European Prospective Investigation into Cancer and 
Nutrition (EPIC)-Potsdam Study. Diabetes, 52, 812-817. 
STEEL, D. M. & WHITEHEAD, A. S. 1994. The major acute phase reactants: C-
reactive protein, serum amyloid P component and serum amyloid A protein. 
Immunology today, 15, 81-88. 
STEINBERG, G. R. & KEMP, B. E. 2007. Adiponectin: starving for attention. Cell 
metabolism, 6, 3-4. 
STENKULA, K. G., SAID, L., KARLSSON, M., THORN, H., KJØLHEDE, P., 
GUSTAVSSON, J., SÖDERSTRÖM, M., STRÅLFORS, P. & NYSTROM, 
F. H. 2004. Expression of a mutant IRS inhibits metabolic and mitogenic 
signalling of insulin in human adipocytes. Molecular and cellular 
endocrinology, 221, 1-8. 
STEPHENS, J. M., LEE, J. & PILCH, P. F. 1997. Tumor necrosis factor-alpha-
induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of 
insulin receptor substrate-1 and GLUT4 expression without a loss of insulin 
receptor-mediated signal transduction. J Biol Chem, 272, 971-6. 
STIENSTRA, R., JOOSTEN, L. A., KOENEN, T., VAN TITS, B., VAN DIEPEN, J. 
A., VAN DEN BERG, S. A., RENSEN, P. C., VOSHOL, P. J., FANTUZZI, 
G. & HIJMANS, A. 2010. The inflammasome-mediated caspase-1 activation 
267 
 
controls adipocyte differentiation and insulin sensitivity. Cell metabolism, 12, 
593-605. 
STIENSTRA, R., VAN DIEPEN, J. A., TACK, C. J., ZAKI, M. H., VAN DE 
VEERDONK, F. L., PERERA, D., NEALE, G. A., HOOIVELD, G. J., 
HIJMANS, A. & VROEGRIJK, I. 2011. Inflammasome is a central player in 
the induction of obesity and insulin resistance. Proceedings of the National 
Academy of Sciences, 108, 15324-15329. 
STRACZKOWSKI, M., DZIENIS-STRACZKOWSKA, S., STÊPIEÑ, A., 
KOWALSKA, I., SZELACHOWSKA, M. & KINALSKA, I. 2002. Plasma 
interleukin-8 concentrations are increased in obese subjects and related to fat 
mass and tumor necrosis factor-α system. The Journal of Clinical 
Endocrinology & Metabolism, 87, 4602-4606. 
STRISSEL, K. J., STANCHEVA, Z., MIYOSHI, H., PERFIELD, J. W., DEFURIA, 
J., JICK, Z., GREENBERG, A. S. & OBIN, M. S. 2007. Adipocyte death, 
adipose tissue remodeling, and obesity complications. Diabetes, 56, 2910-
2918. 
SUGANAMI, T., NISHIDA, J. & OGAWA, Y. 2005. A paracrine loop between 
adipocytes and macrophages aggravates inflammatory changes role of free 
fatty acids and tumor necrosis factor α. Arteriosclerosis, thrombosis, and 
vascular biology, 25, 2062-2068. 
SUGANAMI, T. & OGAWA, Y. 2010. Adipose tissue macrophages: their role in 
adipose tissue remodeling. Journal of leukocyte biology, 88, 33-39. 
SUGANAMI, T., TANAKA, M. & OGAWA, Y. 2011. Adipose tissue inflammation 
and ectopic lipid accumulation. Endocrine journal, 59, 849-857. 
SUMMERS, S., WHITEMAN, E. & MJ, B. 2000. Insulin signaling in the adipocyte. 
International Journal of Obesity (2000)  
SUN, K., KUSMINSKI, C. M. & SCHERER, P. E. 2011. Adipose tissue remodeling 
and obesity. J Clin Invest, 121, 2094-2101. 
SUN, X., CASBAS-HERNANDEZ, P., BIGELOW, C., MAKOWSKI, L., JERRY, 
D. J., SCHNEIDER, S. S. & TROESTER, M. A. 2012. Normal breast tissue 
of obese women is enriched for macrophage markers and macrophage-
associated gene expression. Breast cancer research and treatment, 131, 
1003-1012. 
SUN, X. J., CRIMMINS, D., MYERS, M., MIRALPEIX, M. & WHITE, M. 1993. 
Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1. 
Molecular and Cellular Biology, 13, 7418-7428. 
SUN, X. J., ROTHENBERG, P., KAHN, C. R., BACKER, J. M., ARAKI, E., 
WILDEN, P. A., CAHILL, D. A., GOLDSTEIN, B. J. & WHITE, M. F. 
1991. Structure of the insulin receptor substrate IRS-1 defines a unique signal 
transduction protein. Nature, 352, 73-77. 
268 
 
SWEENEY, G., KEEN, J., SOMWAR, R., KONRAD, D., GARG, R. & KLIP, A. 
2001. High leptin levels acutely inhibit insulin-stimulated glucose uptake 
without affecting glucose transporter 4 translocation in l6 rat skeletal muscle 
cells. Endocrinology, 142, 4806-4812. 
SYKIOTIS, G. P. & PAPAVASSILIOU, A. G. 2001. Serine phosphorylation of 
insulin receptor substrate-1: a novel target for the reversal of insulin 
resistance. Molecular Endocrinology, 15, 1864-1869. 
SYMONDS, M. E. 2012. Adipose tissue biology [electronic book] / Michael E. 
Symonds, editor, New York, NY : Springer, c2012. 
TACK, C. J., STIENSTRA, R., JOOSTEN, L. A. & NETEA, M. G. 2012. 
Inflammation links excess fat to insulin resistance: the role of the interleukin-
1 family. Immunol Rev, 249, 239-52. 
TANIGUCHI, C. M., EMANUELLI, B. & KAHN, C. R. 2006. Critical nodes in 
signalling pathways: insights into insulin action. Nature reviews Molecular 
cell biology, 7, 85-96. 
TANTI, J.-F., GREMEAUX, T., VAN OBBERGHEN, E. & LE MARCHAND-
BRUSTEL, Y. 1994. Serine/threonine phosphorylation of insulin receptor 
substrate 1 modulates insulin receptor signaling. Journal of Biological 
Chemistry, 269, 6051-6057. 
THOMPSON, B. R., MAZURKIEWICZ-MUÑOZ, A. M., SUTTLES, J., CARTER-
SU, C. & BERNLOHR, D. A. 2009. Interaction of adipocyte fatty acid-
binding protein (AFABP) and Jak2 AFABP/AP2 as a regulator of Jak2 
signaling. Journal of Biological Chemistry, 284, 13473-13480. 
THONG, F. S., BILAN, P. J. & KLIP, A. 2007. The Rab GTPase-activating protein 
AS160 integrates Akt, protein kinase C, and AMP-activated protein kinase 
signals regulating GLUT4 traffic. Diabetes, 56, 414-423. 
TILG, H. & MOSCHEN, A. R. 2006. Adipocytokines: mediators linking adipose 
tissue, inflammation and immunity. Nature Reviews Immunology, 6, 772-783. 
TOMIYAMA, K., NAKATA, H., SASA, H., ARIMURA, S., NISHIO, E. & 
WATANABE, Y. 1995. Wortmannin, a specific phosphatidylinositol 3-
kinase inhibitor, inhibits adipocytic differentiation of 3T3-L1 cells. 
Biochemical and biophysical research communications, 212, 263-269. 
TOMLINSON, J. J., BOUDREAU, A., WU, D., SALEM, H. A., CARRIGAN, A., 
GAGNON, A., MEARS, A. J., SORISKY, A., ATLAS, E. & HACHÉ, R. J. 
2010. Insulin sensitization of human preadipocytes through glucocorticoid 
hormone induction of forkhead transcription factors. Molecular 
Endocrinology, 24, 104-113. 
TONTONOZ, P., HU, E., DEVINE, J., BEALE, E. G. & SPIEGELMAN, B. M. 
1995. PPAR gamma 2 regulates adipose expression of the 
phosphoenolpyruvate carboxykinase gene. Molecular and cellular biology, 
15, 351-357. 
269 
 
TORDJMAN, K. M., LEINGANG, K. A., JAMES, D. E. & MUECKLER, M. M. 
1989. Differential regulation of two distinct glucose transporter species 
expressed in 3T3-L1 adipocytes: effect of chronic insulin and tolbutamide 
treatment. Proceedings of the National Academy of Sciences, 86, 7761-7765. 
TORRES-LEAL, F. L., FONSECA-ALANIZ, M. H., OLIVEIRA, A. C. D. & 
ALONSO-VALE, M. I. C. 2012. Adipose Tissue Inflammation and Insulin 
Resistance. 
TORTI, F. M., TORTI, S. V., LARRICK, J. W. & RINGOLD, G. M. 1989. 
Modulation of adipocyte differentiation by tumor necrosis factor and 
transforming growth factor beta. The Journal of cell biology, 108, 1105-1113. 
TOWBIN, H., STAEHELIN, T. & GORDON, J. 1979. Electrophoretic transfer of 
proteins from polyacrylamide gels to nitrocellulose sheets: procedure and 
some applications. Proceedings of the National Academy of Sciences, 76, 
4350-4354. 
TRAYHURN, P. 1993. Brown adipose tissue: from thermal physiology to 
bioenergetics. Journal of biosciences, 18, 161-173. 
TRAYHURN, P. 2007. Adipocyte biology. Obesity reviews, 8, 41-44. 
TRAYHURN, P. & BEATTIE, J. H. Physiological role of adipose tissue: white 
adipose tissue as an endocrine and secretory organ.  PROCEEDINGS-
NUTRITION SOCIETY OF LONDON, 2001. Cambridge Univ Press, 329-
339. 
TRAYHURN, P., HOGGARD, N., MERCER, J. & RAYNER, D. 1999. Leptin: 
fundamental aspects. International journal of obesity and related metabolic 
disorders: journal of the International Association for the Study of Obesity, 
23, 22. 
TRAYHURN, P., WANG, B. & WOOD, I. S. 2008. Hypoxia in adipose tissue: a 
basis for the dysregulation of tissue function in obesity? British Journal of 
Nutrition, 100, 227-235. 
TRAYHURN, P. & WOOD, I. S. 2004. Adipokines: inflammation and the 
pleiotropic role of white adipose tissue. British Journal of Nutrition, 92, 347-
355. 
TRAYHURN P. 1986. Brown adipoe tissue and energy balance; in Brown adipose 
tissue (eds). In: NICHOLLS, P. T. A. D. G. (ed.) Brown adipose tissue. 
London: Edward Arnold. 
TREMBLAY, F. & MARETTE, A. 2001. Amino acid and insulin signaling via the 
mTOR/p70 S6 kinase pathway A negative feedback mechanism leading to 
insulin resistance in skeletal muscle cells. Journal of Biological Chemistry, 
276, 38052-38060. 
270 
 
TRUJILLO, M. & SCHERER, P. 2005. Adiponectin–journey from an adipocyte 
secretory protein to biomarker of the metabolic syndrome. Journal of internal 
medicine, 257, 167-175. 
TSOU, C.-L., PETERS, W., SI, Y., SLAYMAKER, S., ASLANIAN, A. M., 
WEISBERG, S. P., MACK, M. & CHARO, I. F. 2007. Critical roles for 
CCR2 and MCP-3 in monocyte mobilization from bone marrow and 
recruitment to inflammatory sites. The Journal of clinical investigation, 117, 
902. 
UYSAL, K. T., WIESBROCK, S. M., MARINO, M. W. & HOTAMISLIGIL, G. S. 
1997. Protection from obesity-induced insulin resistance in mice lacking 
TNF-alpha function. Nature, 389, 610-4. 
VAN TIENEN, F., VAN DER KALLEN, C., LINDSEY, P., WANDERS, R., VAN 
GREEVENBROEK, M. & SMEETS, H. 2011. Preadipocytes of type 2 
diabetes subjects display an intrinsic gene expression profile of decreased 
differentiation capacity. International journal of obesity, 35, 1154-1164. 
VANDANMAGSAR, B., YOUM, Y.-H., RAVUSSIN, A., GALGANI, J. E., 
STADLER, K., MYNATT, R. L., RAVUSSIN, E., STEPHENS, J. M. & 
DIXIT, V. D. 2011. The NLRP3 inflammasome instigates obesity-induced 
inflammation and insulin resistance. Nature medicine, 17, 179-188. 
VICENNATI, V., VOTTERO, A., FRIEDMAN, C. & PAPANICOLAOU, D. 2002. 
Hormonal regulation of interleukin-6 production in human adipocytes. 
International journal of obesity and related metabolic disorders: journal of 
the International Association for the Study of Obesity, 26, 905-911. 
VIDAL-PUIG, A. J., CONSIDINE, R. V., JIMENEZ-LIÑAN, M., WERMAN, A., 
PORIES, W. J., CARO, J. F. & FLIER, J. S. 1997. Peroxisome proliferator-
activated receptor gene expression in human tissues. Effects of obesity, 
weight loss, and regulation by insulin and glucocorticoids. Journal of clinical 
investigation, 99, 2416. 
VOLLENWEIDER, P. 2003. Insulin resistant states and insulin signaling. Clinical 
chemistry and laboratory medicine, 41, 1107-1119. 
VOZAROVA, B., WEYER, C., HANSON, K., TATARANNI, P. A., BOGARDUS, 
C. & PRATLEY, R. E. 2001. Circulating interleukin-6 in relation to 
adiposity, insulin action, and insulin secretion. Obes Res, 9, 414-7. 
WAJCHENBERG, B. L. 2000. Subcutaneous and visceral adipose tissue: their 
relation to the metabolic syndrome. Endocrine reviews, 21, 697-738. 
WANG, B., JENKINS, J. R. & TRAYHURN, P. 2005a. Expression and secretion of 
inflammation-related adipokines by human adipocytes differentiated in 
culture: integrated response to TNF-α. American Journal of Physiology-
Endocrinology and Metabolism, 288, E731-E740. 
271 
 
WANG, J., ARMOUR, T., GEISS, L. S. & ENGELGAU, M. M. 2005b. Obesity and 
diabetes: dual epidemics on the rise. Current Opinion in Endocrinology, 
Diabetes and Obesity, 12, 174-180. 
WANG, B., WOOD, I. S. & TRAYHURN, P. 2007. Dysregulation of the expression 
and secretion of inflammation-related adipokines by hypoxia in human 
adipocytes. Pflügers Archiv European Journal of Physiology, 455, 479-492. 
WANG, B., WOOD, I. S. & TRAYHURN, P. 2008. Hypoxia induces leptin gene 
expression and secretion in human preadipocytes: differential effects of 
hypoxia on adipokine expression by preadipocytes. Journal of 
Endocrinology, 198, 127-134. 
WANG, N.-D., FINEGOLD, M. J., BRADLEY, A., OU, C. N., ABDELSAYED, S. 
V., WILDE, M. D., TAYLOR, L. R., WILSON, D. R. & DARLINGTON, G. 
J. 1995. Impaired energy homeostasis in C/EBP alpha knockout mice. 
Science, 269, 1108-1112. 
WANG, Y., SULLIVAN, S., TRUJILLO, M., LEE, M. J., SCHNEIDER, S. H., 
BROLIN, R. E., KANG, Y. H., WERBER, Y., GREENBERG, A. S. & 
FRIED, S. K. 2003. Perilipin expression in human adipose tissues: effects of 
severe obesity, gender, and depot. Obesity research, 11, 930-936. 
WATSON, R. T. & PESSIN, J. E. 2001. Intracellular organization of insulin 
signaling and GLUT4 translocation. Recent Progress in Hormone Research, 
56, 175-194. 
WAUGH, D. J. & WILSON, C. 2008. The interleukin-8 pathway in cancer. Clinical 
cancer research, 14, 6735-6741. 
WEILAND, M., SCHURMANN, A., SCHMIDT, W. & JOOST, H. 1990. 
Development of the hormone-sensitive glucose transport activity in 
differentiating 3T3-L1 murine fibroblasts. Role of the two transporter species 
and their subcellular localization. Biochem. J, 270, 331-336. 
WEISBERG, S. P., MCCANN, D., DESAI, M., ROSENBAUM, M., LEIBEL, R. L. 
& FERRANTE JR, A. W. 2003. Obesity is associated with macrophage 
accumulation in adipose tissue. Journal of clinical investigation, 112, 1796-
1808. 
WELLEN, K. E. & HOTAMISLIGIL, G. S. 2003. Obesity-induced inflammatory 
changes in adipose tissue. Journal of clinical investigation, 112, 1785-1787. 
WEN, H., GRIS, D., LEI, Y., JHA, S., ZHANG, L., HUANG, M. T.-H., BRICKEY, 
W. J. & TING, J. P. 2011. Fatty acid-induced NLRP3-ASC inflammasome 
activation interferes with insulin signaling. Nature immunology, 12, 408-415. 
WEYER, C., FOLEY, J., BOGARDUS, C., TATARANNI, P. & PRATLEY, R. 
2000. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, 
predicts type II diabetes independent of insulin resistance. Diabetologia, 43, 
1498-1506. 
272 
 
WHITE, M. & KAHN, C. 1994. The insulin signaling system. J Biol Chem, 269. 
WHITE, M. F. 1997. The insulin signalling system and the IRS proteins. 
Diabetologia, 40, S2-S17. 
WHITE, M. F. 2002. IRS proteins and the common path to diabetes. American 
Journal of Physiology-Endocrinology And Metabolism, 283, E413-E422. 
WHO 1999. Definition, diagnosis and classification of diabetes mellitus and its 
complications. 
WHO 2000. Obesity: preventing and managing the global epidemic. Geneva: World 
Health Organization, Consultation on Obesity. 
WHO 2011. Waist Circumference and Waist–Hip Ratio.Report of a WHO Expert 
Consultation. Geneva. 
WILD, S., ROGLIC, G., GREEN, A., SICREE, R. & KING, H. 2004. Global 
prevalence of diabetes estimates for the year 2000 and projections for 2030. 
Diabetes care, 27, 1047-1053. 
WONG, G. W., WANG, J., HUG, C., TSAO, T.-S. & LODISH, H. F. 2004. A 
family of Acrp30/adiponectin structural and functional paralogs. Proceedings 
of the National Academy of Sciences of the United States of America, 101, 
10302-10307. 
WRIGHT, W. S., LONGO, K. A., DOLINSKY, V. W., GERIN, I., KANG, S., 
BENNETT, C. N., CHIANG, S.-H., PRESTWICH, T. C., GRESS, C. & 
BURANT, C. F. 2007. Wnt10b inhibits obesity in ob/ob and agouti mice. 
Diabetes, 56, 295-303. 
WU, H., GHOSH, S., DAI PERRARD, X., FENG, L., GARCIA, G. E., PERRARD, 
J. L., SWEENEY, J. F., PETERSON, L. E., CHAN, L. & SMITH, C. W. 
2007. T-cell accumulation and regulated on activation, normal T cell 
expressed and secreted upregulation in adipose tissue in obesity. Circulation, 
115, 1029-1038. 
WU, J., BOSTRÖM, P., SPARKS, L. M., YE, L., CHOI, J. H., GIANG, A. H., 
KHANDEKAR, M., VIRTANEN, K. A., NUUTILA, P. & SCHAART, G. 
2012. Beige adipocytes are a distinct type of thermogenic fat cell in mouse 
and human. Cell. 
XIE, L., ORTEGA, M. T., MORA, S. & CHAPES, S. K. 2010. Interactive changes 
between macrophages and adipocytes. Clinical and Vaccine Immunology, 17, 
651-659. 
XU, H., BARNES, G. T., YANG, Q., TAN, G., YANG, D., CHOU, C. J., SOLE, J., 
NICHOLS, A., ROSS, J. S. & TARTAGLIA, L. A. 2003. Chronic 
inflammation in fat plays a crucial role in the development of obesity-related 
insulin resistance. Journal of clinical investigation, 112, 1821-1830. 
273 
 
YADAV, A., KATARIA, M. A., SAINI, V. & YADAV, A. 2013. Role of leptin and 
adiponectin in insulin resistance. Clinica Chimica Acta, 417, 80-84. 
YAMAUCHI, T., KAMON, J., MINOKOSHI, Y. A., ITO, Y., WAKI, H., UCHIDA, 
S., YAMASHITA, S., NODA, M., KITA, S. & UEKI, K. 2002. Adiponectin 
stimulates glucose utilization and fatty-acid oxidation by activating AMP-
activated protein kinase. Nature medicine, 8, 1288-1295. 
YAMAUCHI, T., KAMON, J., WAKI, H., TERAUCHI, Y., KUBOTA, N., HARA, 
K., MORI, Y., IDE, T., MURAKAMI, K. & TSUBOYAMA-KASAOKA, N. 
2001. The fat-derived hormone adiponectin reverses insulin resistance 
associated with both lipoatrophy and obesity. Nature medicine, 7, 941-946. 
YANG, R.-Z., LEE, M.-J., HU, H., POLLIN, T. I., RYAN, A. S., NICKLAS, B. J., 
SNITKER, S., HORENSTEIN, R. B., HULL, K. & GOLDBERG, N. H. 
2006. Acute-phase serum amyloid A: an inflammatory adipokine and 
potential link between obesity and its metabolic complications. PLoS 
medicine, 3, e287. 
YANG, W.-S., LEE, W.-J., FUNAHASHI, T., TANAKA, S., MATSUZAWA, Y., 
CHAO, C.-L., CHEN, C.-L., TAI, T.-Y. & CHUANG, L.-M. 2001. Weight 
reduction increases plasma levels of an adipose-derived anti-inflammatory 
protein, adiponectin. The Journal of Clinical Endocrinology & Metabolism, 
86, 3815-3819. 
YANG, X., JANSSON, P.-A., NAGAEV, I., JACK, M. M., CARVALHO, E., 
SUNNERHAGEN, K. S., CAM, M. C., CUSHMAN, S. W. & SMITH, U. 
2004. Evidence of impaired adipogenesis in insulin resistance. Biochemical 
and biophysical research communications, 317, 1045-1051. 
YAO, R. & COOPER, G. M. 1995. Requirement for phosphatidylinositol-3 kinase in 
the prevention of apoptosis by nerve growth factor. Science, 267, 2003-2006. 
YATURU, S. 2011. Obesity and type 2 diabetes. Journal of Diabetes Mellitus, 1, 79. 
YE, J. 2009. Emerging role of adipose tissue hypoxia in obesity and insulin 
resistance. International journal of obesity, 33, 54-66. 
YE, J., GAO, Z., YIN, J. & HE, Q. 2007. Hypoxia is a potential risk factor for 
chronic inflammation and adiponectin reduction in adipose tissue of ob/ob 
and dietary obese mice. American Journal of Physiology-Endocrinology and 
Metabolism, 293, E1118-E1128. 
YOKOMORI, N., TAWATA, M. & ONAYA, T. 1999. A transcriptional repressor 
regulates mouse GLUT4 gene expression during the differentiation of 3T3-L1 
cells. Diabetes, 48, 2471-2474. 
YU, C., CHEN, Y., CLINE, G. W., ZHANG, D., ZONG, H., WANG, Y., 
BERGERON, R., KIM, J. K., CUSHMAN, S. W. & COONEY, G. J. 2002a. 
Mechanism by which fatty acids inhibit insulin activation of insulin receptor 
substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in 
muscle. Journal of Biological Chemistry, 277, 50230-50236. 
274 
 
YU, J. G., JAVORSCHI, S., HEVENER, A. L., KRUSZYNSKA, Y. T., NORMAN, 
R. A., SINHA, M. & OLEFSKY, J. M. 2002b. The effect of 
thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 
diabetic subjects. Diabetes, 51, 2968. 
ZABOLOTNY, J. M., BENCE-HANULEC, K. K., STRICKER-KRONGRAD, A., 
HAJ, F., WANG, Y., MINOKOSHI, Y., KIM, Y.-B., ELMQUIST, J. K., 
TARTAGLIA, L. A. & KAHN, B. B. 2002. PTP1B regulates leptin signal 
transduction in vivo. Developmental Cell, 2, 489-495. 
ZHANG, H. H., SOUZA, S. C., MULIRO, K. V., KRAEMER, F. B., OBIN, M. S. & 
GREENBERG, A. S. 2003. Lipase-selective functional domains of perilipin 
A differentially regulate constitutive and protein kinase A-stimulated 
lipolysis. Journal of Biological Chemistry, 278, 51535-51542. 
ZHANG, Y., PROENCA, R., MAFFEI, M., BARONE, M., LEOPOLD, L. & 
FRIEDMAN, J. M. 1994. Positional cloning of the mouse obese gene and its 
human homologue. Nature, 372, 425-432. 
ZHOU, Y., LIU, B.-L., LIU, K., TANG, N., HUANG, J., AN, Y. & LI, L. 2008. 
Establishment of the insulin resistance induced by inflammatory response in 
3T3-L1 preadipocytes cell line. Inflammation, 31, 355-364. 
ZIMMERMANN, R., LASS, A., HAEMMERLE, G. & ZECHNER, R. 2009. Fate of 
fat: the role of adipose triglyceride lipase in lipolysis. Biochimica et 
Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, 1791, 494-500. 
ZIMMERMANN, R., STRAUSS, J. G., HAEMMERLE, G., SCHOISWOHL, G., 
BIRNER-GRUENBERGER, R., RIEDERER, M., LASS, A., NEUBERGER, 
G., EISENHABER, F. & HERMETTER, A. 2004. Fat mobilization in 
adipose tissue is promoted by adipose triglyceride lipase. Science, 306, 1383-
1386. 
ZUK, P. A., ZHU, M., ASHJIAN, P., DE UGARTE, D. A., HUANG, J. I., 
MIZUNO, H., ALFONSO, Z. C., FRASER, J. K., BENHAIM, P. & 
HEDRICK, M. H. 2002. Human adipose tissue is a source of multipotent 
stem cells. Molecular biology of the cell, 13, 4279-4295. 
 
 
 
 
 
 
275 
 
 
 
 
 
 
 
                                    Appendix: 9 
Publication associated with this thesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
276 
 
9 Appendix  
 
LIST OF PUBLICATIONS 
Part of the results in this thesis has been presented and published in: 
A. Published articles  
1. Gao, Dan, Madi, Mohamed, Ding, Cherlyn, Fok, Matthew, Steele, Thomas, 
Ford, Christopher and Bing, Chen. (2014). Interleukin-1β mediates 
macrophage-induced impairment of insulin signalling in human primary 
adipocytes. American Journal of Physiology-Endocrinology and Metabolism, 
307(3), E289-E304 
 
B.  Published abstracts and  posters      
1. Madi, M, Gao, D, Trayhurn, P and Bing, C (2012). Interleukin-1β mediates 
macrophage-induced lipolysis and inhibits lipid accumulation in human 
adipocytes. 39
th
   Adipose Tissue Discussion Group (ATDG, 2012), Path, 
UK. 
 
2.  Madi, M, Gao, D, Trayhurn, P and Bing, C (2012). Interleukin-1β mediates 
macrophage-induced lipolysis and inhibits lipid accumulation in human 
adipocytes, European Congress on Obesity (ECO, 2013), Liverpool, UK.   
 
3. Madi, M, Trayhurn, P and Bing, C (2013). Insulin signaling molecules are 
expressed and modulated by insulin and interleukin-1β in human primary 
preadipocytes, 40
th
 Adipose Tissue Discussion Group (ATDG, 2013), 
Edinburgh, UK. 
4. Madi, M, Trayhurn, P and Bing C (2013). Insulin signaling molecules are 
expressed and modulated by insulin and interleukin-1β in human primary 
preadipocytes, European Congress on Obesity (ECO, 2014), Sofia, Bulgaria.   
 
5. Madi, M and Bing, C (2014). Interleukin-1β modulates insulin signalling 
proteins and mediates macrophage-induced release of pro-inflammatory 
factors in human predipocytes, 41
st
 Adipose Tissue Discussion Group 
(ATDG, 2014), Norwich, UK. 
 
277 
 
6. Madi, M and Bing, C (2014), Interleukin-1β modulates insulin signalling 
proteins and mediates macrophage-induced release of pro-inflammatory 
factors in human predipocytes, Libyan Postgraduate Student Conference, 
London, UK. 
 
7. Wilding-Steele, T P, Ding, C, Madi, M, Bing, C and Wilding, J P H. (2013). 
Vitamin D reduces cytokine-induced insulin resistance in human adipocytes. 
Diabetic Medicine, 30. p. 40. ISSN 0742-3071. 
 
 
 
